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ABSTRACT 
As international funding for malaria programmes plateaus, it is critical to better understand how to 
implement interventions such as first-line Artemisinin Combination Therapies (ACTs) most effectively 
through an existing health system.    
This thesis presents an expansion of a mathematical model of malaria transmission to provide insight to the 
role of health systems factors as barriers to the effectiveness of ACTs, and interventions to overcome them; 
considering dimensions of access to care, different sectors through which care is delivered, and the quality of 
care provided.  Data from the IMPACT 2 study in Tanzania was used to parameterise this approach. 
Primary-care based interventions had most impact on transmission.  In low-prevalence scenarios some single 
interventions, e.g. ensuring 100% care-seeking, eliminated parasite prevalence.  Diagnostic-led therapy with 
adequate stocks of ACTs was as effective in all settings as a policy of presumptive treatment, reducing 
parasite prevalence in under-fives in moderate transmission settings by up to 86% depending on the sector 
of implementation.   
Modelling combinations of hospital-based interventions shifted the pattern of severe malaria away from a 
peak at early ages (greater than 70% relative reduction in 0-5 year olds in medium transmission settings) 
towards a more sustained lower incidence across 0-20 years of age as seen in low prevalence settings.  This 
was not immune-mediated and demonstrates the role of health systems interventions preventing the 
development of severe malaria in those at risk, and reducing mortality. 
Weak health systems and a poorly controlled diversity of antimalarial sources act as barriers to deploying 
ACTs effectively both as a control measure and first-line treatment.  Addressing these constraints needs 
consideration of existing healthcare provision and local priorities, e.g. reducing ACT wastage, but through 
specific planning may improve progress towards targets set by Roll Back Malaria to decrease clinical disease 
and mortality, and in low transmission settings, to approach elimination. 
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1 INTRODUCTION 
 
Man ploughs the sea like a leviathan, he soars through the air like an eagle; his voice circles the world in a 
moment, his eyes pierce the heavens; he moves mountains, he makes the desert bloom; he has planted his 
flag at the north pole and the south; yet millions of men each year are destroyed because they fail to outwit 
a mosquito. 
- Paul F. Russell (1931) 
 
Despite being both treatable and preventable, malaria remains one of the most persistent and pressing 
public health problems of our time, with complex upstream social, political, economic and environmental 
determinants.  It is a parasitic infection, caused by one of the five species of the protozoan parasite known to 
infect humans, Plasmodium: namely P. falciparum, P. vivax, P. malariae, P. ovale and the zoonotic species P. 
knowlesi, all transmitted by female Anopheles mosquitoes prevalent throughout Africa, Latin America, and 
Asia (Greenwood et al., 2008).   Of these, P. falciparum is the most virulent and thus will be the focus of this 
thesis, causing the majority of the estimated 207 million cases and 627,000 malaria-related deaths between 
2011-2012 (WHO, 2013), as well as the major morbidities of cerebral malaria and severe anaemia which may 
have long-term sequelae.  This burden falls most heavily on children and pregnant women in sub-Saharan 
Africa, often with the most limited access to health care services (Kiszewski and Teklehaimanot, 2004).  
Malaria is associated with poor levels of development, but in addition the economic consequences of 
malaria are widespread and devastating, with significant direct and indirect costs (estimated at over $12 
billion annually in Africa alone), and have been shown to further hinder development (ESPD: Poverty and 
Social Policy Team, 2005, McKinsey, 2008).    
In recognition of this, since 2000 there has been renewed interest in seeking to control the transmission of 
malaria, even to the point of elimination in some contexts, using widespread targeting of the Anopheline 
vector through deployment of long-lasting insecticide treated nets (LLINs) (Lengeler, 2004) and promoting 
treatment with artemisinin combination therapies (ACTs) as a first-line agent (Sinclair et al., 2009). In 
addition, recent reports demonstrate significant progress towards the development of vaccine candidates 
against clinical forms of malaria in children (Birkett et al., 2013, Moorthy et al., 2013a, Moorthy et al., 2013b, 
Targett et al., 2013, Abdulla et al., 2013).  
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1.1 EPIDEMIOLOGY OF PLASMODIUM FALCIPARUM MALARIA  
An important component of recent malaria control initiatives has been a focus on determining the 
distribution of transmission, morbidity and attributable-mortality in order to evaluate the success of 
interventions. Quantifying malaria transmission is complex (Anderson RM, 1991).  The Entomological 
Inoculation Rate (EIR) is defined as the mean number of infectious mosquito bites per person per year 
(ibppy).  This is calculated from the number of mosquitoes that take a blood meal on a human adult over the 
course of 24 hours and the proportion of these that show evidence of infective forms of the malaria parasite 
(sporozoites; described in section 1.2) in the salivary glands.  However not all infectious bites actually result 
in a malaria human infection; this is given by the force of infection (FOI or lambda ) i.e. the number of 
infectious bites that progress to establish an infection in the host (Anderson RM, 1991).  Also commonly 
used to assess malaria control is the proportion of a population infected with malaria i.e. the parasite 
prevalence or parasite rate (PfPR for P. falciparum) – defined to be the proportion of a cross-sectional cohort 
testing positive for parasites.  The estimates for parasite prevalence are more accurately calculated using 
PCR techniques rather than slide microscopy (Okell et al., 2009b). 
Malaria levels may also be assessed by calculating the clinical burden (Mendis et al., 2009).  Malaria infection 
may present as sub-patent (asymptomatic with no detectable parasitaemia), asymptomatic (with no 
detectable clinical symptoms but parasitaemia may be detectable), or symptomatic disease, which is defined 
as fever plus parasite density above a given threshold (Gething et al., 2011). Clinical incidence is defined as 
the average number of episodes of clinical malaria per person per year.  The morbidity and mortality 
associated with malaria may be estimated as the proportion of clinical episodes that progress to severe 
malaria, which in practice is calculated through cases that present and are admitted to hospital or tertiary 
level facilities (Reyburn et al., 2004). The broad spectrum of manifestations of severe malaria are described 
in section 1.4, and may account for variations in estimates of severe disease incidence (WHO, 2010a).  
However in many malaria-endemic countries, collection of the relevant epidemiological data is handicapped 
by poor health information systems, lack of robust death registries, and health care delivery by a variety of 
providers, who are often informal (Greenwood et al., 2008).  Thus disease burden is often estimated through 
demographic surveillance system and sentinel health facility and community surveys including verbal 
autopsies, as well as clinical data and laboratory reports where available (Lozano et al., 2012, Greenwood, 
2008, Greenwood et al., 2008).   
In 2012, 3.4 billion individuals were deemed at risk of malaria, of which 1.2 billion were classified at high risk 
(namely greater than 1 case per 1000 population per year).  Approximately half of those at high risk (47%) 
reside in Sub-Saharan Africa and 37% in South-East Asia (WHO, 2013). The 2013 World Malaria Report 
estimates that between 2000 and 2012 malaria mortality rates fell by 45% across all ages and by 51% in 
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children under-five (U5s). Of the 103 countries identified to have ongoing malaria transmission, 59 
document falling infection incidence but 41 were unable to sufficiently assess trends in disease due to 
inadequate data (WHO, 2013).   
Figure 1 depicts the distribution of P.falciparum prevalence in 2 to 10 year olds globally, as estimated by the 
Malaria Atlas Project (MAP), indicating high levels of transmission across sub-Saharan Africa, with particular 
hot spots in Nigeria, Democratic Republic of Congo and Tanzania (Gething et al., 2011). 
 
 
Figure 1: The spatial distribution of Plasmodium falciparum endemicity in 2010  
(Gething et al., 2011) 
According to the World Malaria Report 2013, 90% of the estimated 627,000 malaria-attributable deaths in 
2012 occurred in Sub-Saharan Africa; three quarters of which were in U5s.  Furthermore 80% of the global 
burden is estimated to occur in just 18 countries; Nigeria and the Democratic Republic of Congo account for 
40% between themselves.  Greater than 80% of malaria deaths occur within 17 countries (WHO, 2013).  This 
geographic distribution is depicted in Figure 2, based on figures from Roll Back Malaria (RBM) and the WHO 
report of 2012 (WHO, 2012c).   
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Figure 2: Global distribution of malaria deaths per 100,000 population 
(WHO, 2012c) 
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1.2 LIFECYCLE OF THE PLASMODIUM FALCIPARUM PARASITE 
The lifecycle of a P.falciparum infection begins as an infected female Anopheline mosquito bites and blood-
feeds upon humans, injecting Plasmodium sporozoites into the bloodstream (Figure 3; Stage 1).  The 
sporozoites migrate to the liver and invade hepatocytes (Stage 2).  Here they multiply and differentiate into 
merozoites, via a process of schizogonic development that takes approximately 6.5 days.   
 
 
 
Figure 3: The malaria parasite lifecycle  
(Source The National Institute for Allergy and Infectious Diseases, USA (NIAID)  
http://www.niaid.nih.gov/topics/malaria/pages/lifecycle.aspx: accessed 4
th
 February 2014) 
These forms in turn re-enter the blood stream and commence a cycle of red cell invasion and asexual 
replication leading to the rupture and release of more merozoites, known as the erythrocytic phase (Stage 
3). This multiplication process results in thousands of parasite-infected cells in the host bloodstream, leading 
to a detectable parasitaemia. The invasion-rupture sequence occurs typically over a period of two days, 
hence resulting in a periodic fever (“tertiary fever”) every 48 hours.  Plasmodium falciparum is distinguished 
from other species by its ability to sequester in organs such as the brain causing recognised clinical features 
such as splenomegaly and cerebral malaria.  A subset of merozoites develops within red cells into the sexual 
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forms of the parasite, male and female gametocyte (haploid) forms that circulate within the blood stream, 
and may be ingested by a feeding mosquito (Stage 4).    
Once inside the midgut of a mosquito the gametocytes mature to gametes (Stage 5).  If both male and 
female gametes are present, they can fuse to form diploid zygotes, which subsequently develop into 
ookinetes.  These motile forms can invade the gut wall of the mosquito and form oocysts (Stage 6); here they 
undergo multiplication (the sporogonic cycle) from which sporozoites are eventually released into the body 
cavity of the mosquito. The sporozoites go on to invade the mosquito salivary glands, where they render the 
mosquito infectious for its next blood meal on humans, completing the lifecycle. 
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1.3 MALARIA: CLINICAL FEATURES, TRANSMISSION AND IMMUNITY 
Clinical uncomplicated malaria typically presents with a febrile illness and systemic non-specific symptoms 
such as vomiting and headaches; a picture not dissimilar to other childhood diseases.  The symptoms are 
primarily due to schizont rupture with release of metabolic products of parasite growth and destruction of 
erythrocytes. Physical signs include fever, tachycardia, jaundice, and even hepato- and spleno-megaly 
following repeated infections (Eddleston et al., 2008). 
Severe malaria may occur gradually or follow a more fulminant and rapidly progressive course.  Greenwood 
et al. estimate the mean duration between of onset of symptoms and the development of severe features to 
be 1.8 days if untreated (Greenwood et al., 1991). In adults, severe malaria may be complicated by multi-
organ damage including renal failure.  Children are more likely to present with respiratory distress, severe 
anaemia and especially cerebral malaria (Eddleston et al., 2008). 
It is not clearly understood why some individuals progress to severe malaria whilst others may regress to 
asymptomatic infections. The age of the patient and the local intensity of transmission may determine 
susceptibility to develop more serious complications (Reyburn et al., 2005, Okiro et al., 2009, Roca-Feltrer et 
al., 2010), but may also be influenced by genetics (Kwiatkowski, 2005). 
Local transmission is thought to underlie the pattern of protective immunity seen in both children and 
adults. The acquisition of malaria immunity is not fully understood, but is assumed to be both age (Baird, 
1995) and exposure (Snow et al., 1997) dependent, and to develop in a sequential manner.  Immunity to 
severe malaria is attained early in malaria-endemic regions; hence adult severe malaria is not common.  
With time, immunity to symptomatic episodes of malaria may develop and eventually increase to give 
immune tolerance to blood-stage parasites (Langhorne et al., 2008a).  Maternal immunity can be passed 
placentally, and protects infants for a short period post-partum.  The presence of foetal haemoglobin also 
impairs parasite development. This protective effect wanes over the first few months as passively-acquired 
maternal immunity declines and foetal haemoglobin is replaced with adult forms.  This renders children 
under the age of five particularly susceptible to infection and progression to severe states (Riley et al., 2001).  
Figure 4 depicts the patterns of severe disease and malaria mortality in three transmission intensity settings, 
taking into consideration the effect of seasonality.   
The process by which immunity to severe malaria is acquired is believed to be step-wise, and may be rapid 
(Gupta et al., 1999a).  However the rate by which this immunity is acquired is thought to be different for 
different manifestations of severe malaria, e.g. respiratory or cerebral malaria, and also varies with age 
(Roca-Feltrer et al., 2010, Reyburn et al., 2005).  In all transmission settings, levels of severe disease decrease 
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with age, but especially so at medium-high prevalence with a peak in incidence below the age of five 
(Carneiro et al., 2010, Griffin et al., 2014 ). 
 
Figure 4: Age-patterns of P. falciparum malaria in Sub-Saharan Africa  
Percentage of uncomplicated clinical malaria, hospital admissions with malaria and malaria-diagnosed deaths per 
month of age in children under ten years of age, by transmission intensity (TI) and seasonality of malaria 
transmission (Carneiro et al., 2010) 
Development of immunity to symptomatic clinical malaria occurs at a slower rate than immunity to severe 
malaria.  As indicated in Figure 4, the pattern of disease varies with transmission intensity, with a peak in 
children between 1 – 10 years of age (Reyburn et al., 2005, Carneiro et al., 2010).  Age patterns of parasite 
prevalence are determined by multiple complex immune responses that influence the demography and 
proportion of the population that is symptomatically infected and asymptomatic.  
The blood-stage immune response that develops over time results in a reduction in parasite densities and 
hence can lead to a lower proportion of detectable infection in older children and adults compared to young 
children. Parasite prevalence could also be influenced by a pre-erythrocytic immune response that reduces 
the rate of re-infection (Bretscher et al., 2011, Collins and Jeffery, 1999, Griffin et al., 2014).  Whilst the 
magnitude of the acquired pre-erythrocytic response is poorly characterised (White et al., 2013), it may 
24 
 
account in part for the age patterns seen; namely prevalence is highest typically in children and decreases 
with age (Drakeley et al., 2005, Griffin et al., 2014). 
The transmission intensity of malaria, calculated by the factors described in Section 1.2 - namely the EIR and 
the force of infection - is also dependent on vector-related quantities (Hay et al., 2010, Guerra et al., 2008) 
including the biting rate of the mosquito and the human blood index, which measures the proportion of 
mosquito blood meals that are taken from humans (Anderson RM, 1991).  As a result malaria transmission is 
also impacted by changes in mosquito densities resulting in temporal variation and seasonality dependent 
on rainfall (Carneiro et al., 2010, Drakeley et al., 2005).  Malaria transmission may also vary at a community 
level due to local drainage and standing water forming larval breeding site (Smith et al., 2004a) or even due 
to housing with eaves allowing vector entry (Lindsay and Snow, 1988).  Even within households, there may 
be heterogeneous transmission due to heterogeneity in mosquito biting due to use of LLINs and sleeping 
times, skin exposure or other personal characteristics such as smell (Knols et al., 1995, Burkot, 1988).  
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1.4 ERADICATION, ELIMINATION AND CONTROL 
Malaria has haunted mankind for centuries.  Descriptions of the symptoms and signs of malaria date back to 
the origins of recorded history, and recognition of the association with the presence of stagnant water led 
the Romans to initiate drainage programmes and swamp clearance to reduce levels of disease (Feachem et 
al., 2010). From an epidemiological perspective, the aims of strategies to reduce levels of malaria 
transmission are demonstrated in Figure 5, and may be defined as (Mendis et al., 2009, Moonen et al., 
2010): 
1) Control: a reduction of the disease burden to a level at which it no longer represents a public health 
problem 
2) Elimination: the interruption of local mosquito-borne transmission and a deliberate reduction of 
infection incidence to zero in a delineated geographical area; interventions are actively required to 
prevent re-establishment including activities to identify and manage small foci of both clinical and 
asymptomatic infections that may perpetuate transmission. 
3) Eradication: the permanent global reduction of infection incidence to zero through deliberate 
efforts; interventions are thus no longer required.   
 
Figure 5: Epidemiological milestones of reducing malaria transmission  
(Alonso et al., 2011b) 
Initial eradication programmes during the late 1950s collapsed within 20 years, and many of the early gains 
in countries which had not eliminated malaria were quickly reversed. In the 1990s international focus 
returned to disease control through the Millennium Development Goals, and the Roll Back Malaria initiative 
with some significant success (Feachem et al., 2010).  
In October 2007, the Bill and Melinda Gates Foundation altered the paradigm of current efforts by calling for 
a shift of strategy from malaria control to a new goal of global eradication, since echoed by the WHO and 
other major donors (Mendis et al., 2009). The feasibility of eradication is still contentious, given the 
multiplicity of vector species with diverse feeding and breeding habits, and complex epidemiological, 
economic, social and political contexts (Alonso et al., 2011b).  It is however believed that local elimination 
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may be possible in many parts of the world (Greenwood, 2009, Feachem et al., 2010).  Guerra et al. 
estimated that 1 billion people are at risk of unstable malaria transmission, and that in these areas 
elimination is epidemiologically feasible (Guerra et al., 2008).   
Epidemiological planning for the success of malaria control depends in part on the basic reproductive 
number for malaria, R0.  Smith et al. (Smith et al., 2008) estimated R0 for 121 African populations, ranging 
from around one to more than 3,000.  Their results support the conclusion that malaria elimination presents 
varied challenges across the transmission spectrum. In populations where R0 is highest, elimination will 
require multiple, integrated methods, including a focus on those bitten most and who drive transmission.   
At present, of 97 countries in 2013 with ongoing malaria transmission, 12 are classified as in the pre-
elimination phase of malaria control, and 7 in the elimination phase, with a further 7 in the prevention of re-
introduction (WHO, 2013).  
27 
 
1.5 MALARIA CONTROL INTERVENTIONS 
Existing malaria control interventions may be aimed at either treatment or prevention of infections targeting 
both the malaria parasite and the mosquito vector.  Treatment of clinical episodes of malaria may reduce 
symptoms and seeks to clear parasitaemia through elimination of blood-stage parasites.  Recommended 
treatment has evolved over the past two decades due to drug resistance, however the current first-line drug 
as per the WHO guidelines is artemisinin combination therapy (ACT); further discussed in Section 1.6 (WHO, 
2010a).  Antimalarial drugs may also be used to prevent malaria infections, especially in those groups at high 
risk of infection or vulnerable to morbidity, e.g. pregnant women, as listed in Figure 6.  More recently, 
interest has grown in using drugs across entire populations to clear asymptomatic or sub-patent infections in 
order to reduce onward transmission.   
 
Figure 6: Schematic depicting the use of antimalarial drugs as prophylactic malaria control interventions. 
Interventions taregtting in high risk groups (pregnant women (Gross et al., 2011, Gosling et al., 2011), infants (Aponte 
et al., 2009, Schellenberg et al., 2011) and young children (Greenwood, 2006, Gosling et al., 2011)) and as 
population–level measures (Gosling et al., 2011, Okell et al., 2011, Shekalaghe et al., 2011) 
Currently recommended interventions that target the vector are aimed at preventing malaria infection 
occurring through two mechanisms a) by killing the mosquito or any of its life-stages or b) by providing 
barrier-contact between mosquitoes and human.  Figure 7 depicts the most commonly used vector control 
interventions. 
Pregnant women/infant: Intermittent preventative therapy in 
pregnant women (IPTp) - protects women from their second trimester 
onwards through the use of SP, to reduce neonatal and infant death
Infants: Intermittent preventative therapy in infants (IPTi) - protects 
infants in the vulnerable first months of life through doses administered 
alongside childhood vaccinations, ideally requires several doses of SP for 
maximal effectiveness
Young children: Seasonal malaria chemoprophylaxis (SMC) - up to 4 
monthly doses of SP+AS recommended for children (3m-5years) in 
regions with high seasonality of transmission by administering drugs 
throughout the transmission season (previously termed IPT in children)
Mass Drug Administration (MDA) - large-scale treatment of an entire 
population with antimalarials (ACT, primaquine or other drugs) to 
reduce parasite reservoirs (i.e. asymptomatic infections) and thus 
malaria transmission
Mass screen and treat (MSAT) - large scale screening of a population 
using diagnostic tools and only treating those who are parasite positive
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Figure 7: Schematic depicting vector control interventions.  
Interventions targeting house walls with residual insecticide(Pluess et al., 2010) (Indoor Residual Spraying) and 
insecticide-treated nets(Lengeler, 2004) inside the house including long-lasting insecticide treated nets (LLINs)(Kilian 
et al., 2011) 
 
 
  
Indoor residual spraying (IRS): 
• Spraying the inside walls of houses with residual 
insecticide, protecting those within the house by repelling 
mosquitoes
• May also confer community level protection through toxic 
effects thus reducing the local mosquito population.  
• DDT was previously the insecticide most commonly used, 
but newer agents include pyrethroids and carbamates
• Effective against indoor feeding mosquitoes
Insecticide treated bed nets (ITNs & LLINs)
• Protect those who sleep under the net by creating 
a physical barrier against the mosquitoes
• Treated with a pyrethroid insecticide which is toxic 
to mosquitoes that come into contact with the net
• ITNs need regular re-treatment with an insecticide
• LLINs are impregnated with the insecticide and so 
remain efficacious for up to 5 years
29 
 
1.6 THE ROLE OF ACT IN REDUCING TRANSMISSION 
The Artemesia annua plant has long been used as a herbal remedy in China but only recently recognised as 
an effective anti-malarial by policy makers, especially against P. falciparum and even more so when in 
combination with other anti-malarials (White, 1997).  Artemisinins were first used in South-East Asia where 
high levels of resistance were noted in response to other anti-malarials, but use has grown since 2001 and 
Artemisinin Combination Therapies (ACT) are now the first line treatment for uncomplicated and severe 
malaria recommended in WHO guidelines (WHO, 2010a). Several different partner-drug combinations of 
ACTs exist with varying dosage schedules, but the most commonly used ACT in Africa is artemether-
lumefantrine (AL) followed by artesunate-amodiaquine (AS-AQ) (Littrell et al., 2011a). 
 
1.6.1 ACT as treatment 
ACTs are recognised to produce the most rapid clearance of parasites and decline in the symptoms of 
malaria associated with parasitaemia of all anti-malarial therapies in current use (White, 1997, Sinclair et al., 
2009).  Despite a relatively short half-life compared with other treatments (Stepniewska et al., 2008),  ACTs 
are active against all stages of malarial parasite, except late stage gametocytes (Stages 4 and 5 in Figure 3), 
and thus are highly effective at clearing infection provided the full dosage is taken (Sinclair et al., 2009). 
However as a result of the relatively short half-life of artemisinin re-infections may be common and thus the 
partner drug in the combination is important in clearing any residual parasites (Adjuik et al., 2004, White, 
1997, Sinclair et al., 2009).   
 
1.6.2 ACT effects on gametocytaemia and onward infectiousness (transmission) 
The aim of antimalarial treatment is to achieve clearance of the asexual stages of the parasite since these are 
mainly responsible for the symptoms of malaria.  However, effective clearance of asexual parasites should 
also mean clearance of the gametocytes they produce, thereby reducing the individual’s infectiousness to 
any mosquito taking a blood meal and thus onward transmission (Okell et al., 2008b, Warrell, 2002). 
The duration of time for clearance of P. falciparum gametocytes from the circulation of a treated patient is 
longer than the time taken for clearance of asexual stages (White, 1997).  The rate at which the gametocytes 
are reduced varies by the nature of treatment administered, and although most anti-malarials exert some 
anti-gametocyte action (Nosten and White, 2007), some studies show that there are circumstances in which 
the release of gametocytes is promoted by treatment (Sowunmi et al., 2007), thereby increasing an 
individual’s onward infectivity (Dunyo et al., 2006).  The only licensed anti-malarial with a full-spectrum 
action against gametocytes is primaquine, one of the family of 8-aminoquinolines (Price et al., 1996). This 
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drug is used for treatment of Plasmodium vivax as it additionally kills the hypnozoite stage of that infection. 
However, it cannot be used in infants or individuals with G6PD deficiency (WHO, 2010a).  Despite this, low 
dose primaquine has been recommended by the WHO, to be used alongside ACTs in areas of low prevalence 
in order to block onward transmission when moving towards elimination (White, 2013, White et al., 2012).  
Artemisinin derivatives are also known to have specific anti-gametocyte properties (Sinclair et al., 2009, Price 
et al., 1996, Sowunmi et al., 2007), reducing the duration of gametocyte carriage in vivo faster than non-ACT 
antimalarials (Bousema et al., 2010) and reducing onward infectiousness compared to previous first line 
treatments (Sawa et al., 2013, Okell et al., 2008b, Ezzet et al., 2000, White, 2008).  ACTs are thought to also 
be able to reduce malaria transmission through their post-treatment prophylactic effect, which is 
contributed mainly through the partner-drug of the ACT rather than the artemisinin derivative (Sinclair et al., 
2009).  The studies estimating the durations of these effects are discussed further in section 3.3.2.2, but 
ACTs are believed to have a potential role through “treatment-as-prevention” in malaria control and 
elimination efforts (White, 2008). 
 
1.6.3 The use of ACT for transmission control 
Previous campaigns to use curative doses of anti-malarials for transmission control through Mass Drug 
Administration (MDA) have been unsuccessful due to the development of parasite resistance, difficulties 
scaling up to required levels of coverage, drug contraindications (e.g. pregnancy) and individual reluctance 
amongst a wealth of other reasons (Greenwood, 2010).  A recent Cochrane review of MDA programmes over 
the past 50 years concluded that the strategy reduced the initial risk of malaria parasitaemia substantially. 
However, this impact was rarely sustained beyond 6 months, and those that did were conducted on small 
islands or in highland settings (Poirot et al., 2013). 
However, the use of ACT in order to reduce population transmission intensity as a result of its 
gametocytocidal action has garnered much interest recently. Unlike primaquine, ACTs are suitable for 
general first-line treatment of malaria, thus potentially could have a role in reducing overall population-level 
transmission if appropriately rolled out at scale.  Evidence for the impact of ACT on transmission is derived 
mainly from areas where ACT has been deployed as first-line therapy, where subsequent reductions in 
prevalence or clinical disease have been noted.   
Barnes et al (Barnes et al., 2009) published a review of the impact of a large scale deployment of ACTs in 
South Africa, Zambia and Ethiopia. They note that Zambia, one of the first countries to adopt ACT as first-line 
therapy alongside scaling up of vector control, has experienced decreases of 61% in-patient severe cases and 
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66% deaths since their introduction, as well as a 91-93% reduction in severe malaria cases at health facilities 
(Zurovac et al., 2007)  (Figure 8A below). 
A 
 
B 
 
  
Figure 8: Large scale use of ACTs in Zambia and Ethiopia. 
A) Number of cases of severe and uncomplicated malaria in Zambia by year (from 18 cost-effectiveness study sites). 
B) Malaria parasite reservoir in the control and intervention districts of the Tigray study region. Malaria parasite 
reservoir was three-fold lower in the intervention district during 2005 high-transmission season. (Barnes et al., 2009)   
Similarly, in Kwa-Zulu Natal (Barnes et al., 2009, Barnes et al., 2005) treatment with AL was used as first-line 
therapy, in combination with strengthening of vector control.  This provincial use caused the number of 
malaria-related outpatient cases and hospital admissions to each fall by 99% from 2001 to 2003, and 
malaria-related deaths decreased by 97% over the same period, with this sustained for seven years since the 
original deployment. A prospective study with 42 days follow up also showed that AL had a cure rate of 99% 
and prevented gametocyte development in all patients(Barnes et al., 2009).  
In Ethiopia, AL was introduced as first-line anti-malarial treatment in 2004 in the Tigray region in a 
community-based programme (Lemma et al., 2010, Barnes et al., 2009). Over the two-year study period, 
they found that this method of deployment of AL significantly lowered the risk of malaria-specific mortality 
by 37%.  A study comparing the malaria parasite reservoir was three-fold lower in the intervention district 
than in the control district during the 2005 high-transmission season (Lemma et al., 2010), which is depicted 
in Figure 8B above. 
Other reports of the use of ACT reducing transmission include Bhattarai et al. who documented that 
following deployment of ACTs (AS-AQ and AL) in the public sector in Zanzibar 2003 (Bhattarai et al., 2007), 
although malaria-associated morbidity and mortality did not show any change initially, within 2 years 
diagnoses and deaths declined significantly. P. falciparum prevalence in children decreased in this time 
period (2003 – 2006) and LLINs (long-lasting Insecticide-treated nets) were not introduced until 3 years after 
deployment of ACTs.   
32 
 
Nosten et al (Nosten et al., 2000) published some of the first reports of the impact of large-scale use of ACT 
on the Thai-Cambodian border, an area known for high levels of drug resistance (White, 2004, 
Pongtavornpinyo et al., 2008).  The mean monthly incidence of symptomatic malaria was 3.7% in the two 
years prior to the introduction of ACT.  Although incidence and transmission had been decreasing slowly in 
the region at that time, following widespread ACT (AS-MQ) use the incidence of malaria fell to a mean of 
1.58% per month.  This was further substantiated by a further study (Carrara et al., 2006), in a region of the 
border distinct from that studied by Nosten, where a decrease in P. falciparum incidence of 40-50% was seen 
within a year of introducing AS-MQ as first line treatment. 
The results of these studies indicate a trend of the widespread use of ACT as first line treatment for P. 
falciparum malaria being associated with a reduction in malaria transmission, although there are a number 
of confounding factors and it is not clear whether these effects would occur at different transmission 
intensities.   
Okell et al developed a mathematical model to predict the potential impact on transmission outcomes of 
introducing ACT as first-line treatment for uncomplicated malaria, under conditions of varying intensity in 
Tanzania (Okell et al., 2008a, Okell et al., 2008b). They predicted that the relative reductions in prevalence of 
infection and incidence of clinical episodes achieved by ACT would be highest in the areas with low baseline 
transmission. In real terms however, Okell et al  noted that in high transmission areas 54 clinical episodes 
per 100 persons were averted as compared with 5 per 100 persons in low transmission settings assuming 
that coverage of treatment was high (100%)(Okell et al., 2008b).  Okell et al also estimated variations in the 
impact that could be achieved by antimalarials with different efficacy, prophylactic time, and 
gametocytocidal effects.  An efficacious antimalarial regimen without any specific gametocytocidal 
properties but which produces a long duration of inhibitory anti-malaria effect, i.e. long prophylactic time, 
was predicted to be more effective at reducing transmission than a short-acting ACT in the highest-
transmission setting.   
Shekalaghe et al conducted the first study of MDA in mainland Africa using ACTs; a cluster-randomized trial 
in four villages in Tanzania, to test the use of artesunate (with primaquine and SP) given over 3 days in an 
area of very low and seasonal malaria transmission. Parasite prevalence decreased from 2.2-2.7% at baseline 
to undetectable following the intervention in both control and intervention clusters. As a reduction in 
transmission intensity in this region had occurred prior to the intervention, whether due to ITN use or 
presumptive treatment with ACTs, the impact of MDA was difficult to assess in this setting (Shekalaghe et al., 
2011).   
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In contrast to MDA, MSAT involves treating only parasitaemic individuals identified through either field tests 
or more formal laboratory PCR in order to treat asymptomatic carriers and reduce the pool of parasites 
thereby also transmission (Greenwood, 2010).  Tiono et al conducted a cluster randomised-controlled trial of 
community-wide screening and treatment in 18 malaria-endemic villages in Burkina Faso, using rapid 
diagnostic tests (RDTs) and ACTs.  At 12-month follow-up, the incidence of symptomatic malaria episodes in 
under-fives (U5s) did not differ between control or intervention areas.  The authors concluded greater levels 
of parasite clearance may be needed to impact malaria transmission sustainably in such settings (Tiono et 
al., 2013).  Similarly a randomised controlled trial in 101 schools in Kenya using MSAT (with RDTs and ACTs) 
found that over a 2 year follow-up period there were no significant improvements in parasitaemia or 
anaemia.  In addition, there appeared to be no school-wide improvement in the consequences of ill-health 
such as educational indices (Halliday et al., 2014). 
Mathematical modelling of mass treatment by Okell et al predicted MDA could provide sustainable 
reduction in transmission in low transmission settings (for at least 2 years), but this was likely to last less 
than 1 year in high prevalence scenarios (Okell et al., 2011).  Adding vector control measures potentiated the 
impact of recurrent courses of MDA due to a reduction in infectious bites (due to the diminished infectious 
reservoir), indicating that MDA or MSAT strategies need to be in combination with other control 
interventions and repeated for sustainable impact. 
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1.7 MATHEMATICAL MODELS OF MALARIA TRANSMISSION  
Simple models of malaria transmission were amongst the earliest attempts to understand the biological 
processes underlying transmission in a mathematical form, or through ‘a priori’ modelling (Ross, 1911).   
Ross (Ross, 1911) was first to apply mathematical models to infectious disease and is considered the 
forefather of malaria modelling.  Later Macdonald used simple mathematics to capture the critical steps of 
the transmission cycle, involving both human and mosquito (Macdonald, 1957). 
The schematic given in Figure 9 (McKenzie and Samba, 2004) indicates the basic structure of the Ross and 
Macdonald models.  In a steady state population, individuals can be allocated to distinct compartments, 
namely susceptible, infected (i.e. a latent period during which the individual is infected but not able to 
transmit the infection) and infectious.  Infection is assumed to occur as a result of random mixing between 
humans and mosquitoes in the relevant infectious or susceptible states leading to infection spread.  This is 
dependent on relative mosquito population size, human-blood meal rate, the prevalence of infection in both 
human and mosquitoes, and the probability of transmission from human to mosquito and vice versa.  The 
model assumes that mosquitoes die before they recover but that humans can recover from infection. 
 
Figure 9: Schematic diagram of the Ross-Macdonald model   
(McKenzie and Samba, 2004) 
The Ross-Macdonald model can be used to derive the relationship between variables such as the proportion 
of infectious (sporozoite-positive) mosquitoes, parasite prevalence (PfPR), the EIR (number of infectious 
bites each individual receives annually) and the basic reproductive number (R0: the average number of 
secondary infections arising from a typical primary case in a fully susceptible population).  In malaria, this 
consists of the product of reproductive numbers (R0) concerning both mosquito-to-human infections and 
human-to-mosquito infections (Anderson RM, 1991).  Insights from Ross-Macdonald type models, such as 
the sensitivity of transmission to the ability of adult mosquitoes to survive the latent (infected) period, were 
used to inform policies during the eradication efforts of the 1950s, such as the deployment of indoor 
residual spraying (IRS) as a vectorcidal measure (Anderson RM, 1991, Benenson, 1997).  
In the 1970s, a large-scale malaria elimination programme influenced by Ross-Macdonald modelling, was 
undertaken in an area of northern Nigeria with known high transmission.  This landmark programme became 
35 
 
known as the Garki Project (Molineaux and Gramiccia, 1980).  Using the data collected as part of the Garki 
Project, Dietz and Molineaux developed a more sophisticated age-structured transmission model, and 
incorporated both the phenomenon of super-infection, i.e. infection with different parasite clones which 
may extend duration of infection (Anderson RM, 1991) and explicit considerations of human immunity, 
including the loss of infectivity, loss of detectability and increased recovery rate (Dietz et al., 1974, 
Molineaux et al., 1978). The aim of this model was to generate comparative forecasts for specific 
interventions, conditional upon given entomological inputs (Molineaux and Gramiccia, 1980, Molineaux et 
al., 1978). 
Since then, mathematical models of malaria have evolved to reflect our progressive understanding of 
malaria immunology, seasonality and climate dependence, and vector biology, and of the development of 
novel interventions such as transmission blocking treatments such as ACTs and candidate malaria vaccines 
(Smith et al., 2008, Griffin et al., 2010, McKenzie et al., 2002, Griffin et al., 2014).  With the recent policy 
swing towards elimination and eradication, intervention-focussed modelling has been particularly 
emphasised including LLINs (Smith et al., 2009a), increased access and coverage of ACTs (Okell et al., 2008a, 
Griffin et al., 2010), mass treatment with ACTs (Okell et al., 2011), ACT resistance (Yeung et al., 2004, 
Pongtavornpinyo et al., 2008) malaria vaccines (Tediosi et al., 2009, Penny et al., 2008) as well as packages of 
available tools (Smith et al., 2008, Griffin et al., 2010, Griffin et al., 2014). 
A particular difficulty when modelling malaria transmission is the incorporation of immunity.  Plasmodium 
falciparum infections induce an increase in clinical immunity with exposure to the parasite, and this 
acquisition is dependent on an interaction of parasite, vector, host and environmental factors (Miller et al., 
2002).  However this immunity is only partial, and aside from altering risk age-groups for infections, can also 
affect the probability of developing clinical symptoms despite being infectious (Snow et al., 1997, Smith et 
al., 2004b). Thus, despite imperfect understanding of this phenomenon, there has been emphasis on 
exploring and modelling this relationship of immunity with clinical incidence and parasite rates across a 
range of transmission settings (Snow and Marsh, 2002, Filipe et al., 2007) as well as fitted to and validated 
against data collected in the field (Ghani et al., 2009, Smith et al., 2005, Smith et al., 2008, Griffin et al., 2010, 
Griffin et al., 2014, Griffin et al., 2014 ). 
As the feasibility of control and elimination strategies are still being debated, malaria models form a vital 
tool with which to explore the expected impact of interventions against malaria, both individually and in 
combination.  
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1.7.1 Transmission modelling and health systems 
A health system is, according to the WHO definition, “the sum of all organizations, institutions and resources 
whose primary purpose is to improve health” (WHO, 2007). Whilst policymakers often use decision 
analytical and cost-efficiency modelling to guide decisions (Ringel et al., 2010, Weinstein et al., 2001) as well 
as business cases of economic impact (McKinsey, 2008), the implications of health systems issues are not 
frequently explored explicitly in transmission models.   
Tediosi et al used a decision-tree modelling approach to predict incidence and mortality, and integrated this 
into a malaria transmission model to predict the cost-effectiveness of treatment in different prevalence and 
coverage scenarios (Tediosi et al., 2006). Their model predicted high treatment rates exerted a 
proportionately greater epidemiologic impact at low transmission levels, most likely due to increased clinical 
presentation.  Cost-effectiveness analysis has been used to evaluate the use of RDTs to reduce childhood 
mortality in different transmission settings (Rafael et al., 2006, Lubell et al., 2008). However previous studies 
modelling health systems effects on malaria transmission were not identified. 
The impact of health systems and case management on transmission has been explored for other infectious 
diseases.  White et al  considered the need for prompt treatment of sexually transmitted infections, and the 
ability of genitourinary medicine services to provide appropriate and timely care in the face of increasing 
demand (White et al., 2005).  This exploration of the relationship between capacity and demand for care 
demonstrated that at high levels of incidence, inadequate treatment capacity leads to high levels of 
untreated infections which in turn fuel further incidence and demand rendering health care provision even 
more inadequate.  His results suggest that a substantial increase in capacity is essential to interrupt the 
“vicious” cycle in the dynamics of infection and provision of healthcare,  to ensure a more “virtuous” cycle in 
which adequate levels of treatment lead to lower levels of infection, demand, improved health and cost 
savings.  
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1.8 MALARIA AND HEALTH SYSTEMS 
The risk of malaria and its sequelae is influenced not only by immunity, social and behavioural factors but 
also by the prevailing political and economic environment.  Kaplan  highlighted in his analysis of the role of 
epidemiology in poverty reduction that global patterns of malaria are not random nor due to any particular 
biological vulnerability, but instead correspond to global patterns of poverty and resource allocation (Kaplan, 
1998).  Indeed poverty is recognised as the most potent risk factor for malaria (Lucas and McMichael, 2005), 
with the poorest strata of the global population suffering over two-third of all infections (Guerin et al., 2002). 
In addition, the linkages between poverty and worse outcomes are well documented (Farmer, 2005, Sen A, 
1998) as seen in Figure 10 highlighting the countries from sub-Saharan Africa. 
 
 
Figure 10: Relationship between proportion of country’s population living in poverty and malaria mortality rates. 
Source Human Development Report 2011 
Despite promises made at Alma Ata in 1979, reforms due to rising national debts brought widespread cuts in 
public spending on health and education in the late 1970s and 80s (Peabody, 1996), which were followed by 
rising infant mortality rates and a decrease in other measures of population health (Manfredi, 1999).  
Manfredi suggested in his analysis of the resurgence of malaria in the latter half of the 20th century that 
these debt reforms may have laid the terrain for this at both micro and macro levels (Manfredi, 1999).  The 
impoverishment of the public health sector and resulting reduction in government provision of healthcare 
can lead to a greater need for out-of-pocket spending for healthcare.  At the same time rising health care 
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costs may also delay treatment seeking for serious cases of malaria. Economic deprivation leads to 
environmental degradation and also at a policy level can divert the resources necessary to address 
environmental risk factors for malaria.  Finally, worsening women’s health, resulting from the uneven 
allocation of household resources in scarce times, can cause less investment at a household level in child and 
infant health. Peabody suggests that reductions in investment in publicly provided healthcare led to reduced 
staffing levels and impoverished infrastructure (Peabody, 1996).  Packard notes in his history of malaria that 
conditionalities on loans by agencies such as the World Bank such as limits to wages in Zambia, led many 
trained healthcare workers to leave the this sector or take better-paying jobs abroad (Packard, 2007, WHO, 
2006), leaving local African health systems underfunded, understaffed and incapable of delivering of 
antimalarials and other essential healthcare to these areas further ravaged by HIV/AIDS, fuelling a spiral of 
disease and poverty. 
Treatment for malaria has also suffered from neglect in the past due to weak health systems globally. 
Factors believed to limit effective large-scale use of ACTs in sub-Saharan Africa include: availability of ACTs 
and high risk of stock-outs in the public sector; the high cost of ACTs and the rise in the availability of 
counterfeit drugs and continued presence of artemisinin-derived monotherapies through the informal 
sector; a lack of knowledge and public awareness about combination therapies (Newton et al., 2006, Kaur et 
al., 2008, Mutabingwa, 2005, Yeung et al., 2004), and the erosion of primary health care systems throughout 
Africa (Alilio et al., 2004). This is further discussed in Chapter 2. The WHO estimates that a package of 
essential health care services needed to deliver the health-related goals set by the Millennium Development 
Goals (MDG) which include targets for malaria treatment and prevention as well as equitable access to 
quality essential service, requires approximately US$44 per capita per annum in low income countries.  In 
2009, none of the 29 least-developed nations reached this level (Taskforce for Innovative Financing for 
Health Systems, 2009). 
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1.9 THESIS AIMS  
 
Health systems can impact on the outcomes of preventative and curative interventions against malaria.  The 
aim of this thesis is to use mathematical models to provide insight to the effect of health systems factors 
acting as barriers to the effectiveness of ACTs considering dimensions of access to care, the different sectors 
through which care is delivered and the quality of care provided, and to estimate the effect of overcoming 
these barriers. 
 Chapter 2: I review the literature and consider interventions to overcome the health systems 
barriers to successful malaria treatment 
 Chapter 3:  I develop through an iterative process malaria transmission models incorporating 
health systems variables including the treatment of non-malarial febrile illness, private sector 
outlets and tertiary level management of severe disease. 
 Chapter 4: I develop a decision-tree approach to estimating quality of care and explore the 
impact of improving appropriate treatment for fever on malaria and non-malarial febrile illness 
(NMFI) case management  
 Chapter 5: I use the models developed in Chapters 3 and 4 to explore the impact of health 
systems interventions on transmission and clinical outcomes in a mainland Tanzania case study 
 Chapter 6: I discuss the implications of the model findings with respect to health systems 
interventions in malaria control programmes regionally and nationally 
Throughout this thesis I aim to demonstrate that mathematical models provide an ideal framework to 
examine the complexities of health systems strengthening, enabling the synthesis of data and practices from 
across different disciplines and regions, and having a role in guiding malaria control policy. 
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2 OVERCOMING HEALTH SYSTEMS BARRIERS TO SUCCESSFUL MALARIA 
TREATMENT 
2.1 INTRODUCTION: THE CONUNDRUM OF HEALTH SYSTEMS 
Over the past ten years, rapid scale-up of preventative interventions against malaria have resulted in 
substantial declines in the burden of disease (WHO, 2011a). Whilst such trends are encouraging, the risks of 
malaria morbidity and mortality remain influenced by the performance of prevailing health systems (Stratton 
et al., 2008, de Savigny D, 2009). The success of national malaria control programmes is increasingly 
recognised to be handicapped not only by resource constraints but also by the absorptive and technical 
capacities of the health systems to deliver interventions at the required levels of coverage and quality (WHO, 
2011a, de Savigny D, 2009). Given that international funding for such programmes is expected to plateau, it 
is critical to better understand how to implement a proven intervention most effectively through an existing 
system, and where the barriers are to an intervention achieving its predicted potential (WHO, 2011a, Alonso 
et al., 2011a). 
The failure of previous 'vertical' attempts to eradicate malaria (1955 – 1969) illustrates that sustained 
disease control requires integration into a functioning and efficient health system (Stratton et al., 2008, de 
Savigny D, 2009, Alonso et al., 2011a). Although substantial progress has been made in understanding the 
strengthening of health systems, much of the evidence is context-specific, descriptive or qualitative. High 
quality evidence on the effectiveness of strengthening interventions into health systems and their resulting 
impact on health outcomes remain limited.  
There have been few approaches to address the delivery of case management.  The 'systems effectiveness 
framework' (Tanner M 1993) outlined by Tanner et al. describes how interventions decay in efficacy and are 
rendered less effective in practice through a cascade of interacting system barriers.  This may be applied in 
the context of anti-malarial delivery (Figure 11): first-line treatment for malaria, Artemisinin Combination 
Therapies (ACTs), are highly efficacious, but issues such as the proximity of healthcare or availability of 
diagnostics may exert a sequential and cumulative impact leading to low ACT effectiveness i.e. less than 50% 
of febrile children being cured (WHO, 2011a). 
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Figure 11: Illustration of the systems barriers to effectiveness for treatment of children under five with fever 
Using this framework of barriers to effectiveness, I summarise potential systems constraints into two main 
categories:  
(i) timely access to healthcare  
(ii) quality of care at the source of treatment (including human resources, drug stocks and the use of 
diagnostics), 
and review their impact on the implementation of ACT programmes considering both public and private 
sectors. Additionally, I present a systematic summary of the effectiveness of interventions deployed to target 
the identified barriers in both the private and public sectors. 
 
  
30% febrile U5 year 
olds receive treatment 
(WHO 2011: median 
Africa region)
74% ANC coverage: proxy for access 
to primary care: (WHO 2011: mean 
Africa region)
30% acute 
febrile U5 
taken to health 
facility (World 
Malaria report  
2011: mean 
Africa region)
45% febrile attendees 
tested for malaria (World 
Malaria report 2011: mean 
Africa region)
82% clinics have ACT in 
stock on survey day [29]
46 % staff at primary care 
facility trained in malaria 
management and ACT use [21]
100%
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2.2 METHODS 
2.2.1 Search strategy and selection criteria 
From September – November 2011, I searched PubMed, Embase and Ovid Journals databases to identify 
peer-reviewed articles. I used the following search terms and their variations (i.e. Artemisinin Combination 
therapy and ACT) in combination: “Africa”, “malaria”, “falciparum”, “health systems”, “delay”, “distance”, 
“healthcare worker”, “ACT/Artemisinin Combination Therapy”, “antimalarial”, “treatment”, “health facility”, 
“community health worker”, “home management”, “service delivery”, “travel”, “testing”, “microscopy”, 
“RDT/Rapid Diagnostic Test”, “private”, “diagnostics”, “drug seller”, “drug shop”, “subsidy”, “AMF-m”, 
“underdiagnosis”, “overtreatment”, “delivery”, “supply chain”, “stockout”, “staffing”, “shortage”, “training”, 
quality”, counterfeit” and “pharmacy”.  Searches were limited to English-language articles published 
between January 1981 and November 2011. Additional publications not found in the electronic searches 
were selected from bibliographies of relevant articles and literature reviews. A formal review protocol was 
not utilised. 
2.2.2 Data extraction and analysis 
The abstracts of the identified articles were screened for inclusion: I included randomised controlled trials, 
quasi-experimental trials, observational and qualitative studies as well as reports from health agencies, e.g. 
WHO World Malaria Report. I excluded conference abstracts, editorials, letters to the editor, and other grey 
literature. I also excluded studies on pregnant women, or intermittent malaria treatment programmes. 
Although “Asia” was not included in the search terms, studies based outside Africa were not excluded. 
Selected papers were then stratified as either a) summarising barriers to effectiveness or b) reporting on an 
intervention to improve effectiveness, particularly focussing on studies including the recent WHO diagnostics 
guidance. For each paper I extracted the following items: study year, country and district/setting, age group, 
type of study population.  
Under the reports of impact of barriers to effectiveness I extracted data under the following headings: 
distance to healthcare setting with respect to treatment seeking, delays in care and treatment outcomes, 
staffing levels and training, drug stockouts and quality of care (namely diagnosis and use of ACTs) in the 
public sector and private (informal) sector. The impact of user fees and cost of accessing care was not 
considered.  For impact of interventions I extracted data under the following headings: drug stockouts and 
supply chain management, rational case management, training of healthcare workers, community health 
workers, informal sector training and drug subsidies. 
Given the variety of ways in which the data were reported it was not possible to undertake any formal meta-
analysis of the results.   
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2.3 RESULTS 
In total, 135 articles were identified through the primary search of the databases and additional searching of 
reference lists (Figure 12). 
 
 
 
Figure 12: PRISMA diagram: literature search results 
 
2.3.1 Barriers to effectiveness 
2.3.1.1 Impact of geographical access, treatment seeking and delays  
The geographical distance travelled to access care varies widely across different national and regional 
settings, e.g. a median of eight kilometres in Ethiopia (Okwaraji et al., 2012) to two kilometres in Kenya 
(Feikin et al., 2009).  This is also dependent on transport infrastructure; for example, in parts of rural Ethiopia 
over 90% of children live more than 1.5 hours walk from a health centre (Okwaraji et al., 2012). Timely 
access (less than 24-48 hours after symptom onset) to treatment, especially for the lowest two economic 
quintiles, is a Roll Back Malaria and Abuja declaration target (RBM, 2005).  
The impact of distance on seeking treatment for fever differs by country and context. Most studies reviewed 
show a clear reduction in accessing treatment with increasing distance to a health facility, e.g. 13.9% per 
kilometre (Stock, 1983) to 34% per kilometre (Feikin et al., 2009) with access declining to low levels (<10%) 
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once the health facility is more than five kilometres from the home (Feikin et al., 2009). In addition, families 
that live further from primary care facilities wait longer to seek care for their febrile child than those living 
nearby, with a twofold increase in the odds of delay if the distance to healthcare was greater than 
approximately three kilometres (Getahun et al., 2010). 
The impact of distance as a barrier to treating malaria becomes apparent given the narrow time limits for 
malaria infections to develop more serious complications (Greenwood et al., 1987). Delays in seeking 
treatment can lead to disease progression requiring inpatient care. Individuals living in close proximity to 
primary health care services have reduced odds of malaria advancing from mild to severe disease (Feikin et 
al., 2009, O'Meara et al., 2009, Al-Taiar et al., 2008). O’Meara et al. found that the incidence of severe 
malaria more than doubled as travel time to the nearest primary care facility increased from ten minutes to 
two hours in Kenya (O'Meara et al., 2009). In 2002, a Malaria Indicator Survey of Papua New Guinea (Mueller 
et al., 2005) indicated that prevalence of infection was significantly lower in communities living within closer 
reach of a health facility (22.4% versus 35.6%)(Mueller et al., 2005).  Similarly in Côte D’Ivoire the presence 
of a healthcare facility was associated with protection against malaria infections (Raso et al., 2005).  
2.3.1.2 Quality of care 
2.3.1.2.1 Staffing and Training 
Staff shortages are frequently highlighted as a concern. In Kenya, ten of thirty-four public facilities had to 
close on the day surveyed due to staff absence (Chuma et al., 2010). A further Kenyan study of 36 
government facilities in 2008 (Wasunna et al., 2008) identified inadequate staffing as a barrier to adherence 
to ACT prescription guidelines, due to additional time required for counselling, direct observation of the first 
dose, record keeping, and confirming the diagnosis, as well as poor supervision and inadequate quality of 
training. None of the healthcare workers (HCWs) had been exposed to full training in the use of first-line 
ACTs, and only half had experience of the minimum intervention training package in one Kenyan study 
(Wasunna et al., 2010). Similar findings were reported in Uganda, Kenya, Angola and Zambia (Hamer et al., 
2007, Zurovac et al., 2008d, Zurovac et al., 2008c, Rowe et al., 2009a, Njogu et al., 2008). Rural and poor 
areas where the malaria burden is disproportionately high suffer the most critical gaps in trained HCWs 
(WHO, 2011a, Stratton et al., 2008, WHO, 2007).   
2.3.1.2.2 Stockouts 
Effective and sustained expansion of a treatment programme requires reliable and uninterrupted stocks. 
However, poor supply chain management is a common problem (WHO, 2007). In Africa, availability of 
essential medicines in the public sector is 29.4% compared to 54% in the private sector, albeit with diversity 
by country (Cameron et al., 2009). 
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Initially the proportion of public facilities stocking at least one form of ACT, by weight or dosing schedule, on 
survey day ranged from 51% (2004) (Zurovac et al., 2007) to over 95% (Rowe et al., 2009a, Njogu et al., 
2008), with 20% of health centres having no ACT stock (Kangwana et al., 2009). Up to 75% of facilities 
reported stockouts over the preceding 6 months with a median of 49 to 138 days with no stock (Njogu et al., 
2008, Zurovac et al., 2008d, Zurovac et al., 2008c, Zurovac et al., 2007). More recent studies show some 
improvement (Nyandigisi et al., 2011, O'Connell KA, 2011, Rowe et al., 2009a, Uzochukwu et al.), although in 
others the issue remains refractory (Noor et al., 2009, Kangwana et al., 2009, O'Connell KA, 2011). 
Bottlenecks leading to stockouts at the point-of-service include delays to delivery at a facility (8 – 105 days 
since ordering) (Lufesi et al., 2007, Zurovac et al., 2008c), poor forecasting at district and national levels, 
resource allocation, limited information systems, and lack of governance in national procurement (Windisch 
et al., 2011, Hensen et al., 2011). 
In a systematic review of six studies comparing facilities with ACT stock to those without, ACT prescriptions 
increased, and non-recommended prescriptions decreased in the presence of stock, however existence of 
stock did not ensure recommended treatment practice (Hensen et al., 2011). In a Ugandan study only 60% of 
those needing an ACT were prescribed it despite adequate stock (Zurovac et al., 2008d). Interviews with 
Kenyan rural HCWs revealed that nearly all rationed ACTs because of uncertainty in supply; with some 
admitting giving it to patients they felt were most 'deserving' of treatment (Wasunna et al., 2008). In both 
Uganda and Kenya, despite ACT stock difficulties, there was usually an excess of non-recommended 
antimalarials such as chloroquine or amodiaquine (Wasunna et al., 2008, Zurovac et al., 2008d). 
2.3.1.2.3 Underdiagnosis and Overtreatment 
Until recently presumptive treatment and syndromic management was advocated in WHO guidelines and 
national policies. This approach resulted both in overtreatment, ranging from 47% - 95% of patients with 
non-malarial febrile illness (NMFI) being treated with antimalarials (Hamer et al., 2007, Reyburn et al., 2004, 
Zurovac et al., 2008b, Rowe et al., 2009a, Nicastri et al., 2009, Nankabirwa et al., 2009, Okebe et al., 2010, 
Nyandigisi et al., 2011, Bastiaens et al., 2011), and in some cases under-diagnosis of malaria of up to 30-40% 
(Nankabirwa et al., 2009, Nicastri et al., 2009, Bastiaens et al., 2011). Overtreatment is often with non-
recommended antimalarials (Zurovac et al., 2008b, Noor et al., 2009), but may also involve ACTs, with 
between 5.7% and 63.7% of those untested or with negative test results receiving first-line treatment 
(Okebe et al., 2010, Rowe et al., 2009a, Hamer et al., 2007, Nyandigisi et al., 2011, Zurovac et al., 2008b).  
Non-adherence to test results can be detrimental to those patients who are not parasitaemic. A Tanzanian 
study found the case fatality rate in test negative patients to be significantly higher (12.1%) than for test 
positive (6.9%), and over 60% of NMFI were not treated appropriately with antibiotics (Reyburn et al., 2004). 
46 
 
Diagnostic capacity has increased over time; in Zambia 17% of public facilities surveyed in 2004 had access to 
diagnostic facilities for malaria, rising to 73% by 2006, mainly due to the introduction of RDTs (Zurovac et al., 
2008d, Hamer et al., 2007). In other countries diagnostic capacity ranged from 25% to 100% of facilities 
surveyed (Nankabirwa et al., 2009, Zurovac et al., 2008c, Rowe et al., 2009a, Noor et al., 2009). However, 
testing of febrile patients before treatment has been limited (Rowe et al., 2009a, Zurovac et al., 2008b, 
Nankabirwa et al., 2009, Okebe et al., 2010, Noor et al., 2009, Bastiaens et al., 2011) and varies widely 
between and within countries (e.g., 11% in one district of Tanzania to 99% in other districts)(Bastiaens et al., 
2011).  Nankabirwa et al. showed low utilisation of diagnostic tools and reliance on clinical symptoms in high 
transmission areas of Uganda led to almost 40% of children under five years (U5s) not being diagnosed or 
treated despite being parasitaemic (Nankabirwa et al., 2009). 
The under-treatment of confirmed cases is recognised at low levels (0.7-3.8%) (Zurovac et al., 2008d, 
Nyandigisi et al., 2011, Zurovac et al., 2008b, Rowe et al., 2009a, Nicastri et al., 2009, Bastiaens et al., 2011), 
but one Tanzanian study showed up to  18.8% (Nicastri et al., 2009) of patients with a positive diagnostic test 
were not treated with any antimalarial medication. 
2.3.1.2.4 Informal sources of treatment 
Informal sources for antimalarials, ranging from drug shops and pharmacies to general village stores and 
itinerant peddlers, are often geographically closer to home (Alba et al., 2010a, Abuya et al., 2007), less 
expensive to the individual (Kangwana et al., 2011, Chuma et al., 2010, Amin et al., 2003), more likely to 
have drugs in stock (Alba et al., 2010b), and can be perceived as being of better quality than public facilities 
(Patouillard et al., 2010, Goodman et al., 2007a, Rowa et al., 2010). The legal status of private retail outlets 
differs by country but most are not formally licensed to dispense malaria treatment (Goodman et al., 2007b, 
Goodman et al., 2007a). Generally drug retailers are unskilled workers with limited knowledge of the drugs, 
dosages and how to store them appropriately (O'Connell KA, 2011, Abuya et al., 2007, Patouillard et al., 
2010, Goodman et al., 2007a), although in some cases government HCWs may work in drug shops 
(Patouillard et al., 2010, Goodman et al., 2007a). As a result antimalarials are often incorrectly prescribed or 
overprescribed presumptively for NMFI (Kangwana et al., 2011, Noor et al., 2009, Uzochukwu et al., Ringsted 
et al., 2011, Alba et al., 2010a, Littrell et al., 2011b, Littrell et al., 2011a). Sumba et al. found the likelihood of 
full recovery following a febrile illness was significantly less for those who attended private outlets (37%) 
compared to public facilities (85%) (Sumba et al., 2008). 
Private outlets are run as businesses and hence have perverse incentives (Ringsted et al., 2011). The patient 
is a client wanting an affordable product, even if potentially less effective. The seller wants a satisfied 
customer, but also needs to sell a product regardless of actual need. If appropriate diagnostics are deployed 
to confirm the diagnosis, sellers lose their profit margin from dispensing antimalarials (Rowa et al., 2010, 
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Abuya et al., 2010). Two related qualitative Ugandan studies found that although community acceptability of 
RDT use was high regarding improving access to effective treatment of malaria, there were fears that drug 
shops would compensate by overpricing RDTs and not adhere to the results (Chandler et al., 2011, Mbonye 
et al., 2010). 
There is good evidence of extensive distribution through the informal sector of antipyretics, substandard or 
counterfeit antimalarials, and artemisinin monotherapy or chloroquine as first-line treatments, although 
with substantial variation regionally (O'Connell KA, 2011, Kaur et al., 2008, Littrell et al., 2011a, Bate et al., 
2008, Newton et al., 2006, AMFm Independent Evaluation Team, 2012, Littrell et al., 2011b). A recent survey 
by ACT Watch (including DRC, Uganda and Zambia) confirmed that availability of ACTs is particularly low in 
the private sector, while less effective drugs and artemisinin monotherapy are often readily available (Littrell 
et al., 2011b, Littrell et al., 2011a, O'Connell KA, 2011). Quality assured ACTs (QAACTs) represented less than 
20% of the antimalarial market (Kangwana et al., 2011, O'Connell KA, 2011, AMFm Independent Evaluation 
Team, 2012, Ringsted et al., 2011). ACTs are also priced higher in the private sector compared to other 
antimalarials, despite this being the most common point of access.  Recent studies report that older 
treatments such as chloroquine remain very cheap (under one US dollar), whilst ACTs were 4 – 22 times 
more expensive than the most commonly dispensed antimalarial in the private sector (a non-artemisinin 
based treatment in all countries surveyed) (O'Connell KA, 2011, AMFm Independent Evaluation Team, 2012). 
2.3.2 Interventions to improve quality of care 
2.3.2.1 Reducing stockouts 
Evidence of interventions at scale that lead to improved stock at the facility level is scarce (Table 1). A study 
in 24 Zambian districts demonstrated the use of a commodity planner within the district logistics team 
coupled with direct central monthly ordering and pre-packed drugs tailor-made for each facility increased 
the availability of paediatric ACTs to 88% compared with 51% in districts with no intervention. Similar 
improvements were seen for other essential medicines. Stockouts were almost eliminated in some cases, 
with scale-up of this supply chain model estimated to reduce child malaria deaths by 37% (WorldBank, 
2010). 
More recently, mobile phone technology has been applied to supply chain management, albeit limited to 
small studies. In Uganda, a short message service (SMS) reporting system deployed by the government 
resulted in over 85% of the facilities reporting weekly, although ACT stockouts remained at 54% (Asiimwe et 
al., 2011). Promisingly, a Tanzanian study using mobile phones to improve stock-counts showed a substantial 
reduction in the proportion of facilities without any antimalarials from 78% at baseline to 26% at follow-up, 
with stockouts eliminated by week eight in one district (Barrington et al., 2010). Furthermore, a Kenyan 
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study evaluating the use of SMS reporting for stocks of ACTs and RDTs found a reduction in the stockout of 
one or more ACT packs by 38% at the end of the 26 week period, and a decline in RDT stockouts by 24%. 
Importantly, district managers also responded to address to 44% of ACT and 73% of RDT stockout signals 
(Githinji S, 2013).  
Indirect interventions may also improve supply. The introduction of subsidised ACTs in the private sector was 
associated with decreased public-sector stockouts in Kenya, Madagascar, Niger, Nigeria, Tanzania, Uganda 
and Zanzibar, with ACT stock present more than 80% of the time in all except Nigeria and Niger (Alba et al., 
2010b, Alba et al., 2010a, Tougher et al., 2012). Improved stock levels in Tanzania were accompanied with a 
near fivefold increase in treatment seeking amongst adults (Alba et al., 2010a, Alba et al., 2010b). 
  
49 
 
Table 1: Interventions: improving quality of care in public health facilities 
Reference Country Setting Intervention Outcome Impact 
Improved stock management: reducing stockouts 
(WorldBank, 
2010) 
Zambia 24 districts: 8 to 
each intervention 
and 8 control (3 
arms) 
 Both models: logistics 
commodity planner at district 
level  
 Model A: health facilities place 
orders to districts that transfer 
the order to the central level. 
Procured drug kits 
disaggregated at central level 
and distributed to the district 
store for assembly and delivery 
to facilities 
 Model B: direct ordering 
monthly to central level and 
the drugs are packed at the 
central level in sealed packages 
tailor-made for each individual 
facility.  District only delivers to 
facilities. 
 Model A resulted in some 
improvement of drug 
availability in the health 
facilities 
 Model B intervention 
dramatically improved the 
availability of essential 
medicines: e.g. availability of 
paediatric ACT was up to 88%, 
compared with 51% in control 
areas 
 Similar improvements were 
seen for other essential 
medicines, such as antibiotics 
 
 Authors estimated that by 
2015 scaling up this supply 
chain model could reduce child 
malaria deaths by 37% 
 Scaling up: estimated to treat 
an additional 110 000 
children/ year and avert 5400 
child deaths/year  
 Considering improvements 
also in availability of other 
drugs – impact may be greater 
(Asiimwe et 
al., 2011) 
Uganda 2 districts: Gulu, 
Kabale – 147 
facilities 
Ministry of Health 
led  
 SMS-based malaria monitoring 
platform 
 Training at facility and district 
level 
 Set-up cost of $100 USD/health 
facility, local technician 
support of $400 USD per 
month, and a cost of $0.53  
USD/week/clinic 
 ACT stockouts: 54% Kabale and 
54% Gulu 
 RDT stockouts: 48% Kabale and 
71% Gulu 
 > 85% health facilities reported 
weekly and without monetary 
incentives or additional 
supervision 
 
 Potential to improve 
timeliness in reporting of 
specific, time-sensitive metrics 
at modest cost and to manage 
stock data at district level 
(Alba et al., 
2010a) 
Tanzania Kilombero and 
Ulanga districts and 
 Subsidy for ACTs: free for U5s 
and pregnant women and 
 After subsidised ACT 
introduced in 2007 – stocks 
 Treatment seeking amongst 
adults increased by 27% 
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Ifakara town – 10 
facilities 
subsidised price of TSH 300 
(USD $0.25) to others 
were high for >80% months 
observed (90/108 in 2007; 
88/108 in 2008) 
(unadjusted)   
 Treatment seeking adjusted 
for socioeconomic status: 
nearly five-fold increase 
(OR=4.6 p=0.001) 
(Barrington 
et al., 2010) 
Tanzania 3 rural districts: 
Lindi, Kagama, 
Ulanga – 129 
facilities 
(Novartis led) 
 SMS management tool and a 
web-based reporting tool 
 Training at national, district 
and facility levels 
 21 week pilot study 
 Involved 2 weight specific ACT 
packs and injectable quinine  
 95% mean facility response 
rate to SMS requests for stock 
data 
 94% accuracy of stock reports  
 Decrease in facilities with 
stockout of one or more ACTs: 
78% (baseline) to 26% (week 
21) 
 In one rural districts: stockouts 
virtually eliminated by week 8 
 Overall: ACT stocks increased 
by 64% and quinine stock 
increased 36%  
 Use of simple SMS technology, 
via a public-private partnership 
model may be effective 
 
(Githinji S, 
2013) 
Kenya 5 rural districts: 
Machakos, 
Msambweni, Ijara, 
Manga, Vihiga – 87 
public health 
facilities  
 SMS management tool and a 
web-based reporting tool 
 26 week study 
 Training at facility and district 
levels 
 Involved 4 weight specific ACT 
packs and RDTs 
 97% mean facility response 
rate 
 79% accuracy of stock reports 
but 93% accuracy of stockout 
reports 
 38% decrease from baseline to 
26 weeks in stockouts of one 
or more ACT packs 
 Total stockouts reduced by 5% 
 RDT stockouts reduced by 24% 
 District managers responded to 
44% of ACT stockout and 73% 
of RDT stockout signals 
 Incentives were used to 
encourage reporting: may 
introduce reporting bias 
 Web-based platform was 
regularly accessed by national 
and district level teams: 
possibility of better integration 
between levels and 
surveillance-response 
 Important impact on RDT 
stocks also 
Impact of rational (diagnosis-led) case management 
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Reference Country Setting Intervention Outcome Impact 
1) Testing of over 5 year olds whilst presumptive treatment of under five year olds 
(Zurovac et 
al., 2008c) 
Kenya 3 districts: Bondo, 
Siaya, Kericho - 60 
health facilities, 
1540 patients (as 
below) 
 Modelling implications of 
rational case management  
 Primary data from Skarbinski 
2009 (below) 
 Policy: RDT use in all  over 5 
year olds and treatment with 
first-line ACTs  
 High transmission: 61% less 
overtreatment and 21% lower 
costs but potential for 8% 
increase undertreatment 
 Low transmission: reduction in 
undertreatment errors (36% 
less – but low numbers) but 
increase in costs by 41% 
 High transmission: majority 
patients would not be 
correctly treated with ACTs 
despite RDT use 
 High & low transmission: 
adherence to guidelines has 
potential to decrease 
treatment errors with 
acceptable costs 
(Skarbinski et 
al., 2009) 
Kenya 3 districts: Bondo, 
Siaya, Kericho - 60 
health facilities, 
1540 patients 
 Cluster RCT: RDTs plus training, 
guidance and supervision (TGS) 
or TGS alone  
 Policy: RDT use in all over 5 
year olds and treatment with 
first-line ACTs 
 100% RDT availability in 
intervention facilities 
 9%  RDT negatives given ACT 
 Overtreatment low in both 
arms and not significantly 
reduced by RDT provision: 12% 
(p = 0.3) 
 Presumptive treatment 
reduced: 36% (p =0.03) 
 88% RDT positive treated with 
ACTs (vs. 51% of smear-
positive treated with ACTs) 
 RDTs could improve case 
management but more 
effective implementation 
strategies for guidelines 
required 
(Masanja et 
al., 2012b) 
Tanzania Ifakara district (14 
facilities) pre-RDT 
implementation 
and Rufiji district 
(16 health facilities) 
post-RDT 
implementation 
 Policy change: over 5  year 
olds  to be treated after 
use of RDT if possible to 
guide decision making 
 12.6% increase in febrile 
patients tested (p=0.05)  
 7% all test-negatives treated 
with antimalarials (7.8% RDT 
negative): 7.6% reduction from 
pre-baseline (significant only 
for RDT) 
 Overtreatment reduced: 39.1% 
to 24.7% (p=0.01) 
 83.2% RDT-positives treated 
with ACT vs. 41.7% microscopy-
 High adherence to test result 
in rural settings possible 
 Impact of RDTs limited by 
overall low levels of 
appropriate testing 
 Greater impact during high 
transmission season 
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positives 
(Juma and 
Zurovac, 
2011) 
Kenya National cross 
sectional cluster 
survey: 88 facilities 
with diagnostics 
(1096 patients) and 
71 facilities no 
diagnostics (880 
patients) 
 Kenyan national guidelines 
change promoting ACTs and 
parasitological diagnosis in  
over-5 year olds 
 Presumptive treatment 
remained policy in U5s 
 Only results in over-5 age 
group given 
 At facilities with diagnostics: 
53.7% tested (CI: 45.4-61.9) 
 32.8% with negative test 
received ACTs (50.4% of 
negative test received some 
antimalarial treatment) 
 58% untested received ACTs 
 86.5% test-positives received 
ACTs  
 1.2% RDT positives did not 
receive any antimalarial 
treatment 
 ACT use prevailed in all age 
groups 
 Overtreatment remained 
despite test provision 
 Use of diagnostics remained 
limited 
(Ishengoma 
et al., 2011) 
Tanzania 2 districts: 
Korogwe and 
Muheza.  
Longitudinal 
passive detection 
in 6 villages in 
Korogwe and cross 
sectional survey in 
6 villages in both 
districts 
 Supply of RDTs: – 
comparing performance of 
RDT use to microscopy 
with respect to treatment 
 Sensitivity and specificity of 
RDTs in longitudinal study: 88.6 
(87.5-89.7) and 88.2 (87.7 – 
88.7) 
 Sensitivity and specificity of 
RDTs in cross sectional surveys: 
63.4 (59.8 – 67.1) and 94.3 
(93.6 – 95) 
 Using RDTs reduced 
antimalarial dispensing in over-
5 year olds from 98.9% to 
32.1% 
 Post RDT: 3.4% negative RDTs 
in over 5-year olds were 
treated  
 Pre-RDT period: 1.4% (79) 
cases not treated with 
antimalarials including 0.3% 
(19 – including 11 U5s) that 
were slide positive 
 Variation in sensitivity and 
specificity of RDTs depending 
on fever and parasite density 
 RDTs reduced overtreatment 
significantly. 
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Post RDTs: 0.8% (108) over-5 year 
olds not treated with ACTs 
(Zurovac et 
al., 2008a) 
Kenya 3 districts: Bondo, 
Siaya, Kericho - 60 
health facilities, 
1540 patients (as 
below) 
 Modelling implications of 
rational case management  
 Primary data from Skarbinski 
2009 (below) 
Policy: RDT use in all  over 5 year 
olds and treatment with first-line 
ACTs  
 High transmission: 61% less 
overtreatment and 21% lower 
costs but potential for 8% 
increase undertreatment 
 Low transmission: reduction in 
undertreatment errors (36% 
less – but low numbers) but 
increase in costs by 41% 
 High transmission: majority 
patients would not be 
correctly treated with ACTs 
despite RDT use 
 High & low transmission: 
adherence to guidelines has 
potential to decrease 
treatment errors with 
acceptable costs 
2) Universal testing and treatment: all ages 
(Njama-
Meya et al., 
2007)  
Uganda 601 children 
between 1-10 
years recruited 
from census 
population & 
followed in study 
clinic 
 Standard microscopy 
performed if fever – and 
treated only if smear positive 
 6 of 1608 smears falsely 
identified as negative – of 
which 4 went onto develop 
uncomplicated malaria and 2 
cleared parasites without 
treatment 
 13/1602 negative smears 
developed malaria within 7 
days (0.8%) – all uncomplicated 
 32% febrile episodes were 
malaria 
 Withholding treatment on the 
basis of negative smear was 
safe 
 Saved >1600 treatments in 601 
children over 18 months 
(Msellem et 
al., 2009) 
Zanzibar 4 health facilities: 
1187 patients 
 Crossover validation trial 
Comparing clinical diagnosis with 
RDT-aided treatment 
 RDT use associated with lower 
ACT prescription than clinical 
diagnosis: OR – 0.04 (CI: 0.03 – 
0.05, p<0.001) 
 Prescription of antibiotics 
higher after RDT use: OR – 1.8 
(CI 1.5 – 2.2, p<0.001) 
 Re-attendance due to 
perceived unsuccessful cure: 
lower after RDT consultation 
than clinical diagnosis: OR– 0.5 
(CI 0.3 – 0.9, p=0.005) 
 Total average cost per patient 
was similar: USD 2.47 in RDT 
consultation vs. 2.37 for 
clinical diagnosis 
 Some risk of undertreatment if 
RDT false-negative 
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 28/552 smear-positive not 
treated (of which 26 due to 
false-negative RDTs) 
(Mosha et 
al., 2010) 
Tanzania 2 districts: Same 
and Korogwe 
Methods included 
– routine health 
information data, 
health facility cross 
sectional RDT 
survey (8 facilities) 
and passive 
surveillance of 
cohort childhood 
morbidity 
 Modelling cost implications of 
improving diagnosis in children  
 Primary data: RCT of different 
antimalarials for intermittent 
preventative treatment of 
malaria in infants (IPTi: Gosling  
et al Lancet 2009) 
 Comparison of routine care vs. 
RDT aided care 
 Overdiagnosis of malaria with 
routine care compared with 
RDTs: highest in U5 in low 
transmission sites (RR 17.9; CI 
5.8 – 55.3) and then over 5s in 
low transmission site (RR 14.0; 
CI 8.2 – 24.2) 
 Less overdiagnosis risk in 
moderate transmission 
comparing routine vs. RDT (RR 
2.2 in U5 and 4.2 in over 5s) 
 Higher proportion diagnosed 
with respiratory infections in 
under 2 year old RDT cohort vs. 
routine care (42% vs. 26%, 
p<0.001) 
 In low transmission: 
proportion of morbidity 
attributed to malaria was 
lower in under 2 year olds RDT 
cohort compared to routine 
care: 0.08% vs. 28.2% 
(p<0.001) 
 Use of RDT reduced overall 
drug and diagnostic costs: 10% 
in moderate transmission and 
15% in low transmission 
compared with routine care 
 
(d'Acremont 
et al., 2010) 
Tanzania Urban (Dar es 
Salam) and rural 
(Kilombero) - 
Prospective 2 arm 
study: 2 facilities – 
1000 children (603 
negative RDT) 
 No antimalarials if RDT was 
negative 
 Main outcome: occurrence of 
complications in untreated 
children 
 97% children symptom-free by 
day 7 
 600 /603 children were RDT 
negative when repeated after 7 
days 
 3/603 children with negative 
RDT later developed positive 
test within 7 days: no 
complication 
 4 children with negative RDT 
admitted to hospital (NMFI) 
 Not treating RDT negative 
children with antimalarials is 
safe even in U5s 
Impact: training of healthcare workers 
Reference Country Setting Intervention Outcome Impact 
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(Ngasala et 
al., 2008) 
Tanzania 2 districts: Kibaha 
and Bagamoyo: 16 
health facilities – 
3131 children 
 RCT: staff training in clinical 
diagnosis & microscopy vs. 
clinical training alone vs. no 
training 
 Antimalarial prescriptions did 
not significantly reduce in 
training alone arm (95.3% vs. 
99.5% untrained) 
 No difference in antibiotics 
prescriptions 
 No statistical significant 
difference in recovery rates or 
outcomes 
 Additional training and 
supervision did not result in 
any significant impact on 
improving malaria case 
management compared with 
untrained workers 
(Skarbinski et 
al., 2009) 
Kenya 3 districts: Bondo, 
Siaya, Kericho - 60 
health facilities, 
1540 patients 
 Cluster RCT: Training, guidance 
and supervision (TGS) alone vs. 
TGS and provision of RDTs 
 Baseline survey in both groups 
and follow up 
 Results presented here for 
impact of TGS only in control 
group 
 Increased ACT treatment of 
patients with uncomplicated 
malaria: 41% (p=0.05) 
(compared with reduction of 
22% in group with RDTs) 
 Reduction in treatment with 
non-recommended drugs: 46% 
(p=0.003) 
 No significant Increase in over 
treatment with ACT  
 Significant increase in use of 
RDTs: 11% (p<0.001) but no 
overall increase in diagnostic 
testing (any tool): 16% (p=0.07)  
 Overall no significant impact of 
Training, guidance and 
supervision (TGS) alone on 
prescription of ACTs according 
to diagnostic result or by 
clinical diagnosis 
(Rowe et al., 
2009a) 
Benin South eastern 
Benin: 1244 
consultations – 
survey in 1999 then  
 IMCI training plus additional 
study supports including 
supervision/ non-financial 
incentives vs. control group 
with only “usual” IMCI 
supports (job aids/limited 
supervision) 
 Baseline survey in 1999 and 
follow up in 2001 - 2004 
 Performance increased in 
intervention and control 
groups: no significant overall 
difference (but diluted by 
persistence of untrained IMCI 
workers) 
 Per-protocol analyses: IMCI 
training plus study support  
provided better care than 
those with “usual” supports 
 IMCI training is useful but 
insufficient for high levels of 
adherence 
 Additional supports can lead to 
additional improvements and 
are low cost 
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(27.3% improved; p<0.05) 
 Both groups outperformed 
untrained workers 
 Only 29% of supervision visits 
occurred 
(Wasunna et 
al., 2010) 
Kenya Bondo district: 22 
public health 
facilities, 48 HCW, 
386 febrile children 
 Enhanced in service training 
programme of HCW and 
provision of job aids re: new 
malaria management 
guidelines 
No follow up training or 
supervision 
 67% staff received the 
enhanced in service training 
(none received full package) 
Trained HCWs: no significant 
improvement in reported case 
management tasks 
May need to consider inclusion of 
supervision and post-training 
follow-up 
Abbreviations: ACTs: Artemisinin Combination Therapies; CI: confidence interval; HCW: healthcare worker; IMCI: integrated management of childhood illness; NMFI: non-malarial febrile illness; OR: 
Odds Ratio; PCR: Polymerase Chain reaction; RCT: randomised controlled trial; RDT: rapid diagnostic test; RR: Relative Risk; SMS; short message service; U5s: under 5 year olds. 
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2.3.2.2 Universal rational case management  
The 2010 WHO guidelines on the treatment of malaria state that whenever possible 'prompt parasitological 
confirmation by microscopy or alternatively by RDTs is recommended in all patients suspected of malaria 
before treatment is started'. This policy change towards universal 'test and treat' acknowledged the 
widespread overtreatment of malaria and the risk of spreading drug resistance or tolerance, the need for 
improved disease surveillance and better quality of care, including for NMFI (WHO, 2010a). 
As outlined above, implementing rational (diagnostic-led) case-management has proven difficult, especially 
at scale beyond trials under controlled conditions. Guidelines limiting treatment for children over five years 
to diagnosis-confirmed cases did not reduce unnecessary antimalarial use (Table 1), although ACT 
prescription for diagnostic-positive cases did improve (88-98.6%) (Juma and Zurovac, 2011, Skarbinski et al., 
2009, Ishengoma et al., 2011, Masanja et al., 2012b). However, recent studies have found increased 
emphasis on universal RDT use to be associated with reductions in unnecessary antimalarial treatments (up 
to 68% in several studies), albeit varying by transmission setting (D'Acremont et al., 2011, Bastiaens et al., 
2011, Nyandigisi et al., 2011, Msellem et al., 2009, Sserwanga et al., 2011, Ansah et al., 2010, Kyabayinze et 
al., 2010). Undertreatment of test-positive cases at low levels was documented in a few studies (Msellem et 
al., 2009, Bastiaens et al., 2011, Ansah et al., 2010). 
Several studies demonstrated that withholding antimalarials in test-negative cases does not result in 
increased malaria-related deaths or severe morbidity, even in U5s (d'Acremont et al., 2010, Mtove et al., 
2011b, Njama-Meya et al., 2007). Management of test-negative patients has also been shown to improve, 
with substantial decreases in antimalarial prescription and concomitant increases in prescription of 
antibiotics (odds ratio: OR = 1.45-1.8) (Msellem et al., 2009, Bastiaens et al., 2011, D'Acremont et al., 2011). 
However, it is unclear if the latter reflects correct antibiotic treatment. 
The cost implication of adding RDTs has been of concern although several studies show little difference 
compared to clinical diagnosis (Msellem et al., 2009, Mosha et al., 2010, Zurovac et al., 2008a, Batwala et al., 
2011). 
2.3.2.3 Training  
Delivering quality care depends on the capabilities and performance of HCWs. A 2009 review of 23 studies to 
improve HCW management of malaria confirmed very little is known about which interventions work (Smith 
et al., 2009b). Aside from two studies of Integrated Management of Childhood Illness (IMCI) which showed 
significantly improved appropriate treatment (Smith et al., 2009b), one public sector study demonstrated 
training, mainly of limited duration and in didactic or workshop format, was significantly associated with 
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recommended treatment of malaria when supplemented by additional inputs such as job aides or regular 
supervision. 
Recent trials show the link between levels of staff training and clinical performance is not straightforward 
(Table 1). In Uganda, patients were significantly less likely to receive malaria treatment if seen by formally 
qualified HCWs (Zurovac et al., 2008d). In some studies, diagnosis-based management of malaria with ACTs 
did not improve with in-service training, increased access to national guidelines, or provision of malaria wall 
charts (Zurovac et al., 2008d, Nyandigisi et al., 2011, Ngasala et al., 2008), however, in others pre-service and 
in-service training increased the likelihood of ACT prescription (Hamer et al., 2007).  In Kenya (Zurovac et al., 
2008c) and Uganda (Zurovac et al., 2008d) supervision of HCWs was associated with improved adherence to 
guidelines. Multiple surveys (Wasunna et al., 2010, Rowe et al., 2009b, Skarbinski et al., 2009) have found 
that uptake of training programmes is patchy and alone do not result in any significant improvements in case 
management, except a 46% reduction in the use of non-recommended drugs in one Kenyan study 
(Skarbinski et al., 2009).  
Outside malaria, a recent IMCI evaluation suggests frequent supervision and other non-financial 
incentivisation (framed certificates and acknowledgement in local media) may improve care (Rowe et al., 
2009b). 
 
2.3.3 Interventions to increase access 
2.3.3.1 Community case management and community health workers  
A number of countries are addressing the challenge of limited access to facilities in rural and poor areas by 
training local individuals to act as community health workers (CHWs), enabling integrated community case 
management of malaria (iCCMm) often with pre-packaged drugs (Christopher et al., 2011). Implementation 
of CCM programmes across Malawi, Mali and Zambia is estimated to improve effective access (i.e. access to 
a trained provider and to appropriate medicine) from 14% (9-17%) to 30-57% (Guenther et al., 2012). 
Two systematic reviews evaluating presumptive treatment of febrile children by CHWs have been published.  
Hopkins et al. (Hopkins et al., 2007) identified six studies, concluding CHW schemes could improve treatment 
delivery and adherence, especially for groups located far from formal facilities. A second review considered 
evaluations of CHW programmes delivering multiple paediatric treatments and included several studies 
showing reduction in all-cause paediatric mortality up to nine years after programme initiation (Christopher 
et al., 2011). Studies published since concur that CHWs in Africa can successfully provide presumptive ACT 
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treatment along with packages of preventive services in both rural and urban settings (Akweongo et al., 
2011, Staedke et al., 2009, Chinbuah et al., 2012, Kalyango et al., 2012, Rutebemberwa et al., 2012). 
More recent studies (Table 2) evaluating the performance of CHWs in delivering diagnostic-led management 
describe increased treatment-seeking (Yeboah-Antwi et al., 2010, Seidenberg et al., 2012, Elmardi et al., 
2009, Mukanga et al., 2012a) and no increased progression to severe disease (Lemma et al., 2010, Mukanga 
et al., 2012b). In addition, they document reduced overtreatment with ACTs (upto 96.8% adherence to RDT 
results seen in Tanzania (Mubi et al., 2011) ), and improved management of NMFI, including increased 
referral and appropriate treatment for pneumonia (Yeboah-Antwi et al., 2010, Mukanga et al., 2012b). Two 
studies showed a reduction in malaria incidence and parasite prevalence in areas covered by CHW 
interventions, although it is not clear the extent to which this was causal (Lemma et al., 2010, Tine et al., 
2011).  
Predictions of the cost effectiveness of CHW programmes using presumptive treatment vary. Only one study 
considered community level utilisation of RDTs, and found in Zambia the cost per case diagnosed and 
correctly treated was less by iCCM rather than facility-level management (Chanda et al., 2011a).  
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Table 2: Interventions: improving access through community case management of malaria (CCMm) 
Reference Country Setting Intervention Outcome Impact 
(Elmardi et 
al., 2009) 
Sudan South Kordofan 
state: 20 villages 
 Community volunteers  
trained in CCMm (RDT use 
plus ACT treatment) with 
supply from rural HC 
 30% CHW volunteers did not rely 
on negative RDT 
 Improved accessibility to ACTs: 
25% to 64.7% 
 Improved treatment seeking 
behaviour: 83.3% to 100% 
 Issue of overtreatment i.e. test 
negative patients treated 
 Community acceptance of 
programme 
(Yeboah-
Antwi et al., 
2010) 
Zambia Catchment area 
of Chikankata 
hospital: 
Siavonga and 
Mazubuka 
districts: 3215 
children with 
fever 
 Cluster RCT: CHWs with 
access to RDTs, ACTs and 
antibiotics (18) vs. CHWs 
relying on clinical diagnosis 
(19 - control) with access to 
ACTs only in the management 
of matched febrile U5 year 
olds 
 27.5% children in RDT arm 
received ACTs vs. 99.1% in control 
arm (RR 0.23; 95% CI: 0.14-0·38) 
 Non severe pneumonia: 68.2% 
children in RDT arm received 
early and appropriate treatment 
vs. 13.3% in control (RR 5.32; 95% 
CI: 2.19 – 8.94) 
 2 deaths in intervention arm vs. 1 
in control 
 Promising result for reduction in 
overuse of ACTs and increase early 
and appropriate treatment for 
pneumonia and other NMFI 
(Lemma et 
al., 2010) 
Ethiopia Tigray region: 2 
districts 
 2 year pilot study: ACT at 
clinic and CHW level – 50% 
access to RDTs in Year 2 vs. 
control : ACTs and RDTs at 
clinic only 
 Crude parasite prevalence at 
peak of transmission: 7.4% (CI: 
6.1-8.9%) in intervention district 
vs. 20.8% (CI: 18.7-23) in control 
 No difference in all-cause 
mortality (Incidence RR 1.03) 
 Risk of malaria specific mortality 
lower in intervention district 
(Incidence RR 0.6; 95% CI: 0.4-0.9; 
p=0.013) 
 Community based deployment of 
ACTs: reduced malaria 
transmission, lowered case burden 
for facilities and reduced malaria 
mortality and morbidity in study 
period 
(Chanda et 
al., 2011b) 
Zambia 2 districts: 
Chongwe (9 
CHWs for 16079 
populations) & 
Kalomo (7 CHWs 
for 18279 
 CHW as delivery points for 
ACT and RDTs for CCMm 
(adult and paediatric) 
 23 – 35.1% attended at CHW 
 99.2-100% uncomplicated malaria 
treated with ACTs  
 All severe malaria cases and non-
malaria fevers referred 
appropriately 
 Good community reception 
 High levels adherence to test result 
 CCMm more efficient than health 
facility level management 
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population)   Negative RDT cases not 
prescribed ACT: 99.4-100% 
 No progression to severe malaria 
or deaths 
 Cost per case correctly 
diagnosed: USD 4.22 for CCMm 
vs. USD 6.12 for facility level  
 Utilisation of diagnostics and 
adherence to results & guidelines 
higher with CHW than facility 
(Mubi et al., 
2011) 
Tanzania Kibaha District: 5 
villages, 22 
CHWs, 2930 
patients 
 Alternating cluster RCT: 
CHWs trained in RDT use and 
clinical diagnosis – randomly 
assigned to one method on 
alternating weeks 
 ACTs provided to 53.2% patients 
in RDT weeks vs. 96.5% patients 
in clinical weeks (OR 0·039; 95% 
CI: 0.029 – 0.053) 
 CHWs adhered to RDT results: 
96·8% patients (CI: 95.8 – 97.6) 
 Referral: 10% in RDT weeks vs. 
1·6% clinical weeks 
 Perceived non-recovery more 
common after RDT diagnosis 
 No severe or fatal malaria in RDT 
negative patients (not treated 
with ACTs) 
 4 deaths: 2 test positive and 
treated with ACT, 2 RDT negative) 
 Opportunity for improved access, 
timely treatment and improved 
NMFI treatment 
(Tine et al., 
2011) 
Senegal Bocconto health 
post: 8 villages, 
12 CHWs, 1000 
children 
 RCT : CHW trained in CCMm 
(oral for uncomplicated and 
pre-referral rectal for severe 
malaria) compared to this 
plus some CHWs able to 
administer monthly 
intermittent preventative 
therapy to children (IPTc) 
 Incidence of malaria episodes: 
7.1/100 child months at risk (95% 
CI: 3.7-13.7) in IPTc plus CCMm 
communities vs. 35.6/100 child 
months at risk (95% CI: 26.7-47.4) 
– OR 0.2; 95% CI: 0.09 – 0.41; 
p=0.04 
 Parasitaemia prevalence lower in 
communities with IPTc plus 
CCMm (2.05% vs. 4.6%; p=0.03) 
 CHWs are able to deliver both 
CCMm and IPTc 
 Combining these interventions can 
provide significant additional 
benefits 
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 Adjusted OR shows protective 
effect of IPTc plus CCMm against 
anaemia (OR=0.59; 95%CI: 0.42-
0.82; p=0.02) 
(Mukanga et 
al., 2012a) 
Uganda Iganga district: 
423 households 
from 7 villages 
with U5s 
 Semi-structured 
questionnaire for caregivers 
 Acceptability survey following 
one year use of RDTs by 
CHWs in CCM programme 
 86% households lived within 1km 
of CHW home vs. 25% within 1km 
of health facility 
 Households further than 1km 
from facility were more likely to 
use a CHW (OR: 1.72; 95% CI: 
1.11-2.68) 
 89% acceptability of CHWs using 
RDTs 
 CHW programmes increase access 
and were the first choice for more 
than 50% of caregivers sampled  
(Mukanga et 
al., 2012b) 
Burkina 
Faso, 
Uganda, 
Ghana 
Multicentre: 12 
villages in Burkina 
Faso, 16 villages 
in Ghana and 14 
in Uganda 
4216 febrile 
children 
 Open cluster RCT:  two-arm  
 Comparing CHWs 
programmes with diagnostic 
tests, ACTs and antibiotics vs. 
presumptive diagnosis and 
ACTs (plus antibiotics in 
Ghana) 
 High compliance with RDT results 
 4.9% RDT negative children given 
ACTs 
 Antibiotic overuse was common 
in Burkina Faso and Ghana for 
children who were RDT negative 
but also no increased respiratory 
rate 
 RDT use by CHWs limits overuse of 
ACTs 
 Unclear re: impact of diagnostic 
tools by CHW (respiratory rate) on 
antibiotic use 
 No increased fever persistence due 
to use of diagnostic tools 
(Seidenberg 
et al., 2012) 
Zambia Catchment area: 
Chikankata 
Mission Hospital: 
440 women from 
62 villages 
 Cluster RCT: CHWs with A) 
diagnostic tests and ACTs vs. 
B) presumptive diagnosis and 
ACTs 
 Household surveys of 
caregivers of U5s 
 In both arms increase in care 
seeking from CHWs (Relative risk 
1.39 in CHW A and 1.55 in B) 
 Decrease in care seeking at health 
facility and traditional healers 
 For severe symptoms (e.g. 
difficult breathing): increase in 
CHW utilisation only seen in CHW 
with diagnostics areas (A) 
 CHW programmes can reduce 
burden on health facilities 
 Availability of diagnostics increases 
treatment-seeking at CHWs for 
severe symptoms 
Abbreviations: ACTs: Artemisinin Combination Therapies; CCMm: community case management of malaria; CHW: community health worker; CI: confidence interval; IMCI: integrated 
management of childhood illness; IPTc: intermittent preventative therapy for children; NMFI: non-malarial febrile illness; OR: Odds Ratio; PCR: Polymerase chain reaction; RCT: randomised 
controlled trial; RDT: rapid diagnostic test; RR: relative risk; SMS; short message service; U5s: under 5 year olds. 
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2.3.3.2 Targeting the private sector  
Training programmes targeting the performance of private sector drug outlets are included in two 
systematic reviews undertaken prior to RDT introduction (Goodman et al., 2007a, Smith et al., 2009b). In 
both, visual aids and on-site supervision aimed at informal providers were shown to improve performance. 
However, both reviews emphasise the difficulty in incorporating actors operating outside traditional 
regulatory frameworks into treatment programmes, and sustaining behaviour change. Since then, studies 
have further shown training can improve the performance of private retailers; in Kenya trained retailers 
were more likely to sell the correct dose of antimalarial (OR 9.4 in one region and OR 53.5 in another) (Abuya 
et al., 2010), and formally accredited training can reduce the numbers of unregulated drug shops, as shown 
by the Accredited Drug Outlet (ADDO) scheme in Tanzania (Alba et al., 2010a, Alba et al., 2010b) (Table 3).  
The price and quality of ACTs has been a barrier to effectively expanding their use in the private sector. In 
2009, the subsidy programme Affordable Medicines Facility for malaria (AMFm) was launched, seeking to 
reduce price through a co-payment facility, thereby increasing access to quality-assured ACTs (QAACTs) and 
driving out ineffective drugs (AMFm Independent Evaluation Team, 2012) (Table 3). The original AMFm pilot 
study in Tanzania showed significant increases in ACT market share (from 1% to 44.2% sales) (Sabot et al., 
2009), and a randomised controlled trial of subsidised ACTs in Kenya found an increased proportion of 
children receiving ACTs within 48 hours of fever (14.6% to 40.2%), with significant reduction in the use of 
antimalarial monotherapy (Kangwana et al., 2011). In both studies, the drug subsidy was passed to the end 
users. However, spatial analysis of the pilot showed subsidised ACTs were more likely to be stocked in shops 
closer to towns, major roads and with richer clientele, indicating that price reduction alone may not address 
inequities in access (Cohen et al., 2010). One early evaluation from Kenya showed the subsidy was passed to 
customers, but only 11% of drug shops surveyed stocked the subsidised brand (Smith et al.). Two recent 
independent evaluations of AMFm (Phase One) concluded that dramatic increases in QAACT availability 
(26.3-71.3% increase), market share (30-58.7% increase) and affordability had been seen in almost all pilot 
sites (except Niger and Madagascar) with reductions in availability of artemisinin monotherapy, although 
diagnostics stock remained low (AMFm Independent Evaluation Team, 2012, Tougher et al., 2012). 
The Consortium for ACT private sector subsidy (CAPSS) study in Uganda also piloted an AMFm subsidy 
approach to investigate whether access to QAACTs in the private sector could be improved.  Evaluation at 2 
years found increased market share with ACTs accounting for 69% of antimalarial purchases in pilot areas. 
The odds of purchasing an ACT within 24 hours of symptoms onset in an intervention region compared with 
control areas was 6.11 (95% confidence intervals: 4.32-8.62; p<0.0001)(Talisuna et al., 2012). 
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Table 3: Interventions: improving access and quality of care in the informal private sector 
Reference Country Setting Intervention Outcome Impact 
Training of private sector providers 
(Abuya et al., 
2010) 
Kenya 2 districts: 
Kwale and Kisii 
 2 training initiatives for 
private sector retailers 
(PMRs): i) Kwale: 2 day 
Ministry of Health 
training, per diems, no 
follow up plus 
community education ii) 
Kisii: 3 day NGO training, 
per diems and follow up 
visits but no community 
education 
 Kwale: 18.8% trained PMRs sold 
correct dose vs. 2.3% untrained (OR 
9.4; 95% CI: 1.1-83.7) 
 Kisii: 60.5% trained PMRs sold 
correct doses vs. 2.8% untrained (OR 
53.5; 95%CI: 6.7-428.3) 
 Kwale: programme coverage 25.3% 
outlets 
 Kisii: programme coverage 69·7% 
outlets 
 Kwale: potential utilisation of 
48,000 U5s Kisii: potential 
utilisation of 30,000 U5s 
(Alba et al., 
2010b) 
Tanzania Kilombero and 
Ulanga DSS and 
Ifakara town 
 National scheme: 
training accredited drug 
dispensing outlets 
(ADDOs) 
 Subsidised ACTs 
available at ADDO level 
 Increased proportion of cases 
treated with an antimalarial:  31% 
(47/154) in 2004 to 43% (54/127) in 
2008 (Odds ratio OR: 1.68; p=0.038) 
o Confounded by SES (adjusted 
Odds ratio = 1.18; p=0.632) 
and decreased in poorest 
quintile 
o Increase was in patients over 
age 5 (38% in 2004 to 52% in 
2008) and not U5 (25% - 
28%) 
 ACTs supply: 2% in 2006 
(unsubsidised) to 29% in 2008 
 ACT stock in urban area than rural: 
38.1% in Ifakara vs. 20-25.9% in rural 
drug shops 
 Reduction in market share of SP: 64% 
(2005) to 51% (2008): ACT 17%  in 
2008 
 Availability of ACTs is needed 
for subsidy scheme to take 
effect 
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 Reduction in Artemisinin 
monotherapies found: urban - 20% 
outlets (2007) to 12% (2008) 
AMFm and ACT subsidies 
(Sabot et al., 
2009) 
Tanzania 2 districts: 
Maswa and 
Kongwa plus 
Shinyanga 
district as 
control 
 AMFm subsidy pilot: 
ACTs at 90% subsidy 
through private supply 
chain reviewed Aug 
2007 upto Aug 2008 
 Increased stocking of ACTs: 0% - 72% 
(p<0.001) 
 % customers purchasing ACTs rose 
from 1% baseline to 44.2% at 1 year 
(p<0.001) 
 Increase in ACT purchase for U5s 
significantly higher than for adults 
(p=0.005) 
 No change in control districts 
 Consumers paid mean USD 0.58 for 
ACT (similar to SP price) 
 Highly populated areas more likely to 
stock ACTs than remote (p<0.001) 
 Subsidy passed to consumers 
successfully 
 Price similar to other 
alternative antimalarials 
(Cohen et al., 
2010) 
Tanzania 2 districts: 
Maswa and 
Kongwa 
 AMFm subsidy pilot: 
reviewed at Nov 2007 
upto Nov 2008 
 Total ACT stocks rose: 55.8% -72.9% 
(SP unchanged) 
 % sales ACT: 31.5% - 39.3% (although 
total sales increased) 
 Geographic variation in stocking & 
sales: In shops closer to district town 
(p<0.01), major roads (p<0.01) and in 
those with higher SE clientele 
(p<0.01) 
 Overall increase in ACT 
availability  
 Similar geographic disparity 
patterns to other antimalarials 
need to be addressed 
 
(Kangwana 
et al., 2011)  
Kenya 3 districts – 
Busia, Butere-
Mumias, Teso 
 RCT comparing 
subsidised ACTs through 
private sector retailers 
with training and 
community awareness. 
No interventions in 
control arm 
 95.3% of those in intervention who 
bought ACTs purchased it at subsidy 
price (USD 0.25) 
 % children receiving ACT within 48 
hours of fever increased by 14.6% in 
control group vs. 40.2% in 
intervention (25% difference in 
means: 95% CI 14.1-35.9; p=0.0001) 
 Cost subsidy can increase ACT 
coverage  
 No significant difference in 
adequacy of dosing obtained 
or provided despite training in 
intervention arm 
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 Significant difference between 
groups in % children receiving 
antimalarial monotherapy (reduction 
-10.4%; 95% CI-3.9 to -16.9; 
p=0.0074) 
(Smith et al., 
2011) 
Kenya Webuye DSS 
area: 97 shops 
and 13 mission 
facilities 
 National AMFm subsidy 
scheme: review at 5 
months 
 ACT stocked by 44% retailers;  
 Quinine most stocked (61% 
shops),SP: 57% 
 47% retailers regularly report 
stockouts of all antimalarials 
 11% retailers stocked the subsidised 
brand ACT 
 Subsidised brands of ACT - mean cost 
USD 1.60:  40% less than non AMFm 
brands of ACT (mean cost USD 2.86) 
 Artemisinin monotherapies cost 
more than twice as much as subsidy 
brands (USD 5.40) 
 SP cost USD 0.50 compared to mean 
cost ACT (USD 2.7) 
 Cost subsidy is apparent for 
AMFm brands of ACT 
 Large difference still between 
effective and ineffective 
therapies 
(AMFm 
Independent 
Evaluation 
Team, 2012) 
Kenya, 
Niger, 
Ghana, 
Tanzania, 
Nigeria, 
Uganda, 
Madagascar, 
Zanzibar 
Evaluation of 
AMFm pilots in 
8 countries 
 National AMFm subsidy 
scheme; Phase 1 
evaluation 
 Of the 8 pilots, success benchmarks 
met in 5 pilots for availability & 
QAACT price relative to most popular 
non-QAACT antimalarial and 4 pilots 
for QAACT market share  
 Large increases in QAACT availability, 
decreases in QAACT prices, and 
increases in QAACT market share 
(except Niger and Madagascar) 
 Response similar in rural and urban 
areas 
 The price of co-paid QAACTs: variable 
across pilots, ranging from USD 0.51 
in Madagascar to USD 1.96 in Uganda 
 Subsidy schemes can result in 
increases in QAACT availability 
and affordability (seen in 
almost all pilot sites (except 
Niger and Madagascar) with 
reductions in availability of 
artemisinin monotherapy 
 However diagnostics stock and 
use in the private sector 
remained low 
 Impact was limited in 
Madagascar and Niger: 
possibly due to lack of full-
scale mass media campaigns 
and the structure of the 
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 In Nigeria and Zanzibar where 
artemisinin monotherapy was 
previously common,  large and 
significant falls were observed with 
AMFm 
private for-profit antimalarial 
sector (higher proportion of 
general stores, and in Niger 
itinerant vendors) 
  
(Talisuna et 
al., 2012) 
Uganda 
(CAPSS 
study) 
4 pilot districts: 
Kamuli, Kaliro, 
Pallisa, Budaka 
(104 public 
health facilities 
and >750 
private outlets) 
and 1 control 
district: Soroti. 
 
 As per AMFm approach 
i.e. subsidised ACTs with 
supporting interventions 
including provider 
training and demand 
generation. 
 QAACT accounted for 69% of market 
share in intervention districts  
 Purchase of ACT within 24 hours of 
symptom onset for U5s increased 
from 0.8% at baseline to 26.2% (95% 
CI: 23.2-29.2%)  
 Odds of purchasing ACT within 24h  
in intervention vs control district: 
6.11 (95% CI: 4.32-8.62; p<0.0001) 
 6-fold increase in all people 
(10-fold in U5) purchasing 
effective malaria treatment 
within 24 hours of symptom 
onset 
 70% caregivers who purchased 
ACT complied with treatment 
schedule 
 Affordable treatment drives 
availability and uptake 
(Tougher et 
al., 2012)  
Ghana, 
Kenya, 
Madagascar, 
Niger, 
Nigeria, 
Uganda, 
Tanzania & 
Zanzibar 
Evaluation of 
AMFm pilots in 
8 countries  
 National AMFm subsidy 
scheme: 6-15 months 
after rollout 
 In all pilots except Niger and 
Madagascar: large increases in 
QAACT availability (26.3-71.3%) and 
in market share (15.6-58.7%) in the 
private sector 
 Fall in median price for QAACTs per 
adult dose in private sector from USD 
1.28 – 4.82 (in 6/8 pilots) 
 Decreased market share of oral 
artemisinin monotherapies in Nigeria 
and Zanzibar (where previously >5%) 
 Also found increases in QAACT 
availability in public sector facilities 
especially Niger, Nigeria and 
Madagascar 
 Limited effect in Madagascar 
and Niger at this stage 
 Impact mainly observed in the 
private sector although some 
improvement in public sector 
stocks 
 Small scale pilots can be 
replicated at scale 
Abbreviations: ACTs: Artemisinin Combination Therapies; ADDOs: accredited drug dispensing outlets (ADDOs); AMFm: Affordable medicines facility (Malaria); CCMm: community case 
management of malaria; CHW: community health worker; CI: confidence interval; IMCI: integrated management of childhood illness; IPTc: intermittent preventative therapy for children; 
NMFI: non-malarial febrile illness; PMR: Private medical retailer; QAACT: quality assured ACT; RCT: randomised controlled trial; RDT: rapid diagnostic test; SES: socioeconomic status; SP: 
Sulfadoxine-pyrimethamine; SMS; short message service; U5s: under 5 year olds. 
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2.4 DISCUSSION 
The relationship between improving treatment delivery through health systems and resulting impact on 
health outcomes of infectious diseases is not straightforward (de Savigny D, 2009). Ethiopia, South Africa, 
Zambia and Zanzibar (Barnes et al., 2009, Bhattarai et al., 2007) provide examples of how large-scale 
distribution of long-lasting insecticide treated nets (LLINs) and ACTs through formal health channels may be 
associated with reductions in malaria prevalence, admissions and deaths.  
From a public health perspective, the key to reducing malaria mortality is to ensure diagnosis-led, first-line 
treatment in a timely fashion, before infections progress to severe disease. The INDEPTH-Network 
Effectiveness and Safety Studies (INESS) group studied the decay in efficacy of ACTs in Ghana, and estimated 
the systems effectiveness of ACTs to be 13.5% (i.e. 865 of 1000 patients were not treated effectively), with 
the steepest decline due to lack of access to treatment within 24 hours (Binka et al., 2012).  
In this review, I have outlined the barriers posed by health systems factors limiting the potential success of 
malaria treatment programmes, and presented a review of interventions targeting these barriers. The 
population effects of improving individual dimensions of care are unknown and very difficult to predict or 
quantify in isolation, however, a few insights into potential strategies to alleviate delivery bottlenecks 
emerge (Figure 13). 
 
Figure13: Summary of health systems barriers to implementation and potential strategies to alleviate delivery 
bottlenecks 
CHWs have been successfully deployed in several settings to reduce delays in accessing care, increase 
treatment-seeking, and provide diagnostic-led care of high quality including administration of pre-referral 
rectal artesunate to decrease the risk of severe malaria (Gomes et al., 2009). Although the cost-effectiveness 
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of a community-based strategy may vary with transmission intensity and local infrastructure, CHW schemes 
are especially valuable for communities that are traditionally hard to reach. 
Interventions to improve the quality of care provided within the public sector present a mixed picture and 
are likely interdependent. The impact of stockouts on treatment delivery is evident and the threat of 
stockouts appears to alter both provider and patient behaviour with reports of stock-withholding, 
prescription of non-recommended drugs and reluctance of patients to seek care at venues where they 
cannot be guaranteed treatment. Unfortunately there is a paucity of published research on interventions to 
improve supply-chains, although mobile phone technologies appear to offer hope with implications for other 
essential drugs. By contrast, there have been many evaluations of training in the public sector but few have 
shown sustained improvement in performance, further underscoring the importance of robust supply-chains 
as without drugs, training has little impact. Supervision may increase adherence to treatment guidelines and 
mobile phone technologies may also be used to improve performance (Zurovac et al., 2012).   
The impact of increasing use of diagnostics is also complicated. There are individual benefits of ensuring that 
NMFI are correctly treated, but also community benefits of limiting potential emergence of ACT resistance. 
Conversely overtreatment may potentially be associated with reduced risk of malaria transmission due to 
the prophylactic effect of ACTs (Okell et al., 2008a), and so a universal test-and treat policy may in theory 
lead to increased transmission and altered demographics of infection. 
The private informal sector may be seen as a barrier to national malaria strategies, or instead acknowledged 
as an important source of care and included in the spectrum of malaria control efforts. Schemes such as 
AMFm provide an innovative attempt to harness the private sector; however, challenges to success include 
ensuring a reliable supply chain and passing the subsidy to the patient. Lower prices encourage use of first-
line drugs. Training interventions aimed at private outlets have been partially successful in Kenya and 
Tanzania, although long-term sustainability is unclear, and none of these studies address introducing 
diagnosis-led treatment. 
The Research Agenda for Malaria Eradication (MalERA) collaboratively identified key knowledge gaps and 
strategies for health systems in reducing malaria transmission. They concluded that the overarching systems 
issue was the ability to assess bottlenecks to effective coverage of interventions, and the integration of 
interventions into health systems.  In addition the group defined specific research priorities; at facility level 
identifying HCW performance, at district level highlighting greater applications of existing strengthening 
tools, surveillance, and the importance of linking surveillance to actions i.e. surveillance-response, and at 
national level using disease specific programmes to strengthen health-systems (Alonso et al., 2011a).  
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The barriers to successful malaria treatment identified in this review are consistent with the MalERA 
approach and equally applicable to other parasitic and infectious diseases managed at a primary care level.  
The review of interventions to address these barriers show that improving access and quality of care is a 
complex, interdependent process, often with unpredictable outcomes. Traditional strategies such as training 
appear to have less impact than hoped, whilst use of technologies to ease stockouts, task-shifting to CHWs, 
and incorporation of informal points of care into planning appear more promising. As malaria control 
improves, such interventions may need to be tailored for surveillance as well as delivery, for example using 
the SMS data on stockouts to improve disease surveillance and linking this with appropriate control 
responses (surveillance-response). These interventions require further research extending beyond controlled 
small-scale trials, but may be critical to the sustained success of malaria control strategies. 
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3 DEVELOPMENT OF TRANSMISSION MODELS INCORPORATING HEALTH 
SYSTEMS 
3.1 INTRODUCTION   
Transmission of malaria depends on the presence of gametocytes in the blood of human hosts, which 
eventually progress to sexual reproduction following ingestion by mosquitoes. Mosquitoes become 
infectious to humans once sporozoites appear in the salivary glands(Warrell, 2002).  ACTs are known to clear 
malarial parasites in man and also improve clinical symptoms of malaria more rapidly than alternative 
antimalarials (Sinclair et al., 2009). Artemisinin derivatives are also known to have specific anti-gametocyte 
properties (Sinclair et al., 2009, Price et al., 1996, Sowunmi et al., 2007), reducing the duration of 
gametocyte carriage in vivo (Bousema et al., 2010) and reducing onward infectiousness compared to 
previous first line treatments (Okell et al., 2008b),(Sawa et al., 2013). The mean duration of gametocyte 
carriage varies between different ACTs (Sawa et al., 2013).  ACTs may additionally be able to reduce malaria 
transmission through their post-treatment prophylactic effect, which is contributed mainly through the 
partner-drug of the ACT rather than the artemisinin derivative (Sinclair et al., 2009). Therefore ACTs 
potentially also have a “treatment-as-prevention” role in malaria control and elimination (White, 2008) if 
they can be delivered at the required levels of coverage and quality. 
Large-scale ACT programmes, implemented alongside LLIN distribution and IRS schemes, have resulted in 
reductions in clinical disease, hospitalisations and mortality in multiple settings (Barnes et al., 2009, Barnes 
et al., 2005, Lemma et al., 2010) (Bhattarai et al., 2007, Nosten et al., 2000). However the impact of 
widespread ACT delivery on malaria transmission has been less tangibly demonstrated. The malaria parasite 
reservoir was three-fold lower in districts with ACT programmes compared with control districts in Ethiopia 
(Lemma et al., 2010), and in Zanzibar P. falciparum prevalence in children decreased following ACT 
deployments (and before introduction of LLINs (Bhattarai et al., 2007)). However there are a number of 
confounding factors and it is not clear what the differential impact of ACTs would be at different 
transmission intensities.   
Mathematical modelling (Okell et al., 2008a) predicts that the relative reduction in prevalence of infection 
and in the incidence of clinical episodes achieved by ACTs as first-line treatment would be highest in the 
areas with low baseline transmission, assuming high levels of treatment coverage.  However, in contrast, the 
public health impact is predicted to be greatest in high transmission settings. Okell et al also considered the 
impact of reducing presumptive treatment of malaria, which appeared to reduce the number of treatment 
courses required, at the expense of a loss of impact on transmission (Okell et al., 2008a). Thus earlier 
modelling, as described in Section 1.6.3, suggests that with high rates of coverage and adherence, ACTs do 
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potentially have a public health impact in reducing transmission. However there have been no modelling 
studies to date that consider the most efficient way to increase coverage by improving access to and quality 
of care.  
Here I describe the extension of a previously developed model for the transmission of P. falciparum malaria 
(Griffin et al., 2010) to investigate the potential role of health systems and ACT delivery in reducing malaria 
morbidity, mortality and transmission. The impact of health systems barriers on delivery of efficacious 
treatment interventions was described in Chapter 2. The literature review also included the potential impact 
of overcoming barriers such as access to treatment and the quality of care received (Rao et al., 2013a).  
Using the results from this review, I focus on:  
 Treatment seeking and access to healthcare 
 Different sectors through which individuals access treatment 
 The quality of care received by symptomatic cases of malaria (here  the probability of receiving the 
correct antimalarial) 
 Inappropriate prescription of antimalarials to non-malarial febrile illnesses and the potential role of 
diagnostics 
 The role of community and tertiary level care for cases of severe malaria 
I extend the original model iteratively to incorporate the systems barriers above to understand the 
bottlenecks to achieving predicted levels of ACT coverage and impact, and effect of interventions to 
overcome these critical junctures. 
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3.2 BASELINE TRANSMISSION MODEL  
The model extensions are based on the compartmental version of the malaria transmission model published 
by Griffin et al. (Griffin et al., 2010). This model incorporates the transmission cycle in both the vector and 
humans and has been fitted to a large dataset on the relationship between EIR and parasite prevalence (by 
microscopy and/or PCR) and more recently to age-stratified patterns of clinical disease incidence across 23 
sites with varying transmission intensity in Africa (Griffin et al., 2014).  Throughout I assume both human and 
mosquito population sizes remain constant over time (i.e. there is no movement of individuals, growth in the 
population or seasonality in vector abundance). This section briefly summarises the original model (Figure 
14).  
Individuals are born into the population susceptible to infection (state S) but with a degree of partial 
maternal immunity (see later).  Susceptible individuals become infected at a rate Λ  (the force of infection ) 
determined by vector density relative to humans (m), the ratio of infected vectors to uninfected and the 
biting rate of vectors on humans (ζ) (influenced by age and exposure) as well as an individual’s level of 
immunity which is described later. 
Infection is followed by a latent liver stage infection, which is included as a delay in the force of infection of 
duration . The infection process is identical for susceptible individuals and for those re-infected via 
superinfection. After parasites emerge from the liver, individuals may become clinically symptomatic with 
probability φ, influenced by both acquired immunity to disease and maternal immunity (see later).  
Otherwise they enter into an Asymptomatic patent (i.e. detectable) infection state (A) with probability 1-φ.  
The recovery rate from Asymptomatic to a Sub Patent state (U) is rA; the rate by which this occurs, i.e. the 
detectability of the infection is altered by anti-parasitological immunity (see later).  Those in the sub-patent 
state U are cleared at rate rU and individuals return to the state S.  Superinfection (the possibility of 
becoming re-infected despite the presence of an existing infection), is included in both Asymptomatic and 
Sub-patent states. 
Clinically symptomatic infected individuals may be treated with probability fT after which they move to a 
treated state (T).  In the original model, this probability is fixed, and this is something that will be refined 
later in this thesis.  Those who are treated clear their gametocytaemia at rate rT to enter a prophylaxed state 
(P).  Transition from being prophylaxed back to susceptible occurs at rate rP. Those who are not treated or 
who fail treatment enter a diseased state D with probability 1-fT.  Those in this state eventually clear clinical 
symptoms and recover to the asymptomatic state A at rate rD. The average period of prophylaxis (1/rP) is 
assumed to be the duration of minimum inhibitory anti-malarial concentrations in the blood against blood 
stage parasites.  
Ed
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Figure 14: Baseline Transmission Model - Flow diagram for the human infection states.  
S - Susceptible; T - Treated; D – untreated clinical disease; P - prophylaxis; A - asymptomatic patent infection; U - 
asymptomatic sub-patent infection. People move between these states with rates/probabilities as marked on the 
arrows. 
The partial differential equations for the model are given below, with t representing time and a representing 
age. 
 
Individuals in all infected states, including treated states, contribute to the infectious reservoir. Those with 
disease are assumed to have higher parasite densities and thus be more infectious than asymptomatic or 
sub-patent infections.  Individuals treated with ACTs contribute a lower onward infectivity to mosquitoes.   
The force of infection acting on mosquitoes (ΛV) is the sum of the contribution to mosquito infection from 
the different human infectious states, as is described in Section 3.2.2. 
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3.2.1 Effect of Immunity 
Both maternal and acquired immunity (pre-erythrocytic and blood stage) are included in the model. 
Acquired immunity to infection is assumed to modify the probability of infection acquisition following an 
infectious bite (pre-erythrocytic (PE) immunity, IB), and is capped, irrespective of age, at a 50% relative 
reduction in infection risk compared with non-immune individuals (similar to that observed with high-levels 
of vaccine-induced PE immunity). The probability of acquisition occurring given an infectious bite is: 
, 
where b0 is the probability of acquisition of infection if no immunity exists, and b0b1 is the minimum 
probability that acquisition of infection occurs with high levels of immunity. IBO and κB are fitted scale and 
shape parameters. 
Acquired immunity also changes the probability of developing clinical disease following infection (ICA) 
(termed clinical immunity, representing one consequence of blood-stage immunity). In addition, blood-stage 
acquired immunity alters the probability of detection of infection (ID) due to reductions in parasite density 
(termed anti-parasite immunity). The probability that an (asymptomatic) infection is detectable (i.e. remains 
patent) is given by q: 
 , 
where d1 is the minimum probability of detection at maximum immunity and ID0 and κD are shape and scale 
parameters. The age dependent nature of anti-parasite immunity is determined by the parameter fD. 
Maternal immunity (ICM) determines the probability of developing clinical disease following infection in 
young infants. At birth it is assumed to be a proportion (PM) of the acquired immunity accumulated by a 20 
year old in the same transmission setting and then decays at a rate 1/dM. Therefore the probability of 
developing clinical disease when infected is modified by both maternal immunity (ICM) and acquired clinical 
immunity (ICA): 
 , 
where Φ0 is the probability that clinical disease develops in the presence of no immunity against malaria 
infection, and Φ0 Φ1 is the minimum probability that clinical disease may develop.  IC0 and κC are shape and 
scale parameters.   
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All three acquired forms of immunity are modelled to increase with exposure and/or age and to wane with 
time. The partial differential equations for changes in acquired immunity with time (t) and age (a) are given 
below: 
  
where dX represents the mean duration of immunity (of type X) and uX represents a period during which 
immunity of type X cannot be boosted as a result of a prior boost.  ε here represents EIR at age a. 
3.2.2 Vector Model 
The vector model is also based on the structure of a model developed by Griffin et al. and is dynamically 
modulated by changes in transmission from humans (Griffin et al., 2010). The differences between various 
malaria vector species such as Anopheles gambiae and Anopheles arabiensis have not been considered.  I 
also do not consider seasonality here. 
At any time, the vector (denoted by the subscript v) can be in one of three states: susceptible (Sv), latent (Ev) 
or infectious (Iv) after time τV where malaria sporozoites appear in the salivary glands.  It is assumed that 
mosquitoes do not clear infection before death, and that the death rate of a mosquito is not affected by 
their infectious state.  New adults emerge at a rate and die at rate  where V is the total adult 
population. Thus the mosquito population is assumed to remain constant over time.   
The Entomological Inoculation Rate (EIR) is a measure of the number of bites by infectious mosquitoes per 
person per unit time.  It is determined by the Human Blood Index (HBI) i.e. the proportion of blood meals 
taken on humans rather than animals, as well as the human biting rate of mosquitoes, i.e. the number of 
bites per person per day by vector mosquitoes, and the fraction of vector mosquitoes that are infectious (the 
"sporozoite rate").  In this model, it is assumed that there is heterogeneity in biting rates that varies with age 
(through body size) and between individuals. To incorporate heterogeneity, the relative biting rate ( ) in 
category i follows a log-normal distribution between people with a mean of 1, and standard deviation on the 
log scale of σ: 
 
Hence EIR (ε) for the exposure category i - is calculated as: 
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 , 
where ε0 is the mean EIR for adults, a refers to age, and ρ and a0 are fixed biting parameters with respect to 
An. gambiae that are age dependent.  1-ρ is the relative biting rate at birth compared to adults and a0 
determines the time-scale of the increase in biting rate with age. The force of infection (Λ) is therefore
 where b is the probability of infection if bitten by an infectious mosquito (see Section 3.2.1).  
In the model simulations, I use the relationship between the EIR and the density of mosquitoes to humans 
(m) to generate simulations at fixed values of the EIR. The mosquito density required to achieve a given EIR 
is: 
, 
where ω is a normalising constant for biting rate by age and exposure given by: 
. 
Here µh is the death rate for an exponential human population distribution that has been fitted to an 
estimate of the population of Tanzania.  The proportion of mosquitoes that are infectious, VI , is found by 
calculating the human and mosquito equilibrium states conditional on the EIR, as in Griffin et al(Griffin et al., 
2014). 
3.2.3 Infectiousness to Mosquitoes 
Mosquitoes become infected at a rate , the force of infection acting on mosquitoes. This is the sum of the 
contribution to mosquito infection from the different human infectious states.  Onward infectiousness (c) is 
dependent on parasite density and detectability (q), i.e. the probability of an infection remains patent as 
defined in section 3.2.1. 
Infectiousness varies with host state e.g. cD for infectiousness of state D and is estimated through the 
relationship between asexual parasite density (Ross et al., 2006a).  Treatment with ACTs results in reduced 
onward infectiousness to mosquitoes within the model. 
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where , ,  and  are the onward infectivity to mosquitoes of these different states.  The 
expression includes a time-lag between parasitemia with asexual parasite stages and gametocytaemia 
(infectivity to mosquitoes) in the host to account for the lag in gametocyte development characteristic of P. 
falciparum, but has not been expanded here for simplicity. The expression was defined 
earlier in this chapter. 
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3.3 MODEL 1: INCLUSION OF TREATMENT ACCESS AND SEVERE DISEASE 
The model developed by Griffin et al   assumes a constant rate of treatment for those who are clinically 
symptomatic (Griffin et al., 2010). However, as outlined in Chapter 2, the actual probability of receiving an 
ACT for an episode of malaria is known to be variable (estimated to be less than 50%) across sub-Saharan 
Africa depending on where treatment is sought (WHO, 2013).  Hence my aim in this first extension of the 
original transmission model is to incorporate the two main community sources of treatment - public sector 
health facilities and private sector informal outlets. I capture how access to healthcare and the quality of 
care received varies through the following parameters:- 
(i) Following onset of symptoms, the probability of not seeking treatment (i.e. lack of access), the 
probability of attending a health facility and the probability of accessing a private drug shop 
(sector preference) 
(ii) time taken to seek treatment at either a private outlet or a public facility, by those who do 
access care (i.e. delays to access) 
(iii) probability of receiving an ACT for malaria infection in the public and private sectors (i.e. quality 
of care) 
3.3.1 Model 1: Mathematical Details 
In this first iteration, the main transmission model structure is maintained (grey section in Figure 15) but the 
clinical disease states are expanded to consider potential pathways for treatment seeking (black section in 
Figure 15). The process of infection and clinical symptoms is represented in two steps - becoming infected 
under the force of infection (Λ) and the probability of becoming clinically symptomatic once infected (Φ) - 
for greater clarity. Infections that are asymptomatic occur with probability 1-Φ and this is similarly 
represented as two steps.  The effect of immunity, both acquired and maternal, is maintained as in the 
original model.   
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Figure 15: Flow diagram for the Health systems model 1.  
S - susceptible; NT – not seeking treatment; Pr – Seeking treatment at private outlet/drug seller; CL – Seeking treatment at primary care health facility/government 
clinic; PrNT – not treated at private outlet/drug seller; CLNT – not treated at primary care health facility/government clinic; Tx – On treatment; D – untreated clinical 
disease; Sev – Severe disease; P - prophylaxis; A - asymptomatic patent infection; U - asymptomatic sub-patent infection. People move between these states with 
rates/probabilities as marked on the arrows 
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Symptomatic individuals may choose to attend a public sector primary health facility (CL) with 
probability f_CL or seek treatment at a private sector drug shop or retail outlet (Pr) with probability 
f_PR.  As described in Chapter 2, the private sector may vary from accredited drug shops such as the 
ADDOs (Accredited Drug Dispensing Outlets) in Tanzania to general stores and itinerant drug 
peddlers (Goodman et al., 2007a).  In this model, I have not considered each potential type of 
private drug outlet separately due to a lack of comparability and different nomenclature of sub-
categories across the region.  Instead I have used only one category for the private sector, and 
parameterised this using data regarding all forms of private informal sources of care except private 
doctor surgeries.  Individuals who do not seek treatment with the probability f_NTX = 1 - (f_CL+ f_PR) 
pass into an untreated state (NT).   
Delays in accessing care and treatment are known to increase risks of morbidity and mortality 
(Greenwood et al., 1987).  I therefore incorporate a delay from the onset of symptoms to when care 
is received; for those seeking care from the private sector, treatment is received at the rate r_PR (i.e. 
the inverse of the average duration in days of the time taken to receive treatment at a drug shop 
from the time clinical disease developed) and for those attending public sector health facilities, 
treatment is received at the rate r_CL.  The probability of receiving an ACT is assumed to differ by 
source, with ftr_CL denoting the probability of receiving an ACT at a public facility and ftr_PR the 
probability of receiving an ACT at a private outlet or shop.  Once treated (defined as receiving an ACT 
at either a public or private outlet), individuals pass to a treated state Tx.   
Those who are treated go on to clear gametocytaemia at rate r_ACT and recover to enter a 
prophylaxis state (P), with a probability of fEFF.  Transition from prophylaxis back to susceptible 
occurs at rate r_P.  No other antimalarials except ACT are included in the model, and treatment with 
any other antimalarial is considered in the context of the model as equivalent to non-treatment.  
Although levels of SP administration may still be high (Littrell et al., 2011a), this was not modelled as 
affording a potential prophylactic effect given reports of SP resistance in many settings (Gesase et 
al., 2009, Pearce et al., 2013, Ogouyemi-Hounto et al., 2013). 
As in the original model, super-infection is included for both Asymptomatic and Sub-patent states, 
with similar probabilities of clinical symptoms dependent on immunity.  Individuals moving into one 
of the “waiting for treatment” states i.e. CL and Pr as well as the not treated state NT are assumed to 
be no longer susceptible to super-infection. 
Most malaria deaths can be prevented when clinical cases are promptly diagnosed and effectively 
treated, and studies suggest that major factors affecting the outcome of clinical malaria and the 
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onset of severe disease are health-seeking behaviour and determinants of access to health services 
(WHO, 2012c, Getahun et al., 2010, Dillip et al., 2009). I have attempted to capture this through 
three different pathways:  
1. If no treatment is sought (with probability f_NTX) hence moving to state NT 
2. If individuals do not receive ACTs at the source of treatment or are incorrectly treated (with 
probability 1-ftr_CL at the health facility or 1-ftr_PR at a private outlet) moving to waiting 
states CLNT or PrNT respectively.  The reasons this may occur are explored in Chapter 4. 
3. If ACT treatment fails (with probability 1-f_EFF) moving to either the Diseased (D) state or the 
Severe disease (Sev) state 
The probability of accessing more than once source of healthcare is not included at this stage.  
Those individuals who do not seek treatment exit the state NT at a rate r_NTX. Those leaving CLNT 
and PrNT do so at a rate r_NTXPR or r_NTXCL, which is adjusted by the times taken to seek treatment (r_PR 
or r_CL) to ensure that overall duration along all routes is the same.   
All those who are not treated or incorrectly treated (with other anti-malarials or following ACT 
treatment failure) may either develop severe disease (Sev) with probability ε or pass to a clinical 
disease state (D) with probability 1 – ε.  Individuals eventually recover from state D (at rate r_D) to 
become patently asymptomatic (A) as in the original model.  The probability ε is set to vary only with 
age since the impact of immunity has already been included in the probability of developing clinical 
disease.   
In this first model, no specific management is included for severe cases.  It is assumed that the 
majority of severe cases die, with probability ε_sev.  The proportion of severe cases that survives, 
i.e. 1 - ε_sev, eventually go on to recover from clinical symptoms and move to the asymptomatic 
state A at the rate r_D. 
All deaths, from each state and from severe disease are reborn to maintain a stable population. 
The equations for the human infection cycle in this model are in Appendix A. 
The force of infection acting on mosquitoes in this model is simply extended to reflect the additional 
disease states, which are all assumed to have transmission probability cD:  
 
 As previously, individuals treated with ACTs contribute a lower onward infectivity to mosquitoes 
 01 exp( / [ Tx]v D A U D D D D D D TXc D c A c U c c CL c NT c CLNT c NT ca a P Sev cr Pr           
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3.3.2 Model 1:  Parameters 
Parameter estimates for the vector model and underlying transmission models match those used in 
the fitted model developed by Griffin et al. (Griffin et al., 2014) and are summarised in Table 4. 
Parameters for the health systems components are based on the literature review presented in 
Chapter 2 and are described in this section. 
Table 4: Model 1 – Vector; Immunity and Transmission; Host infection &clinical disease parameters  
4A. Vector parameters (Griffin et al., 2014, Griffin et al., 2010)  
Name Definition Value Range Value Used  References 
HBI 
proportion of blood meals 
on humans 
0.73 - 1.0 - varies by 
species 
0.92 
(Griffin et al., 
2010, Dabire 
et al., 2008, 
Dia et al., 
2003, Ndiath 
et al., 2008, 
Tirados et al., 
2006, Griffin 
et al., 2014)  
 Α biting rate per day  0.02-0.465 0.33 
(Gillies, 1953, 
Bruce-Chwatt, 
1960, Killeen 
et al., 2000, 
Griffin et al., 
2010, Griffin 
et al., 2014) 
 Lifespan of vector (days) 5.6-25.0 15 
(Dawes et al., 
2009, 
Anderson 
RM, 1991, 
Griffin et al., 
2010, Griffin 
et al., 2014) 
 
Latent period in 
mosquitoes (days) 
9 – 11 10 
(Anderson 
RM, 1991, 
Molineaux 
and 
Gramiccia, 
1980, Griffin 
et al., 2010, 
Griffin et al., 
2014) 
a0 
Age-dependent biting 
parameter 
Fixed 8 years 
(Griffin et al., 
2010, Griffin 
et al., 2014) 
Ρ 
Age-dependent biting 
parameter 
Fixed 0.85 
(Griffin et al., 
2010, Griffin 
et al., 2014) 
 
Variance of log of 
heterogeneity in biting 
rates 
Fixed 1.67 
(Griffin et al., 
2010, Griffin 
et al., 2014) 
M 
Ratio of mosquitoes to 
humans (V/H) 
0-500 (varied to 
determine EIR for a 
 - 
(Griffin et al., 
2010, Griffin 
et al., 2014) 
1/ V
V
2
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setting) 
 
4B Immunity and Transmission parameters (Griffin et al., 2014, Griffin et al., 2010) 
Name Definition 95% credible interval Value Used  References 
cD 
Probability of transmission 
from disease state to 
vector: not including 
immunity 
0.039-0.123 0.067  
(Griffin et al., 
2010)  
cA 
Probability of transmission 
from asymptomatic state 
to vector 
As above 0.067 
(Griffin et al., 
2010)  
cU 
Probability of transmission 
from subpatent state to 
vector 
0.00056 – 0.018 0.0.0062 
(Griffin et al., 
2010)  
cTx 
Probability of transmission 
from an ACT treated 
Human TO vector on biting 
0.044-0.583 x cD 0.05094 x cD 
(Bousema et al., 
2006, Okell et 
al., 2008a, Okell 
et al., 2008b, 
Chen et al., 
1994, Cairns et 
al., 2011)  
γI 
Relates infectiousness to 
probability of detection 
t ½: 0.16 – 15 (3.6) 
time: 0.6-8.48 
1.84 
(Griffin et al., 
2010) 
Immunity reducing probability of detection (detection immunity ID).   
d1 
Probability with maximum 
immunity: decays with age 
0.088 – 0.237 0.158 
(Griffin et al., 
2010)  
dID Duration of decay Fixed 10 years 
(Griffin et al., 
2014) 
ID0 Scale parameter 0.2-6.17 1.51 
(Griffin et al., 
2014) 
κD Shape parameter 0.270-0.786 0.456 
(Griffin et al., 
2014) 
uD 
Duration in which 
immunity is not boosted 
3.66-19.4 9.61 days 
(Griffin et al., 
2014) 
aD 
Scale parameter relating 
age to immunity 
19.2-25.2 21.9 years 
(Griffin et al., 
2014) 
fD0 
Parameter relating age to 
immunity 
0.00055-0.0305 0.00959 
(Griffin et al., 
2014) 
γD 
Shape parameter relating 
age to immunity 
3.73-6.2 4.75 
(Griffin et al., 
2014) 
Immunity reducing probability of infection (pre-erythrocytic immunity, IB) 
b0 
Probability of infection 
following infectious bite 
with no immunity 
0.409-0.868 0.615 
(Griffin et al., 
2014) 
b1 
Maximum relative 
reduction 
Fixed 0.5 
(Griffin et al., 
2014) 
dB Duration of decay Fixed 10 years 
(Griffin et al., 
2014) 
IB0 Scale parameter 24.8 – 140 70.3 
(Griffin et al., 
2014) 
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κB Shape parameter 1.20 – 2.88 2.10 
(Griffin et al., 
2014) 
uB 
Duration in which 
immunity is not boosted 
2.17 – 13.9 6.17 days 
(Griffin et al., 
2014) 
Immunity reducing probability of clinical disease: modulated by acquired clinical immunity (ICA) and 
maternal immunity (ICM) 
IC0 Scale parameter 10.2 – 23.1 15.6 
(Griffin et al., 
2014) 
κC Shape parameter 1.86 – 2.6 2.16 
(Griffin et al., 
2014) 
uC 
Duration in which 
immunity is not boosted 
3.03 – 11.4 6.32 days 
(Griffin et al., 
2014) 
PM 
New-born immunity 
relative to mother’s (PM): 
calculated as a 20 year old 
in this setting 
0.744 – 0.998 0.939 
(Griffin et al., 
2014) 
dM 
Duration of decay of 
maternal immunity from 
birth 
33.3 – 46.7 39.1 days 
(Griffin et al., 
2014) 
 
4C Host infection and clinical disease parameters (Griffin et al., 2014, Griffin et al., 2010) 
Name Definition 95% credible interval Value Used  References 
Φ 
Probability of developing 
clinical symptomatic 
disease  
Fitted as Griffin 
model to 23 
African sites: age 
and immunity 
structured 
(Griffin et al., 
2010, Griffin et 
al., 2014) 
Φ0 
Probability of developing 
clinical disease following 
infection with no immunity 
0.56 - 0.963 0.8 
(Griffin et al., 
2014) 
Φ1 
Maximum relative 
reduction (assumed 
through acquisition of anti-
parasite immunity) 
0.00004 – 0.0025 0.00071 
(Griffin et al., 
2014) 
dC Average duration of decay Fixed 30 years 
(Griffin et al., 
2014) 
Τ 
Average human latent 
period (days)  
12 
(Griffin et al., 
2010, Griffin et 
al., 2014) 
1/r_D 
Average time taken to 
progress for an 
uncomplicated 
symptomatic episode with 
no treatment to 
asymptomatic (days) 
4.2 - 13.1 5 
(Griffin et al., 
2010, Griffin et 
al., 2014) 
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recA 
Average time taken to 
progress from 
asymptomatic to sub-
patent infection (days): 
structured to increase with 
acquired anti-parasite 
immunity 
195 (Calculated from 
other parameters) 
Fitted as Griffin 
model to 23 
African sites: age 
and immunity 
structured 
(Bekessy et al., 
1976, Griffin et 
al., 2010, Griffin 
et al., 2014)  
 
Average duration of sub-
patent infection (days) 
87-131 110 
(Griffin et al., 
2010, Griffin et 
al., 2014) 
 
Mean of cross-sectional 
age distribution (years)   
21 
(Griffin et al., 
2010, Griffin et 
al., 2014) 
 
3.3.2.1 Additional human infection parameters 
The time taken for a severe episode without treatment to become asymptomatic was assumed to be 
the same as the length of time of an uncomplicated episode (1/r_D), given that severity is a clinical 
state in the model and not defined by parasitaemia levels.  
Lubell et al (Lubell et al., 2011) undertook a Delphi survey with malaria experts on the consequences 
of untreated malaria to estimate the probability of developing severe disease if untreated or the 
probability of death from untreated severe disease for comparison of malaria case management for 
low and medium/high transmission settings.  The survey produced consensus on some probabilities 
given below in Table 5 as follows: 
Age Probability of developing severe 
disease if malaria untreated 
Probability of severe malaria leading 
to death 
 Low Transmission Medium/High 
transmission 
Low Transmission Medium/High 
transmission 
U5 30% (10–58%) 13% (7–30%) 73% (50–85%) 60% (45–80%) 
Adult 18% (5–25%) 3% (1–5%) 70% (50–80%) 45% (30–71%) 
Table 5: Delphi survey estimates for children under 5 years of age and adults: median and interquartile 
range  
(Lubell et al., 2011) 
These were higher than those estimated in a report for Roll Back Malaria produced by Shilcutt et al 
(Shillcutt et al., 2008) (5 -10%), in which there is an acknowledgement that in a medium transmission 
setting by the time a child reaches the age of 5 they would have experienced and survived at least 
malaria infection and would have developed immunity to subsequent infections.  In such settings 
however the levels of all-cause under five mortality is high (WHO, 2012a). 
1/ Ur
1/ h
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Based on these surveys, I assumed that in low transmission settings, there is a higher probability of 
developing the symptoms of severe malaria, and a higher probability of death from severe malaria.  
The role of immune modulation has already been included in the likelihood of developing disease, 
and thus ε and ε_SEV are modelled as a constant proportion of those with untreated clinical disease 
(albeit with different values for under-fives and over-fives).  These parameters are summarised in 
Table 6. 
Table 6: Additional Human infection and clinical disease parameters 
Name Definition Value Range Value Used  References 
ε Proportion of untreated infections that 
progress to severe disease 
0.05 - 0.58  U5: 0.13 
Adult: 0.03 
(Shillcutt et al., 2008, 
Lubell et al., 2011, 
Gupta et al., 1999b) 
ε_SEV Proportion of untreated severe 
infections that progress to death 
0.15 - 0.85  U5: 0.6 
Adult: 0.45 
(Lubell et al., 2011, 
Shillcutt et al., 2008) 
 
3.3.2.2 Treatment and drug parameters 
Limited data exist on the duration of reduction in gametocytaemia (i.e. infectiousness) and the 
duration of minimum inhibitory anti-malarial concentrations of ACTs against blood stage parasites.  
A pooled analysis (Okell et al., 2008b) ,as well as other studies (Ezzet et al., 2000, White, 2005) and  
(2005), show a trend of reduced duration of infectivity in those treated with ACTs compared with 
other gametocytocidal and gametostatic antimalarials, i.e. ACTs induce a faster rate of reduction in 
gametocytaemia than non-ACT antimalarials.  Bousema et al  estimated the duration of gametocyte 
carriage using molecular methods to be an average of 55 days (95% CI 28.7 - 107.7) for non-ACT 
treatment compared to 13.4 days (95% CI 10.2-17.5) in those receiving ACT treatment, i.e. a 75% 
reduction in duration (Bousema et al., 2010).   
Estimates of the probability of onward infectiousness of ACT treated individuals range from 0.044 -
0.583 (Okell et al., 2008a, Bousema et al., 2006, Chen et al., 1994), and of non-ACT treated 
individuals from 0.014 – 0.259 (Chen et al., 1994, Bousema et al., 2006, Okell et al., 2008a, Okell et 
al., 2008b) or 0.05 – 0.17 derived from Garki data (Griffin et al., 2010).  In this model, the relative 
infectiousness of a treated individual (in any state) is assumed to be reduced compared to their 
untreated infectious state by a factor of 0.05, i.e. a 95% reduction.  For simplicity the onward 
infectivity of individuals treated with non-ACT treatments is assumed to be the same as in non-
treated individuals  
The duration of post-treatment prophylaxis is dependent on the partner drug used in the 
combination of the ACT, and has been estimated to range from 8.5 – 12.4 days for ACT, in particular 
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Artemether-Lumefantrine, the most commonly used ACT in Africa (Ezzet et al., 2000, Sinclair et al., 
2009).  In the original model, the average period of prophylaxis is estimated to be 25 days assuming 
that the ACT is partnered with other drugs such as SP with a longer prophylactic time (Griffin et al., 
2010). Here I used the average duration of ACT-induced prophylaxis alone which is estimated to be 
10 days (Bousema et al., 2010, Okell et al., 2008b) due to reported high levels of SP resistance in 
many areas of sub-Saharan Africa (Ogouyemi-Hounto et al., 2013, Iriemenam et al., 2012, Gesase et 
al., 2009).   
Differences in the impact of ACT by formulation or means of administering were not included.  ACT, 
when given correctly as per protocol, is assumed to be 95% efficacious on the basis of a Cochrane 
review (Sinclair et al., 2009).  The parameters relating to the impact of ACT treatment are 
summarised in Table 7. 
Table 7: Drug related parameters 
Name Definition Value Range Value 
Used  
References 
f_EFF ACT efficacy 0.95 – 0.97 0.95 (Sinclair et al., 
2009) 
1/r_ACT  Average duration of 
gametocytaemia after treatment 
with ACT treatment (days) 
10.2-17.5 
(unpublished 6.3: AS -
14.9:AL)  
13.4 
 
(Okell et al., 
2008b, 
Bousema et 
al., 2010) 
1/r_P Average uration of prophylaxis 
after ACT treatment (days) 
8.5-12.4 (AL) 10 (Okell et al., 
2008b, Ezzet 
et al., 2000, 
Sinclair et al., 
2009, 
Bousema et 
al., 2010) 
cTx % reduction in average 
infectiousness compared to state 
occupied prior to treatment 
80.6% * cD 0.05 (Griffin et al., 
2014)
 
 
3.3.2.3 Health system parameters 
Baseline values for these parameters were derived from the literature but their impact is explored 
by varying them in sequence.  A full review of this literature is presented in Chapter 2.   
Several sources indicate that distance to healthcare impacts on treatment seeking behaviour 
(O'Meara et al., 2009, Feikin et al., 2009, Noor et al., 2003, Gething et al., 2004, Stock, 1983, Al-Taiar 
et al., 2008).  The distance to healthcare beyond which access decreases more rapidly varies by 
setting, with some studies suggesting 5-6km (Gething et al., 2004, Noor et al., 2003) whilst others 
report a threshold of 2km (Amin et al., 2003, Alba et al., 2010a, Hetzel et al., 2008).  The probability 
of treatment seeking for fever independent of distance was estimated to be 50%, based on Chuma’s 
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review (Chuma et al., 2009) of barriers to access to ACTs and studies reported by Zurovac et al. 
(Zurovac et al., 2008d, Zurovac et al., 2008b) across both private and public sectors.  The probability 
of accessing treatment was the main rate-limiting step in Krause’s analysis of barriers to 
effectiveness (21%) (Krause and Sauerborn, 2000).  Many studies report a patient preference for 
private drug sellers as a first action, although this does vary by region, distance and provision 
(Sumba et al., 2008).  I therefore assumed 60% of those who seek care for a febrile illness attend 
private drug sellers and 40% attend public sector government health facilities (Mangham et al., 
2012, Mangham et al., 2011, Alba et al., 2010a).  The average delay to access a public sector clinic 
was assumed to be longer than a private drug seller, based on durations reported by Chuma: 86% 
attended a health facility in 2 days (Chuma et al., 2010), Amin: median delay of 2 days to seek care at 
public sector facilities (Amin et al., 2003) and al-Taiar (Al-Taiar et al., 2008).   
As described in Chapter 2, distance from health care not only reduces the probability of seeking care 
but can also lead to delays in seeking treatment, which in turn may influence clinical outcomes.  
Studies by al-Taiar (Al-Taiar et al., 2008), Feikin (Feikin et al., 2009) and Rutemberwa 
(Rutebemberwa et al., 2009) showed that a distance greater than 1-2km was associated with an 
increased risk of severe disease, and O’Meara et al found that the incidence of severe (hospitalised) 
malaria more than doubled as travel time and delays increased (O'Meara et al., 2009).  I 
incorporated this effect by doubling the probability of developing severe disease if there are delays 
in seeking care of greater than the average time set for untreated cases to develop severe disease 
i.e. greater than 3 days.  These parameters relating to access to healthcare both in the public and 
private sectors are summarised in Table 8. 
Table 8: General healthcare access parameters 
Name Definition Value Range Value Used  References 
f_NTX Probability of not seeking or 
accessing early treatment if 
infected and symptomatic  (1-
f_PR– f_CL) 
0.3 – 0.77 0.5 (Noor et al., 2003, Amin 
et al., 2003, Al-Taiar et 
al., 2008, Littrell et al., 
2011a, Kangwana et al., 
2011, Mangham et al., 
2012, Mangham et al., 
2011, Chuma et al., 
2010, Chuma et al., 
2009, de Savigny et al., 
2004, Getahun et al., 
2010, Rutebemberwa 
et al., 2009, Hetzel et 
al., 2008, Sumba et al., 
2008) 
 
f_CL  Probability of accessing care at 
a primary care clinic/public 
sector health facility for a mild 
0.14 - 0.67 0.4*(1-f_NTX) (Chuma et al., 2009, 
Rutebemberwa et al., 
2009, Chuma et al., 
2010, Krause and 
90 
 
episode (1-f_NTX – f_PR) Sauerborn, 2000, Amin 
et al., 2003, Noor et al., 
2003, Sumba et al., 
2008) 
f_PR Probability of accessing care at 
a private trader/ informal 
outlet for a mild episode (1-
f_NTX-f_PR) 
0.17 - 0.83 0.6*(1-f_NTX)  (Marsh et al., 2004, 
Gupta et al., 1999b, 
Alba et al., 2010a, Alba 
et al., 2010b, Krause 
and Sauerborn, 2000, 
Rutebemberwa et al., 
2009, Amin et al., 2003, 
Sumba et al., 2008, 
Goodman et al., 2007a) 
1/r_CL Average time taken to seek 
treatment at clinic/formal 
sector (days) 
24h – 7 days 2 (Chuma et al., 2009, 
Chuma et al., 2010, 
Sumba et al., 2008, 
Rutebemberwa et al., 
2009, Amin et al., 2003, 
Al-Taiar et al., 2008) 
1/r_PR  Average time taken to seek 
treatment seeking at 
informal/private trader (days) 
2h  -5days 1 (Chuma et al., 2009, 
Chuma et al., 2010, 
Sumba et al., 2008, 
Rutebemberwa et al., 
2009, Amin et al., 2003, 
Al-Taiar et al., 2008) 
r_NTX  Average time taken to enter 
disease (D) or Severe states if 
untreated 
1.8-3 3 (Greenwood et al., 
1987, Greenwood et al., 
1991, Miller, 1958) 
1/r_NTXPR Average time taken to enter 
disease (D) or Severe states if 
not treated with an ACT at 
informal/private trader (days) 
from the time of consultation 
 1/r_NTX -
1/r_PR 
 
1/r_NTXCL Average time taken to enter 
disease (D) or Severe states if 
not treated with an ACT at 
clinic/formal sector (days) from 
the time of consultation 
 1/r_NTX -1/r_CL  
ε Proportion of untreated 
infections that progress to 
severe disease 
0.05 - 0.58  U5: 0.13/ 
0.26 if 
delays>3 days 
Adult: 0.03/ 
0.06 if delays 
> 3days 
(Shillcutt et al., 2008, 
Lubell et al., 2011, 
Gupta et al., 1999b, 
O'Meara et al., 2009, 
Al-Taiar et al., 2008, 
Feikin et al., 2009, 
Rutebemberwa et al., 
2009) 
 
3.3.2.4 Quality of care parameters 
The parameters for access to care in the public and private settings were taken from the outputs 
from Chapter 4. These are summarised in Table 9.  
Table 9: Clinic parameters 
Name Definition Value Range Value Used  References 
ftr_CL Probability of receiving ACTs at 0 – 1 Baseline: 0.5 See 
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a public sector/government 
health clinic for clinical malaria 
episode 
 Chapter 4 
ftr_PR  Probability of receiving ACT 
treatment at private sector 
drug shop or outlet for clinical 
malaria episode 
0 - 1 Baseline: 0.05 
 
 See 
Chapter 4 
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3.4 MODEL 1: RESULTS 
3.4.1 Relationship between EIR, prevalence and disease incidence 
When considering the management of malaria, it is important to understand the epidemiology of 
the infection in the population to appreciate which age groups are likely to be infected, symptomatic 
or at risk of progression to complications.   Figure 16 shows the modelled relationship between EIR 
and parasite prevalence in different age groups. As observed elsewhere, the model captures the 
non-linear relationship between these two quantities, with parasite prevalence greatest in the 2-10 
year age group at high values of EIR. 
 
Figure 16: Model 1 – Relationship of Entomological Inoculation Rate (EIR) to the prevalence of malaria 
infection (% parasite prevalence in the age groups 0 – 5 years, 2 – 10 years and all ages) 
 
The age-pattern of parasite prevalence in Figure 16 may be understood through Figures 17-19.  In 
higher transmission settings, there is more clinical (symptomatic) infection in 0-5 year olds than 
older age groups.  It follows that symptomatic infections are more likely to get treated, and hence 
infection durations are reduced.  Therefore prevalence is higher in those between 2-10 years, who 
are less able than older age groups of clearing their infection but less likely to be symptomatic and 
treated than 0-5 year olds (Warrell, 2002, Carneiro et al., 2010).  
Figure 17 shows the modelled incidence of symptomatic episodes of clinical malaria per 1000 
persons per year in various age groups plotted against total parasite prevalence (all ages).  The 
model captures the peak of clinical disease in the youngest age group at high transmission intensity, 
with incidence rates of approximately 2.5 episodes per child per year when all-age parasite 
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prevalence is greater than 50%.  In contrast, at lower transmission, the incidence of disease is more 
evenly distributed across age-groups, albeit at a much lower rate. 
 
Figure 17: Model 1 – Relationship of prevalence of malaria infection in the population (all ages) to the 
incidence of clinically apparent or symptomatic infection episodes per 1000 persons per year (in age groups 
0 - 5 years, 5 – 15 years and all ages) 
 
3.4.2 Relationship between age, prevalence and disease incidence 
 
Figure 18: Model 1 – Age-prevalence curves at the 4 different transmission settings 
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Figures 18 and 19 depict parasite prevalence , incidence of clinical disease  and incidence of severe 
disease  in 4 different transmission settings, namely overall (i.e. over all ages) slide prevalence of 1%, 
10%, 25% and 50% given baseline assumptions regarding treatment effectiveness.  Slide prevalence 
is highest in all transmission settings in the 2-10 year old age groups, rising from birth and falling in 
adolescence.  In high transmission settings, the incidence of clinical episodes and severe disease 
both peak at an early age (0-5 years) and then fall to low levels after the age of 15.  In lower 
transmission settings, clinical and severe disease incidence rises with age and falls after 20 years.  
Malaria related mortality shows a similar pattern using this model. The age-patterns of the model 
outputs are similar to those described in a systematic analysis by Carneiro et al with respect to 
severity and transmission intensity (Carneiro et al., 2010). 
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Figure 19: Model 1 – Age-incidence curves at 4 different transmission settings - 19A) Incidence of clinical 
disease (per 1000 persons per year); 19B) Incidence of severe disease (per 1000 persons per year) 
 
3.4.3 Impact of health system parameters on transmission and clinical outcomes 
Figure 20 shows the impact of access to treatment on transmission as captured by the EIR in 4 
different transmission settings (1%, 10%, 25% and 50% all-age parasite prevalence).  Improved 
access to healthcare, modelled here as a reduction in the probability of not seeking treatment, is 
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associated with a modest absolute decrease in EIR, though this is higher in high transmission 
settings. For example, at 50% all-age parasite prevalence (baseline EIR 109) this results in an 
absolute reduction of 0.72 whereas at all-age parasite prevalence of 1% (baseline EIR 0.06) this gives 
an absolute reduction of 0.05. However, this represents a relative reduction of 73% at 1% slide 
prevalence but less than 1% relative reduction in EIR at 50% parasite prevalence.  A similar pattern is 
seen when considering the impact on parasite prevalence (not shown).  
At baseline, the probability of receiving ACTs for a malaria episode at either treatment source is not 
high (50% at public clinics and 5% at private sector outlets).  I have assumed that 40% of those who 
seek treatment do so in the public sector and 60% attend a private outlet.  Hence overall less than 
25% of all malaria cases that seek treatment actually receive ACTs.  It is therefore not surprising that 
at the assumed probabilities of a malaria infection being treated with an ACT, varying levels of 
treatment seeking does not noticeably impact on malaria transmission in high transmission settings. 
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Figure 20: Model 1 - The impact of access to treatment on EIR at 4 different transmission settings. 
The probability of not seeking treatment - f_NTX is varied from a probability of 0 (i.e. all cases seek treatment) to 1 (no treatment seeking).  A probability of f_NTX = 0.5 
is the baseline value.  20A) absolute change in EIR at the 4 prevalence settings considered and 20B) the change relative to the EIR at baseline.  The ratio of f_CL and f_PR 
in those that do attend remains the same. Baseline EIR values using Model 1 are: 0.06 at 1% prevalence; 1.04 at 10% prevalence; 6.22 at 25%  prevalence and 109.2 at 
50% prevalence. 
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Figure 21 shows the change in incidence of severe malarial disease in 0-5 year olds as the probability 
of not seeking treatment (f_NTX) is varied.  At a prevalence of 50% (all ages), at baseline health 
systems assumptions the model predicts 39 cases of severe disease per 1000 persons per year, 
compared with 0.24 cases per 1000 persons per year at 1% slide prevalence.  
In this model, severe disease occurs at low levels, and only as a complication of untreated disease, 
inadequate treatment or delayed treatment.  As expected the incidence of severe disease cases 
increases if access to healthcare is limited and cases do not seek treatment, with up to 5 cases of 
severe disease per 1000 persons per year potentially averted in high prevalence settings if treatment 
access is 100%.  As before, the absolute impact is greater in high transmission settings but the 
relative impact greatest in low transmission settings. 
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Figure 21:  Model 1 - The impact of access to treatment on severe disease episodes in 0-5 year olds (per 1000 persons per year) at 4 different transmission settings. 
The probability of not seeking treatment - f_NTX is varied from a probability of 0 (i.e. all cases seek treatment) to 1 (no treatment seeking).  21A) depicts the absolute 
change in incidence of severe disease episodes in 0 – 5 year olds at the 4 prevalence settings considered and 21B) depicts the change relative to the severe disease 
episodes at baseline assumptions for each context. Baseline values for incidence of severe disease (per 1000 persons per year) using Model 1 are: 0.24 at 1% 
prevalence; 3.8 at 10% prevalence; 19.4 at 25% prevalence and 39 at 50% prevalence. 
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Figure 22A shows the impact of improved quality of care in the private sector (i.e. increasing the 
probability of receiving an ACT for clinical malaria - ftr_PR) on parasite prevalence in 0-5 year olds.  In 
the highest transmission setting (50% all-age slide prevalence), increasing the probability of receiving 
an ACT for malaria at a private outlet from 0 to 1 is predicted to decrease slide prevalence in 0-5 
year olds from 68.8% to 61.3%.  In the lowest transmission setting (1% all-age slide prevalence), this 
increase is predicted to interrupt transmission. Figure 22B shows the associated impact on the 
incidence of severe disease in 0-5 year olds. In the highest transmission setting (50% all-age slide 
prevalence), increasing care quality could reduce incidence by 12.9 cases per 1000 population per 
year.  Compared to the baseline value for the quality of care in the private sector, the model predicts 
a 31.5% relative reduction in severe disease incidence in the highest transmission setting and a 
99.7% relative reduction in the lowest transmission setting.  The relative reduction in severe disease 
incidence in 0-5 year olds is greater than the relative reduction in slide prevalence in 0-5 year olds in 
all transmission settings, indicating that quality of care may have a larger impact on clinical 
outcomes than on transmission.  A similar pattern is seen for mortality in the same age group. 
Figure 23 shows the same outcomes in 0-5 year olds when the quality of case management in the 
public sector i.e. ftr_CL is varied (baseline probability = 0.5).  For both outcomes, the impact of 
improving care in the public sector is predicted to be less than the equivalent impact in the private 
sector.  This is due to the better baseline level of care currently in the public sector and a lower level 
of utilisation compared with the private sector. However, substantial improvements in outcomes are 
still observed by improving the quality of case management in the public sector.   
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Figure 22: Model 1 - Parameter plot showing the impact of increasing the probability of malaria cases receiving ACTs in the private sector (ftr_PR varied from 0-1) on 
22A) the prevalence in 0-5 year olds  and 22B) on the incidence of severe disease in 0-5 year olds (per 1000 persons per year).  
 Both plots show the decline in the relevant outcome.  The baseline value for ftr_ PR = 0.05. 22A) Baseline values for % slide prevalence in 0-5 year olds using Model 1 
are: 0.47% at 1% all age prevalence; 6.58% at 10% prevalence; 24.2% at 25% prevalence and 68.4% at 50% e prevalence.  22B) Baseline values for incidence of severe 
disease (per 1000 persons per year) using Model 1 are: 0.24 at 1% prevalence; 3.8 at 10% prevalence; 19.4 at 25% prevalence and 39 at 50% prevalence. 
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Figure 23: Model 1 - Parameter plot showing the impact of increasing the probability of malaria cases receiving ACTs in  public  sector health facilities (ftr_CL varied 
from 0-1) on 23A)  prevalence in 0-5 year olds  and 23B)   incidence of severe disease in 0-5 year olds (per 1000 persons per year).   
Both plots show the decline in the relevant outcome.  The baseline value for ftr_ CL = 0.5. 23A) Baseline values for % prevalence in 0-5 year olds using Model 1 are: 
0.47% at 1% all age prevalence; 6.58% at 10% prevalence; 24.2% at 25% prevalence and 68.4% at 50% prevalence.  23B) Baseline values for incidence of severe disease 
(per 1000 persons per year) using Model 1 are: 0.24 at 1% prevalence; 3.8 at 10% prevalence; 19.4 at 25% prevalence and 39 at 50% prevalence. 
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3.5 MODEL 2: INCLUSION OF OVERTREATMENT OF NON-MALARIAL FEBRILE ILLNESS 
A limitation of Model 1 is that it assumes that only the symptomatic malaria cases receive ACTs.  
However, until recently, presumptive treatment and syndromic management of all fevers as malaria 
was advocated in WHO guidelines and national policies, especially U5s.  As described in Chapter 2, 
this has resulted in 47% - 95% of patients with non-malarial febrile illness (NMFI) receiving 
antimalarials unnecessarily (Zurovac et al., 2008b, Okebe et al., 2010, Bastiaens et al., 2011, Nicastri 
et al., 2009, Reyburn et al., 2004, Nankabirwa et al., 2009, Nyandigisi et al., 2011).  Overtreatment is 
often with non-recommended antimalarials, although may sometimes also involve first-line ACTs 
(Okebe et al., 2010, Rowe et al., 2009a, Hamer et al., 2007, Nyandigisi et al., 2011, Zurovac et al., 
2008b).   
Although this inappropriate management of NMFI with antimalarials occurs in both public and 
private sectors, it is known to be prevalent within the private sector (Littrell et al., 2011b, O'Connell 
KA et al., 2011). The results from Model 1 highlight the potential value of inclusion of the private 
sector in malaria control efforts but the impact of potential excessive antimalarial use may also have 
consequences. Okell et al. (Okell et al., 2008a) showed that presumptive treatment may allow the 
prophylactic effect to extend to individuals without malaria and therefore reduce transmission.  
However the management of NMFI has become an increasingly important policy issue since the 
case-fatality rate in malaria test-negative patients treated with anti-malarials can be higher than the 
case-fatality rate in malaria cases (Reyburn et al., 2004), as well as worries regarding the costs of 
wasting of ACT and the ability to meet future global demand (WHO, 2013).  In addition, there is 
some anxiety about the potential spread of resistance to ACTs due to overtreatment, which may 
occur if sub-therapeutic levels of the ACT coincide with a new incoming infection, and particularly 
concerns the partner drug in the combination (which has a longer half-life)(Klein, 2013).   
I therefore extended the model to investigate the clinical and transmission outcomes arising from 
policies of:- 
1. Presumptive treatment in the private sector 
2. Improved levels of diagnostic-led management (and hence quality of care) in private and 
public sectors. 
I included the probability of febrile individuals (any cause) without malaria receiving ACTs at both 
private outlets and public health facilities.  There are three main groups involved in the 
overtreatment of NMFI cases with ACTs:- 
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1. Febrile cases with no malaria infection 
2. Febrile cases with subpatent malaria infection (i.e. undetectable by standard malaria testing) 
3. Febrile cases with asymptomatic malaria infection (i.e. detectable by malaria testing). 
3.5.1 Model 2: Mathematical Details 
I extended the structure of the model to include a rate of developing a febrile illness not due to 
malaria (r_NMFI) which is structured by age. The same rate of developing NMFI is assumed to apply to 
those in the susceptible state (S) and to those in the two infected states A (Asymptomatic) and U 
(sub-patent).  The probability of seeking care (1-f_NTX or ftr_CL + ftr_PR ), and the preference for 
private sector or public sector health facilities for NMFI cases is assumed to be the same as for 
febrile illness due to malaria i.e. f_CL or f_PR.  
Figure 24 demonstrates the additional pathways in this mode, i.e. how individuals asymptomatic for 
malaria but febrile from other causes (NMFI) enter the care-seeking pathway at the age-related rate 
(r_NMFI) and with a probability of 1-f_NTX. Those that do not seek treatment remain in the 
asymptomatic state A.   
As these individuals have patent (detectable) infection, they have the same probability of receiving 
an ACT at either source as a clinically symptomatic malaria case i.e. ftr_CL and ftr_PR; any treatment 
administered is not considered overtreatment but instead as opportunistic treatment. 
 Asymptomatic malaria cases that are not successfully treated with an ACT do not enter the pathway 
that may lead to severe disease but instead re-enter the asymptomatic compartment. Asymptomatic 
malaria cases that are treated opportunistically with ACTs progress to a prophylaxed state at rate 
r_ACT and then return to the susceptible state S. 
For clarity, the treatment of uncomplicated symptomatic malaria, whether from state S, or via super-
infection from U or A has not been included in the diagrams however it is included in the model and 
is given in the equations in Appendix A. 
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Figure 24: Model 2 - Flow diagram for the Overtreatment model: Asymptomatic NMFI cases opportunistically treated  
S - susceptible; P - prophylaxis; A - asymptomatic patent infection; U - asymptomatic sub-patent infection. UPr – Sub-patent seeking treatment for NMFI at private 
outlet/drug seller; UCL – Sub-patent seeking treatment for NMFI at primary care facility; UTx: Sub-patent treated with ACTs; SPr – NMFI seeking treatment at private 
outlet/drug seller; UCL – NMFI seeking treatment at primary care facility; APr – Asymptomatic malaria case with NMFI seeking treatment at a private outlet/drug seller;  
ACL – Asymptomatic malaria case with NMFI seeking treatment at a primary care facility; ATrTx – Asymptomatic malaria case with NMFI treated with ACT.   People 
move between these states with rates/probabilities as marked on the arrows 
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The pathway for cases of subpatent disease that develop NMFI at r_NMFI is shown in Figure 25.  
Individuals leave the sub-patent state at the age-related rate of developing an NMFI and with the 
probability of seeking treatment f_CL or f_PR. Those that do not seek treatment remain in the sub-
patent state U.   
The probability of receiving an ACT is denoted by ftr_NMFICL and ftr_NMFIPR for those seeking care in the 
public and private sectors respectively. Sub-patent malaria cases are assumed to be undetectable by 
standard diagnostic techniques at community level.  The parameters that contribute to their 
probability of receiving ACT are outlined in Chapter 4.  They relate to the quality of care at each 
outlet including the presence and use of, as well as compliance with, diagnostic tools to reflect the 
probability of overtreatment since there is no detectable parasitaemia.  If treated, NMFI cases move 
to the new state UTx.  
If an NMFI case who is subpatently infected with malaria receives a course of ACT, then the 
individual is assumed to be treated and prophylaxed in a similar fashion to malaria cases treated for 
P. falciparum infection.  Thus the individual moves to the state P at a rate r_ACT reflecting the rate of 
reduction in gametocytes as previously explained in Model 1. Those that do not receive an ACT or 
are unsuccessfully treated (1-f_EFF) return to the sub-patent state U. 
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Figure 25: Model 2 - Flow diagram for the Overtreatment model. Sub-patent NMFI cases opportunistically treated 
S - susceptible; P - prophylaxis; A - asymptomatic patent infection; U - asymptomatic sub-patent infection. UPr – Sub-patent seeking treatment for NMFI at private 
outlet/drug seller; UCL – Sub-patent seeking treatment for NMFI at primary care facility; UTx: Sub-patent treated with ACTs; SPr – NMFI seeking treatment at private 
outlet/drug seller; UCL – NMFI seeking treatment at primary care facility; APr – Asymptomatic malaria case with NMFI seeking treatment at a private outlet/drug seller;  
ACL – Asymptomatic malaria case with NMFI seeking treatment at a primary care facility; ATrTx – Asymptomatic malaria case with NMFI treated with ACT.   People 
move between these states with rates/probabilities as marked on the arrows. 
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Unnecessary treatment with ACTs is also included for individuals who are not infected with malaria, 
i.e. in state S.  Cases leave the susceptible state at the same age-related rate of developing an NMFI 
and with the probability of seeking treatment f_CL or f_PR.  As previously, the probability of receiving 
an ACT is denoted by ftr_NMFICL and ftr_NMFIPR for those seeking care in the public and private sectors 
respectively.  If an NMFI case who is not infected with malaria receives an effective (i.e. f_EFF) course 
of ACT, then the individual is assumed to be prophylaxed immediately, i.e. moves directly to state P. 
Those that do not receive an ACT return to the susceptible state S. The pathway for uninfected cases 
with NMFI is similar and shown in Figure 26. 
The new set of equations for the human component of this model is included in Appendix A. 
The infectivity of the extended set of states is 
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Figure 26: Model 2 - Flow diagram for the Overtreatment model. Susceptible NMFI cases over treated 
 S - susceptible; P - prophylaxis; A - asymptomatic patent infection; U - asymptomatic sub-patent infection. UPr – Sub-patent seeking treatment for NMFI at private 
outlet/drug seller; UCL – Sub-patent seeking treatment for NMFI at primary care facility; UTx: Sub-patent treated with ACTs; SPr – NMFI seeking treatment at private 
outlet/drug seller; UCL – NMFI seeking treatment at primary care facility; APr – Asymptomatic malaria case with NMFI seeking treatment at a private outlet/drug seller;  
ACL – Asymptomatic malaria case with NMFI seeking treatment at a primary care facility; ATrTx – Asymptomatic malaria case with NMFI treated with ACT.   People 
move between these states with rates/probabilities as marked on the arrows. 
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3.5.2 Additional Parameters for Model 2 
3.5.2.1 Non-malarial febrile illness 
To estimate the rate of non-malarial febrile illness, unpublished data from two  cross-sectional 
surveys (n=11,532)(Drakeley et al., 2005) in the Kilimanjaro and Tanga regions of Tanzania from ages 
1-45 years were used. Demographic and clinical information was collected during the short and long 
rainy seasons (short rains in Nov-Dec versus long rains in March-May), as well as samples for malaria 
microscopy.  An unpublished analysis has estimated the relationship between non-malarial fever and 
age (Okell, 2014).  The prevalence of fever by yearly age groups up to age 45 years was standardised 
into relative age-specific prevalence by dividing by the total prevalence of fever in the surveys.  
Survey data were grouped by season and subdivided by parasite-prevalence in U5s (<5%, 5-10%, 10-
20%, 20-40%, >40%). The model developed by Griffin et al. (Griffin et al., 2010) was used to estimate 
the incidence of clinical malaria by age, taking account of seasonality by  adjusting the mean annual 
EIR to match the slide-prevalence in under-fives at the time of year that the survey was done.  The 
authors then used the model output to estimate the age-specific fever prevalence due to malaria 
during this time by calculating the proportion of people with symptomatic (clinical) malaria during 
the average fortnight.  It was assumed that each new malaria infection would not cause a fever that 
was longer than 2 weeks. The age-specific fever prevalence due to malaria was then subtracted from 
total fever prevalence, giving an estimated prevalence of fevers due to other causes.  They 
estimated 13% of the population (age up to 45 years) reported NMFI in the preceding 2 weeks, 
averaged in the two rainy seasons and over low to high transmission intensities.  This translates into 
an average of 3.38 NMFI episodes per person per year.  
I then used these reported fever rates and demographic data from DHS/MIS Tanzania to calculate an 
age structured estimate of NMFI per person from the age of 0-44 years.  Ages of 45 year and older 
were assumed to be the same rate as 44 years. 
The rates of treatment seeking and sector preference for NMFI are assumed to be the same as for 
malarial fevers, i.e. f_NTX, f_CL and f_PR remain the same for all febrile illness.  
The calculation of the probability of receiving an ACT unnecessarily for NMFI at a clinic or at a private 
outlet is fully described in Chapter 4.  The probability of overtreatment with an ACT relates to the 
probability of receiving presumptive (i.e. not on the basis of testing) antimalarial treatment.  
Unnecessary treatment of NMFI with antimalarials is known to be high at private outlets; however it 
is often the case that other non-ACT antimalarials are dispensed in these cases (Mangham et al., 
2012, Noor et al., 2009, Uzochukwu et al., 2010).  Overtreatment is also a significant issue at public 
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sector facilities (Bastiaens et al., 2011, Okebe et al., 2010).  This may be due to non-compliance with 
diagnostic test results (Nyandigisi et al., 2011, Nankabirwa et al., 2009), or test quality (sensitivity 
and specificity) as well as ACT stockouts.  My baseline parameter estimates are based on studies 
reviewed in Chapter 2 and summarised in Table 10.  
Table 10: Parameters regarding Non-malarial Febrile Illness rates and treatment  
Name Definition Value Range Value Used  References 
r_NMFI Rate of non-malarial febrile illness 
per person per year 
2.3 – 4.95 (age 
dependent) 
Age-specific 
rates: overall 
3.38 
(Drakeley et al., 
2005),(Okell, 
2014) 
ftr_NMFICL Probability of receiving ACTs for 
NMFI at public sector clinic/health 
facility 
0-1 Baseline: 0.5  
 
See Chapter 
4 
ftr_NMFIPR Probability of receiving ACTs for 
NMFI at private outlet (drug shop 
or general shop) 
0-1 Baseline: 0.05 
 
See Chapter 
4 
 
3.5.2.2 Treatment parameters 
The relative infectiousness of a treated individual (in any state) is reduced compared to their 
infectious state as in Model 1. The infectiousness of any sub-patent malaria infections 
opportunistically treated with ACTs when attending with an NMFI is also reduced (Table 11). 
Table 11: Treatment parameters for sub-patent infections 
Name Definition Value Range Value 
Used  
References 
UTx % reduction in average 
infectiousness compared to state 
occupied prior to treatment 
80.6% * cD 0.05 (Dunyo et al., 
2006), (Griffin 
et al., 2014) 
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3.6 MODEL 2: RESULTS 
The probability of receiving an ACT for an NMFI at a public sector clinic was set at baseline at 0.5 and 
the probability of receiving an ACT for an NMFI at a private sector outlet at 0.05; these estimates are 
based on the decision-tree modelling in Chapter 4.   
3.6.1 Impact of treating with ACTs NMFI on transmission and clinical outcomes 
Figure 27 depicts the impact of increasing the probability of receiving ACT treatment for an NMFI at 
public sector health facilities (solid line) or private informal outlets (dashed lines) on severe disease 
incidence in 0-5 year olds and parasite prevalence in 0-5 year olds in the 4 transmission settings. It 
was anticipated that reduction in overtreatment would cause a rise in malaria prevalence due to the 
lack of prophylactic protection afforded by unnecessary ACTs.  
 However, the results indicate that if all other parameters are maintained, there may be negligible 
impact on slide prevalence or severe disease incidence in 0-5 year olds, even in low prevalence 
settings. At 1% all-age prevalence, eliminating all overtreatment in the private sector (but 
maintaining baseline levels of malaria case management with ACTs) may lead to a less than 0.5% 
reduction in prevalence in 0-5 year olds relative to baseline, whilst eliminating all overtreatment at 
the public sector may lead to a 13% relative reduction, despite higher levels of treatment seeking in 
the private sector.  However, as seen in Figure 27 the absolute changes seen are very limited, and 
relative impact is small even at 1% prevalence. 
This finding is due to assumed higher levels of overtreatment with ACTs at public sector facilities, 
whereas overtreatment in the private sector is assumed to be with other antimalarials (as described 
in Chapter 4), although this may change in the future with the onset of AMFm.  The results are 
similar for the incidence of severe malaria (Figure 27).  
Hence if overtreatment of NMFI is reduced in either sector, for example through the mandatory use 
of diagnostic testing and if all negative tests were not treated, the impact on reducing transmission 
and severe disease would be very limited, given assumed baseline levels of malaria treatment. 
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Figure 27: Model 2 - Parameter plot showing the impact of increasing the probability of NMFI cases receiving ACT treatment  
Solid line: ACT treatment of NMFI at public sector health facilities for a non-malarial febrile illness (ftr_NMFICL) and dashed lines: ACT treatment of NMFI at private outlets 
(ftr_NMFIPR) (dashed lines) on 27A) incidence of severe malaria in 0-5 year olds (per 1000 persons per year) & 27B) % prevalence in 0-5 years olds 
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3.6.2 Combinations of interventions 
I next compared the potential impact of single and combinations of interventions to the health 
system for the 4 transmission settings, namely: 
1. 100% access (i.e. 100% treatment seeking : f_NTX = 0 - keeping sector preference and 
probability of treatment the same as baseline), 
2. Perfect clinic treatment: 100% chance of receiving ACTs for malaria at public sector clinics 
(ftr_CL = 1) and 0% overtreatment at clinics (ftr_NMFICL = 0)  
3. 100% access (f_NTX = 0)  and perfect clinic treatment 
4. 100% presumptive treatment in public and private sectors: i.e. all fevers treated as malaria 
(ftr_CL = 1; ftr_NMFICL = 1; ftr_PR = 1; ftr_NMFIPR = 1) 
5. 100% access and 100% Presumptive (clinic and private) treatment  
6. 100% Presumptive private treatment: all fevers in private sector given an ACT (ftr_PR = 1; 
ftr_NMFIPR = 1) 
7. 100% access and 100% Presumptive private treatment  
8. Perfect treatment (clinic and private): 100% chance of receiving ACTs for malaria  and 0% 
overtreatment in all sectors (ftr_CL = 1; ftr_NMFICL = 0; ftr_PR = 1; ftr_NMFIPR = 0) 
9. 100% access and Perfect treatment (clinic and private) 
The results from a 1% (low) transmission setting indicate that each of the above list of interventions 
reduce parasite prevalence in 0-5 years olds to 0% and have a similar effect on severe disease 
incidence in 0-5 years olds. Figure 28 shows relative changes compared to baseline for each group of 
interventions for the 10%, 25% and 50% total prevalence settings. 
The juxtaposed figures indicate that various health systems interventions have differing relative 
impacts on slide prevalence and severe malaria incidence in 0-5 year olds due to the dynamics of age 
groups affected by the disease and its consequences. Introducing 100% access to healthcare in the 
1%, 10% and 25% settings is predicted to have a greater relative impact on slide prevalence than 
severe disease incidence.  However at the highest transmission setting (50% all-age prevalence) this 
intervention led to a 14% relative decrease in severe disease incidence but only a 7% reduction in 
parasite prevalence in 0-5 year olds. This is because at a higher prevalence, symptomatic clinical 
disease is mainly seen in the youngest age groups, whilst the main reservoir of parasites is in older 
age groups (2-10 years) as seen in Figures 17-19. Therefore through increased levels of treatment, 
the consequence of untreated disease i.e. severe malaria is averted but the transmission outcomes 
such as parasite prevalence are less affected.  In the other prevalence settings, the epidemiology of 
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clinical disease and prevalence may overlap more i.e. those that are parasitaemic are also likely to be 
symptomatic and so increased treatment does impact on prevalence.   
At the 10% setting, improving access alone without improvements in the quality of healthcare may 
not sufficiently reduce the transmission of malaria or severe disease incidence.  Perfect care in the 
public sector clinic alone has less impact than improving access (i.e. the probability of treatment 
seeking) to any source.    
Presumptive treatment of all fevers (malaria and NMFI) in the private sector at 25% slide prevalence 
may reduce both outcomes by 50%, and by 62% if this policy of presumptive treatment is applied in 
both sectors. Slide prevalence and severe disease incidence are not reduced by improvements in 
quality of care alone in this setting but may approach nearly 100% reductions if in combination with 
100% access to healthcare. 
At the highest prevalence setting, no combination of interventions of care quality and access cause 
greater than a 45% reduction in parasite prevalence in 0-5 year olds.  However important reductions 
in severe disease incidence in this age group may be possible with 100% treatment of all malaria 
cases (in both sectors) along with 100% access.  As indicated by Figure 28, there is little increase in 
the impact of either outcome if all NMFI cases are treated with ACTs (presumptive treatment) 
compared with the impact if no NMFI cases are given ACTs as long as all malaria cases are given ACTs 
(perfect treatment). 
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Figure 28: Model 2 Figure depicting impact of combinations of interventions in 3 transmission settings (10%; 
25%; 50% parasite prevalence in all ages) 
Impact on % parasite prevalence in 0-5 year olds (grey bars) and Severe disease incidence in 0-5 year olds 
(red bars) in the 10%, 25% and 50% total prevalence settings.  The change relative to baseline values for 
each is shown.  Values for all except 100% change indicated. 
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3.6.3 Inclusion of Management of Severe Disease: Model 3 
Models 1 and 2 concern management of malaria only at community level and do not include any 
management of severe malaria.  In these earlier iterations, severe disease occurs as a result of a lack 
of ACT treatment, whether not sought, delayed or ineffective.  Severe cases either progress to death 
or recover to an asymptomatic state.   
In Model 3 I aim to investigate: 
1. The impact of health systems on the morbidity and mortality associated with malaria 
2. The role of tertiary level health institutions e.g.  district hospitals in the management of 
severe malaria and its consequences 
I expand the model to include two pathways by which severe malaria may develop and incorporate 
the treatment of severe malaria both at community and tertiary level. 
Prompt diagnosis and timely malaria treatment can reduce illness progression to severe stages and, 
therefore, decrease mortality (Warsame et al., 2007, Getahun et al., 2010, Byakika-Kibwika et al., 
2009).  As in Models 1 and 2, delayed or unsuccessful treatment is included here as a potential route 
to develop severe malaria.  However treatment delay may not be the only cause of severe malaria. 
The risk of developing acute severe malaria is known to diminish with repeat infections of P. 
falciparum (Gupta et al., 1999b), but the rate of acquisition of immunity is still poorly understood 
(Langhorne et al., 2008b). Manifestations of severe malaria have been shown to vary with age and 
transmission setting (Langhorne et al., 2008b, Reyburn et al., 2005, O'Meara et al., 2008b, Carneiro 
et al., 2010, Ross et al., 2006b).  In Model 3 I have attempted to reflect this risk of acute severe 
malaria by including the possibility that some individuals are more likely to develop severe malaria at 
presentation, i.e. that severe cases do not only occur from delay in treatment of non-complicated 
malaria. To capture this I included a new pathway from those who develop clinical disease. A 
proportion of these individuals θ are assumed to have severe disease on presentation. This is 
determined by levels of acquired immunity, whilst the remainder follow the pathway previously 
described in which severe disease may occur as a result of delayed treatment. 
The WHO guidelines for management of the small percentage of Plasmodium falciparum infections 
that progress to severe malaria promote intravenous administration of artesunate as first-line 
followed by a course of ACTs (WHO, 2010a, Dondorp et al., 2010).  In Model 3 I extended the 
previous models to incorporate the possibility of treatment of severe malaria infections at an 
appropriate level facility (e.g. district hospital or tertiary level facilities).  Patients may reach the 
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hospital as a first source of care, following referral from a community source of care or following 
unsuccessful treatment at a community source of care. 
A study by Gomes et al. (Gomes et al., 2009)  suggests that very early administration of rectal 
artesunate may prevent death and disability in those at risk of severe malaria.  There is concern 
regarding the effect of such an intervention if administered more than 6 hours after onset of 
symptoms (Grobusch, 2009), however it reiterates the importance of early access.  The original trial 
used rectal artesunate as a pre-referral tool, however in the model this has been incorporated as an 
assumption that early administration of artesunate (intravenous or rectal) with a course of ACTs will 
prevent progression to fulminant severe disease in these individuals. Early administration of 
artesunate may occur at the health facility or private outlet level especially since early evaluation 
suggests a reluctance of caretakers to take children to hospital after a suppository of artesunate 
(Simba et al., 2010).   
In summary, in Model 3 the management of severe malaria is included in three different ways: 
1. Prevention of progression to fulminant severe disease in those at risk of early acute severe 
malaria by treatment with rectal artesunate and ACTs – which may occur at public facilities 
or private outlets 
2. Referral of those at risk of early acute severe malaria to hospital/tertiary level facilities – 
which may occur from public facilities or private outlets 
3. Treatment of severe malaria at a hospital/tertiary level facility with artesunate and ACTs – 
which may be early acute severe malaria or those uncomplicated symptomatic malaria cases 
that may not have sought treatment or were unsuccessfully treated either at a public facility 
or private outlets. 
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Figure 29: Model 3 - Flow diagram for the Severe treatment model: Community management of acute severe malaria risk 
S - susceptible; NT – not seeking treatment; Pr – Seeking treatment at private outlet/drug seller; CL – Seeking treatment at primary care health facility/government 
clinic; PrNT – not treated at private outlet/drug seller; CLNT – not treated at primary care health facility/government clinic; Tx – On treatment; D – untreated clinical 
disease; Sev – Severe disease; P - prophylaxis; A - asymptomatic patent infection; U - asymptomatic sub-patent infection; WSev – untreated progressing early severe 
PrSev – Severe case seeking treatment at private outlet/drug seller ; CLSev – Severe case seeking treatment at primary care facility; Href – Severe case referred to 
hospital or tertiary facility by either health facility or private outlet; TxSev – Severe case that has received treatment at clinic/health facility or private outlet; CLSevNT – 
severe case not treated at primary care facility/government clinic; PrSevNT – severe case not treated at private outlet/drug seller;- HTx – Sever case treated in hospital 
or tertiary facility;  HSev – untreated severe case in hospital or tertiary facility. People move between these states with rates/probabilities as marked on the arrows 
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In this model, a symptomatic individual has a risk of developing severe disease early (θ).  This is a 
proportion of those who have clinical symptoms and is determined by maternal and acquired 
immunity. However if the individual accesses treatment at this stage (with probability 1-f_NTX) then 
progression to fulminant severe disease may be avoided, provided correct treatment is 
administered.  
This is depicted in Figure 29.  For clarity, the treatment of NMFI, whether from state S, U or A has 
not been included in the diagrams however it is included in the model and is given in the equations 
in Appendix A. 
I assume that the probability of seeking care at community/primary level (i.e. either a private outlet 
or a government facility) for these acute severe cases is similar as previously defined i.e. f_CL or f_PR 
leading to state CLSev and PrSev respectively. I assume the delay in accessing care is also similar 
(that is, progression from seeking treatment to accessing care occurs at a rate r_CL and r_PR for the 
public and private sectors respectively).   
For those at risk of early severe disease who seek care at the primary level (clinic or drug shop), 
there are three possible outcomes at each source of care: 
1. Referral to hospital (with probabilities ftr_REFCL and ftr_REFPR for public and private sectors 
respectively) moving to Href state  
2. Correct treatment at each source of care, which is modified to incorporate the presence and 
use of rectal or intramuscular artesunate, thus giving the probabilities ftr_sevcl and ftr_sevpr 
for public and private sectors respectively, subsequently moving to the TxSev state.  This 
treatment may be successful with a probability of f_eff, and so individuals progress at rate 
r_ACT to recovery and into the prophylaxed state (P). 
3. To neither receive treatment or referral (with probability 1-ftr_refcl – ftr_sevcl or 1-
ftr_refpri-ftr_sevpri respectively). We will consider those who are not treated or not referred 
later in this chapter. 
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Figure 30: Model 3 - Flow diagram for the Severe treatment model: Pathways to develop Severe disease  
S - susceptible; NT – not seeking treatment; Pr – Seeking treatment at private outlet/drug seller; CL – Seeking treatment at primary care health facility/government 
clinic; PrNT – not treated at private outlet/drug seller; CLNT – not treated at primary care health facility/government clinic; Tx – On treatment; D – untreated clinical 
disease; Sev – Severe disease; P - prophylaxis; A - asymptomatic patent infection; U - asymptomatic sub-patent infection; WSev – untreated progressing early severe 
PrSev – Severe case seeking treatment at private outlet/drug seller ; CLSev – Severe case seeking treatment at primary care facility; Href – Severe case referred to 
hospital or tertiary facility by either health facility or private outlet; TxSev – Severe case that has received treatment at clinic/health facility or private outlet; CLSevNT – 
severe case not treated at primary care facility/government clinic; PrSevNT – severe case not treated at private outlet/drug seller;- HTx – Sever case treated in hospital 
or tertiary facility;  HSev – untreated severe case in hospital or tertiary facility. People move between these states with rates/probabilities as marked on the arrows 
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As shown in Figure 30, a symptomatic individual with a risk of developing severe disease early (with 
probability θ) who does not access early treatment (with probability f_ntx) then enters a waiting 
state WSev (to ensure times are equivalent on all pathways to enter Severe disease state). 
 Figure 30 also highlights that, in contrast to the earlier models, those with uncomplicated clinical 
malaria who do not receive treatment at the initial source, or who fail treatment, enter into the 
same severe disease compartment with the probability ε.  In previous models there was no further 
treatment opportunity for these cases – but in Model 3, they have the opportunity to seek hospital 
treatment with the probability f_H.  Those who do not seek treatment, (1-f_H), either die (ε_sev) or 
those that survive (1 - ε_sev) eventually clear clinical symptoms and move to the asymptomatic state 
A at the rate r_D.   
In addition, those symptomatic patients at risk of early severe disease who enter the PrSev and 
CLSev compartments but  
a. who are not treated promptly or referred (i.e.  1-ftr_REFCL – ftr_SEVCL or 1-ftr_REFPRI - ftr_SEVPRI) or 
b.  who fail treatment (1-f_EFF) 
also enter the severe disease compartment.  Waiting states PrSevNT and CLSevNT have been 
included to ensure times to develop severe disease are consistent in all pathways at rates r_NTXPR 
and r_NTXCL respectively. 
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Figure 31: Model 3 - Flow diagram for the Severe treatment model: Management of severe malaria at hospital/tertiary care level 
S - susceptible; NT – not seeking treatment; Pr – Seeking treatment at private outlet/drug seller; CL – Seeking treatment at primary care health facility/government 
clinic; PrNT – not treated at private outlet/drug seller; CLNT – not treated at primary care health facility/government clinic; Tx – On treatment; D – untreated clinical 
disease; Sev – Severe disease; P - prophylaxis; A - asymptomatic patent infection; U - asymptomatic sub-patent infection; WSev – untreated progressing early severe 
PrSev – Severe case seeking treatment at private outlet/drug seller ; CLSev – Severe case seeking treatment at primary care facility; Href – Severe case referred to 
hospital or tertiary facility by either health facility or private outlet; TxSev – Severe case that has received treatment at clinic/health facility or private outlet; CLSevNT – 
severe case not treated at primary care facility/government clinic; PrSevNT – severe case not treated at private outlet/drug seller;- HTx – Sever case treated in hospital 
or tertiary facility;  HSev – untreated severe case in hospital or tertiary facility. People move between these states with rates/probabilities as marked on the arrows 
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Figure 31 details the potential treatment pathways for severe disease.  Following onset of severe 
symptoms, cases may seek treatment at a hospital or a tertiary centre (with probability f_H) at a rate 
r_H.   In addition cases at risk of early severe disease that have been referred from either private 
vendors or government health facilities (Href) seek treatment at hospitals or tertiary care centres at 
rate r_H.  It is assumed that the probability of attending a hospital as a first choice source of 
treatment (f_H) is the same as the probability of attending following referral. 
If cases are correctly treated at the higher level health facility, with a probability of ftr_H, they then 
enter the treated state HTx.  These cases progress to being prophylaxed (P) at rate r_ACT with a 
probability that the treatment is effective (fEFF).  First-line treatment of severe malaria at hospital is 
assumed to be with Artesunate as per the WHO guidelines(WHO, 2010a). Those who are not treated 
(with probability 1-ftr_H) or who fail treatment then progress to a late severe disease stage (HSev). 
Patients leave this state at rate r_D and either die with a probability of ε_SEV, or slowly clear the 
disease entering the asymptomatic state A with a probability of 1- ε_SEV. 
The equations for the full model are given in Appendix A. 
The force of infection acting on mosquitoes in this model is simply extended to reflect the additional 
disease states, which are all assumed to have transmission probability cD. Hence the infectivity of the 
extended set of states is:- 
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3.6.4 Additional Parameters for Model 3 
3.6.4.1 Human infection parameters 
Community level risks of acute severe malaria are difficult to assess since most studies present 
hospital level data and case fatality rates.  Gupta et al. modelled the risk of acute severe disease in 
hospitalised cases decreasing with progressive exposure to infections (Gupta et al., 1999b). Ross et 
al. constructed an epidemiologic model of severe morbidity and mortality caused by P. falciparum, 
and predict that the risk of severe disease decreases with exposure, but that other factors also affect 
the risk of acute severe presentation including age, presence of co-morbidities and transmission 
setting such that severe disease can occur in older individuals at low transmission settings (Ross et 
al., 2006b). In this model, I use estimates for Θ fitted by Griffin et al. using hospital data from 
Tanzania (Griffin et al., 2014 ). 
It is known that at low transmission intensities, once infected there is a higher probability of 
developing severe symptoms and a greater risk of death from severe malaria. The role of immune 
modulation has already been included in the likelihood of developing disease, and thus ε and ε_SEV 
are modelled as a constant proportion of under and over fives with untreated clinical disease.  As 
previously described, there is a higher risk of developing disease if there is a delay in treatment 
seeking. 
The time taken to progress to developing severe disease in those at risk if untreated, w_SEV , is set at 
3 days in order to make this time equal to other pathways that result in severe disease. 
Table 12: Severe disease Host infection and clinical disease parameters 
Name Definition Value Range Value Used  References 
Θ Probability of presenting with severe 
disease (i.e. not due to treatment delay 
or failure) 
0.03-0.15 Fitted to 
hospital 
data from 
Tanzania 
(Griffin et al., 2014 ) 
w_SEV Time taken to progress to severe illness if 
no treatment (days) 
1.8 - 3 3 (Miller, 1958, 
Greenwood et al., 
1987) 
 
3.6.4.2 Treatment and drug parameters 
The traditional parenteral treatment for severe malaria is intravenous quinine.  However the WHO 
2010 guidelines on management of severe malaria now recommend the use of intravenous 
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artesunate for both adults and children due to the rapid clearance of parasitaemia leading to 
reduced mortality and reduced incidence of complications such as hypoglycaemia as well as its 
gametocidal activity discussed previously in section 3.3.2.2 (WHO, 2010a). The guidance suggests 
that this treatment should be given for 24 hours and thereafter, the patient should receive a full 
course of the locally recommended ACT (WHO, 2010a).  Thus I have used the same values for the 
reduction in parasitaemia and reduction in infectiousness due to gametocytaemia as previously 
outlined in section 3.2.3.5.  I have not included the use of quinine in the models, since I am 
considering the impact of ACTs and also because the guidelines recommend a second oral agent 
should be added if using quinine therapy - there are little data regarding how this is implemented 
(WHO, 2010a). 
As summarised earlier, a study by Gomes et al. investigated the use of early administration of rectal 
artesunate in cases of severe malaria as a pre-referral tool and found that it may prevent death and 
disability (Gomes et al., 2009).  There is uncertainty regarding the effect of such an intervention if 
given more than 6 hours after the onset of symptoms (Grobusch, 2009), highlighting the importance 
of early access to treatment.  
In this model I assume that early administration of artesunate (intravenous or rectal) with a course 
of ACTs will prevent progression to fulminant severe disease in these individuals, and may occur at 
the health facility or private outlet level.   
Table 13: Severe Disease Drug related parameters 
Name Definition Value Range Value 
Used  
References 
cSevTx/HTx % reduction in average 
infectiousness compared to 
state occupied prior to 
treatment 
80.6% * cD 0.05 (Dunyo et al., 
2006), (Griffin 
et al., 2014) 
 
3.6.4.3 Clinic Health system parameters 
The use of pre-referral rectal or intramuscular artesunate is included at community level in order to 
prevent progression to severe disease in those at risk of developing early severe disease.   Given the 
recent change in guidance regarding the use of pre-treatment with artesunate, very little data are 
available on the frequency of its use.  A study in Uganda (Sears et al., 2013) found that amongst 
patients who were given a diagnosis of severe malaria or who were referred for admission due to 
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the severity of their symptoms, the most frequently prescribed antimalarial was still quinine.  Only 
6.5% were given ACTs (Sears et al., 2013). Also from Uganda Kyabayinze et al. noted that at tertiary 
level facilities, 70% of the patients referred from lower level health facilities had received pre-
referral antimalarial drugs but none had been prescribed pre-referral rectal artesunate (Kyabayinze 
et al., 2012). 
Hence I estimated the probability of the treatment of severe disease (ftr_SEVCL) at clinical level, i.e. 
using rectal artesunate and ACTs, by multiplying the probability of receiving ACTs at a public sector 
clinic (ftr_CL) and the probability of having artesunate stock.  The method for deriving ftr_CL is 
described in Chapter 4. 
Stocks of rectal or intravenous artesunate are not commonly reported. In Uganda, Kyabayinze 
surveyed 125 primary care clinics across 11 districts and found rectal artesunate for pre-referral 
medication was only available in one health centre (Kyabayinze et al., 2012). I estimated the 
probability of artesunate availability at public facilities using the AMFm evaluation (AMFm 
Independent Evaluation Team, 2012) which reports on both the proportion of outlets with 
artemisinin monotherapy (all forms) in stock and the proportion of outlets with oral artemisinin 
monotherapy in stock, across 8 countries. I assumed that the difference accounts for rectal and 
intravenous preparations of artesunate. 
There is little published data on the probability of severe cases being referred to tertiary care 
facilities and hospitals for in-patient care from public sector health facilities. The IMPACT 2 study in 
Tanzania, described in greater detail in Chapter 5, did not record any referrals from clinics to 
hospitals. Kyabayinze documents that of 186 patients that were referred to hospitals for severe 
malaria, only 10% had received adequate referral care including notes and transport support 
(Kyabayinze et al., 2012).  Hence I used this figure to estimate the probability of referral for severe 
disease to higher level facilities. 
Table 14: Severe disease Clinic parameters 
Name Definition Value Range Value Used  References 
ftr_SEVCL Probability of severe case 
receiving Artesunate and ACT 
at a public sector/government 
health clinic 
Artesunate in stock: 0 – 
0.38 
0.2*0.5 = 0.1 
(See Chapter 
4 for ftr_CL) 
(AMFm 
Independent 
Evaluation 
Team, 2012, 
Mangham et 
al., 2012, 
Kyabayinze et 
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al., 2012) 
ftr_REFCL Probability of a severe case 
seen at public 
sector/government health 
clinic being referred to in-
patient/tertiary care/hospital 
for treatment 
 0.1 (Kyabayinze 
et al., 2012, 
Berendes et 
al., 2012) 
 
3.6.4.4 Informal sector parameters 
I estimated the probability of receiving rectal or intravenous artesunate and ACTs at a private sector 
outlet (ftr_SEVPR) by multiplying the probability of suitable artesunate preparations in stock with the 
probability of receiving ACTs for malaria at a private outlet (ftr_PR). The method by which ftr_PR is 
estimated is described in Chapter 4.  Estimates of artesunate stocks in the private sector were used 
from surveys in Nigeria (Berendes et al., 2012, Okeke and Uzochukwu, 2009, Mangham et al., 2011) 
and Cameroon(Mangham et al., 2012) as well as the AMFm evaluation. Reducing the use of oral 
artemisinin monotherapy at private sector outlets has been identified as a target for the AMFm 
initiative, and this policy objective may have affected the reporting, use and stock of other 
artesunate monotherapy preparations at drug and general shops. 
Private sector outlets are increasingly included within national malaria control strategies, especially 
through subsidy schemes such as AMFm. Hence it is a quality of care concern that private outlet staff 
are able to recognise the symptoms of severe disease and understand the urgency of referral to a 
health facility or tertiary level clinic. A recent study in Kenya found that over a quarter of 
interviewed drug shop owners knew to ask about at least one symptom of severe disease. However 
only 1% knew what the appropriate actions were if a child did not recover or was vomiting their 
medication (Kangwana et al., 2013). Similar results were seen in a study in Nigeria by Berendes et al, 
who estimated that after training, 14% (CI: +/- 7.63%) of shop owners could recognise the symptoms 
needing referral (Berendes et al., 2012). 
Table 15: Severe Disease Informal sector parameters 
Name Definition Value Range Value Used  References 
ftr_SEVPR Probability of severe case 
receiving ACT at private sector 
drug shop or outlet 
Artesunate in 
stock: 0 – 0.57 
0.2*0.05 = 
0.01  
(See Chapter 
(Mangham et 
al., 2012, 
Mangham et 
al., 2011, 
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4 for ftr_PR) AMFm 
Independent 
Evaluation 
Team, 2012, 
Berendes et al., 
2012, Okeke 
and 
Uzochukwu, 
2009) 
ftr_REFPR Probability of a severe case seen 
at private sector drug shop or 
outlet being referred to in-
patient/tertiary care/hospital for 
treatment 
0.002 – 0.26 0.01  (Kangwana et 
al., 2013, 
Berendes et al., 
2012) 
Unpublished 
data 
(IMPACT 2 
study) 
 
3.6.4.5 Hospital parameters 
The SEAQUAMAT (Dondorp et al., 2005) and AQUAMAT (Dondorp et al., 2010) trials have favourably 
compared the use of intravenous artesunate to quinine for the treatment of severe malaria and the 
most recent WHO guidance recommends artesunate followed by ACTs as first line treatment (WHO, 
2010a). Yet data regarding the care capacity and quality at a hospital level in sub-Saharan Africa is 
limited.  A study by Achan et al. surveyed case management of severe malaria in Uganda at 83 lower 
level facilities and 22 in-patient facilities, before the change in guidance recommending artesunate 
as first-line treatment for severe malaria (Achan et al., 2011).  Microscopy was available in 77.3% of 
inpatient hospital units and 51% of the higher level clinics.  In the preceding 3 months only 54% of 
the hospital and higher level facilities had consistent availability of parenteral quinine, while fewer 
had consistent stocks of oral quinine (16.2%) and ACTs (33.3%). None of the inpatient facilities had 
consistent availability of all seven components of a basic care package for severe malaria 
management (parenteral quinine, intravenous fluids, 50% dextrose, blood for transfusion, 
transfusion sets, IV giving sets and syringes). The most common stockouts were for blood (only in 
4.5% units), 50% dextrose (32% units) and 5% dextrose and transfusion sets (35.4%). The majority of 
the staff at inpatient and higher level facilities were nurses/midwives, with only 2 doctors noted on 
survey days. Approximately 52% of workers at the higher level facilities were able to write an 
appropriate prescription for a child with severe malaria, and only 22% had received in service 
training on severe malaria or supportive supervision. Whilst over 90% of patients prescribed IV 
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quinine were prescribed it correctly, the dose of IV artesunate was incorrect in all 8 of the patients it 
was given to. Overall only 16.9% of patients hospitalised with severe malaria were given full correct 
management: initial parenteral antimalarial medicine, dosing regimen, and mode of administration, 
although the actual dosage of quinine and regimen was correct in 70%, administration in the correct 
volumes of dextrose etc. was only correct in 18%.  
Noor et al. in Somalia found that at hospital facilities 95.5% of health workers reported use of ACTs 
as first line treatment (as opposed to 0% in the peripheral health posts) and 91% used quinine for 
severe malaria or treatment failure (Noor et al., 2009). However 54.5% of hospitals had stockouts on 
the day of survey of the first-line treatment.  Given the paucity of evidence at this level, I have 
therefore assumed that the probability of receiving artesunate and ACTs for malaria at a tertiary 
level facility (ftr_H) is the probability of having these preparations in stock. 
Manongi et al. found that in rural Tanzania the mortality impact of poor access to tertiary care for 
severe disease was potentially substantial, but constrained by uncertainty in the quality of in-patient 
care (Manongi et al., in submission). Treatment seeking at a hospital for severe disease was 
estimated from unpublished data from the IMPACT 2 study in Tanzania (described in Chapter 5) as 
well as data describing hospital visits following attendance at another facility first (Agyepong and 
Kangeya-Kayonda, 2004): 9% surveyed attended hospital as a first choice for fever where as 43% 
attended as a second choice if their symptoms became worse. I assumed that the probability of 
attending a hospital as a first choice source of treatment (f_H) is the same as the probability of 
attending following referral. 
Table 16: Hospital Parameters 
Name Definition Value Range Value 
Used  
References 
f_H  Probability of accessing care at a 
hospital-level facility per severe 
episode  
0– 0.43  0.1  (Noor et al., 
2009, Achan et 
al., 2011, 
Agyepong and 
Kangeya-
Kayonda, 2004), 
Unpublished 
data IMPACT 2 
1/r_H Average time taken to seek treatment 
at appropriate level facility for severe 
malaria 
1.3 - 7.25  
(data from 
hospitalised 
2 (Feikin et al., 
2009, Al-Taiar 
et al., 2008, 
Rutebemberwa 
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patients: time from 
start of infection) 
et al., 2009) 
Unpublished 
data IMPACT 2 
ftr_H Probability of receiving correct 
treatment at hospital or high level 
facility for severe malaria (i.e. 
probability of artesunate and ACTs in 
stock) 
0.28-0.82 0.5  Unpublished 
data IMPACT 2 
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3.6.5 Results from Model 3: Severe disease and Hospital model 
3.6.5.1 Impact of public sector health interventions on clinical outcomes 
Model 3 includes pathways for those at risk of acute severe disease as well as those who develop 
severe disease after failing to be successfully treated for uncomplicated malaria.  Figure 31 shows 
the impact on malaria mortality in 0-5 year olds of altering:  
1. probability of an uncomplicated malaria case receiving an ACT at a public sector clinic (ftr_CL)  
2. probability of a malaria case at risk of acute severe disease receiving an ACT and pre-referral 
rectal or intramuscular Artesunate at a public sector clinic as per WHO guidelines (ftr_SEVCL) 
3. probability of a potentially severe malaria case being referred to hospital or tertiary care 
facility from a public sector clinic (f_REFCL)  
4. the probability of a severe malaria case seeking care at a hospital or tertiary care facility (f_H)  
5. probability of a severe malaria case being treated at a hospital or tertiary care facility with 
artesunate and ACTs as per WHO guidelines (ftr_H) 
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Figure 32: Model 3 - The impact on malaria mortality, in 0-5 year olds at 4 prevalence settings, of varying the probability of being treated at clinic, being referred to 
hospital, accessing hospital care and receiving Artesunate plus ACTs at hospital/tertiary care. 
1) probability of uncomplicated  malaria case receiving an ACT at a clinic (ftr_CL: dark blue); 2) probability of a malaria case at risk of severe disease receiving an ACT and 
rectal /IM  Artesunate (ftr_SEVCL: red); 3) probability of a potentially severe malaria case being referred to hospital from clinic (f_REFCL: green); 4) the probability of seeking 
care at a hospital (f_H: purple); 5) probability of being treated for severe malaria at a hospital or tertiary care facility with artesunate and ACTs as per guidelines access 
to treatment (ftr_H: light blue). 
0
1
2
3
4
5
6
7
8
9
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
ftr_cl (baseline 0.5)
ftr_sevcl (baseline 0.1)
ftr_refcl (baseline 0.1)
f_h (baseline 0.1)
ftr_h (baseline 0.5)
1
%
:
M
al
ar
ia
 m
o
rt
al
it
y
(p
e
r 
1
0
0
0
 p
e
rs
o
n
s 
p
e
r 
ye
ar
):
 b
as
e
lin
e
 0
.9
0
1
2
3
4
5
6
7
8
9
10
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
1
0
%
: M
al
ar
ia
 m
o
rt
al
it
y
(p
e
r 
1
0
0
0
 
p
e
rs
o
n
s 
p
e
r 
ye
ar
):
 b
as
e
lin
e
 8
0
5
10
15
20
25
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
2
5
%
; M
al
ar
ia
 m
o
rt
al
it
y
(p
e
r 
1
0
0
0
 p
e
rs
o
n
s 
p
e
r 
ye
ar
):
 b
as
e
lin
e
 1
7
.4
0
5
10
15
20
25
30
35
40
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
5
0
%
: M
al
ar
ia
 m
o
rt
al
it
y
(p
e
r 
1
0
0
0
 p
e
rs
o
n
s 
p
e
r 
ye
ar
):
 b
as
e
lin
e
 3
2
.3
134 
 
At low transmission settings, varying the quality of community (health facility) treatment of 
uncomplicated malaria impacts most greatly on malaria mortality, whereas altering the access to 
and quality of tertiary care does not greatly affect this outcome.  At higher transmission settings, the 
quality of treatment for uncomplicated malaria does not appear to drive rates of malaria mortality 
as much as access to tertiary care where IV artesunate is assumed to be available.  This is further 
demonstrated in Table 17 which lists the maximal reduction relative to baseline achieved with each 
of the 5 interventions (i.e. when each parameter is equal to 1) on severe disease incidence and 
malaria mortality in 0-5 years olds.   
Table 17: Relative change (%) in malaria mortality and severe disease incidence from baseline in each 
prevalence setting 
 1% slide prevalence 10% slide 
prevalence 
25% slide 
prevalence 
50% slide 
prevalence 
Mortality Severe 
Disease 
Mortality Severe 
Disease 
Mortality Severe 
Disease 
Mortality Severe 
Disease 
ftr_CL=1 -99.9 -99.9 -95.4 -95.3 -10.3 -11 -7.7 -9.4 
ftr_SEVCL=1 -33.6 -35.5 -14.6 -16.7 -10.8 -10.3 -7.6 -5.2 
f_REFCL=1 -14.8 -26.3 -6 -17.8 -4.4 -10.9 -3.1 -5.5 
f_H=1 -68 -66.5 -41.2 -38.4 -41.4 -36 -41.4 -34 
ftr_H=1 -27.3 -17.3 -12.3 0.2 -12.2 -0.1 -12 -0.02 
 
Improving the probability of receiving ACTs for uncomplicated malaria (from 50% at baseline to 
100%) is the most effective of the interventions considered here in reducing both malaria mortality 
and severe disease incidence in this age group at lower transmission settings.   
At 25% and 50% prevalence settings, ensuring cases seek treatment at a hospital (from baseline 10% 
to 100%, and thus are treated there (even at baseline assumed levels of hospital treatment with 
ACTs) may decrease malaria mortality by up to 40%.  This also impacts the incidence of severe 
disease. This is due to the structure of the model, whereby acute severe disease cases referred from 
clinics or drug shops to the hospital bypass the severe disease state. Hence severe disease is averted 
so long as appropriate treatment at hospital occurs. Improving the quality of treatment at hospital 
does not affect the incidence of severe disease (as cases arrive to hospital either from the severe 
disease state or via referral from community, bypassing the severe disease state) but may reduce 
malaria mortality.  
Further results using Model 3 are described in Chapter 5.  
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3.7 CONCLUSION 
This chapter defines a model investigating the effect of first-line antimalarial delivery on malaria 
transmission and clinical outcomes at varied malaria prevalence settings.  The model was iteratively 
constructed incorporating (a) access to primary level or community sources of ACTs, i.e. public 
sector health facilities and informal private sector outlets, and (b) the quality of care in the different 
sectors, i.e. the probability of a malaria case receiving an ACT and NMFI unnecessarily receiving 
ACTs.  In addition, the final model reflects the role of health systems on the incidence of severe 
malaria and the different pathways by which the development of severe disease may be prevented 
or treated in the community and at tertiary level health facilities.  
The results from the initial model incorporating severe disease as a consequence of absent, delayed 
or ineffective treatment in addition to public and private sources of antimalarials suggest that 
improvements in the quality of care (i.e. the probability of receiving an ACT for a malaria infection) in 
either sector may have a larger impact on clinical outcomes than on transmission.  The model 
outputs indicate the relative reduction in severe disease incidence in 0-5 year olds is greater than 
the relative reduction in slide prevalence in 0-5 year olds in all transmission settings, with a similar 
pattern for malaria-related mortality in this age group.  This is likely to be due to the age distribution 
of clinically symptomatic malaria infections, i.e. in young children in medium-high transmission 
settings who are therefore treated as quality of care improved, whilst those who are infected but 
not symptomatic (i.e. over 5 years) continue to function as an infection reservoir. 
The second iteration of the model included the treatment of NMFI with ACTs, including 
asymptomatic and sub-patent malaria infection as well uninfected individuals.  Eliminating NMFI 
treatment with ACTs in both the private and public sectors had negligible impact on parasite 
prevalence and severe disease incidence, at baseline levels of malaria treatment.  This suggests that 
addressing the treatment of NMFI as a policy issue may not lead to unwanted rises in infection as 
feared, at present levels of quality of care. 
The final model, extended to capture tertiary level treatment of severe disease as well as early 
management of acute disease at a community level to avert fulminant severe disease, demonstrates 
that improved management of uncomplicated disease at community level is sufficient to reduce 
levels of malaria mortality at low transmission settings.  However at medium-high prevalence levels, 
investment in tertiary care both in terms of access and the ability to treat with artesunate is required 
to improve treatment of severe malaria and its complications and in turn reduce malaria-related 
mortality. 
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The model is limited by the assumption that I only considered ACTs as treatment, and hence 
assumed that any other antimalarials do not exert an effect on clinical outcomes or transmission. 
Furthermore the parameter values regarding the efficacy of ACTs are based on AL (Artemether 
Lumefantrine), and thus may vary for other combinations.  The average period of prophylaxis (1/rP) 
is assumed to be the fixed duration of minimum inhibitory anti-malarial concentrations in the blood 
against blood stage parasite, although this may also vary with immunity.  In addition, the model does 
not account for repeat treatment-seeking in any sector, and thus may overestimate the impact of 
stockouts.  Further work is required on health seeking behaviour, especially in the private sector to 
understand whether patients will attend several sources of care if drugs are unavailable or accept 
other non-first line medication.  
The analysis finds that access to local sources of anti-malarial treatment (i.e. probability of seeking 
treatment) has the greatest relative impact at lower prevalence settings on both transmission-
related and clinical outcomes.  At higher prevalence scenarios, interventions which increase use of 
ACTs are most effective in addressing malaria morbidity and mortality. Reducing transmission 
through treatment with ACTs in higher transmission settings will require investment across private 
and public sectors both with respect to access to these sources of care and the ability of these 
sources to prescribe ACTs to those in need, whilst avoiding the treatment of those who do not.  
The next Chapter will consider how to estimate the quality of care received at health facilities and 
private outlets and investigate which interventions are most likely to result in malaria cases receiving 
ACTs appropriately. 
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4 IMPROVING MALARIA AND NON-MALARIAL FEBRILE ILLNESS CASE 
MANAGEMENT 
 
4.1 INTRODUCTION 
Until recently, presumptive treatment of all fevers as malaria was advocated in WHO guidelines and 
national policies for malaria-endemic areas, especially for children under 5 years (U5s).  As described 
in Chapter 2,  studies estimate between 47-95% of patients with a non-malarial febrile illness (NMFI) 
receive antimalarials unnecessarily in both public sector health facilities and private sector outlets 
(Hamer et al., 2007, Reyburn et al., 2004, Zurovac et al., 2008b, Rowe et al., 2009a, Nicastri et al., 
2009, Nankabirwa et al., 2009, Okebe et al., 2010, Bastiaens et al., 2011, Nyandigisi et al., 2011, 
Harchut et al., 2013, Mangham et al., 2012). Overtreatment is often with non-recommended 
antimalarials (Zurovac et al., 2008b, Noor et al., 2009, Mangham et al., 2012, Mangham et al., 2011), 
but may involve first-line ACTs (Okebe et al., 2010, Rowe et al., 2009a, Hamer et al., 2007, Nyandigisi 
et al., 2011, Zurovac et al., 2008b, Mangham et al., 2012, Mangham et al., 2011). In 2010, the WHO 
revised the protocols for the treatment of malaria to state that whenever possible:  
“... prompt parasitological confirmation by microscopy or alternatively by rapid diagnostic test (RDT) 
is recommended in all patients suspected of malaria before treatment is started. Treatment solely on 
the basis of clinical suspicion should only be considered when a parasitological diagnosis is not 
accessible” (WHO, 2010a).  
In 2012, the WHO launched “T3: Test. Treat. Track”(WHO, 2012b), an initiative to reduce routine 
overtreatment of NMFI with antimalarials, to expand disease surveillance and to improve quality of 
care for both malaria and NMFI. Though its likely impact remains a subject of debate (Graz et al., 
2011, Bjorkman and Martensson, 2010, English et al., 2009, D'Acremont et al., 2009, Masanja et al., 
2011), the strategy has been widely adopted in guidelines across malaria endemic countries (WHO, 
2012b).  
The WHO estimates that net expenditure on antimalarial treatment may decrease as a result of 
testing before treatment (Feachem et al., 2010). However non-compliance with test results by 
healthcare workers (HCWs), i.e. treating with antimalarials despite a negative test for malaria, is 
common (Chandler et al., 2012, Chandler et al., 2010, Chandler et al., 2008a) and can be detrimental 
to those patients who are not parasitaemic. For example, a Tanzanian study found the case fatality 
rate, in albeit hospitalised, test-negative patients treated with antimalarials, to be significantly 
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higher (12.1%) than for test-positive patients (6.9%), and over 60% of NMFI were not treated with 
antibiotics (Reyburn et al., 2004). A study, in a high malaria transmission region of Tanzania, of 
severe hospitalised NMFI found that half of the bacteraemic patients were not prescribed empirical 
antibiotics; whilst three quarters of all febrile admissions were diagnosed on admission with severe 
malaria, only 20% were found to be parasitaemic (Nadjm et al., 2012). 
As described in Chapter 2, private outlets such as drug stores and general shops are often staffed 
with poorly qualified staff. Not only are antimalarials often overprescribed presumptively for fever 
(Kangwana et al., 2011, Ringsted et al., 2011, Littrell et al., 2011a, Littrell et al., 2011b), there is good 
evidence of use of substandard or counterfeit antimalarials, as well as artemisinin monotherapy or 
chloroquine as first-line treatments (Kaur et al., 2008, Bate et al., 2008, Newton et al., 2006, Noor et 
al., 2009, Alba et al., 2010b, Amuasi et al., O'Connell KA et al., 2011, Littrell et al., 2011b). Quality 
assured ACTs (QAACTs) as certified by organisations such as AMFm and ACTWatch represented less 
than 20% of the antimalarial market (O'Connell KA et al., 2011, Ringsted et al., 2011, Kangwana et 
al., 2011). ACTs are also priced higher in the private sector compared to other antimalarials, despite 
this being the most common point of access (O'Connell KA et al., 2011). 
The price and quality of Artemisinin Combination Therapies (ACTs) has been a barrier to effectively 
expanding their use in the private sector. In 2009, the subsidy programme Affordable Medicines 
Facility for malaria (AMFm) was launched, seeking to reduce the price through a co-payment facility, 
and therefore aiming to increase access to QAACTs and drive out ineffective drugs and 
monotherapies(Laxminarayan R and H, 2009).  As reported in Chapter 2, the price subsidy is 
acknowledged to have been passed widely onto customers (AMFm Independent Evaluation Team, 
2012, Tougher et al., 2012) and the market share of QAACTs has increased (Tougher et al., 2012, 
AMFm Independent Evaluation Team, 2012). However it is not yet clear whether drug subsidies have 
translated into a higher standard of malaria treatment in the private sector. 
Effective malaria control requires the delivery of interventions at sustained high levels of coverage 
and quality, ensuring those who need treatment receive it, and that those febrile patients who do 
not have malaria infections, are not needlessly treated. There have been relatively few modelling 
approaches to address the delivery of treatment for case management of malaria and NMFI (Tediosi 
et al., 2006, Rafael et al., 2006, Lubell et al., 2008, Zurovac et al., 2008a). 
The “systems effectiveness framework” (Tanner et al., 1993) described in Chapter 2, illustrates how 
interacting health-systems barriers may sequentially reduce the in-field effectiveness of treatment 
interventions (Hetzel et al., 2008, Krause and Sauerborn, 2000, Littrell et al., 2013). This has proved 
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valuable as a means of analysing the steps to optimal case management. However outcomes such as 
the proportion of malaria cases that receive first-line treatment through all pathways (i.e. not solely 
via diagnostic-led management) and the levels of unnecessary treatment of NMFI with antimalarials 
are not addressed by this approach. Such outcomes are important given the limited budgets for the 
purchase and distribution of antimalarial treatment courses. The INESS project in Ghana, using this 
framework for delivery in the public sector, estimated that just 13.5% of simple malaria fevers were 
treated effectively, with the greatest loss due to failure to access care within 24-48 hours (Binka et 
al., 2012). Patient adherence was included in this analysis and constituted the second largest 
bottleneck (Binka et al., 2012). However this differs from WHO estimates of cases of malaria treated 
with ACTs and other published studies (Mangham et al., 2012, Sserwanga et al., 2011) in part 
because it does not include alternative non-recommended pathways to receiving treatment. 
In Chapter 3, I defined a model investigating the effect of first-line antimalarial delivery on malaria 
transmission and clinical outcomes, at varied malaria prevalence settings. The model was 
constructed in stages incorporating access to community sources of ACTs, i.e. public sector health 
facilities and informal sector outlets, as well as considering the quality of care in the different 
sectors.   
In this Chapter, I extend the systems effectiveness framework into a decision-tree tool to derive and 
compare estimates of the quality of care in the private and public sectors. In the model outlined in 
Chapter 3, quality of care parameters are ftr_CL and ftr_PR, namely the probability of a malaria case 
receiving an ACT at either a public sector clinic or a private outlet, and ftr_NMFICL and ftr_NMFIPR, i.e. the 
probability of NMFI unnecessarily receiving ACTs at a public sector clinic or a private outlet. The 
decision-tree outputs are used as the baseline parameters in the models described in Chapter 3. 
Decision-tree approaches have previously been used to consider the role of diagnostics in reducing 
the burden of childhood malaria in Africa (Rafael et al., 2006, Lubell et al., 2008). Here I include 
considerations of treatment seeking, diagnostic availability, use and quality, as well as ACT stock in 
order to compare interventions to improve case management in a context specific manner. I also use 
this tool to undertake an early evaluation of the impact of the revised WHO guidelines on treatment 
outcomes for malarial and non-malarial fever, and the impact of AMFm on the management of fever 
in the private sector. 
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4.2 METHODS 
4.2.1 Systems Effectiveness and Decision-Tree Approach 
I consider two approaches to evaluate the impact of improvements in case management on the 
appropriate treatment of fevers in malaria endemic settings. The first follows the published stepwise 
systems effectiveness framework for case management (Tanner et al., 1993, Mumba et al., 2003, 
Hetzel et al., 2008, Krause and Sauerborn, 2000), whilst the second is a decision-tree approach to 
malaria treatment (Figure 33) extending previous similar decision-tree models for diagnostics (Lubell 
et al., 2008, Rafael et al., 2006).  The entry point is a febrile case seeking treatment, for both public 
sector health facilities and private sector drug and general shops. I next stratify on their true 
(unobserved) cause of fever as either malaria or non-malarial febrile illness (NMFI). The case 
management process then involves five steps:  
1. the availability of an RDT 
2. whether the RDT is used 
3. the outcome of the RDT given the true underlying cause of fever (based on the sensitivity 
and specificity of the diagnostic) 
4. whether an ACT is in stock 
5.  whether an ACT is prescribed given the RDT result or clinical diagnosis.   
I do not consider the possibility of a co-morbid condition causing fever as well as malaria at this 
stage.   
This leads to three outcomes:  
1. correct treatment – namely ACTs for malaria, and NMFI not receiving any ACT (both shown 
as green circles),  
2. under-treatment of malaria (shown as a purple circle, i.e. not given ACTs),  
3. overtreatment of an NMFI with ACTs (shown as a red circle).   
In a perfect case management system there would be no under- or over-treatment. Treatment 
following clinical (i.e. non-diagnostic guided) diagnosis is included in the decision tree, but was not 
included in the published systems effectiveness framework (Tanner et al., 1993, Binka et al., 2012). 
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Figure 33: Decision tree modelling approach to malaria case management in the public sector.   
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The outcome of the systems effectiveness approach is the proportion of malaria cases that receive 
correct diagnostic-led treatment with ACTs. In contrast, the decision-tree allows a wider spectrum of 
outcomes to be evaluated: 
1. Correct treatment of malaria with ACTs (diagnostic-led or clinically diagnosed) 
2. Under-treatment of malaria cases (i.e. those not given ACTs) 
3. Overtreatment of NMFI with ACTs  
4. Overall number of febrile patients treated appropriately (i.e. both malaria cases given ACTs 
and NMFI not treated with ACTs).   
Staff availability and training in malaria management were not included at this stage as, despite 
having potential impact, their effects can be difficult to quantify as described in Chapter 2 (Rao et al., 
2013a) . Stockouts of treatment for NMFI were not considered given the diversity of possible 
bacterial and non-bacterial causes, uncertainty regarding the need for antibiotics, and the high 
likelihood of basic antibiotics being available. In addition  the focus here is the impact of the health 
system, hence patient adherence to ACTs prescribed and drug failure were not included in either 
approach.  
 
4.2.2 Model Parameters: Public sector/government health facility 
Parameters for the moderate-high transmission setting analysis were derived from the literature 
review in Chapter 2 (Rao et al., 2013a). The parameters were restricted to data presented in studies 
published between January 2004 (following adoption of ACT as first-line treatment in most 
countries) and November 2012.  The model parameters are shown in Table 18. For each health-
systems parameter I extracted any relevant data from the papers restricting my analysis to medium-
high transmission settings (as reported in the papers included).  I also stratified by whether the study 
was conducted before or after the introduction of the WHO guidelines regarding universal rational 
(diagnostic-led) treatment in 2010 (WHO, 2010a). Parameters for diagnostic performance were 
derived from published values for the sensitivity and specificity of RDTs. I did not limit this to a 
specific type of RDT nor did I differentiate between the various types of RDTs or microscopy for 
parameters of diagnostic availability and use. In this public sector model, I used estimates for “all 
doses of ACT” being available assuming this to be paediatric and adult preparations. Case 
management values for low prevalence scenarios were limited, and so I included studies published 
in regions outside Africa (including Afghanistan).   
143 
 
For the baseline scenario I calculated the median of the extracted estimates for each parameter and 
the 25th and 75th percentiles for the parameter range.  These ranges were chosen so as not to skew 
the results by sampling outliers. To calculate uncertainty intervals I generated 1000 random 
parameter samples, drawing each parameter independently from a Uniform distribution between 
the 25th and 75th percentiles.  
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Table 18: Parameter estimates for each process in the cascade and decision-tree models in the public sector 
 Pre universal 
rational 
treatment 
guidelines  
Post  universal 
rational 
treatment 
guidelines  
Pre universal 
rational 
treatment 
guidelines  
Post  universal 
rational 
treatment 
guidelines  
References 
 All Studies Tanzania  
Probability of patient with 
fever seeking treatment at 
public sector clinic 
0.28 (0.26-0.39) 0.29 (0.26-0.40) 0.28 (0.26-0.39) 0.29 (0.26-0.40) (Littrell et al., 2011a, Tipke et al., 2009, Mangham et al., 
2012, Chuma et al., 2009, Chuma et al., 2010, Sumba et 
al., 2008, Amin et al., 2003) 
Probability fever is due to 
malaria 
0.22 (0.13-0.33) 0.22 (0.13-0.33) 0.18  0.1  (WHO, 2010c, WHO, 2012c, Hay et al., 2004, O'Meara et 
al., 2010, D'Acremont et al., Carneiro et al., 2010, Leslie 
et al., 2012, Okebe et al., 2010) 
Probability that a diagnostic 
is available 
0.54 (0.36-0.97) 0.58 (0.50-0.83) 0.35 (0.34-0.36) 0.61 (0.55-0.68) (Rowe et al., 2009a, Leslie et al., 2012, Mangham et al., 
2012, Littrell et al., 2011a, AMFm Independent 
Evaluation Team, 2012, Zurovac et al., 2008b, 
Nyandigisi et al., 2011, Skarbinski et al., 2009, Juma and 
Zurovac, 2011, Noor et al., 2009, Abdelgader et al., 
2012, Masanja et al., 2012b, Nankabirwa et al., 2009, 
Hamer et al., 2007, Uzochukwu et al., 2010) 
Probability that a diagnostic 
is used if available 
0.39 (0.29-0.58) 0.46 (0.34-0.46) 0.69 (0.47-0.71) 0.71 (0.52-0.83) (Okebe et al., 2010, Rowe et al., 2009a, Leslie et al., 
2012, Littrell et al., 2011a, Mangham et al., 2012, 
Zurovac et al., 2008b, Zurovac et al., 2008c, Nyandigisi 
et al., 2011, Skarbinski et al., 2009, Juma and Zurovac, 
2011, Abdelgader et al., 2012, Masanja et al., 2012b, 
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Bastiaens et al., 2011, D'Acremont et al., 2011, 
Nankabirwa et al., 2009, Sserwanga et al., 2011, 
Kyabayinze et al., 2010) 
Diagnostic sensitivity 0.90 (0.78-0.92) 0.86 (0.72- 0.92) 0.82 (0.63-0.92) 0.82 (0.62-0.86) (Abeku et al., 2008, Masanja et al., 2012b, Ishengoma et 
al., 2011, Mtove et al., 2011b, Msellem et al., 2009, 
Baiden et al., 2012) 
Diagnostic specificity 0.86 (0.8-0.92) 0.91 (0.82-0.98) 0.89 (0.83-0.95) 0.98 (0.91-0.98) (Baiden et al., 2012, Abeku et al., 2008, Masanja et al., 
2012b, Ishengoma et al., 2011, Mtove et al., 2011b, 
Msellem et al., 2009, Leslie et al., 2012) 
Probability that all dose 
packages of ACT are 
available 
0.65 (0.54-0.73) 0.64 (0.62-0.68) 0.59 (0.51-0.67) 0.85 (0.81-0.90) (Rowe et al., 2009a, O'Connell KA et al., 2011, 
Mangham et al., 2012, AMFm Independent Evaluation 
Team, 2012, Njogu et al., 2008, Zurovac et al., 2008b, 
Zurovac et al., 2008c, Kangwana et al., 2009, Nyandigisi 
et al., 2011, Juma and Zurovac, 2011, Sudoi et al., 2012, 
Noor et al., 2009, Mangham et al., 2011, Abdelgader et 
al., 2012, Masanja et al., 2012b, Zurovac et al., 2008d, 
Zurovac et al., 2007, Uzochukwu et al., 2010) 
Probability that ACT is 
prescribed/dispensed if test 
positive 
0.99 (0.91-1.0) 0.98 (0.76-0.99) 1.00 (0.99-1.00) 1.00 (0.87-1.00) (Rowe et al., 2009a, Bisoffi et al., 2009, Mangham et al., 
2012, Ansah et al., 2010, Zurovac et al., 2008b, Zurovac 
et al., 2008c, Nyandigisi et al., 2011, Skarbinski et al., 
2009, Juma and Zurovac, 2011, Abdelgader et al., 2012, 
Masanja et al., 2012b, Masanja et al., 2010, Ishengoma 
et al., 2011, Bastiaens et al., 2011, D'Acremont et al., 
2011, Kyabayinze et al., 2010, Sserwanga et al., 2011) 
Probability that ACT is 
prescribed/dispensed if test 
0.51 (0.39-0.71) 0.25 (0.11-0.53) 0.77 (0.53-0.81) 0.12 (0.08-0.20) (Rowe et al., 2009a, Bisoffi et al., 2009, Mangham et al., 
2012, Ansah et al., 2010, Zurovac et al., 2008b, Zurovac 
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negative et al., 2008c, Nyandigisi et al., 2011, Skarbinski et al., 
2009, Juma and Zurovac, 2011, Abdelgader et al., 2012, 
Nicastri et al., 2009, Masanja et al., 2012b, Ishengoma 
et al., 2011, Bastiaens et al., 2011, D'Acremont et al., 
2011, Nankabirwa et al., 2009, Kyabayinze et al., 2010, 
Sserwanga et al., 2011, Okebe et al., 2010, Leslie et al., 
2012) 
Probability that ACT 
prescribed/dispensed if 
untested  
0.67 (0.65-0.84) 0.49 (0.23-0.71) 0.89 (0.79-0.95) 0.15 (0.08-0.21) (Zurovac et al., 2008b, Okebe et al., 2010, Bastiaens et 
al., 2011, Nyandigisi et al., 2011, Mangham et al., 2012, 
Leslie et al., 2012, Skarbinski et al., 2009, Juma and 
Zurovac, 2011, Abdelgader et al., 2012, Masanja et al., 
2012b, Zurovac et al., 2008c, Kyabayinze et al., 2010, 
Zurovac et al., 2008d, Bisoffi et al., 2009, Ansah et al., 
2010) 
The median and interquartile range from the published studies are presented. For the probability of seeking treatment at the public sector clinic, diagnostic sensitivity and diagnostic 
specificity, separate values for Tanzania were not available and so the general parameters were used. The probability of fever being due to malaria was assumed the same both before and 
after the institution of the WHO guidelines in the aggregated analysis but set to reflect the reduction in malaria incidence seen in Tanzania from 2007 to 2011. In the Tanzanian case study, the 
probability of at least one dose of ACT being in stock was used rather than the probability of all doses of ACT being in stock due to limited data on the latter. 
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4.2.3 Model Parameters: Private outlet/drug shop 
A similar approach was taken to derive model parameters for private outlets such as drugs shops 
and other general shops that sell antimalarials, as defined in Chapter 2, drawing from the systematic 
review presented in Chapter 2 (Rao et al., 2013a) as well as from evaluation of the AMFm 
programme in Tanzania by the IMPACT 2 study (Thomson et al., in submission, Thomson, 2011) 
which is described in greater detail in Chapter 5. These drug shops are known by several names 
across Africa, e.g. duka la dawa baridi (DLDB) but also include general local shops. I did not include 
private medical clinics staffed by doctors since these are rare and not present across the region. The 
model parameters are shown in Table 19.  
For each health-systems parameter I extracted any relevant data from medium-high transmission 
settings (as reported in the papers included). In addition, I also stratified the data by whether the 
study was conducted before or after the introduction of the subsidised ACTs as part of the AMFm 
rollout (AMFm Independent Evaluation Team, 2012) if the data were from any of the eight AMFm 
pilot countries. Data on the dispensing practices of vendors were scarce. Hence the probability of 
receiving either any ACT or a QAACT when untested or test-negative at baseline was assumed to be 
the same due to the low levels of testing and lack of data regarding vendor compliance to test 
results.  
The probability that a QAACT is given following a positive diagnostic result or if untested was 
estimated by multiplying the probability that any ACT was used by the proportion of patients known 
to receive QAACTs overall, i.e. market share of QAACTs.  In addition, the probability of at least one 
dose of ACT/QAACT being in stock was used rather than the probability of all doses of ACT/QAACT 
being in stock due to limited data on the latter. This was felt to be reasonable since the practice of 
“dose stacking” is recognised, where individuals are treated with multiple lower dose packs if the 
correct dosage is not available. Values for diagnostic sensitivity and specificity were the same as 
used in the public sector models since little data have been published from this setting.   
The probability of treatment seeking after the rollout of AMFm was assumed to be the same as 
before rollout in the absence of any evidence to suggest otherwise, and since there was little time 
between the studies for substantial change to have occurred.  
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Table 19: Parameter estimates for each process in the cascade and decision-tree models in the private sector 
 Pre AMFm and 
drug subsidy 
pilots 
Post  AMFm and 
drug subsidy 
pilots  
Pre AMFm and 
drug subsidy 
pilots 
Post  AMFm and 
drug subsidy 
pilots 
References 
 All Studies Tanzania  
Probability of seeking 
treatment at private outlet 
0.55 (0.25-0.68) 0.55 (0.25-0.68) 0.50 (0.37-0.59) 0.50 (0.37-0.59) (Alba et al., 2010a, de Savigny et al., 2004, Littrell et al., 
2011a, Kangwana et al., 2011, Mangham et al., 2012, 
Mangham et al., 2011, Sumba et al., 2008, Nabyonga 
Orem et al., 2013, Thomson, 2011) 
Probability fever is due to 
malaria 
0.22 (0.13-0.33) 0.22 (0.13-0.33) 0.1  0.1  (WHO, 2010c, WHO, 2012c, Hay et al., 2004, O'Meara et 
al., 2010, D'Acremont et al., Carneiro et al., 2010, Leslie et 
al., 2012, Okebe et al., 2010) 
Probability that a diagnostic 
is available 
0.02(0.00-0.09) 0.04 (0.01-0.12) 0.01 (0.01-0.02) 0.05 (0.04-0.05) (Mangham et al., 2012, Mangham et al., 2011, AMFm 
Independent Evaluation Team, 2012, Albertini, 2012, 
Uzochukwu et al., 2010, O'Connell KA et al., 2011, 
Mbonye et al., 2013, Thomson, 2011) 
Probability that a diagnostic 
is used if available 
0.04 (0.02-0.1) 0.04 (0.02-0.1) 0.04 (0.04-0.04) 0.02 (0.02-0.02) (Littrell et al., 2011a, Mangham et al., 2012, Uzochukwu 
et al., 2010, Thomson et al., in submission) 
Diagnostic sensitivity 0.90 (0.78-0.92) 0.86 (0.72- 0.92) 0.82 (0.63-0.92) 0.82 (0.62-0.86) (Baiden et al., 2012, Abeku et al., 2008, Masanja et al., 
2012b, Ishengoma et al., 2011, Mtove et al., 2011b, 
Msellem et al., 2009, Leslie et al., 2012) 
Diagnostic specificity 0.86 (0.8-0.92) 0.91 (0.82-0.98) 0.89 (0.83-0.95) 0.98 (0.91-0.98) 
Probability that any doses of 
QAACT are available 
0.11 (0.08-0.21) 
Any ACTs: 0.39 (0.14-
0.59) 
0.35 (0.12-0.66) 
Any ACTs: 0.44 (0.21-
0.68) 
0.07 (0.05-0.05)  
Any ACTs: 0.29 (0.23-
0.32) 
0.50 (0.41-0.58) 
Any ACTs:0.74 (0.72-
0.77) 
(O'Connell KA et al., 2011, Littrell et al., 2011a, AMFm 
Independent Evaluation Team, 2012, Kangwana et al., 
2011, Smith et al., Berendes et al., 2012, Mangham et al., 
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2012, Mangham et al., 2011, Noor et al., 2009, Alba et al., 
2010a, Amuasi et al., Cohen et al., 2010, Kyabayinze et al., 
2012, Mbonye et al., 2013, Thomson et al., in submission, 
Bruxvoort et al., 2013) 
Probability that QAACT is 
prescribed/dispensed  if test 
positive 
0.04 (0.05-0.06) 
Any ACTs: 0.26 (0.26-
0.26) 
0.33 (0.32-0.33) 
Any ACTs: 0.38 (0.35-
0.4) 
0.02 (0.02-0.02) 
Any ACTs: 0.26 (0.26-
0.26) 
0.4 (0.28-0.38) 
Any ACTs: 0.38 (0.35-
0.4) 
(Cohen et al., 2012, Thomson et al., in submission) 
Probability that QAACT is 
prescribed/dispensed if test 
negative 
0.02 (0.01-0.05) 
Any ACTs: 0.11 (0.08-
0.21) 
0.09 (0.07-0.08) 
Any ACTs: 0.09 (0.09-
0.09) 
0.01 (0.01-0.01) 
Any ACTs: 0.19 (0.19-
0.19) 
0.1 (0.08-0.11) 
Any ACTs: 0.09 (0.09-
0.09) 
(Cohen et al., 2012, Thomson et al., in submission) 
Probability that QAACT 
prescribed/dispensed if 
untested  
0.02 (0.01-0.05) 
Any ACTs: 0.11 (0.08-
0.21) 
0.26 (0.22-0.22) 
Any ACTs: 0.25 (0.25-
0.26) 
0.01 (0.01-0.01) 
Any ACTs: 0.19 (0.19-
0.19) 
0.27 (0.25-0.3) 
Any ACTs: 0.26 (0.25-
0.26) 
(Cohen et al., 2012, Kangwana et al., 2011, Mangham et 
al., 2012, Mangham et al., 2011, Littrell et al., 2011a, 
Mbonye et al., 2013, Hansen et al., 2013, AMFm 
Independent Evaluation Team, 2012, Alba et al., 2010a, 
Uzochukwu et al., 2010, Harchut et al., 2013, Thomson et 
al., in submission) 
The values are stratified by whether the data were collected before or after the pilot of the drug subsidy scheme – Affordable Medicines facility for malaria. Values specific to a Tanzanian 
case study are also shown. The median and interquartile range from the published studies is presented. For diagnostic sensitivity and diagnostic specificity, separate values for the private 
sector were not available and hence the same values at the public sector were used. The probability of fever being due to malaria was assumed the same in the aggregated analysis but set to 
reflect the malaria incidence seen in Tanzania (2011). In the private sector analysis, the probability of at least one dose of ACT being in stock was used rather than the probability of all doses 
of ACT being in stock as per the public sector analysis.  Probability of treatment seeking was assumed to be the same for both pre and post AMFm rollout. The probability of receiving either 
any ACT or a QAACT when untested or test-negative at baseline was assumed to be the same due to the low levels of testing, and lack of data regarding vendor performance on test 
compliance.
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4.2.4 Case Management Scenarios 
Parameters based on the literature prior to the publication of the 2010 WHO guidelines were used 
as a baseline scenario representing current practice, since the rollout of guidance is in its early stage. 
I then investigated how improving case management at different points along the patient care-
pathway impacted on the four outcomes in the decision-tree model. Table 20 summarises the set of 
scenarios considered. 
Table 20: Scenarios for improved malaria case management.   
Scenario Modified Parameters 
Baseline  
100% diagnostic availability Probability that a diagnostic is available = 1 
100% diagnostic use Probability that a diagnostic is used = 1 
100% ACT stock Probability that all (public) or any (private) doses 
of ACT are available = 1 
100% compliance with test results (i.e. 
treatment of test-positive only) 
Probability that ACT is received if test positive = 1  
Probability that ACT is received if test negative =0 
Perfect diagnostic 
 
Diagnostic sensitivity = 1 
Diagnostic specificity = 1 
100% diagnostic availability & use  Probability that a diagnostic is available = 1  
Probability that a diagnostic is used = 1 
100% diagnostic availability & ACT 
stock 
Probability that a diagnostic is available = 1  
Probability that all doses of ACT are available = 1 
100% diagnostic use and compliance 
with results   
Probability that a diagnostic is used = 1  
Probability that ACT is received if test positive = 1  
Probability that ACT is received if test negative =0 
100% diagnostic availability, use & 
compliance 
Probability that a diagnostic is available = 1  
Probability that a diagnostic is used = 1  
Probability that ACT is received if test positive = 1 
Probability that ACT is received if test negative =0 
100% diagnostic availability, use & 
compliance & ACT stock 
Probability that a diagnostic is available = 1  
Probability that a diagnostic is used = 1  
Probability that all doses of ACT are available = 1 
Probability that ACT is received if test positive = 1 
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Probability that ACT is received if test negative =0 
100% perfect diagnostic availability, 
use & compliance & ACT stock 
Probability that a diagnostic is available = 1  
Probability that a diagnostic is used = 1  
Diagnostic sensitivity and specificity= 1 
Probability that all doses of ACT are available = 1 
Probability that ACT is received if test positive = 1 
Probability that ACT is received if test negative =0 
Presumptive treatment Probability that a diagnostic used = 0 
Probability that QAACT is received if untested = 1 
 
4.2.5 Tanzania: case study 
I performed the same scenarios using only data from Tanzania as a case-study, in order to compare 
modelled outcomes using published data from before and after the early stages of the rollout of the 
new WHO guidance in the public sector.  I also compared outcomes in the private sector using data 
published prior to and following the initial implementation of the AMFm pilot in Tanzania.  Due to a 
paucity of published information, the values from all sub-Saharan Africa studies were used for the 
probability of seeking treatment at a public sector clinic. In addition, in both the Tanzanian case-
studies (public and private sectors), the probability of at least one dose of ACT being in stock was 
used rather than the probability of all doses of ACT being in stock due to limited data on the latter. 
Tables 18 and 19 summarise the model parameters for the Tanzanian case-study in each sector. 
  
152 
 
4.3 RESULTS: PUBLIC SECTOR HEALTH FACILITIES 
 
4.3.1 Comparison of systems effectiveness and decision tree approaches: public sector 
Figure 34 shows the outcomes from the systems effectiveness model for public sector facilities.  The 
grey bars show the probabilities for each step for malaria case management whilst the orange line 
and values show the cumulative probability along this pathway.  Data here is taken from studies 
published across sub-Saharan Africa prior to the rollout of the WHO guidelines on universal rational 
management.  
Using the baseline parameters in the systems effectiveness model, I estimate that 4.7% (95% 
uncertainty interval [UI]: 2.1 – 8.8%) of all malaria cases present in the population, and 14.7% (95% 
UI: 6.9 – 25.6%) of those malaria cases that actually attend the health facility, will be treated 
correctly.   
 
Figure 34: Estimated proportion of malaria cases at each case management point in the systems 
effectiveness pathway in public sector health facilities 
The grey bars show the probabilities for each step for malaria case management whilst the red line and 
values show the cumulative probability along this pathway.   
 
In contrast, using the decision tree model, which allows for the correct outcome being possible 
despite imperfect case management (e.g. a case may receive an ACT despite not being tested) I 
estimate that 54% (95% UI: 48.9 – 59.3%) of all febrile attendees in the public sector will be correctly 
managed. The decision tree calculates that 49% of malaria cases attending a public facility would 
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receive first line ACTs (95% UI: 40.6 – 59.2%).  This is similar to the WHO estimate of malaria cases 
being treated with ACTs at health facilities (WHO, 2012c, WHO, 2013) and hence appears to 
represent a rational model for case management evaluation.  I also estimate using this approach 
that 44% (95% UI: 35 – 54.8%) of NMFI cases attending the clinic would unnecessarily receive an 
ACT. 
 
4.3.2 Case-management interventions: public sector 
Modelling 100% attendance at the facility resulted in 49.6% all malaria cases in the population (95% 
UI: 40.9 – 58.6%) receiving an ACT compared with 16.2% (95% UI: 11.8 – 20.8%) at baseline.  
Increased treatment-seeking was the most effective single step in increasing the proportion of all 
febrile cases in the population that would be correctly managed and all malaria cases receiving an 
ACT.  However this has little effect in improving case management of those patients attending the 
clinic.   
Perfecting a single step in the care pathway almost always resulted in an overall predicted increase 
in the proportion of fever cases attending clinic that are correctly treated.  The one exception was a 
scenario of improving ACT stock alone (i.e. 100% availability), under which our model predicted a 
13% point reduction (95% UI: 5.0 – 21.6%) in correct management of all febrile cases. This is 
explained by a breakdown of correct overall “fever” management into the proportion of malaria 
cases receiving an ACT and the risk of NMFI being over-treated with an ACT as shown in Figure 35.   
 
154 
 
 
Figure 35: Results from the decision tree model for cases attending the public sector health facility in idealised case management scenarios 
Figure 35A) depicts the percentage of malaria cases correctly treated with an ACT (grey bars) and percentage of NMFI overtreated with an ACT (red bars) in a variety of 
scenarios as defined in Table 20.  Figure 35B) shows the percentage point change relative to baseline of malaria cases correctly treated with an ACT (grey bars) and 
NMFI overtreated with an ACT (red bars) in each of the scenarios depicted in Figure 35A). 
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Provision of 100% stock of ACTs predicted a 28.9% point (95% UI: 20.5 – 36.1%) increase in the 
proportion of malaria cases given an ACT, i.e. 59% increase relative to baseline.  However, this was 
also accompanied by a 26% point (95% UI: 17.0 – 34.7%) anticipated increase in the overtreatment 
of NMFI, potentially resulting in 70% NMFI cases (95% UI: 56.4 – 79.2%) receiving an ACT.  Thus the 
modelled decrease in correct management of all febrile cases in a scenario of 100% ACT stock is due 
to a larger proportion of NMFI cases predicted to receive ACTs since there is no limitation by drug 
stock. 
Single interventions aimed at increasing availability or use of diagnostic tools, were forecast to have 
little effect on improving the management of malaria cases or reducing NMFI overtreatment.  
Modelling perfect compliance with diagnostic results without any increase in diagnostic stock or use 
(i.e. positive tests treated with ACTs and negative tests not treated with ACTs) led to little change in 
the proportion of malaria cases receiving an ACT but anticipated an 8.9% point reduction (95% UI: 
2.6 – 19%) in NMFI overtreatment with ACTs (18% relative reduction).  Improved diagnostic quality, 
(100% sensitivity and specificity) also led to small predicted improvements in malaria treatment and 
a decrease in NMFI overtreatment even when all other conditions were maintained at baseline.   
Combinations of improvements to diagnostics deployment however did show an effect on NMFI 
management results. For example, increasing the availability and use of diagnostics reduced 
overtreatment of NMFI with ACTs to 38% (95% UI: 27.3 – 50.7%), i.e. a 14% point reduction from 
baseline. This scenario also improved overall management of malaria cases, with 57% (95% UI: 47.7 
– 65.8%) of malaria cases receiving ACTs, i.e. a 7% point increase (95% UI: -1.4 – 16.8%).  
 
4.3.3 Tanzania case study: WHO guidelines on diagnostic led management in public sector 
Using Tanzania as a case-study, I compared predicted case management outcomes using papers 
published before and after the 2010 WHO guidelines. The Tanzanian HIV/AIDS and Malaria Indicator 
Study (THMIS) reported that malaria prevalence amongst U5s had dropped from 18% in 2007/8 
(TACAIDS et al., 2008) to 9% in 2011/12 (TACAIDS et al., 2013). The data collected from studies 
published in the year following the guidelines rollout are summarised in Table 18, and indicate stock 
levels of any dose of ACTs had increased (from 59% to 85%) as well as availability of any diagnostic 
tools (from 35% to 61%).  At this stage, levels of diagnostic usage were not seen to have substantially 
increased (69% compared to 71%), although compliance to test results had improved (the 
probability of receiving an ACT with a negative test result reduced from 67% to 14%) and treatment 
of untested cases had also decreased (from 86% in untested febrile cases to 15%). Using these 
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parameters in the decision-tree, Figure 36 depicts the predicted change in the overall proportion of 
all fever cases correctly treated, the proportion of malaria cases correctly treated and the proportion 
of NMFI over-treated in Tanzania.   
 
Figure 36: Change in case management outcomes at public sector health facilities after early rollout of WHO 
2010 guidelines in Tanzania.  
The absolute percentage point change is shown by the grey bar, and percentage change relative to the 
baseline scenario is depicted in red. 
I estimate that a 30% point increase (95% UI: 26.5 – 33.6%) in the proportion of all attending febrile 
cases correctly treated would have occurred  in the early stages of the implementation of the 
guidelines, i.e. 59% increase relative to pre-WHO guidance baseline.  Contributing to this overall 
predicted improvement is a 35% point reduction (95% UI: 31.2 – 39.8%) in the proportion of NMFI 
treated inappropriately with ACTs, resulting in only 13% of NMFI patients being over-treated 
following the guidance rollout.  
 However I also predict a 19% reduction (95% UI: 11 to 27.2%) in the proportion of malaria cases 
receiving an ACT if they attend a clinic may have ensued following rollout of the new WHO 
guidelines, i.e. only 37.5% of attending malaria cases are given ACTs.  Overall the percentage of all 
malaria cases in the community treated with ACTs is modelled to have reduced from 16.8% to 
10.6%.   
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Thus despite improved access to diagnostics, improved ACT stock and compliance to test results (but 
no increase in the overall proportion tested), my results suggest a reduction in the proportion of 
malaria cases given ACT.  This does not mean that these malaria cases were not treated at all since I 
have not included other antimalarials aside from ACTs in this analysis.  
Exploration of the different pathways by which a malaria case may receive ACTs reveals a greater 
than twofold increase in the modelled probability of a malaria case being tested and receiving 
treatment on the basis of a positive test result (9.4% vs. 24%), i.e. rational diagnostic-led treatment.  
However there is greater than fourfold reduction in the predicted probability of malaria cases 
receiving ACTs through other pathways (42.5% vs. 8.9%), i.e. opportunistic treatment in those 
untested or in those who falsely test negative and are hence untreated. Similar outputs are seen 
when comparing the combined dataset from all countries.  
 
4.3.4 Estimating Treatment gap and Treatment excess: public sector 
Figure 37 depicts the percentage treatment gap and percentage overtreatment (treatment excess) 
of all febrile patients attending public health facilities using Tanzania as a case study, in the scenarios 
defined in Table 20.  Desirable outcomes, namely malaria cases receiving ACTs and NMFI cases not 
being treated with ACTs are depicted in green. The malaria treatment gap i.e. cases that need ACTs 
but that do not receive ACTs are depicted in yellow.  The percentage treatment excess i.e. cases that 
do not need antimalarials but are given ACTs unnecessarily are depicted in red. 
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Figure 37: The percentage treatment gap and percentage overtreatment (treatment excess) of all febrile patients attending public sector health facilities in Tanzania, in 
the scenarios defined in Table 20.   
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At baseline there is a high degree of NMFI overtreatment, with less than a quarter of patients that 
receive ACTs actually needing antimalarials, whilst there is a substantial treatment gap (i.e. malaria 
cases not given ACTs) with only half of patients needing antimalarial treatment forecast to actually 
receive ACTs.  Overtreatment can be reduced by improving compliance with diagnostic results, as 
well as diagnostic availability; although a treatment gap may remain.  In contrast high levels of ACT 
stock alongside high availability, use and compliance to diagnostic tests reduce the treatment gap, 
i.e. increase the likelihood that those in need of treatment receive ACTs. However, this may also 
increase over treatment (i.e. NMFI given ACTs unnecessarily). If additionally the performance of the 
diagnostic test is improved (i.e. assume 100% specificity and sensitivity), there is perfect case 
management, i.e. no further treatment gap or treatment excess.   
Figure 37 illustrates the potential trade-off between increasing diagnostic use and compliance versus 
increasing ACT stock with respect to reducing the treatment gap and limiting treatment excess at 
medium-high transmission settings. Figure 38 shows the balance of promoting ACT stocks against 
increasing diagnostic availability and use. In this case currently reported levels of compliance to test 
results are kept unchanged.  At medium-high transmission, improving malaria treatment is 
achievable with increased ACT stock, but will require high levels of diagnostic availability and usage 
to prevent high levels of NMFI overtreatment. Importantly, high levels of diagnostic usage allow 
improved malaria treatment at lower levels of ACT stock than if diagnostic use had been low.   
At low transmission, data is scarce but my modelling suggests that given current assumptions of 
compliance to diagnostics, there is little relationship between diagnostic availability and appropriate 
treatment and thus reducing NMFI overtreatment is more challenging than improving levels of 
malaria treatment.  
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Figure 38: Density plot: balance of diagnostic availability and use versus ACT stock for malaria and NMFI at 
public sector health facilities - 38A) Medium-high prevalence malaria; 38B)  
Low prevalence malaria. The colour density map depicts the percentage of malaria correctly treated and the 
percentage of NMFI overtreated at a) medium – high transmission scenario using values obtained from all 
studies published after the rollout of the WHO guidance and b) low transmission scenario using values 
obtained from studies published from all countries (including studies from countries outside Africa).  The 
colour scale depicts desirable outcomes as green, i.e. high levels of malaria treatment and low levels of 
NMFI overtreatment, whilst undesirable outcomes are red, namely low malaria treatment and high NMFI 
overtreatment.  Contour lines indicate similar colour densities 
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4.4 RESULTS: PRIVATE SECTOR OUTLETS AND DRUG SHOPS 
4.4.1 Comparison of systems effectiveness and decision-tree approaches 
Figure 39 shows the outcomes from the systems effectiveness model for the private sector, namely 
drug and general shops. In this analysis and all further results for the private sector model, I have 
used the stock and use of QAACTs rather than all ACTs despite the restrictively low estimates since 
this is the aim of AMFm. Data here is taken from studies published across sub-Saharan Africa prior to 
the piloting of AMFm and other drug subsidy schemes. 
Using the baseline parameters in the systems effectiveness approach, I estimate that only 0.00008% 
(95% uncertainty interval [UI]: 0.00003-0.0028%) of all malaria cases in the population, and 0.002% 
(95% UI: 0.0001 – 0.01%) of those malaria cases that attend a drug or general shop will be treated 
correctly with a QAACT.  If we consider all ACTs (i.e. not just QAACTs), then this approach estimates 
that 0.01% of all malaria cases in the population and 0.02% of malaria cases that attend a shop 
would be treated with any ACT.  
 
Figure 39: Estimated proportion of malaria cases at each case management point in the systems 
effectiveness pathway at private sector outlets (drug and general shops).   
The grey bars show the probabilities for each step for malaria case management whilst the red line and 
values show the cumulative probability along this pathway.   
In contrast, using the decision tree model, which allows for the correct outcome being possible 
despite imperfect case management (e.g. a malaria case may receive a QAACT despite not being 
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tested, and NMFI cases may not receive a QAACT), I estimate that 70.53% (95% UI: 67.3 – 86%) of 
any febrile cases that visit drug or general shops will be correctly managed, but that only 0.44 % of 
malaria cases that attend these shops would receive QAACTs (95% UI: 0.13 – 0.89%).  This 
corresponds to just 0.2% (95% UI: 0.05 – 0.89%) of all malaria cases in the community receiving 
QAACTs.   I also estimate that 0.44% (95% UI: 0.14 – 0.87%) of NMFI cases attending a private outlet 
would unnecessarily receive a QAACT.  The low numbers of NMFI patients that receive QAACTs 
therefore contribute to the high proportion of patients being treated “correctly”.  These low 
estimates are driven by the paucity of QAACTs at baseline (i.e. pre-AMFm) in the drug shops, but 
may also be due to provider or purchaser preference.  If we consider the use of all ACTs, I estimate 
that 4.75% of malaria cases that attend a shop would be treated with an ACT (95%UI: 1.26-10.47%).   
It is important to note that NMFI patients may purchase other non-QAACT antimalarials and that this 
is not included in my analysis  
 
4.4.2 Case management interventions: private sector 
As in the public sector, increased treatment-seeking was the most effective single step in increasing 
the proportion of all febrile cases in the community that would be correctly managed. However 
unlike the public sector analysis, improving attendance was not the most effective single step to 
improving all malaria cases in the population receiving a QAACT.  Modelling 100% attendance at the 
facility resulted in 0.44% all malaria cases in the community (95% UI: 0.13 – 0.9%) receiving a QAACT, 
i.e. double the estimate at baseline. As in the public sector, the model is structured so that that 
attendance does not impact upon improving case management of those patients attending a drug or 
general shop.  
Perfecting a single step in the care pathway had little effect on the proportion of fever cases 
attending a drug shop that are correctly treated.  The breakdown of correct fever management into 
the proportion of malaria cases receiving a QAACT and the risk of NMFI being over-treated with a 
QAACT is shown in Figure 40.   
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Figure 40: Results from the decision tree model for cases attending drug or general shops (private drug outlets) in idealised case management scenarios 
Figure 40A) depicts the percentage of malaria cases correctly treated with a QAACT (grey bars) and percentage of NMFI overtreated with a QAACT (red bars) in a variety 
of scenarios as defined in Table 20.  Figure 40B) shows the percentage point change from baseline of malaria cases correctly treated with a QAACT (grey bars) and 
change from baseline of NMFI overtreated with a QAACT (red bars) in each of the scenarios depicted in Figure 40A. 
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Despite the low baseline levels of correct malaria treatment with QAACTs, no single step intervention was 
predicted to significantly improve this outcome.  Provision of 100% stock of QAACTs led to a 2.6% (95% UI: 
0.66 – 4.57%) increase in the proportion of malaria cases attending a private drug shop given an ACT.  
However, this was also mirrored by a 2.6% point (95% UI: 0.66 – 4.56%) increase in the overtreatment of 
NMFI, i.e. 3% NMFI cases (95% UI: 1.13 – 5.02%) receiving a QAACT.  Even with such a small increase, 
provision of 100% QAACT stock was still the most effective single step to improving all malaria cases in the 
community receiving a QAACT, from 0.2% at baseline (95%UI: 0.05-0.48) to 3.04% (95%UI: 1.1 – 5.02). 
Single interventions aimed at increasing availability or use of diagnostic tools did not have significant effects 
on improving the management of malaria cases or reducing NMFI overtreatment in private outlets.  
Combinations of improvements to diagnostics deployment have the potential to show a greater effect.  
Perfect availability, use of, and compliance with diagnostics may increase the proportion of attending 
malaria cases treated with QAACTs up to 12.32% (95% UI: 7.1 – 18.1%), whilst only increasing NMFI 
overtreatment to 2% (95% UI: 0.87 - 3.6%).  Adding 100% QAACT stock alongside 100% availability, use and 
compliance with diagnostic tools, increases the percentage of malaria cases receiving QAACT to 84.8% (95% 
UI: 78.4 – 91.4%).   A scenario of presumptive treatment, i.e. no use of diagnostic testing and treatment of all 
untested febrile patients with QAACTs, predicted 14.6% of malaria cases at the shop would receive QAACTs 
(95% UI: 8.34 – 20.5%).  However this would be accompanied by 14.3% (95% UI: 8.3 – 20.6%) of patients 
with an NMFI also being needlessly treated with QAACTs. 
The poor results for baseline quality of care at private outlets or the improvement brought about by single 
step interventions is minimal because the baseline parameter values for the components of case 
management are low.  Combinations of interventions, for example perfect QAACT stock, as well as use and 
compliance with diagnostics may give improvements in the proportion of malaria cases modelled to receive 
ACTs.  However if even one of the component interventions is reduced back to baseline, then the results fall 
back to low levels.  
 
4.4.3 Tanzania case study: AMFm and drug subsidies in the private sector 
Using Tanzania as a case-study, I compared predicted case management outcomes using data before and 
from the initial stages of the AMFm drug subsidy scheme.  Data collected from the IMPACT 2 study and 
other studies published in the year following the drug subsidy programme  are summarised in Table 19, and 
indicate stock levels of any dose of QAACTs had increased (from 7% to 50%) although the availability of any 
diagnostic tool did not mirror this (increase from 1% to 5%). Estimates of diagnostic usage barely changed 
(2% compared to 1%). Although compliance to positive test results had improved (the probability of 
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receiving a QAACT with a positive test result increased from 2% to 40%), the treatment of negative tests and 
untested cases had also increased (proportion of negative tests given QAACTs rose from 1% to 10%, and 
untested febrile cases from 1% to 27%). Using these parameters in the decision-tree model, Figure 40 
depicts the predicted change in the proportion of all fever cases correctly treated, the proportion of malaria 
cases correctly treated with QAACTs and the proportion of NMFI overtreated with QAACTs. 
 
Figure 41: Change in case management outcomes after the AMFm drug subsidy pilot scheme in Tanzania.   
The absolute percentage change following the introduction of the drug subsidies and the AMFm pilot in Tanzania is 
shown by the grey bar, and the percentage change relative to the baseline (before drug subsidies) is depicted in red 
in 1) estimated proportion of attending cases correctly treated (both malaria and NMFI); 2) proportion of malaria 
cases correctly treated with QAACTs and 3) proportion of NMFI cases given a QAACT. 
Using this model, I estimate that a 10.8 % decrease (95% UI: 8.7 - 13.1%) in the proportion of all attending 
fever cases correctly treated may have occurred following the AMFm pilot. Contributing to this overall 
predicted change is a 13.5% increase (95% UI: 20.9 – 16.5%) in the proportion of NMFI treated 
inappropriately with QAACTs; resulting in 13.5% of NMFI patients potentially being overtreated following the 
drug subsidy rollout. The percentage of malaria cases treated with a QAACT rises from 0.07% at baseline to 
13.6% (95% UI: 10.8 – 16.6%) following the rollout of AMFm in Tanzania at private sector outlets.   
Overall, on the basis of published drug and general shop data in Tanzania and from the IMPACT 2 household 
and outlet surveys, the percentage of all malaria cases in the community treated with QAACTs is modelled to 
have increased from 0.03% to 6.8%. Similar outputs are seen when comparing the combined dataset from all 
countries.   
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4.4.4 Treatment gap and treatment excess: Private sector 
In Figure 42, desirable outcomes, namely malaria cases receiving QAACTs and NMFI cases not being treated 
with QAACTs are depicted in green. The treatment gap i.e. cases that need QAACTs but that do not receive 
QAACTs are depicted in purple.  The treatment excess i.e. cases that do not need antimalarials but are given 
QAACTs unnecessarily are depicted in red. 
At baseline I predict that there is a large treatment gap (purple), with the great majority of those assumed to 
need QAACTs failing to receive them, whilst in contrast there is only a low level of treatment excess (i.e. 
NMFI cases unnecessarily given QAACTs).  The treatment gap in the private sector can be reduced by high 
levels of diagnostic availability and use coupled with improved compliance with test results.  This is further 
increased with 100% probability of QAACTs being in stock.  However this may elevate levels of treatment 
excess. The figure suggests that improving levels of malaria treatment with QAACTs, i.e. narrowing the 
treatment gap in the private sector, would require strengthening all components of the case management 
chain simultaneously, rather than just one or two areas of focus as per the AMFm strategy. A policy of 
presumptive treatment, previously advocated in high transmission settings, may serve to increase NMFI 
overtreatment much more than reducing the treatment gap for malaria cases 
  
167 
 
 
 
Figure 42: The percentage treatment gap and percentage overtreatment (treatment excess) of all febrile patients attending drug or general shops using aggregated sub-
Saharan data as baseline, in the scenarios defined in Table 20.   
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4.5 DISCUSSION 
This simple decision-tree model can provide insight into the aspects of delivering care most likely to impact 
on care quality and programme efficiency, and can quantify the intuitive qualitative effects of refining 
different steps of the care pathway in order to help to inform decisions and guide investments in improving 
fever management. 
Both models suggest that improving timely attendance whether at a health facility or at a drug shop, would 
be the most important single intervention to increase the overall percentage of all febrile cases managed 
correctly, and improving attendance at the health facility would also increase the proportion of all malaria 
cases in the community treated with ACTs. 
Considering only those who attend a primary health facility, increased ACT stock level was the most critical 
intervention in potentially improving in the proportion of febrile malaria cases receiving treatment with 
ACTs.  In contrast, the greatest predicted reduction in NMFI cases being overtreated at a primary care clinic 
following a single health system intervention was due to improved compliance with diagnostic results.  
However this was also associated with a reduction in the proportion of malaria cases receiving ACTs.  Multi-
pronged intervention strategies were most effective in balancing possible improvements in malaria 
treatment with the risks of NMFI overtreatment.  Substantial improvements in malaria case treatment were 
not predicted without increasing ACT stock levels. Modelling interventions targeted at diagnostic tool 
availability, use and compliance improved NMFI management rather than significantly impacting on malaria 
treatment. 
The results of the private sector model indicate that at baseline there are very low levels of malaria cases 
receiving QAACTs (drug subsidy schemes had barely started) but also negligible amounts of overtreatment of 
NMFI with first-line QAACTs, although other antimalarials may be prescribed. If the use of any ACT (i.e. 
QAACTs and non-assured ACTs) are considered in the analysis then estimates of the probability of receiving 
appropriate treatment are naturally higher. Single interventions, whether diagnostic-related or QAACT stock, 
appeared to not result in any significant improvements in case management, due to the low baseline 
parameter estimates for the private sector.  Emphasis on diagnostic tool availability, use and compliance did 
not produce reductions in the malaria treatment gap.  Modelling solely improved levels of QAACT stock was 
not as effective in the private sector as in the public sector with respect to expanding the proportion of 
malaria cases receiving first-line treatment. This is due to the baseline parameter indicating low provider 
preference in prescribing QAACTs even when present at drug shops.  However it is unclear whether the basis 
of this in the literature is actually prescriber preference, or may also be due to the preference of particular 
patients that attend private outlets. I have not included the role of patients in deciding which antimalarial 
they request, whether due to price or familiarity, nor accounted for the perverse incentive for retailers to 
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satisfy their customer’s requests, e.g. selling antimalarials whether a patient needs them or not irrespective 
of a diagnostic result (Chandler et al., 2011). 
A combination of diagnostic and QAACT stock interventions are predicted to narrow the treatment gap in 
the private sector.  However my assumptions regarding test performance, i.e. using sensitivity and specificity 
estimates for RDTs for all diagnostic tests, mean that the NMFI treatment excess is also increased. The 
model suggests that whilst improving case management in the private sector is possible, significant 
investments across the entire treatment-pathway would be needed, rather than individual interventions.  
The Tanzanian public sector case study explored the impact of the recent WHO guidance advocating 
diagnostic-led therapy for malaria. Despite published reports of improved access to diagnostics and 
compliance with their results, as well as expanded ACT stocks, the model predicted the proportion of malaria 
cases treated with ACTs to have reduced following rollout of new WHO guidelines. The levels of NMFI 
overtreatment are predicted to have decreased.  This is due to a large modelled reduction in the numbers of 
malaria cases that previously were untested yet still received ACTs (i.e. presumptive treatment) and in those 
who test falsely negative and hence are not given ACTs. The model did not differentiate between the 
likelihood in receiving ACTs if untested due to healthcare/provider choice or lack of diagnostic availability.  
However, this result highlights the need for improved quality of testing, and also proper communication of 
the new WHO guidance to healthcare workers to prevent any malaria under-treatment if diagnostics are 
unavailable.  My analysis did not include patients receiving antimalarials other than ACTs. 
In contrast, the Tanzanian private sector case study considered the potential impact of the AMFm pilot.  
Early reports confirm that the programme had met its target of increasing coverage of QAACTs with an 
increased proportion of outlets stocking the first-line antimalarials (AMFm Independent Evaluation Team, 
2012, Littrell et al., 2011a, Tougher et al., 2012). However, there are limited data to suggest that any training 
as part of the AMFm scheme has also led to an increase in use of diagnostic tools, although this was not a 
stated target of the programme (AMFm Independent Evaluation Team, 2012). The modelled results suggest 
that the scheme may have successfully expanded the use of QAACTs to treat malaria in the Tanzanian 
private sector from 0.41% to 18.2% (Figure 9); however this still represents less than 20% of malaria cases 
that attend drug shops and hence a large treatment gap remains. I have not included other ACTs or 
antimalarials in this analysis as the objective was to consider the consequences of the AMFm drug subsidy 
scheme on treatment delivery. Levels of any ACT distribution are likely to be higher, and I will use this more 
inclusive measure (i.e. QAACTs and non-assured ACTs) when exploring transmission and clinical impact in 
Chapter 5.  Non-ACTs are not included as they are not the recommended first line therapy. 
Health system interventions for case management of malaria must be guided by whether the priority is 
improvement in malaria cases receiving ACTs, i.e. reducing the treatment gap, reducing ACT waste through 
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unnecessary treatment of NMFI, i.e. treatment excess, increasing appropriate treatment of all febrile illness 
or expanding the most cost-effective solution for that particular epidemiological environment.  
The decision tree results shown here suggest that the recent emphasis on rollout of RDTs and the WHO 
guidance may be effective in reducing ACT waste, but also highlight the need to focus on stock-management 
and improving HCW training in diagnostics to improve the quality of care dispensed to malaria cases. These 
priorities and the most cost-effective way to manage fevers may vary by transmission setting.  Lubell et al. 
used a decision-tree cost modelling approach to demonstrate that use of diagnostics at moderate and low 
levels of transmission was more cost-beneficial than presumptive treatment (providing compliance to test 
results was high), but that this was less clear in high transmission settings (Lubell et al., 2008). I found a 
paucity of data on case management indicators in low malaria prevalence settings, but our results mirror 
intuitive assumptions that the high levels of diagnostic use and compliance with results may have an 
important role to play in reducing levels of overtreatment with ACTs of NMFI cases especially when malaria 
cases are scarce.  
In the private sector, this trade-off between treating malaria cases whilst avoiding overtreatment of those 
not infected with malaria, is highlighted by the model outputs in the presumptive treatment scenario.  The 
results suggest malaria treatment gap would be reduced by a policy of treating all fevers with an ACT 
without testing at drug shops to such an extent that it could only be surpassed with high levels of diagnostic 
availability, use, and compliance along with QAACT stock.  Although presumptive treatment would naturally 
increase NMFI unnecessary treatment, this may be acceptable in settings where this was not considered a 
priority. 
A limitation of this decision-tree approach is the assumption that the parameters are independent of each 
other. For example it is recognised that improved drug stock levels can motivate treatment seeking (Alba et 
al., 2010a), or increased treatment seeking may increase HCW workload leading to reduced time for 
performing diagnostics and dispensing appropriate treatment.  It would seem likely that the availability and 
use of diagnostics are related to each other, and stock levels of ACTs may also influence whether testing 
occurs, but there is little data to parameterise such an association. I did not include staff or shopkeeper 
training in this analysis at this stage, as there is much uncertainty about the impact of training on HCW 
performance especially in the public sector (Chandler et al., 2008a, Chandler et al., 2008b, Chandler et al., 
2012).  In addition I used the same probability of receiving ACTs when untested irrespective of the presence 
of diagnostics, which may not reflect reality and will need further study of HCW and provider behaviour.  In 
the literature review in Chapter 2, I used aggregated data from several countries from across Africa (and 
outside Africa for a low prevalence scenario), but these are unlikely to be comparable between countries, 
given there was substantial variation in data collection methods, sample sizes and the nature of the data 
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collected. However data from Tanzania, used as a single country case study did give similar pattern of results 
for both the private and public sector models as the aggregated data. I chose only to include drug and 
general shop data in my private sector analysis but there is also significant variation in the standards of these 
across Africa. In addition there were extremely limited data on the performance of drug or general shop 
keeper behaviour with respect to compliance with test results, and so several parameters have been derived 
from estimates of drug use and market share. In the analysis of the impact of AMFm, much of the data used 
were from the official evaluation of the programme and some of this may also have been reproduced in 
country specific publications, which were counted separately. In addition there is very limited data on 
provider behaviour compliance to tests and anti-malarial preference. Despite these limitations, the results 
demonstrate the feasibility of such a decision-tree approach to quantify the effects of investing in changing 
health systems parameters, which could be made site-specific if such data were available. 
Further work is required to explore the most cost-effective targets to expand the delivery of antimalarials 
and reduce ACT waste, given limited malaria control budgets and the potential rise of ACT resistance.  The 
results concerning the potential impact of interventions in the private sector to improve overall care 
illustrate the need to understand the ability, cost and acceptability of such improvements across the chain of 
delivery in drug and general shops, especially in the context of the future of programmes such as AMFm. In 
addition, this approach could be extended to delivery through other sectors including community health 
care workers.  I will consider whether improving access to and the performance of public and private health 
systems may allow reductions in malaria transmission intensity and disease mortality and morbidity in 
Chapter 5 by using these estimates, i.e. the probability of a malaria case receiving an ACT and the probability 
of an NMFI cases receiving an ACT in both the public and private sectors, within the models outlined in 
Chapter 3. As malaria transmission declines and appropriate treatment for NMFI becomes of increasing 
importance, it will become necessary to adopt a holistic approach to investing in improving fever 
management, improving our understanding of both malaria and NMFI, taking into consideration the 
particular characteristics of the health systems, including the contributions of public, private and community 
delivery.  
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5 THE IMPACT OF HEALTH SYSTEMS INTERVENTIONS ON TRANSMISSION 
AND CLINICAL OUTCOMES IN TANZANIA 
5.1 INTRODUCTION 
Over the past decade, global funding and commitment to malaria control have led to malaria mortality rates 
almost halving, especially in children under five, and a 30% drop in malaria infections overall (WHO, 2013) 
(O'Meara et al., 2010).  Malaria modelling estimates up to 3.3 million malaria deaths may have been averted 
between 2001 and 2012, the majority of which are in areas of high burden (WHO, 2013).  However in the 18 
countries with the highest burden of disease, which account for 80% of malaria cases, surveillance data is 
still not sufficient to robustly assess trends. If transmission is not addressed in these high prevalence 
countries, it is unlikely that the global reductions in incidence and mortality will continue their trajectory to 
reach 2015 targets and may even reverse  with declining funding levels (Feachem et al., 2010, WHO, 2013). 
Model estimates suggest that the rate of decline in malaria mortality may have slowed more recently.  This 
may in part be due to a levelling off in ITN coverage and IRS over the same period (2011-2012)(WHO, 2013) .  
Although delivery of ACTs increased from 11 million courses in 2005 to 331 million in 2012, and the numbers 
of procured rapid diagnostic tests (RDTs) have increased, many people with confirmed infections do not 
receive appropriate treatment with a quality assured antimalarials (AMFm Independent Evaluation Team, 
2012, WHO, 2013), although estimating this proportion is challenging.  
The World Malaria Report 2013 (WHO, 2013) acknowledges that predicting the percentage of patients with 
malaria that receive antimalarials is limited by the quality of surveillance data, but estimates that in 2012 
this had risen to 60% across both private and public sectors. In a subset of 9 African countries surveyed, 68% 
of children under five that received an antimalarial were given an ACT, i.e. approximately 40% of under-fives 
with malaria attending healthcare receive an ACT, and other surveys suggest even lower estimates (WHO, 
2013). As described in Chapters 2 and 4, this may be due to a sequence of health systems barriers, which 
vary by region both between countries and within. 
Whilst national malaria control strategies must rely on international guidelines and policy, decisions as to 
what package of interventions are required need to be tailored to local vector patterns and epidemiology.  
Similarly, interventions to improve case management of malaria need to also be steered by the healthcare 
provision mix in the region and directed towards the local, national or international priority, whether limiting 
malaria transmission, preventing the development of parasite drug resistance, or reducing malaria related 
morbidity and mortality. The development and evaluation of such tailored malaria control strategies would 
require considerable input of evidence and resources. Randomised controlled trials of health systems 
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interventions or novel methods of intervention delivery would require impractical numbers of participants 
to achieve statistical significance.  Mathematical modelling therefore offers the opportunity to estimate the 
potential impact of such policies at scale. 
In this chapter I aim to demonstrate the need to adapt health systems improvements of ACT treatment 
programmes to local needs and epidemiology. To do this, I first use data collected by the IMPACT 2 study 
group at government health facilities and private drug shops in 3 regions of Tanzania (mainland) in 2010 and 
2012 to estimate the probability of malaria and NMFI cases receiving an ACT in the private and public sectors 
employing the decision tree approach described in Chapter 4. I use these parameters in the model outlined 
in Chapter 3 to identify points in the implementation pathway in each region which have a critical impact on 
the effectiveness of ACTs in reducing transmission and preventing malaria mortality. I then consider the 
potential impact of single and combinations of health systems interventions to overcome the critical barriers 
for each region in order to develop strategies to improve malaria control. 
  
174 
 
5.2 COUNTRY CONTEXT: MAINLAND TANZANIA 
Mainland Tanzania has a population of approximately 47.8 million, spread across 950 thousand square 
kilometres but predominantly living in the areas surrounding Dar-es-Salaam, Lake Victoria and in the 
Northern and Southern Highlands (WorldBank, 2013: accessed February 2014, NBS/ICF, 2011). Data were 
obtained from three regions, namely Lake (Mwanza), Southern Highlands (Mbeya) and Southern (Mtwara). 
The Gross National Income per capita was $570 in 2012, and Tanzania ranks 177 out of 194 countries 
worldwide by per capita Gross Domestic Product (WorldBank, 2013: accessed February 2014).  Life 
expectancy at birth is estimated at 58.9 years; with a median age of 17.5 years, and the mean years of 
schooling are 5.1.  The economy is primarily agricultural and over 50% of the population lives on less than $2 
a day (WorldBank, 2013: accessed February 2014). 
1.1.1 Health Services  
The WHO estimates that the government annual per capita expenditure on healthcare in 2011 was $42.4 
(PPP: purchasing power parity), representing 11% of all government expenditure (WHO, 2012a). The annual 
per capita total expenditure on health was $107.4 (PPP), i.e. 60% of expenditure on health is private (WHO, 
2011b). Healthcare provision is typically pyramidal, as depicted in Figure 43A, structured around primary 
care provision through health posts and health centres. These are often staffed by village health workers and 
clinical assistants especially in rural areas, with limited in-patient capacity (Kwesigabo et al., 2012). The WHO 
African Health Observatory estimated nurses and midwives comprise 27% of the health workforce (50% is 
the average for Africa) and trained doctors constitute 1.7% of the health workforce compared to 9.7% in the 
rest of Africa (WHO, 2010b). The chronic shortage of healthcare workers affects all levels of healthcare but 
particularly primary care (Figure 43B). 
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Figure 43 Health Services provision in Tanzania 
43A) Hierarchy or health service provided in Mainland Tanzania B) Healthcare workers available and required in 
government facilities (Kwesigabo et al., 2012) 
43A 
43B 
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5.2.1 Malaria in Mainland Tanzania  
Plasmodium falciparum accounts for almost 100% of malaria infections in mainland Tanzania, transmitted 
mainly by Anopheles gambiae and Anopheles funestus mosquitoes (WHO, 2013). 
 Transmission patterns vary with the geography of Tanzania (Hay et al., 2009). The Malaria Atlas Project 
estimates that 91% of the population lives in an area where malaria is endemic, and the risk of malaria 
transmission is stable (MAP (Malaria Access Project), acccessed February 2014).  Areas of high altitude 
(greater than 2000m) such as Arusha and Kilimanjaro are at very low risk of malaria (Hay et al., 2009). High 
transmission intensity with seasonal variation occurs along coastal regions, near Lake Victoria and in the 
southern lowlands, which includes two of the sites used in the analysis: Mwanza (Lake Victoria) and Mtwara 
(Southern)(Hay et al., 2009). The 2011-2012 Tanzania HIV/AIDS and Malaria survey (THMIS) estimates an 
overall prevalence by RDT of 9% in children aged 6-59 months, varying from greater than 30% near Lake 
Victoria to less than 1% in the highlands (Figure 44) (TACAIDS et al., 2013), and represents a 50% reduction 
from an estimated 18% prevalence in children under 5 in the 2008 survey (TACAIDS et al., 2008). 
 
Figure 44: Malaria prevalence in young children by region: % of children 6-59 months testing positive by RDT  
(TACAIDS et al., 2013) 
 
The World Malaria Report 2013 estimates that there were almost 11 million cases of malaria in 2013 
(including all suspected, presumed and confirmed cases), and approximately 40 confirmed cases per 1,000 
population (WHO, 2013). Calculating malaria-attributable mortality is difficult and estimates vary from 7,812 
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inpatients deaths in 2012 (World Malaria Report 2013) to an annual death toll across all ages of 60,000-
80,000 deaths in the mainland in 2009 according to the Tanzanian National Malaria Control Programme 
(NMCP) (NBS/ICF, 2011). Although malaria related mortality has declined over the past decade (Figure 44) 
(TMIERG, 2012), it is still the primary cause of death in children under 5 with 24% of deaths directly 
attributed to malaria; under-five mortality is Tanzania is high at approximately 81 deaths per 1000 live births 
(TMIERG, 2012, WHO, 2012a). This figure excludes indirect malaria mortality through chronic anaemia or 
exacerbation of other co-morbidities.  
5.2.1.1 Diagnostics and Treatment for malaria in Tanzania 
Chloroquine was the first-line treatment in Tanzania up to 2001.  The national guidelines were subsequently 
changed to Sulphadoxine-Pyrimethamine (SP) for uncomplicated malaria, due to chloroquine drug 
resistance, and intravenous quinine recommended for severe malaria.  Resistance to SP emerged rapidly, 
and in 2006, ACTs (Artemether-Lumefantrine) were adopted as the new first line therapy.  This was rolled 
out in the public sector in 2006/2007 (TMIERG, 2012). Government policy stipulates that malaria treatment 
at all public sector facilities, whether community or hospitals, is free of charge for children and pregnant 
women, however this is not always observed (Njau et al., 2006).   
Presumptive treatment for all ages at a community level, with the use of malaria microscopy limited to 
tertiary level facilities, was standard practice until 2006. In line with WHO guidance, the NMCP changed their 
protocol to advocate presumptive diagnosis in the U5s only in 2006. Since 2010, Tanzania has adopted the 
policy of diagnostic-led malaria treatment in all age groups with a phased rollout of RDTs along with the T3 
(Test, Treat, Track) Initiative (Bruxvoort et al., 2013). 
 
5.2.1.2 Burden of malaria on primary healthcare 
Health service statistics for Tanzania are scanty, and there are limited national data regarding the burden of 
confirmed malaria on health services, especially since improved diagnostics were introduced. The 2011-2012 
THMIS estimated that 77% of febrile U5s sought treatment at any source (TACAIDS et al., 2013).  Khatib et al. 
reported that between 36-41% of febrile U5s in Tanzania had access to an authorised provider of ACTs 
within 24 hours of the onset of fever (Khatib et al., 2013). Similarly, THMIS reports that a quarter of febrile 
children in Tanzania that attended public facilities were tested, and 54% of U5s with a fever were 
administered an antimalarial, of whom a third were treated either the same day or the next following the 
onset of their illness (within 24-36 hours) (TACAIDS et al., 2013, NBS/ICF, 2011).   
In 2011/2012, of the children who received an antimalarial, 66% received an ACT, 19% quinine, 16% 
amodiaquine and 4% SP. Overall 38% of those who were treated with antimalarials actually took an ACT 
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within 24-36 hours of fever onset, i.e. approximately 19% of all febrile under-fives. The average price of an 
ACT was 1,372 Tanzanian Shillings (less than £1.00)(TACAIDS et al., 2013). In the 2007/2008 survey, 14% of 
children were treated with a first-line antimalarial within 24-36 hours (TACAIDS et al., 2008). 
 
5.2.1.3 Burden of malaria on tertiary healthcare 
Earlier surveys estimate that 40% of under-five outpatient consultations and inpatient admissions are 
diagnosed with malaria (TMIERG, 2012). The World Malaria Report 2013 (Figure 45) reports 500 admissions 
for malaria per 100,000 population across all ages, down from approximately 1000 per 100,000 in the 2012 
Report (WHO, 2013, WHO, 2012c). The 2012 evaluation from the Tanzania Malaria Impact Evaluation 
Research Group considered admissions in the U5s at two hospitals, namely Ifakara and Bagamoyo District 
hospitals. In Ifakara District, 30% of cases of admissions tested positive for malaria with an increasing trend 
from 2006 -2010 (although reduced from prior to 2006), whereas in Bagamoyo slide positivity of admissions 
declined from 60% (2006) to 23% (2010).  Over diagnosis of malaria in children and adults with severe febrile 
illness is common (Nadjm et al., 2012, Reyburn et al., 2004).  Mtove et al. noted that the incidence of severe 
malaria declined amongst cases referred to Muheza hospital from 2006 to 2010 but that the age of cases 
admitted also increased from 1.7 years to 2.5 years (p<0.0001) as malaria prevalence fell (Mtove et al., 
2011a).  This age-shift in severe malaria incidence in Tanzania has also been described by Okiro et al. and 
similarly in other east African sites (Okiro et al., 2009, O'Meara et al., 2008a, O'Meara et al., 2010).   
 
Figure 45: World Malaria Report 2013: Tanzania profile.  Microscopically confirmed cases, admissions and deaths per 
100,000 population (WHO, 2013). 
 
5.2.1.4 Private sector and Affordable Medicines for Malaria (AMFm) in Tanzania 
Aside from the government funded public sector healthcare, the Tanzania mainland has various other 
private sector outlets, which are registered by the government to provide medical care services to the 
population. These registered private sources of antimalarials include drug shops (Part Two drug shops 
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known locally as Duka la Dawa Baridi - DLDB), Accredited Drug Dispensing outlets (ADDOs) and Part One 
pharmacies (POPs) (Alba et al., 2010b, Alba et al., 2010a, Thomson, 2011, Tougher et al., 2012). Other 
sources of medicines do exist such as general shops as in other African countries (Goodman et al., 2004), but 
it is now not legal for these to sell ACTs and they are becoming increasingly less common (Thomson, 2011, 
Tougher et al., 2012). 
DLDBs are registered to sell only a limited subset of drugs, medicines and cosmetics, including antimalarials. 
They are common nationally but not staffed by qualified pharmacists.  Accredited Drug Dispensing Outlets 
(ADDOs) are upgraded DLDB with dispensers that are qualified to dispense a wider range of medications.  
Part One pharmacies (POPs) are staffed by fully trained pharmacists, and are less common in rural areas 
(Thomson, 2011).  
Tanzania hosted the original AMFm pilot (Sabot et al., 2009) and one of the eight national-scale programmes 
introduced in 2010. The first co-paid ACTs, designated by a green-leaf logo as a mark of quality assurance, 
were distributed in October 2010.  Interventions to support the rollout of AMFm were added in early 2011, 
including mass media campaigns at national and local levels to improve awareness of the logo, 
understanding of co-paid drugs and their recommended pricing.  An independent evaluation of the initial 
phase of the national rollout (conducted in 2010 and 2011) showed that 10.7% of private for profit outlets 
had a quality-assured ACT (QAACT): 65% of POPs stocked QAACTs but less than 10% of DLDBs and drug 
shops. Availability was higher in urban populations and stockists close to major transport links and roads 
(Thomson, 2011, Cohen et al., 2010).  The median price of an adult equivalent treatment dose (AETD) was 
$4.93, although higher in urban areas ($7.04) compared to rural ($1.41) (Thomson, 2011, Tougher et al., 
2012). This early data and data from surveys conducted by the IMPACT 2 team once the AMFm initiative was 
more established (Thomson et al., in submission) are included in my analysis and described further in Section 
5.3. 
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5.3 MONITORING INTERVENTIONS TO IMPROVE ARTEMISININ-BASED COMBINATION TREATMENT 
(ACT) ACCESS AND TARGETING IN TANZANIA THROUGH HOUSEHOLD AND HEALTH FACILITY 
SURVEYS (IMPACT 2 STUDY) 
 
In order to explore the role of regional health systems in malaria control and ACT programme planning, I 
used data collected by the IMPACT 2 study in Tanzania. This study commenced in 2010 and aimed to 
evaluate the operational success of two programmes, namely the introduction of RDTs in government 
facilities and of subsidised ACTs in private retail outlets as the national rollout commenced in three regions: 
Mwanza, Mtwara and Mbeya. Funding for the study was provided through the Bill and Melinda Gates 
Foundation through the ACT Consortium, based at the London School of Tropical Medicine and Hygiene with 
sub-grants to Ifakara Health Institute in Tanzania and the US Centres for Disease Control. The protocol 
consisted of  
1) household and facility surveys (Bruxvoort et al., 2013, Thomson et al., in submission) 
2) national outlet survey (Thomson et al., in submission) (which informed the early evaluation of AMFm 
Tanzania report (Thomson, 2011)) 
3) drug availability inventory 
4) qualitative study of sociocultural factors influencing the implementation of malaria prevention, 
diagnosis and treatment interventions 
5) additional quantitative studies of treatment availability and adherence 
Mwanza region is located near Lake Victoria with a population of 3,771,000; 20.8% of whom lie in the 
poorest national wealth quintile.  Mbeya is a southern highland region, with a population of 2,822,000 (7.7% 
in the poorest wealth quintile).  Mtwara lies along the southern border with Mozambique and is the poorest 
region with 35.5% of its 1,375,000 population in the lowest wealth quintile (Bruxvoort et al., 2013, NBS/ICF, 
2011). The estimated regional prevalence of malaria in under-fives is: Mwanza 18.6%, Mtwara 17.4, Mbeya 
0.5% (TACAIDS et al., 2013). 
Outlet surveys were conducted across Tanzania within the independent evaluation of AMFm (Thomson, 
2011, Thomson et al., in submission, Tougher et al., 2012). Baseline data were collected from September – 
November 2010 and endline from October 2011 – January 2012 (Figure 46). In the regions selected, every 
outlet that had the potential to sell antimalarials, including private and public health facilities, drug shops, 
ADDOs, and general kiosk stores was surveyed. Data presented here are from the three selected regions as 
well as all Tanzania, for all private outlets except private health facilities staffed by trained doctors. 
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The protocol of the household surveys is fully described by Thomson et al. (Thomson et al., in submission).  
Baseline collection of household data occurred in June to October 2010. Endline surveys were conducted in 
May – September 2012. Participants were questioned on household demographics and if any reported a 
fever in the 14 days prior to the interview, they were then questioned about whether care was sought and at 
which source as well as other questions regarding testing and treatments obtained. RDTs were performed 
on those who consented. 
The protocol for the health facility surveys is described by Bruxvoort et al. (Bruxvoort et al., 2013). Baseline 
surveys were conducted in 2010 and endline post-implementation surveys in 2012; in Mwanza: April –May, 
Mbeya: May-June and Mtwara: June-July.  In each region 35 health facilities were surveyed at baseline and 
60 in 2012 (Figure 46). Patients attending with a fever were questioned, and also tested by the study team 
by both RDT and microscopy for malaria. Health facility staff were interviewed and the facility itself audited 
for stock and other components of case management. 
The ADDO programme for upgrading drug shops (DLDB) was implemented prior to 2010 (baseline data 
collection) in Mtwara and Mbeya regions but not in the Mwanza area until after the endline surveys in 2012 
(Thomson et al., in submission). The public sector rollout of RDTs occurred in Mwanza and Mbeya in 
February 2011 but only in May 2012 in Mtwara, i.e. just prior to the endline survey (Bruxvoort et al., 2013) 
(Figure 46). 
 
 
Figure 46: Timeline for IMPACT 2 study data collection at baseline (BL) and endline (EL) 
Timeline for outlet survey, household survey (HHS) and health facility survey (HFS) as well as the rollout of 
Accredited Drug Dispensing Outlets (ADDOs) and the Affordable Medicines facility for malaria (AMFm).  
Q2 Q3Q1 Q4 Q2 Q3Q1 Q4 Q2 Q3Q1 Q4
Outlet Survey
HHS Survey
ADDO rollout
AMFm rollout
HFS: Mwanza
HFS: Mtwara
HFS: Mbeya
BL EL
BL EL
Mtwara
/Mbeya
Mwanza
AMFm
BL
BL
BL
EL
EL
EL
RDT
RDT
RDT
2010 2011 2012
182 
 
5.4 IMPACT 2 STUDY DATA SUMMARY  
5.4.1 Data 
Data were used from the IMPACT 2 study as described in section 5.3 (in the form of summary statistics).  
Sampling, data collection methods and questionnaires used as well as other results have been published by 
the IMPACT 2 group (Bruxvoort et al., 2013, Thomson et al., in submission). The data were analysed by the 
IMPACT 2 team using Stata 11.0 (Stata Corporation, College Station, USA), using survey commands to 
account for the two-stage survey design (Bruxvoort et al., 2013, Thomson et al., in submission). 
In total, 138 facilities were surveyed at baseline (11 hospitals, 24 health centres and 105 dispensaries) in 
May-October 2010 and 176 health facilities (13 hospitals, 31 health centres, 132 dispensaries) at endline in 
April-July 2012. The initial household survey interviewed 20,874 household members of whom 1,410 (369 
under-five) reported a fever in the past 2 weeks (6.75%). At endline 1,683 of 20,102 interviewees (424 
under-five) gave a history of febrile illness in the preceding fortnight (8.37%)(Thomson et al., in submission). 
In this analysis, to assess the performance of the private sector, and to avoid overlap with the public sector 
health facilities, I included only drugs shops, pharmacies and general stores that sold medicines, but not 
private health facilities staffed by medical personnel.  At baseline, of 602 outlets that met the IMPACT study 
criteria, staff at 559 outlets were interviewed.  535 of these outlets had the full range of information 
required for the analysis in this thesis and so were included for an all-Tanzania analysis: 33 were in Mwanza, 
17 in Mbeya and 9 in Mtwara.  At endline, 708  met the IMPACT 2 criteria, 707 were interviewed of which 
700 outlets had sufficient information to be included in the all-Tanzania analysis: 77 were in Mwanza, 43 in 
Mbeya and 3 in Mtwara (Thomson et al., in submission). 
 
5.4.1.1 Slide prevalence of malaria in febrile care-seekers 
The prevalence of malaria in febrile patients attending a health facility who consented to be tested with an 
RDT and blood slide is shown in Table 21. As previous studies have shown, the parasitaemia prevalence 
among febrile patients in the same area is similar in both age groups at both health facilities and private 
outlets (Kachur et al., 2006). These values were used in decision-tree modelling for both sectors. As only 
summary statistics were available from the IMPACT 2 study, the means of the two samples (baseline and 
endline) were compared using the 2 sample z-test, with a two-tailed comparison; significance was defined as 
p<0.05 (assuming a Normal approximation).  The methodology is described in the Oxford Handbook of 
Medical Statistics (Peacock and Peacock, 2010), and implemented through the web-based tool: 
http://epitools.ausvet.com.au/content.php?page=z-test-
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2&p1=0.14&p2=0.02&n1=138&n2=176&Conf=0.05&tails=2&samples=2). The validity of regional sample 
differences is limited by small sample sizes. 
The under-five population parasite prevalence values estimated by THMIS are 9% nationwide; 17% in 
Mtwara; 19% in Mwanza and 0.5% in Mbeya. The study values in febrile patients seeking treatment are 
higher than the population estimates for Mtwara and Mbeya but less in Mwanza, and have increased in the 
time period; this is contrast to the overall population estimates which are estimated to have decreased from 
the 2007/8 THMIS  and 2011/12 THMIS surveys (TACAIDS et al., 2008, TACAIDS et al., 2013). 
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Table 21: Mean malaria parasite prevalence in under-fives and over-five years of age (children and adults) in the three regions surveyed in the Health Facility Survey from 
IMPACT 2. 
95% confidence intervals in brackets; significant difference (p<0.05) between the means of baseline and endline samples is indicated by an asterix  
 
Malaria 
Prevalence 
 
All 3 
regions 
 
 
Mtwara  
 
Mwanza  
 
Mbeya  
 
 Age 
Baseline 
138 
Endline 
176 
Sig 
diff Baseline 
44 
Endline 
59 
Sig 
diff Baseline 
39 
Endline 
60 
Sig 
diff Baseline 
55 
Endline 
57 
Sig 
diff 
Probability fever 
is due to malaria 
<5 
years  
0.12 
(0.1-0.16) 
0.16 
(0.13-0.2) 
 
0.27  
(0.21 - 0.33) 
0.3  
(0.24 - 0.37) 
 
0.09  
(0.06 - 0.15) 
0.12 
(0.08 - 0.17) 
* 
0.01  
(0.02 - 0.04) 
0.04  
(0.01 - 0.12) 
 
>5 
years  
0.05 
(0.03-0.11) 
0.17 
(0.14-0.21) 
* 
0.11  
(0.06 - 0.19) 
0.35  
(0.28 - 0.42) 
* 
0.02  
(0.01 - 0.05) 
0.08  
(0.04 - 0.15) 
 
0.02  
(0.01 - 0.05) 
0.07  
(0.03 - 0.13) 
* 
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5.4.1.2 Access to healthcare: public health facilities, private outlets and tertiary care 
In Chapter 2, I presented the evidence that access to treatment, whether determined by distance or 
travelling time, as well as the source of treatment were important determinants of the effectiveness of a 
treatment programme. Table 22 shows IMPACT 2 study summary estimates of the probability that febrile 
patients seek care for their illness, as well as their preferred sector.  
I have only included private and public sector preferences in this analysis and have not considered other 
sources of treatment such as traditional healers or drugs from family members.  The data are taken from the 
household surveys, which allowed multiple sources of treatment to be selected. For example, a patient may 
attend a health facility first then subsequently go to a drug shop to purchase medications that had been out 
of stock at the initial source of care.  Therefore the sum of the probabilities from the original IMPACT 2 study 
regarding seeking at either private or public sector sources do not equal one. As I am not including the 
chance of a patient attending multiple sources of primary-level care, I have used both IMPACT 2 data and 
data from THMIS (TACAIDS et al., 2008, TACAIDS et al., 2013) to estimate the probably that a febrile 
individual who seeks treatment  does so in either at a private retail outlet or public sector health facility. 
These values that are used in the transmission model are given in italics in the table. 
Overall, more than 80% of children under-five years (U5) and over 60% of those over-five seek treatment for 
fever. In Mbeya (low prevalence) and Mwanza (medium-high) there was a marked preference for the private 
sector both at baseline and endline whereas is Mtwara (medium-high prevalence) the difference is less clear 
at baseline but changes to private preference at endline. The probability of attending a hospital for a severe 
febrile illness is low throughout. 
The time taken to access each source of care indicates that overall individuals take longer to access care in 
the public sector than the private although the difference in unlikely to be significant since the 95% 
confidence intervals overlap.  
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ACCESS   All Mtwara Mwanza Mbeya 
 
 
 
HFS 
Baseline 
138 
Endline 
176 
Baseline 
44 
Endline 
59 
Baseline 
39 
Endline 
60 
Baseline 
55 
Endline 
57 
 
OS 
HH 
 
535 
1510  
(U5: 369,  
O5: 1141) 
700 
1653 
(U5: 424, 
O5: 1228) 
9 
375 
(U5: 93, 
O5: 282) 
3 
345 
(U5: 74, 
O5: 270) 
33 
786 
(U5: 196; 
O5: 590) 
77 
940 
(U5: 268, 
O5: 671) 
17 
349 
(U5:80; 
O5:296) 
43 
368 
(U5: 81;  
O5: 287) 
Probability of patient 
with fever seeking 
treatment  
<5 years 
of age 
0.81  
(0.75-0.86) 
0.84 
(0.78-0.88) 
0.87  
(0.82 - 0.91) 
0.76  
(0.63 - 0.86) 
0.8  
(0.7 - 0.88) 
0.87  
(0.82 - 0.91) 
0.83  
(0.72 - 0.9) 
0.65  
(0.58 - 0.71) 
5 years 
and over 
0.66  
(0.62-0.69) 
0.7 
(0.66-0.73) 
0.73  
(0.69 - 0.77) 
0.63  
(0.56 - 0.7) 
0.67  
(0.62 - 0.72) 
0.73  
(0.69 - 0.77) 
0.62  
(0.55 - 0.87) 
0.65  
(0.58 - 0.71) 
Probability of patient 
with fever seeking 
treatment at public 
sector clinic 
<5 years 
of age 
0.62 (0.6) 
(0.55-0.68) 
0.71 (0.6) 
(0.65-0.77) 
0.58 (0.65) 
(0.43 - 0.72) 
0.32 (0.4) 
 (0.19 - 0.48) 
0.28 (0.35) 
(0.21 - 0.37) 
0.28 (0.35) 
(0.21 - 0.35) 
0.11 (0.3) 
(0.06 - 0.2) 
0.15 (0.35) 
(0.1 - 0.23) 
5 years 
and over 
0.8 (0.7) 
(0.76-0.83) 
0.88 (0.6) 
(0.8-0.86) 
0.27 (0.35) 
 (0.19 - 0.35) 
0.15 (0.25) 
(0.1 - 0.2) 
0.15 (0.2) 
(0.12 - 0.2) 
0.1 (0.15) 
(0.08 - 0.13) 
0.29 (0.35) 
(0.21 - 0.37) 
0.15 (0.25) 
(0.1 - 0.23) 
Time taken to seek 
treatment at clinic 
(days) 
 
<5 years 
of age 
1.4 
(1.1-1.7) 
1.9 
(1.7-2.1) 
1.3  
(0.8 - 1.8) 
1.7  
(1.1 - 2.4) 
1.3  
(0.9 - 1.7) 
2  
(1.7 - 2.3) 
1.6  
(0.9 - 2.3) 
1.8  
(1.2 - 2.3) 
5 years 
and over 
2.1 
(1.7-2.4) 
2.2 
(1.8-2.5) 
1.9  
(1.5 - 2.3) 
2.5  
(1.6 - 3.4) 
1.9  
(1.4 - 2.5) 
2.3  
(1.7 - 2.8) 
2.4  
(1.7 - 3) 
1.8  
(1.2 - 2.3) 
Probability of patient 
with fever seeking 
treatment at private 
outlet 
<5 years 
of age 
0.46 (0.4) 
(0.39-0.42) 
0.55 (0.4) 
(0.48-0.61) 
0.28 (0.35) 
(0.17 - 0.42) 
0.48 (0.6) 
 (0.34 - 0.62) 
0.57 (0.65) 
(0.48 - 0.65) 
0.58 (0.65) 
(0.49 - 0.66) 
0.34 (0.7) 
(0.22 - 0.44) 
0.45 (0.65) 
(0.31 - 0.59) 
5 years 
and over 
0.63 (0.3) 
(0.58-0.67) 
0.69 (0.4) 
(0.65-0.73) 
0.56 (0.65) 
(0.47 - 0.65) 
0.61 (0.75) 
(0.58 - 0.68) 
0.71 (0.8) 
(0.66 - 0.72) 
0.73 (0.85) 
(0.68 - 0.77) 
0.47 (0.65) 
(0.37 - 0.57) 
0.62 (0.75) 
 (0.53 - 0.7) 
Time taken to seek 
treatment at private 
outlet(days) 
 
<5 years 
of age 
1 
(0.8-1.2) 
1.6 
(1.3-1.8) 
0.6  
(0.1 - 1) 
1.1  
(0.8 - 1.4) 
1  
(0.8 - 1.3) 
1.5  
(1.3 - 1.7) 
0.9  
(0.4 - 1.4) 
1.9  
(0.9 - 3) 
5 years 
and over 
1.4 
(1.2-1.5) 
1.6 
(1.5-1.7) 
1  
(0.8 - 1.2) 
1.5  
(1.2 - 1.9) 
1.5  
(1.3 - 1.8) 
1.6  
(1.4 - 1.8) 
1.1  
(0.6 - 1.6) 
1.6  
(1.4 - 1.7) 
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Hospital  All 3 regions  Mtwara Mwanza Mbeya 
n 
Age Baseline 
11 
Endline 
13 
Baseline 
5 
Endline 
5 
Baseline 
2 
Endline 
3 
Baseline 
4 
Endline 
5 
Probability of patient 
with fever seeking 
treatment at a 
hospital 
<5 years 
of age 
0.43 
(0.4-0.53) 
0.35 
(0.29-0.41) 
0.67  
(0.53 - 0.78) 
0.36  
(0.23 - 0.53) 
0.35 
 (0.27 - 0.43) 
0.16  
(0.13 - 0.2) 
0.57  
(0.44 - 0.7) 
0.22  
(0.15 - 0.3) 
5 years 
and over 
0.27  
(0.23-0.31) 
0.18 
(0.15-0.21) 
0.33  
(0.25 - 0.43) 
0.21 
 (0.16 - 0.24) 
0.21  
(0.17 - 0.25) 
0.16  
(0.13 - 0.2) 
0.33  
(0.27 - 0.46) 
0.22  
(0.15 - 0.3) 
Time taken to seek 
treatment at hospital 
(days) 
 
<5 years 
of age 
1.5  
(1.1-1.8) 
1.9 
(1.7-2.1) 
1.3 
(0.9 - 1.8) 
1.7  
(1.1 - 2.3) 
1.5  
(0.9 - 2.1) 
2.3  
(1.9 - 2.7) 
1.5  
(0.9 - 2) 
2.3  
(1.5 - 3.2) 
5 years 
and over 
2.1 
(1.8-2.4) 
2.3 
(1.9-2.3) 
1.8  
(1.4 - 2.2) 
2.3  
(1.8 - 3) 
2.1 
 (1.5 - 2.6) 
2.3  
(1.9 - 2.7) 
2.3  
(1.7 - 2.9) 
2.3  
(1.5 - 3.2) 
 
Table 22: Access to healthcare: public health facilities, private outlets and hospital using household, health facility and outlet surveys from IMPACT 2  
Mean and 95% confidence intervals in brackets.  The values used in the transmission model for the probability that a febrile individual that decides to seek treatment goes to a 
public facility or a private retail outlet are estimated from both IMPACT 2 and THMIS data and are given in italics in the table. 
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5.4.1.3 Quality of care in public sector facilities 
As discussed in Chapter 4, the probability of receiving an ACT (whether for malaria or NMFI) in the public 
sector depends not only on the availability of stocks of ACTs but also on diagnostics and healthcare worker 
compliance with test results. The decision tree approach showed that ACTs may be prescribed through a 
variety of pathways, and not solely via the diagnostic-led route recommended by the T3 guidance.  Quality 
of care estimates in government primary care facilities (from urban clinics facilities to village health posts) 
from the IMPACT 2 Health Facility baseline and endline surveys are shown in Table 23.   
As previously described, the difference between the means of the two samples (baseline and endline) were 
compared using the 2 sample z-test, with a two-tailed comparison; significance was defined as p<0.05 
(assuming a Normal approximation). The validity of regional sample differences is limited by small sample 
sizes. 
Values regarding the sensitivity and specificity of malaria diagnostic tools are derived from the endline 
health facility survey in 2012.   Facility blood smears and RDTs were compared to reference blood smears, 
which were double-read at the Ifakara Health Institute by two blinded microscopists, with contradictory 
readings read by a third microscopist. Facility smears gave a sensitivity and specificity of 70.6% and 63.7% 
respectively (n=119 patients). In contrast the sensitivity and specificity of RDTs performed at the facility 
compared with reference blood smears were 91.3% and 88.0%, respectively (n = 746). Overall the RDT 
positive predictive value was 69.3% and the negative predictive value of 97.3%.  Due to the numbers 
involved, these estimates were not broken down by region, although some studies suggest that the 
performance of some RDTs may vary by age and malaria prevalence (Laurent et al., 2010). In the 
transmission model I have used the sensitivity and specificity values for RDTs in both baseline and endline 
respectively, since estimates were only derived at endline, when most of the tests performed were by RDT.  
At baseline although the majority of tests performed were by microscopy, there were very low levels of 
testing overall.    
Mwanza suffered more complete stock outs of ACTs than the other regions in both surveys, and also of RDTs 
in the endline survey in 2012. This was despite the rollout of RDTs in this region in February 2011.  Both 
stock and use of diagnostics increased from baseline to endline, as well as adherence to test results.  
Artesunate stocks were low in all regions and no referral of severe patients to tertiary level facilities was 
recorded. 
Values are given for the use of RDTs and ACTs overall for each regions and also for use if each commodity is 
in stock, e.g. use of RDTs overall and use of RDTS if RDTS are in stock. The use of ACTs is stratified by 
whether an individual has tested positive, negative or has not been tested. 
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The stock and use of diagnostics increased significantly in all regions, as did the percentage of tests 
performed that used an RDT. In addition, the treatment of negative test results or those who were untested 
with ACTs decreased significantly in Mtwara and Mbeya, but not in Mwanza despite the rollout of T3 
guidance and RDTs in this region. 
These stock-dependent values were used in a decision tree model, as described in Chapter 4, to estimate the 
probability of a malaria case receiving an ACT and an NMFI case being treated with an ACT. I used the 
probability of at least one dose of ACT being present, as the phenomena of dose “stacking” and “splitting” 
were observed during the IMPACT 2 study surveys. The probability of an acute severe case receiving rectal or 
intramuscular artesunate as well as ACTs, as per WHO guidelines, is calculated as the product of the 
probability of a febrile malaria case being treated with an ACT and the probability that artesunate is in stock, 
as described in Chapter 3.  
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PUBLIC SECTOR 
FACILITIES 
 
All 3 
regions 
 
 
Mtwara  
 
Mwanza  
 
Mbeya  
 
 Age 
Baseline 
138 
Endline 
176 
Sig 
diff Baseline 
44 
Endline 
59 
Sig 
diff Baseline 
39 
Endline 
60 
Sig 
diff Baseline 
55 
Endline 
57 
Sig 
diff 
Probability that 
a diagnostic is 
available  
<5 
years  
0.12  
(0.08-0.18) 
0.74 
(0.66-0.8) 
* 
0.25  
(0.13 - 0.44) 
0.89  
(0.77 - 0.95) 
* 
0.12  
(0.05 - 0.26) 
0.6  
(0.46 - 0.73) 
* 
0.05  
(0.03 - 0.11) 
0.79  
(0.64 - 0.88) 
* 
>5 
years  
0.12  
(0.08-0.18) 
0.74 
(0.66-0.8) 
* 
0.25  
(0.13 - 0.44) 
0.89  
(0.77 - 0.95) 
* 
0.12  
(0.05 - 0.26) 
0.79  
(0.64 - 0.88) 
* 
0.05  
(0.03 - 0.11) 
0.79  
(0.64 - 0.88) 
* 
Probability that 
a diagnostic is 
used  
<5 
years  
0.15  
(0.1-0.21) 
0.55 
(0.48-0.62) 
* 
0.32  
(0.19 - 0.49) 
0.72  
(0.58 - 0.83) 
* 
0.04  
(0.01 - 0.11) 
0.5  
(0.39 - 0.62) 
* 
0.11  
(0.06 - 0.2) 
0.48  
(0.34 - 0.62) 
* 
>5 
years  
0.18 
(0.12-0.26) 
0.54 
(0.47-0.61) 
* 
0.3  
(0.18 - 0.46) 
0.7  
(0.55 - 0.82) 
* 
0.13  
(0.05 - 0.3) 
0.44  
(0.33 - 0.56) 
* 
0.15  
(0.07 - 0.29) 
0.48  
(0.34 - 0.62) 
* 
Probability that 
a diagnostic is 
used if available  
<5 
years  
0.45  
(0.32 – 0.6) 
0.69 
(0.62-0.76) 
* 
0.71  
(0.53 - 0.85) 
0.83  
(0.72 - 0.9) 
 
0.06  
(0.01 - 0.38) 
0.67  
(0.53 - 0.78) 
* 
0.33  
(0.18 - 0.53) 
0.47  
(0.63 - 0.33) 
 
>5 
years  
0.47 
(0.32-0.62) 
0.66 
(0.58-0.74) 
* 
0.64  
(0.46 - 0.78) 
0.8  
(0.65 - 0.9) 
 
0.27  
(0.07 - 0.63) 
0.65  
(0.49 - 0.78) 
* 
0.5  
(0.25 - 0.75) 
0.47  
(0.63 - 0.33) 
 
Diagnostic 
sensitivity  
<5 
years  
0.93  
(0.86-0.96) 
0.93  
(0.86-0.96) 
n/a 
0.93  
(0.86-0.96) 
0.93  
(0.86-0.96) 
n/a 
0.93  
(0.86-0.96) 
0.93  
(0.86-0.96) 
n/a 
0.93  
(0.86-0.96) 
0.93  
(0.86-0.96) 
n/a 
>5 
years  
0.91 
(0.78-0.96) 
0.91 
(0.78-0.96) 
n/a 
0.91 
(0.78-0.96) 
0.91 
(0.78-0.96) 
n/a 
0.91 
(0.78-0.96) 
0.91 
(0.78-0.96) 
n/a 
0.91 
(0.78-0.96) 
0.91 
(0.78-0.96) 
n/a 
Diagnostic 
specificity  
<5 
years  
0.89  
(0.83-0.93) 
0.89  
(0.83-0.93) 
n/a 
0.89  
(0.83-0.93) 
0.89  
(0.83-0.93) 
n/a 
0.89  
(0.83-0.93) 
0.89  
(0.83-0.93) 
n/a 
0.89  
(0.83-0.93) 
0.89  
(0.83-0.93) 
n/a 
>5 
years  
0.87 
(0.81-0.91) 
0.87 
(0.81-0.91) 
n/a 
0.87 
(0.81-0.91) 
0.87 
(0.81-0.91) 
n/a 
0.87 
(0.81-0.91) 
0.87 
(0.81-0.91) 
n/a 
0.87 
(0.81-0.91) 
0.87 
(0.81-0.91) 
n/a 
Probability that 
all dose 
packages of ACT 
are available  
<5 
years  
0.57  
(0.45-0.68) 
0.49 
(0.41-0.58) 
 
0.58  
(0.37 - 0.76) 
0.19  
(0.1 - 0.34) 
* 
0.35  
(0.2 - 0.55) 
0.43  
(0.3 - 0.58) 
 
0.72  
(0.54 - 0.85) 
0.52  
(0.38 - 0.67) 
* 
>5 
years  
0.41 
(0.28-0.55) 
0.27 
(0.2-0.36) 
* 
0.52  
(0.23 - 0.8) 
0.12  
(0.05 - 0.24) 
* 
0.23  
(0.1 - 0.43) 
0.16  
(0.08 - 0.31) 
 
0.53  
(0.32 - 0.73) 
0.52  
(0.38 - 0.67) 
 
Probability at 
least one dose 
<5 
years  
0.77  
(0.75-0.86) 
0.71 
(0.62-0.78) 
 
0.91  
(0.76 - 0.97) 
0.57  
(0.39 - 0.74) 
* 
0.56  
(0.38 - 0.73) 
0.57  
(0.43 - 0.71) 
 
0.84  
(0.7 - 0.92) 
0.96  
(0.85 - 0.99) 
* 
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package of ACT 
is available  
>5 
years  
0.78 
(0.68-0.85) 
0.78 
(0.78-0.85) 
 
0.94  
(0.79 - 0.98) 
0.8  
(0.6 - 0.92) 
* 
0.56  
(0.38 - 0.73) 
0.61  
(0.47 - 0.74) 
 
0.86  
(0.72 - 0.93) 
0.98  
(0.85 - 1) 
* 
Probability that 
ACT 
prescribed/disp
ensed if test 
positive  
<5 
years  
0.67  
(0.52-0.79) 
0.5 
(0.37-0.64) 
* 
0.81  
(0.57 - 0.93) 
0.63  
(0.47 - 0.77) 
* 
0.17  
(0.01 - 0.84) 
0.16  
(0.06 - 0.36) 
 
0.93  
(0.53 - 0.99) 
0.9  
(0.55 - 0.99) 
 
>5 
years  
0.61 
(0.4-0.0.79) 
0.68 
(0.53-0.8) 
 
0.52  
(0.23 - 0.8) 
0.76  
(0.6 - 0.88) 
* 
0.21  
(0.01 - 0.85) 
0.25  
(0.08 - 0.56) 
 
0.85  
(0.52 - 0.97) 
0.9  
(0.55 - 0.99) 
 
Probability that 
ACT 
prescribed/disp
ensed if test 
positive and 
ACT is in stock 
<5 
years  
0.82  
(0.69-0.8) 
0.77 
(0.63-0.86) 
 
0.84  
(0.62 - 0.95) 
0.82  
(0.74 - 0.89) 
 
0.2  
(0.01 - 0.81) 
0.45  
(0.15 - 0.79) 
* 
0.93  
(0.61 - 0.99) 
0.9  
(0.57 - 0.98) 
 
>5 
years  
0.86 
(0.63-0.96) 
0.88 
(0.75-0.95) 
 
0.67  
(0.39 - 0.86) 
0.91  
(0.8 - 0.97) 
* 
0.27  
(0.02 - 0.85) 
0.63  
(0.16 - 0.94) 
* 
0.85  
(0.58 - 0.96) 
0.9  
(0.57 - 0.98) 
 
Probability that 
ACT 
prescribed/disp
ensed if test 
negative 
<5 
years  
0.43  
(0.37-0.5) 
0.07 
(0.1-0.04) 
* 
0.34  
(0.13 - 0.65) 
0.04  
(0.02 - 0.11) 
* 0 
0.06  
(0.03 - 0.12) 
 
0.33  
(0.1 - 0.7) 
0.16  
(0.08 - 0.3) 
* 
>5 
years  
0.33 
(0.27-0.4) 
0.08 
(0.04-0.14) 
* 
0.12 
(0.04 - 0.32) 
0.07  
(0.02 - 0.23) 
 0 
0.02  
(0.01 - 0.1) 
 
0.33  
(0.13 - 0.62) 
0.16  
(0.08 - 0.3) 
* 
Probability that 
ACT 
prescribed/disp
ensed if test 
negative and 
ACT is in stock 
<5 
years  
0.63  
(0.55-0.67) 
0.07 
(0.05-0.11) 
* 
0.35  
(0.14 - 0.64) 
0.05  
(0.02 - 0.12) 
* 0 
0.07  
(0.03 - 0.14) 
 
0.33  
(0.11 - 0.66) 
0.16  
(0.08 - 0.3) 
* 
>5 
years  
0.45 
(0.37-0.53) 
0.09 
(0.17-0.05) 
* 
0.13  
(0.05 - 0.32) 
0.08  
(0.02 - 0.25) 
 0 
0.04  
(0.01 - 0.15) 
 
0.29  
(0.1 - 0.57) 
0.16  
(0.08 - 0.3) 
 
Probability that 
ACT 
prescribed/disp
ensed if 
untested 
<5 
years  
0.43  
(0.35-0.5) 
0.21 
(0.14-0.3) 
* 
0.63  
(0.52 - 0.72) 
0.4  
(0.19 - 0.65) 
* 
0.25  
(0.15 - 0.38) 
0.11  
(0.06 - 0.19) 
 
0.52  
(0.4 - 0.64) 
0.33  
(0.19 - 0.51) 
* 
>5 
years  
0.33 
(0.27-0.4) 
0.19 
(0.12-0.29) 
* 
0.54  
(0.42 - 0.66) 
0.3  
(0.13 - 0.55) 
* 
0.15  
(0.08 - 0.26) 
0.07  
(0.02 - 0.18) 
 
0.26  
(0.3 - 0.39) 
0.33  
(0.19 - 0.51) 
 
Probability that 
ACT 
prescribed/disp
<5 
years  
0.63  
(0.56-0.69) 
0.31 
(0.22-0.42) 
* 
0.66  
(0.57 - 0.74) 
0.47  
(0.25 - 0.7) 
* 
0.55  
(0.4 - 0.69) 
0.23  
(0.15 - 0.35) 
* 
0.66  
(0.56 - 0.75) 
0.33  
(0.2 - 0.51) 
* 
>5 0.48 0.29 * 0.58  0.42   0.27  0.14   0.54  0.33  * 
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ensed if 
untested and 
ACT is in stock 
years  (0.4-0.56) (0.19-0.4) (0.46 - 0.68) (0.21 - 0.66) (0.16 - 0.41) (0.06 - 0.31) (0.39 - 0.68) (0.2 - 0.51) 
Probability that 
diagnostic used 
is an RDT 
<5 
years  
0.08  
(0.03-0.21) 
0.8 
(0.7-0.87) 
* 
0.08  
(0.02 - 0.27) 
0.87  
(0.72 - 0.94) 
* 
0.14  
(0.01 - 0.7) 
0.76  
(0.55 - 0.89) 
* 
0.06  
(0.01 - 0.39) 
0.81  
(0.64 - 0.91) 
* 
>5 
years  
0.05 
(0.02 – 
0.13) 
0.82 
(0.74-0.88) 
* 
0.06  
(0.01 - 0.2) 
0.88  
(0.74 - 0.95) 
* 
0.08  
(0.01 - 0.41) 
0.75  
(0.59 - 0.86) 
* 0 
0.81  
(0.64 - 0.91) 
* 
Probability that 
Artesunate 
(rectal or 
intramuscular) 
is in stock 
All 
0.14 
(0.07-0.24) 
0.02 
(0.01-0.08) 
* 
0.18  
(0.08 - 0.26) 
0 * 
0.18  
(0.07 - 0.38) 
0.03  
(0.01 - 0.21) 
* 
0.09  
(0.03 - 0.25) 
0.02  
(0.07 - 0.01) 
 
Probability a 
severe case is 
referred to 
hospital 
All 0 0  0 0  0 0  0 0  
Table 23: Care Quality indicators in public sector health facilities: IMPACT 2 Health facility Survey  
Mean with 95% confidence intervals in brackets.  A significant difference (p<0.05) between the means of baseline and endline samples is indicated by an asterix  
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5.4.1.4 Quality of care in private sector outlets 
 
The decision-tree approach to estimating the probability of receiving an ACT for a malaria infection or NMFI 
is described in Chapter 4.  In order to calculate this quality of care value for the private sector (from general 
stores and DLDB to part one pharmacies with qualified pharmacists) in the three regions of Tanzania being 
considered, the component from the IMPACT 2 Household and outlet surveys are shown in Table 24.  
As stated in section 5.4.1.1, given that only summary statistics were available from the IMPACT 2 study, the 
difference between the means of the two samples (baseline and endline) were compared using the 2 sample 
z-test, with a two-tailed comparison; significance was defined as p<0.05 (assuming a Normal approximation).  
The validity of regional sample differences is limited by small sample sizes. 
Levels of test stock and testing were universally poor. Values regarding whether individuals were treated if 
they test positive are based on individuals in the household survey who recalled being tested and treated, 
and not from observation at the outlet survey itself. Thus, these values of private sector prescription 
performance are not dependent on stock levels at the outlet. For example, there were no outlets surveyed 
in Mtwara with ACT stock however in the household survey individuals reported attending an outlet in the 
past 14 days and being treated with an ACT. Due to low numbers of tests performed, estimates of treatment 
probability are not stratified by age for each region, for example only 27 patients recalled having a positive 
test at a private outlet in the household study. 
Table 24 gives values for ACT stock and use, which includes both quality assured ACTs (QAACTs) and non-
quality assured ACTs; which were almost always Artemether-Lumefantrine in both cases.  Stocks were low in 
all three regions in retail outlets at baseline but improved significantly in Mbeya and Mwanza by endline, to 
the extent that there was a higher probability of an outlet having ACTs stocks than a health facility in 
Mwanza. 
In Mtwara, at endline, none of the outlets surveyed carried any ACT stock, but the number of outlets was 
very small.  Artesunate stocks were low in all regions and no referral of severely ill patients to tertiary level 
facilities was recorded from a private retail outlet. The structure of the survey did not capture whether 
severely ill patients then sought care elsewhere. The household and outlet surveys did not ask any questions 
regarding stock or use of ACTs with the AMFm “green-leaf” logo at baseline. Table 25 shows nationwide 
estimates at endline for stocks of QAACTs with the AMFm logo, and their use on patients with a positive test 
(n=27) and in those who were untested. 19% of test positive patients received a QAACT compared with 9% 
of those who were untested.  These are lower than the estimates for use of any ACT.  It is unclear whether 
this is due to provider or patient preference. 
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As described in Section 5.4.1.3, these values were used in a decision tree model to estimate the probability 
of a malaria case receiving an ACT for their fever as well as an NMFI unnecessarily being treated with an ACT.  
The probability of at least 1 dose of an ACT in stock was used here rather than the probability of all doses 
being present as the practices of dose stacking and splitting were observed. Of the few patients who were 
tested, only one negative test was recorded in the survey.  Hence I used the same probability of receiving an 
ACT if untested as for those who test-negative in the decision-tree model. 
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Table 24: Care Quality indicators in private outlets (Drug shops including DLDB and ADDOs, pharmacies including POP and general stores): from IMPACT 2 Household and Outlet 
surveys 
Mean with 95% confidence intervals in brackets.  A significant difference (p<0.05) between the means of baseline and endline samples is indicated by an asterix  
 
 
All 3 regions Mtwara Mwanza Mbeya 
N 
 
OS 
HH 
Baseline 
535 
1510  
(U5: 
369*0.4,  
O5: 
1141*0.3) 
Endline 
700 
1653 
(U5: 
424*0.4, 
O5: 
1228*0.4) 
Sig 
diff 
Baseline 
9 
375 
(U5: 
93*0.35, 
O5: 
282*0.65) 
Endline 
3 
345 
(U5: 74*0.6, 
O5: 
270*0.75) 
Sig 
diff 
Baseline 
33 
786 
(U5: 
196*0.65; 
O5: 
590*0.8) 
Endline 
77 
940 
(U5: 
268*0.65, 
O5: 
671*0.85) 
Sig 
diff 
Baseline 
17 
349 
(U5:80*0.7; 
O5:296*0.6
5) 
Endline 
43 
368 
(U5: 
81*0.65;  
O5: 
287*0.75) 
Sig 
diff 
 
Probability that a 
diagnostic is 
available  
All  
 
0 
(0 - 0.01) 
0.03 
(0.01-0.05) 
* 0 0  0 0  0 
0.03  
(0.01 - 0.08) 
 
Probability that a 
diagnostic is used  
<5 
years  
0.04 
(0.02-0.09) 
0.02 
(0.01-0.05) 
 0 0 
 
0 
0.02  
(0.01 - 0.05) 
 0 
0.05 (0.01 - 
0.2) 
 
>5 
years  
0.03 
(0.02-0.06) 
0.02 
(0.01-0.03) 
 0 0 
 
0 
0.02  
(0.01 - 0.05) 
* 0 0 
 
Probability that all 
dose packages of 
ACT are available  
<5 
years  
0.03  
(0.02-0.06) 
0.33 
(0.24-0.42) 
* 0 0 
 
0 
0.35  
(0.56 - 0.19) 
* 
0.15  
(0.05 - 0.38) 
0.2  
(0.09 - 0.4) 
 
>5 
years  
0 
 
0.1 
(0.06-0.14) 
* 0 0 
 
0 
0.05  
(0.02 - 0.13) 
 0 
0.05  
(0.01 - 0.15) 
 
Probability at least 
one dose package 
<5 
years  
0.03  
(0.02-0.06) 
0.33 
(0.24-0.42) 
* 
0.11  
(0.11 - 0.11) 
0 
 0.03 
(0.01 - 0.17) 
0.71  
(0.59 - 0.8) 
* 
0.3  
(0.26 - 0.34) 
0.68  
(0.67 - 0.7) 
* 
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of ACT is available  >5 
years  
0.18 
(0.11-0.27) 
0.70 
(0.61-0.78) 
* 
0.11  
(0.11 - 0.11) 
0 
 0.03  
(0.01 - 0.17) 
0.71  
(0.59 - 0.8) 
* 
0.3  
(0.26 - 0.34) 
0.68  
(0.67 - 0.7) 
* 
Probability that 
ACT 
prescribed/dispens
ed if test positive  
<5 
years  
0.26   
(0.09-0.55) 
0.43 
(0.21-0.69) 
* 
0.26  
(0.09 - 0.55) 
0.43  
(0.21 - 0.69) 
n/a 
0.26  
(0.09 - 0.55) 
0.43  
(0.21 - 0.69) 
n/a 
0.26  
(0.09 - 0.55) 
0.43 
(0.21 - 0.69) 
n/a 
>5 
years  
0.61 
(0.4-0.79) 
0.43 
(0.21-0.69) 
* 
Probability that 
ACT 
prescribed/dispens
ed if test negative 
<5 
years  
0.18  
(0.14-0.23) 
0.32 
(0.25-0.4) 
* 
0.22  
(0.14 - 0.31) 
0.27  
(0.19 - 0.35) 
 
0.18  
(0.13 - 0.24) 
0.24  
(0.2 - 0.29) 
* 
0.17  
(0.09 - 0.29) 
0.21  
(0.14 - 0.29) 
 
>5 
years  
0.18  
(0.14-0.23) 
0.2 
(0.17-0.25) 
 
Probability that 
ACT 
prescribed/dispens
ed if untested 
<5 
years  
0.20  
(0.13-0.3) 
0.32 
(0.25-0.4) 
* 
0.22  
(0.14 - 0.31) 
0.27  
(0.19 - 0.35) 
 
0.18  
(0.13 - 0.24) 
0.24  
(0.2 - 0.29) 
* 
0.17  
(0.09 - 0.29) 
0.21  
(0.14 - 0.29) 
 
>5 
years  
0.18  
(0.14-0.23) 
0.2 
(0.17-0.25) 
 
Probability that 
Artesunate (rectal 
or intramuscular) 
is in stock 
 
All 0 
 
0.0 
(0-0.01) 
 
0 0 
 
0 0 
 
0 
0.21  
(0.14 - 0.29) 
* 
Probability a 
severe case is 
referred to 
hospital 
 
All 0.01 
(0-0.01) 
0.01 
(0-0.01) 
 
0 0 
 
0 0 
 
0 0 
 
 
  
197 
 
Table 25: Estimates of stocks and usage of QAACTs (with the AMFm green leaf logo) in private outlets at endline: IMPACT 2 Outlet and household surveys 
(mean with 95% confidence intervals in brackets) 
Survey  
(All 
regions) 
N 
Probability that all dose 
packages of QAACT are 
available 
Probability at least one  
dose package of QAACT is 
available 
Probability that QAACT 
prescribed/dispensed if 
test positive (n=27) 
Probability that 
QAACT 
prescribed/dispensed 
if test negative (n=1) 
Probability that QAACT 
prescribed/dispensed if 
untested 
Endline 
OS: 700 
HHS: 1653 
<5 years: 
424 
0.3 (0.22-0.4) 0.33 (0.24-0.42) 
0.19 (0.048-0.52) 0 0.094 (0.074-0.12) 
>5 years: 
1228 
0.09 (0.06-0.13) 0.66 (0.57-0.74) 
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5.4.1.5 Quality of care in tertiary care facilities 
As discussed in Chapter 3, access to and quality of tertiary care may be an important determinant of 
mortality, especially in medium to high transmission settings.  
Table 26 describes data from the Health Facility survey that pertains to hospitals and other tertiary care 
facilities. The numbers here are small since only 11 hospitals were included in the baseline survey and 13 
hospitals in the endline interviews. 
Diagnostic availability increased in all regions at endline, and quinine stock levels were high both at baseline 
and endline throughout.  However the probability of artesunate being in stock on a given day never 
exceeded 50%. 
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Table 26: Quality of care in hospitals and other tertiary care facilities from the IMPACT 2 Health facility survey 
Hospital  All 3 regions Mtwara Mwanza Mbeya 
n 
Age Baseline 
11 
Endline 
13 
Baseline 
5 
Endline 
5 
Baseline 
2 
Endline 
3 
Baseline 
4 
Endline 
5 
Probability of 
diagnostic availability 
in hospital 
All 
0.38 
(1.1-1.7) 
100 0 100 
0.48  
(0.07 - 0.91) 
100 
0.16  
(0.03 - 0.76) 
100 
Probability of 
artesunate in stock in 
hospital 
All 
0.29 
(0.64-0.86) 
0.38 
(0.16-0.82) 
0.26  
(0.05 - 0.73) 
0 
0.37  
(0.03 - 0.91) 
0.48  
(0.07 - 0.92) 
0.24  
(0.03 - 0.76) 
 
0.16  
(0.02 - 0.65) 
Probability of quinine 
in stock in hospital  
All 100 
0.83 
(0.46-0.97) 
100  
0.8  
(0.28 - 0.98) 
100 
0.85  
(0.32 - 0.99) 
100 
0.8  
(0.02 - 0.97) 
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5.4.2 Mathematical model 
I aim to use mathematical modelling techniques to estimate the impact made by changes in health systems 
factors such as access to healthcare and the components of delivering ACTs on the clinical outcomes of 
malaria (e.g. malaria mortality) as well as parasite prevalence on a national and regional basis. This 
modelling approach allows analysis of the effects of packages of interventions that would be difficult to 
explore through other study methods such as randomised controlled trials. 
The IMPACT 2 data summarised in the previous section was used to obtain parameters for Model 3 in 
Chapter 3, shown in full in Figures 47 and 48.  
ACTs may be prescribed on the basis of a positive diagnostic test, however as demonstrated in Chapter 4 
there are several pathways through which an individual with malaria may receive an ACT.  In both the public 
and private sectors, febrile cases not infected with malaria may also be prescribed or purchase ACTs.  Hence, 
parameters for the probability of receiving an ACT for a malaria infection (including an asymptomatic 
infection) or an NMFI (including sub-patent infections) in both public health facilities and private outlets are 
calculated using IMPACT 2 data in the decision-tree model described in Chapter 4.  Scenarios in which the 
steps of treatment delivery are optimised were run using the decision tree for both public and private 
sectors separately for U5s and over fives, in the three regions of Tanzania. These case management 
scenarios are summarised in Table 30 (Section 5.5.6).  The values derived from the decision tree results were 
then used to consider the impact of these interventions on malaria transmission and clinical sequelae.   
In addition I investigated how improving hospital access and severe disease management affected these 
model outcomes. Table 31 (Section 5.5.7) summarises the set of tertiary care scenarios considered and the 
relevant parameterisation.  
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Figure 47: Flow diagram for the final health systems malaria transmission model (Model 3): Treatment of NMFI pathways 
S - susceptible; NT – not seeking treatment; Pr – Seeking treatment at private outlet/drug seller; CL – Seeking treatment at primary care health facility/government clinic; PrNT – 
not treated at private outlet/drug seller; CLNT – not treated at primary care health facility/government clinic; Tx – On treatment; D – untreated clinical disease; Sev – Severe 
disease; P - prophylaxis; A - asymptomatic patent infection; U - asymptomatic sub-patent infection. UPr – Sub-patent seeking treatment for NMFI at private outlet/drug seller; 
UCL – Sub-patent seeking treatment for NMFI at primary care facility; UTx: Sub-patent treated with ACTs; SPr – NMFI seeking treatment at private outlet/drug seller; UCL – 
NMFI seeking treatment at primary care facility; APr – Asymptomatic malaria case with NMFI seeking treatment at a private outlet/drug seller;  ACL – Asymptomatic malaria 
case with NMFI seeking treatment at a primary care facility; ATrTx – Asymptomatic malaria case with NMFI treated with ACT.    People move between these states with 
rates/probabilities as marked on the arrows 
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Figure 48: Flow diagram for the final health systems malaria transmission model (Model 3): Pathways for treating symptomatic malaria (uncomplicated and severe) 
S - susceptible; NT – not seeking treatment; Pr – Seeking treatment at private outlet/drug seller; CL – Seeking treatment at primary care health facility/government clinic; PrNT – 
not treated at private outlet/drug seller; CLNT – not treated at primary care health facility/government clinic; Tx – On treatment; D – untreated clinical disease; Sev – Severe 
disease; P - prophylaxis; A - asymptomatic patent infection; U - asymptomatic sub-patent infection; WSev – untreated progressing early severe PrSev – Severe case seeking 
treatment at private outlet/drug seller ; CLSev – Severe case seeking treatment at primary care facility; Href – Severe case referred to hospital or tertiary facility by either health 
facility or private outlet; TxSev – Severe case that has received treatment at clinic/health facility or private outlet; CLSevNT – severe case not treated at primary care 
facility/government clinic; PrSevNT – severe case not treated at private outlet/drug seller;- HTx – Severe case treated in hospital or tertiary facility;  HSev – untreated severe 
case in hospital or tertiary facility. People move between these states with rates/probabilities as marked on the arrows 
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5.5 RESULTS 
5.5.1 Probability of receiving an ACT: comparison of Decision tree outputs to IMPACT 2 study data 
The decision tree approach, described in Chapter 4, was used to derive the probability that a malaria or 
NMFI case would receive an ACT (in both public and private sectors). These values were compared to the 
same probabilities estimated in the IMPACT 2 study.  The health facility survey collected finger prick blood 
samples on all enrolled consenting patients attending each health facility. In the household study an RDT 
was performed on all consenting members who had a fever in the past fortnight. 
Table 27 shows the estimated probability that a patient who was malaria test positive or negative by RDT 
had received an ACT in the IMPACT 2 study, using data from all regions. As previously, the means of the two 
samples (baseline and endline) were compared using the 2 sample z-test, with a two-tailed comparison; 
significance was defined as p<0.05 and shown in the table using an asterix.   
These estimates are compared with the outputs from the decision-tree model parameterised using IMPACT 
2 data, estimating the number of malaria cases that have been treated with an ACT (whether tested or not) 
and the number of NMFI cases that have been treated unnecessarily.  Through bootstrapping the decision 
tree outputs, I generated a distribution for the difference between baseline and endline estimates for the 2 
outcomes (i.e. the probability of receiving an ACT for a malaria case and for an NMFI case) in U5s and over-
fives in both public and private sectors.  The difference between endline and baseline was assumed to be 
significant if the distribution of the difference did not cross zero, and this is depicted in Figure 49.  Only the 
probability of a malaria case over-five receiving an ACT in the public sector did not change significantly at 
endline.  This is likely due to a more long-standing practice of diagnostic-led treatment in this age group. 
The proportions treated in the private sector are significantly different between the two approaches, with 
confidence intervals that do not overlap for any age group at baseline or endline. For example, using the 
decision-tree I estimate 0.8% (95% UI: 0.28-1.51%) of U5s with malaria at baseline are given ACTs at a 
private outlet compared to an estimate of 24% (95%CI: 12.2-41.7) from the IMPACT 2 study.  The most likely 
explanation for these differences is that the decision-tree estimates are based on the reported probabilities 
of ACT stock levels for a given survey day and thus do not account for patients visiting several treatment 
sources in order to obtain drugs.  Differences may also be due to provider preference, customer preference 
to use other antimalarials or to the ability of the patients to search other sources of ACTs as well as patient 
recall regarding their treatment which is known to be sub-optimal in other settings (Eisele et al., 2013). 
In the private sector, the decision tree outputs suggest that the probability of being treated with an ACT 
(malaria and NMFI) was approximately 9% greater at the endline survey for both age groups.  In the IMPACT 
2 survey, this was estimated to be a difference of up to 12% in the U5s. In contrast to the decision tree 
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estimates, there was little change in the percentage of over-five malaria cases treated in the private sector 
observed for those over-five, despite increased levels of over-treatment.   
In the public sector, the estimated proportion of NMFI cases treated with an ACT using the decision-tree was 
similar to the percentage of study test negatives that received an ACT in the IMPACT 2 study at both baseline 
and endline. However the estimated proportion of malaria cases that receive an ACT obtained from the 
decision-tree model was lower than the proportion of study test positive patients given an ACT at the health 
facility in both the baseline and endline surveys; although the confidence intervals do overlap between the 
estimates of the IMPACT 2 study and the decision tree approach. The difference between the IMPACT 2 
study estimates and the decision tree outputs may be due to sampling bias at the facility or more likely due 
to a dependency between input variables that is not captured in the decision tree, e.g. the probability of 
prescribing an ACT may be associated with test availability as well as ACT availability. This may also 
contribute to the differences seen in the private sector decision tree outputs and those from the household 
survey. 
In both the decision-tree outputs and the IMPACT 2 study estimates, the probability of an NMFI case being 
treated with an ACT decreases from baseline to endline, by almost 30% in U5s and approximately 15% in 
over-fives. The difference in prescribing behaviour between age groups may be due to the practice of 
presumptive treatment in U5s being more prevalent than in over-fives as a result of previous guidelines.   
Additionally, in both the IMPACT 2 and decision-tree estimates, the probability of an U5 malaria case being 
treated with an ACT reduces by approximately 12% in each case compared to baseline. Thus the decision 
tree estimates that only 35% (95%UI: 28.3-43%) of U5s receive an ACT at a health facility, whilst IMPACT 2 
estimates that only 45% (95%CI: 34-56%) are treated with a first-line antimalarial at endline.  In contrast, 
42% (95%UI: 35-49.5%) of over fives are treated with an ACT using the decision tree, and 60% (95%CI: 47-
71% using the IMPACT 2 data. 
This undertreatment of malaria cases at health facilities is likely due to stockouts of ACTs, especially in the 
Mwanza region. However even at facilities where ACTs were in stock, ACTs were still not prescribed in 
approximately 20% of cases where the case was facility-test positive, which is similar to that reported in an 
evaluation of the RDT rollout in a single Tanzanian district (Masanja et al., 2012a). This rationing may have 
been due to a past history of poor stock levels - Wasunna et al have documented withholding of ACTs in fear 
of future stockouts but few other studies have identified similar levels of undertreatment in other countries 
(Wasunna et al., 2008).  
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Table 27: Estimates derived from the decision tree approach and the IMPACT 2 study for the probability of receiving an ACT for a malaria infection or an NMFI in the public and 
private sectors, using IMPACT input data for all regions of Tanzania considered.   
Mean with 95% uncertainty intervals given in brackets. A significant difference (p<0.05) between the means of baseline and endline IMPACT 2 survey samples is indicated by an 
asterix  
 Age Decision Tree (Public) IMPACT 2 (Public) Decision Tree (Private) IMPACT 2(Private) 
  
% Malaria given 
ACT 
% NMFI given 
ACT  
% Study + given 
ACT 
% Study - given 
ACT  
% Malaria given 
ACT 
% NMFI given 
ACT  
% Study + given 
ACT 
% Study - 
given ACT  
Baseline U5 
47.78  
(40.53 - 56.02) 
47.06  
(39.82 - 55.22) 
67  
(51 - 79) 
43  
(36 - 50) 
0.8  
(0.28 - 1.51) 
0.8  
(0.28 - 1.52) 
24  
(12.2 - 41.7) 
19.1  
(11.6 - 30) 
Endline U5 
35.25  
(28.3 - 43.18) 
16.69  
(12.36 - 21.7) 
45  
(34 - 56) 
15  
(11 - 20) 
10.02  
(6.48 - 14.44) 
10.14  
(6.17 - 14.32) 
36.7  
(23.7 - 51.9) 
30.5  
(22.6 - 39.7) 
Difference 
between 
endline and 
baseline 
 
-12.62*  
(-4.98 -19.93) 
-30.23*  
(-24.79 -34.64) 
 * 
9.30*  
(5.76  13.75) 
9.31*  
(5.85  13.89) 
* * 
Baseline Over 5 
38  
(30.44 - 46.28) 
36.78  
(29.52 - 44.77) 
61 
 (40 - 79) 
33  
(27 - 40) 
1.99  
(1.29 - 2.82) 
1.97  
(1.27 - 2.83) 
16.4  
(10.6 - 24.7) 
19.4  
(14.8 - 25) 
 
Endline Over 5 
42.15  
(35 - 49.49) 
21.09  
(15.7 - 26.55) 
60  
(47 - 71) 
15.7  
(12.1 - 22) 
14.63  
(11.3 - 18.53) 
14.71  
(11.3 - 18.42) 
14  
(7.4 - 24.8) 
30.5  
(22.6 - 39.7) 
 
Difference 
between 
endline and 
baseline 
 
4.36  
(11.86  -3.62) 
-15.85*  
(-10.43 -21.22) 
 * 
12.67*  
(9.3 16.48) 
12.71*  
(9.32 16.61) 
 * 
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Figure 49: Difference between endline and baseline estimates derived from the decision tree approach on the probability of receiving an ACT for a malaria infection or an NMFI: 
“all-Tanzania” scenario  
The absolute percentage change is shown for the public sector (grey) and private sectors (red). Significant difference is indicated by an asterix.   
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5.5.2 Comparison of Baseline and Endline parameters in transmission model: Impact on parasite 
prevalence and clinical outcomes using decision-tree and IMPACT 2 estimates 
In order to estimate the effect of health systems changes seen from baseline to endline surveys on 
prevalence and clinical outcomes, the values listed in Table 28 were input into the transmission model as the 
parameters: ftr_CL and ftr_PR for the probability of a malaria case being treated at a clinic or private outlet 
and ftr_NMFICL and ftr_NMFIPR representing the probability of an NMFI case receiving ACTs at each respective 
source.  The transmission model was then used to compare the expected impact of the changes in access to 
care on transmission (parasite prevalence and EIR) and clinical outcomes (clinical disease, severe disease 
incidence and malaria mortality). All other parameters regarding probability of treatment seeking, sector 
preference and hospital case management were taken from the IMPACT 2 data summarised in Tables 22-26.  
In order to compare the impact of the changes in ACT delivery, the model was run to equilibrium using the 
parameters from the baseline survey and then the run from this point to the new equilibrium using the 
parameters from the endline survey. I assumed that the baseline population parasite prevalence in under-
fives was 9% (TACAIDS et al., 2013), representing Tanzania as a whole. 
Using the IMPACT 2 study derived parameters, the model predicted an increase in all clinical and 
transmission outcomes at endline compared with the baseline scenario, as summarised in Table 28. In 
contrast, using the decision-tree generated parameters for the probability of receiving treatment led to a 
modest decrease in all modelled outcomes from baseline except the incidence of severe disease, assuming 
these systems changes were sustained.  These results using the decision-tree outputs in the transmission 
model follow the pattern of reductions in prevalence and mortality described in recent reports, both in 
Tanzania and globally (WHO, 2013, WHO, 2012c). The effects were greatest in the U5 age-group, which is 
the group most likely to be symptomatic and attend a source of care. 
Table 28: Percentage change relative to baseline in modelled outcomes using IMPACT 2 study estimates and 
Decision-tree generated outputs to parameterise the transmission model  
 
Prevalence: 
all ages 
Prevalence: 
2-10 years 
Prevalence: 
0-5 years EIR  
Clinical 
Incidence: 
0-5 years 
Severe 
incidence: 
0-5 years 
Malaria 
Mortality: 
0-5 years 
% change: 
IMPACT 2  6.5 8.1 9.5 5.8 5.6 19.2 9.6 
% change: 
Decision-tree  -12.0 -14.9 -16.1 -10.7 -10.2 2.7 -5.4 
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5.5.3 Regional comparison of Baseline and Endline health systems surveys: Impact on parasite 
prevalence and clinical outcomes 
Figure 50: Age-incidence and Age-prevalence curves depicting the impact of changes in malaria treatment delivery 
from baseline to endline in 3 regions of Tanzania on clinical and severe disease incidence (per 1000 persons per year) 
and %population parasite prevalence.   
Baseline is indicated in blue and endline in red. 
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Figure 50 depicts the baseline and endline age-incidence and age-prevalence curves for each of the three 
regions considered.  The baseline models were parameterised to match the 2011 parasite prevalence for 
U5s for each region obtained in the THMIS survey (TACAIDS et al., 2013). Parameter values were generated 
from the decision-tree approach, using the regional IMPACT 2 data in table 22-26, and are listed in Table 29.  
Baseline curves are in blue and endline in red. The baseline curves are as expected for medium to high 
prevalence settings (Mwanza and Mtwara) and for low prevalence settings (Mbeya) (Griffin et al., 2014, 
Griffin et al., 2014 ).  In Mwanza, the model predicts that parasite prevalence in all ages would be reduced by 
the health systems changes to ACT delivery reported by IMPACT 2.  Clinical incidence is predicted to be 
reduced in the young, but to a lesser extent in older ages. Severe disease incidence is not predicted to 
change substantially.  Mortality curves are not shown here but malaria mortality is not discernibly impacted 
(less than 10% change relative to baseline).   
In Mbeya, a low prevalence setting, the model predicts a reduction in parasite prevalence as a result of the 
improvements in case management with ACTs seen from baseline to endline in the IMPACT 2 study.  Severe 
disease and malaria mortality are low and are predicted to be further reduced in all ages, with mortality 
levels in those under-15 years particularly impacted; approximately 3 fewer children per 1000 per year are 
predicted to die. 
The baseline prevalence in Mtwara in 0-5 years was 17.4% in 2011 according to THMIS (TACAIDS et al., 
2013).  Here the model predicted an increase in parasite prevalence in all age-groups, with a 3% increase in 
those aged 0-5 years and 3.5% increase in the 2-10 year age group. Despite this I estimated very little change 
in malaria morbidity or mortality would have occurred due to any changes in ACT delivery from baseline to 
endline. This rise in prevalence is due to high levels of preference for the private sector in this region 
combined with a complete stockout of ACTs reported at endline.  Hence no treatment was given to the 
estimated 75% of over-fives and 60% of U5s with fever that seek care at drug shops, whether for malaria or 
NMFI.  Severe disease and mortality levels are less affected in this medium to high transmission setting since 
community level barriers to treatment of uncomplicated malaria only affect one pathway by which severe 
disease is captured in the model, as discussed further in the results Section 5.5.6.   
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Table 29: Decision tree estimates: for the probability of receiving an ACT for a malaria infection or an NMFI in the public and private sectors for the three regions of Tanzania. 
Mean with 95% confidence intervals in brackets. 
Probability of 
receiving an ACT 
 All Mtwara Mwanza Mbeya 
 
 
% Malaria 
given ACT  
% NMFI given 
ACT  
% Malaria 
given ACT 
% NMFI given 
ACT 
% Malaria 
given ACT 
% NMFI given 
ACT  
% Malaria 
given ACT 
% NMFI given 
ACT 
Public sector 
(baseline) 
U5 
47.78  
(40.53 - 56.02) 
47.06  
(39.82 - 55.22) 
58.13 
(47.9-69.76) 
52.77 
(42-64.7) 
29.9 
(17.79-44.41) 
29.27 
(17.27-44.15) 
53.51 
(42.42-65.71) 
52.64 
(4.97-64.95) 
Over 5 
38  
(30.44 - 46.28) 
36.78  
(29.52 - 44.77) 
50.66 
(39.82-62.52) 
45.68 
(34.98-56.76) 
16.03 
(8.27-26.24) 
15.18 
(7.58-25.57) 
44.78 
(31.97-59.08) 
29.94 
(19.77-41.77) 
Private sector 
(baseline) 
U5 
0.8  
(0.28 - 1.51) 
0.8  
(0.28 - 1.52) 
2.52 
(1.62-3.37) 
2.49 
(3.37-1.67) 
1.64 
(0.18-3.38) 
1.6 
(0.17-3.41) 
5.73 
(2.86-9.02) 
5.73 
(2.76-8.96) 
Over 5 
1.99  
(1.29 - 2.82) 
1.97  
(1.27 - 2.83) 
2.49 
(1.62-3.37) 
2.5 
(1.61-3.38) 
1.59 
(0.18-3.36) 
17.06 
(12.98-21.86) 
5.76 
(2.81-8.88) 
5.71 
(2.84-8.9) 
Public sector  
(endline) 
U5 35.25  
(28.3 - 43.18) 
16.69  
(12.36 - 21.7) 
37.74 
(25.53-51.41) 
14.24 
(8.35-22.92) 
18.26 
(9.41-29.38) 
11.52 
(6.9-17.46) 
49.33 
(38.15-60.53) 
52.64 
(41.97-64.95) 
Over 5 42.15  
(35 - 49.49) 
21.09  
(15.7 - 26.55) 
50.85 
(37.18-66.5) 
22.97 
(13.35-34.85) 
19.77 
(7.91-34.67) 
9.93 
(4.8-16.14) 
44.57 
(31.43-58.86) 
29.94 
(19.77-41.17) 
Private sector 
(endline) 
U5 10.02  
(6.48 - 14.44) 
10.14  
(6.17 - 14.32) 
0 0 16.94 
(12.8-21.93) 
17.08 
(12.89-21.85) 
14.79 
(9.92-19.75) 
14.77 
(9.89-19.6) 
Over 5 14.63  
(11.3 - 18.53) 
14.71  
(11.3 - 18.42) 
0 0 16.96 
(12.97-21.84) 
17.06 
(12.98-21.86) 
14.88 
(9.81-19.72) 
14.8 
(9.94-19.67) 
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5.5.4 Treatment seeking, sector preference and access to hospitals 
The IMPACT 2 data gives an estimate of between 63% - 87% of febrile patients seeking treatment across all 
ages, a figure that is consistent with national surveys (TACAIDS et al., 2013). In all three regions, there was a 
preference for private sector outlets expressed in the endline survey, especially in the over-five age group.  
Overall the probability of seeking care at a tertiary facility was low. 
The potential impact of overcoming barriers of access to healthcare was investigated using three separate 
scenarios: 
A) 100% access i.e. all febrile cases (malaria and NMFI) seek treatment:  f_NTX = 0 
B) 100% clinic treatment only i.e. all of those who seek community treatment have access to public health 
facilities only (i.e. no private outlets supply care): f_CL = 1- f_NTX (i.e. f_PR = 0/ f_NTX = baseline) 
C) 100% access to a hospital/tertiary level care whether referred or direct:  f_H = 1 
The results are shown in Figure 51.  In low prevalence Mbeya, increased attendance at any source of care 
(Scenario A, B or C) reduced levels of parasite prevalence, clinical (uncomplicated) and severe disease 
incidence and malaria-related mortality. In Mwanza, eliminating barriers to accessing care, i.e. here through 
increased treatment seeking to any source (Scenario A) had a greater impact on parasite prevalence in both 
the U5 and 2-10 years age groups than if febrile cases that sought treatment did so only at a clinic (Scenario 
B i.e. the private sector is eliminated). This is due to the fact that Mwanza’s public sector clinics had a 
greater probability of stockouts than other regions, and thus the probability of a malaria case receiving an 
ACT at a health facility was low and similar to that in the private sector, whereas the probability of an NMFI 
receiving an ACT in the health facility was lower than the private sector.  Hence in this region, increasing the 
proportion of treatment-seeking febrile patients attending public clinics has a limited impact on prevalence.  
In contrast in Mtwara at the endline survey, the private outlets had no stocks of ACTs. In this setting the 
model predicts improved clinical and transmission outcomes under Scenario B; this is greater than that 
expected from the average across all regions. 
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Figure 51: The percentage change relative to baseline under three idealised conditions A) 100% treatment seeking; B) 
Access only to clinic treatment in the community; C) 100% access to hospital care, with respect to four outcomes: 
slide prevalence in 0-5 years; slide prevalence in 2-10 years; severe disease incidence in 0-5 years and malaria 
mortality in 0-5 years. 
In order to reduce the risk of severe disease and mortality, malaria programmes are often evaluated on the 
proportion of malaria patients that were able to access care within 24 hours. I therefore considered a 
scenario in which the time taken to access either private or public sector care in each region was reduced to 
half a day i.e. on average those seeking treatment access care the same day as symptoms arise. This could 
be achieved through a programme of community healthcare workers, as described in Chapter 2.  In Mbeya, 
this was predicted to have little impact, with less than a 2% change relative to baseline in the parasite 
prevalence, disease incidence or malaria mortality in U5s. In Mtwara and Mwanza, the impact in the 
population as a whole was also limited. However mortality in the youngest age group, which has a greater 
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probability of continuing to severe disease or death if untreated (Lubell et al., 2011), was estimated to be 
reduced by approximately 25% relative to baseline. This was predicted to occur in both private and public 
sectors in Mwanza. However in Mtwara, since the private outlets are assumed to have no ACT stock, there 
was no predicted change in either outcome. Overall modelling this scenario predicted a greater impact on 
morbidity than other community-level interventions (see sections 5.5.5 and 5.5.6) but had only limited 
impact on parasite prevalence since it does not affect the proportion of those treated. Thus reducing the 
delay in accessing care is most relevant in areas of high morbidity. 
Finally I modelled a scenario of perfect access to a hospital, whether referred from a community source for 
being at risk of severe malaria or if severe cases attend directly (Scenario C).  As expected, this intervention 
had little impact on parasite prevalence.  Severe disease levels were predicted to be reduced. This is due to 
the structure of the model that allows patients with the potential to develop acute severe malaria to by-pass 
the Severe state and enter either the Hospital treated state (HTx) or the Hospital untreated/failed treatment 
Severe state (HSev) if they are referred from a community treatment source.  Hence the reduction in severe 
disease seen here represents the individuals referred from a private sector outlet or government health 
facility that would avoid progression to severe disease if they could be appropriately treated in a hospital.   
Improving access to hospitals within the model predictably also leads to reductions in malaria mortality, 
except in the case of Mtwara where at endline the hospitals surveyed did not have stocks of artesunate.  
This does not suggest severe disease patients were untreated as 80% of the hospitals had stock of 
intravenous quinine, which is not included as an appropriate treatment in this model. 
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5.5.5 Treatment vs. Diagnostics 
Two major malaria control initiatives introduced over the past 3 years are the emphasis on diagnostic-led 
management and the focus on stocks of quality ACTs, especially in the private sector but also in public health 
facilities. In Chapter 4 I discussed the balance of the use of RDTs and improved ACT stocks with respect to 
the probability of a malaria case receiving an ACT (whether tested or not) and the probability of an NMFI 
being unnecessarily treated with an ACT.   
To evaluate the likely impact of these initiatives I considered the two scenarios of perfect ACT stock and 
100% diagnostic stock and use. Using the decision tree I generated probabilities for each region of malaria 
cases and NMFI receiving an ACT. I then explored the impact of these changed values in the transmission 
model and compared the outcomes to those generated at endline of the IMPACT study, in essence 
considering the further effect such interventions may have on the existing setting.  From this point onwards, 
the endline of the IMPACT 2 scenarios will be considered as baseline. The probability of malaria being 
treated with an ACT will also affect asymptomatic cases presenting with an NMFI since these infections are 
patent. The probability of an NMFI receiving an ACT will affect sub-patent malaria infections presenting with 
an NMFI since these are assumed to not be detectable by current diagnostics. 
The impact of overcoming ACT stockouts in the public sector (solid bars) in the three regions is predicted to 
be less than that of improving stocks in the private sector (hatched bars) since the private sector is preferred 
in all three settings (Figure 52A).  In the “all-Tanzania” scenario (where the household survey data is from 
more than just the three regions and is also derived from the THMIS data (TACAIDS et al., 2013)), the public 
sector is preferred overall and hence increased availability of ACT leads to greater reductions in prevalence 
and mortality.   
In relative terms, the impact on prevalence is greater than the impact on mortality.  This is likely to be due to 
the treatment of asymptomatic cases and subpatent infections with NMFI, which are thought to constitute a 
reservoir for transmission (Okell et al., 2012, Manjurano et al., 2011). In the model, improving ACT stock may 
prevent uncomplicated malaria progressing to severe states by increasing treatment, but does not affect the 
acute severe cases that in the model require artesunate or referral to hospital. The exception to this is the 
“all Tanzania” scenario, where 100% ACT stock in the private sector is predicted to result in an 18% relative 
reduction in mortality compared with a 4% reduction in parasite prevalence.  This is due to the fact that a 
greater proportion of the “all-Tanzania” population is assumed to preferentially seek treatment in the public 
sector. Therefore increasing ACT availability in the private sector does not impact on the treatment of NMFI 
with asymptomatic and sub-patent infections that drive infection transmission. However since the quality of 
treatment in the private sector is less than that in the public sector, a greater proportion of severe disease 
cases are generated through this pathway as a result of a lack of or delayed treatment.  Improving drug stock 
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in the private sector (in this setting of public sector preference) averts severe disease and mortality, which 
occurs as a consequence of private sector stockouts, to greater relative extent than affecting parasite 
prevalence. 
Figure 52B depicts the potential relevant reductions in slide prevalence and malaria mortality due to 
improved stock of diagnostics and their use in all febrile patients.  Compliance with test results has not been 
varied here. The relative impact of diagnostic deployment is less than that predicted to occur following the 
improved stocks of ACTs in each matching scenario except when comparing the effect of diagnostics on 
parasite prevalence and malaria mortality in the Mwanza private sector.   
The relative reduction in these two outcomes is higher for the private sector in Mwanza with increased 
diagnostic deployment compared with 100% ACT stock. This is due to Mwanza’s private outlets having 
adequate levels of ACT stock; hence the change relative to baseline is less.  In addition in the private outlets 
in Mwanza’s drug shops, compliance with positive test results is not constrained by a lack of ACT stock.  
Hence addition of diagnostics improves levels of under-treatment, thereby avoiding progress to clinical 
sequelae.  In Mtwara, outcomes in the private sector are unaffected by diagnostic deployment due to lack of 
ACT stock in this setting.  
Modelling improved access to and use of testing is not predicted to increase malaria mortality, as 
compliance with positive test results is high.  I have assumed here, due to scanty data, that compliance with 
negative test results is low (i.e. there is the same probability of being treated if not tested). Multiple 
interventions simultaneously implemented as packages of improvement together are considered in Section 
5.5.6. 
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Figure 52: Reduction relative to baseline in population parasite prevalence and malaria mortality in the under-fives under conditions of A) perfect ACT stock B) 100% stock of 
RDTs and 100% use in all febrile patients. 
Results are shown for each region in public (solid) and private (hatched) sectors Data labels are shown for values greater than 10% relative reduction. 
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5.5.6 Impact of packages of multiple interventions at community level 
The full potential impact of a single intervention to address a systems barrier may not be realised until it is 
delivered in combination; the value of diagnostic testing may be enhanced by improving levels of compliance 
to test results. Using the decision-tree, I generated the probabilities of malaria cases and NMFI receiving 
ACTs in the private and public sectors for both age groups for each of the scenarios summarised in Table 30. 
Table 30: Scenarios for improved malaria case management in public and private sectors using IMPACT 2 data 
Scenario for primary care (private and public sectors) Decision tree Parameters 
Baseline   
100% diagnostic availability & ACT stock Probability that a diagnostic is available = 1  
Probability that all doses of ACT are available = 1 
100% diagnostic use and compliance with results   Probability that a diagnostic is used = 1  
Probability that ACT is received if test positive = 1  
Probability that ACT is received if test negative =0 
100% diagnostic availability, use & compliance Probability that a diagnostic is available = 1  
Probability that a diagnostic is used = 1  
Probability that ACT is received if test positive = 1 
Probability that ACT is received if test negative =0 
100% diagnostic availability, use & compliance & 
ACT stock 
Probability that a diagnostic is available = 1  
Probability that a diagnostic is used = 1  
Probability that all doses of ACT are available = 1 
Probability that ACT is received if test positive = 1 
Probability that ACT is received if test negative =0 
Presumptive treatment Probability that a diagnostic used = 0 
Probability that QAACT is received if untested = 1 
 
Figure 53A shows the predicted relative reduction in two outcomes: parasite prevalence in U5s and malaria 
mortality in U5s for each of the 6 packages of case management interventions using the “All Tanzania” 
scenario.  In this “All Tanzania” model, the impact on prevalence of 100% ACT stock in the public sector 
(Figure 53A)  is only surpassed by a policy of presumptive ACT treatment for all fevers in clinic (ACT stock 
allowing) or with a scenario of 100% stock and 100% diagnostic stock, use and adherence, which is 
associated with less overtreatment of NMFI.  In the private sector 100% use and compliance with diagnostic 
tests is predicted to result in a small increase in prevalence, likely due to a reduction in the prophylactic 
effect of treating uninfected individuals and the lack of treatment of sub-patent infections with NMFI. 
Figures 53B to D shows the missing impact in each region if a package is implemented nationally, i.e. the 
difference between the effects anticipated on the basis of all Tanzania predictions and the effect in each 
region for these outcomes.  Positive values indicate the impact is less than anticipated (i.e. missing) and 
negative values indicate impact greater than anticipated. 
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All interventions in Mbeya whether private sector or public sector exceed the anticipated relative 
nationwide effects, as although the absolute changes are small their relative impact in a low prevalence 
setting is large. The exception to this is the scenario of under-five presumptive treatment, i.e. treating all 
febrile under-fives with ACTs, as per the previous international treatment guidance before the T3 initiative 
(WHO, 2012b). This is most likely due to the fact that most clinical cases at low prevalence occur in ages 
above five and thus mortality is not impacted by presumptive treatment of under-fives, whilst that for over-
fives remains unchanged. 
 In Mwanza and Mtwara the predicted impact of interventions in the public sector is less than predicted 
nationally, both in relative terms but also in absolute terms despite having higher parasite prevalence.  This 
is due to sector preference i.e. patients are more likely to go to the private sector when febrile in these 
regions, and therefore the anticipated impact of public sector interventions is diminished. 
In Mtwara, private sector interventions that do not include ACT stock are not predicted to have any effect 
since the outlets surveyed by IMPACT 2 in this region all reported stockouts.  
Improvements made to treatment delivery in Mwanza through the private sector all exceed the anticipated 
nationwide relative effect on slide prevalence in the U5s, but are less than expected with respect to U5 
mortality with the packages of 1) 100% diagnostic and ACT stock and 2) 100% diagnostic use and 
compliance. 
Within the structure of this model, malaria mortality is avoided by increasing the probability of an 
uncomplicated malaria case receiving ACTs, by a potentially severe case being treated with ACTs and rectal 
or intramuscular artesunate or being referred to hospital.  In a medium-high prevalence setting, improving 
diagnostic use and compliance in the private sector is an insufficient intervention to increase proportions of 
malaria cases following the three pathways above, since although uncomplicated cases may have a higher 
chance of being treated with an ACT, management of the potential acute severe cases is not affected.   
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Figure 53: Impact of package of interventions on parasite prevalence and malaria morbidity in under-fives.  
A) depicts the relative reduction compared to baseline if these packages are introduced in the private and public 
sectors using All Tanzania setting.  Figures B-D depict the missing impact: i.e. the difference between the effect 
anticipated (all Tanzania) and the effect in each region for these outcomes.  Positive values indicate the impact is less 
than anticipated (i.e. missing) and negative values indicate impact greater than anticipated. 
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Increasing the stock in drug shops of ACTs and diagnostics alone, without improving diagnostic use or 
compliance (given that these are not dependent on stock), overcomes the constraints of stock levels hence 
reducing the proportion of untreated uncomplicated disease that may progress to severe disease but does 
not avert the risk of those with early severe disease. 
Thus in a medium-high transmission setting a larger package of interventions than just improving supply-
chains is needed to match the relative impact expected in lower transmission settings. Therefore when 
striving to meet international targets such as the Roll Back Malaria targets of a 75% reduction in malaria 
mortality by 2015, a broader suite of interventions will be needed in higher transmission settings, addressing 
both community level management of uncomplicated malaria but also the pathways by which severe 
disease and mortality may be averted. 
In Mwanza (medium-high prevalence), modelling referral of all potentially severe cases for hospital 
management decreased the incidence of malaria mortality in under-fives by 28% relative to baseline (clinic 
referral) and 37% relative to baseline (private referral).  There was negligible impact on slide prevalence as 
community level treatment especially of NMFI is not affected.  In Mtwara (medium-high prevalence) this 
effect was not seen as the hospitals surveyed did not have artesunate in stock, and hence within the model 
no effective hospital treatment was possible.  
As described previously in Chapters 2 and 4, until recently a policy of presumptive treatment for febrile U5s 
was internationally recommended. Modelling this policy in the “all-Tanzania” scenario decreases mortality 
levels in the U5s but has little impact on parasite prevalence levels in the same age group in comparison to a 
policy of presumptive treatment for all ages, which reduces prevalence in U5s by approximately 40% 
whether in the private or public sector. At a regional level, this strategy of paediatric presumptive treatment 
also has minimal effect on parasite levels, whereas the effectiveness of all-age presumptive treatment is 
constrained by regional preferences for the private sector and high levels of ACT stockouts in the private 
sector (Mtwara) and the public sector (Mwanza). The results show that to reduce prevalence and 
transmission targeting just the U5 age group, which is not the main reservoir for parasite infection, is not 
effective. In contrast this strategy does appear to be effective in reducing levels of U5 mortality, by 
prevention of uncomplicated disease progressing to severe disease if left untreated, in the medium-high 
settings where most clinical disease is in this age group.  However as seen in the Mwanza public sector and 
Mtwara private sector, ACT stockouts are a barrier to this potential effect. 
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5.5.7 Impact of packages of multiple interventions at hospital/tertiary level 
Table 31 summarises 11 scenarios that I explored for each region considering their impact on the incidence 
of severe disease and malaria mortality.  The impact of increased treatment seeking for febrile illness has 
been described in Section 5.5.3 and the effects of increased referrals for potentially acute severe cases from 
private and public community sources discussed in Section 5.5.6. 
Table 31: Scenarios for improved access and severe malaria case management 
Scenario for access and severe case management Model Parameters 
100% access/treatment seeking  f_NTX = 0 
100% hospital access/treatment seeking f_H = 1 
100% treatment of all hospitalised severe malaria 
patients with ACTs and artesunate  
ftr_H = 1 
Duration of delay to seek care/access hospital 1/r_H= 0.5 
100% referral of severe cases to hospital from clinic ftr_REFCL= 1 (and hence ftr_SEVCL= 0) 
100% referral of severe cases to hospital from private 
outlets   
ftr_REFPR= 1 (and hence ftr_SEVPR= 0) 
100% stock of artesunate in clinics for potential acute 
severe malaria treatment  
ftr_SEVCL= 1* ftr_CL 
100% treatment of all potential acute severe malaria in 
clinic 
ftr_SEVCL= 1 (and hence ftr_REFCL= 0) 
100% referral of acute severe patients from private and 
public sectors & 100% treatment of all hospitalised 
severe malaria 
ftr_REFCL= 1 (and hence ftr_SEVCL= 0) 
ftr_REFPR= 1 (and hence ftr_SEVPR= 0) 
ftr_H= 1 
100% treatment seeking at hospital & reduced duration 
of delay to seek care at hospital 
f_H = 1 
1/r_H= 0.5 
100% referral of acute severe patients from private and 
public sectors & 100% treatment of all hospitalised 
severe malaria & 100% access to hospitals 
ftr_REFCL= 1 (and hence ftr_SEVCL= 0) 
ftr_REFPR= 1 (and hence ftr_SEVPR= 0) 
f_H= 1 
 ftr_H= 1 
 
The health systems interventions considered here have little effect on parasite prevalence levels since they 
do not concern the majority of infections that are either uncomplicated, asymptomatic or subpatent.  Due to 
the structure of the model, severe infections may be prevented by referral of those at risk of acute severe 
malaria if they are then treated successfully at hospital. 
Increasing the probability of receiving treatment at hospital is effective only in reducing malaria mortality, 
but not preventing severe disease. In this work, I have assumed that treatment for severe disease is the 
recommended first-line regime of Artesunate plus ACTs and have considered quinine equivalent to non-
treatment. Figure 54 illustrates the impact of single and packages of interventions in preventing severe 
disease incidence and reducing malaria-related mortality by age for each region.  
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The most effective single interventions to prevent the incidence of severe disease in U5s are improved 
probability of seeking treatment at a hospital and reducing the time taken to access a hospital (52% 
reduction from baseline in Mwanza; 35% in Mtwara and 47% all regions).  As discussed previously, these 
figures represent malaria cases that are referred from the community to hospital and thus bypass the severe 
disease state in the model. If they are not appropriately treated, individuals enter the hospitalised severe 
(HSev; figure 48) state with a high probability of death.  With increased delay to seek care, levels of severe 
disease rise as expected.   
Combinations of intervention such as 100% referral to hospital from both community sectors or 100% 
referral with 100% probability of attending a hospital, also affect the group of patients who could potentially 
avoid severe disease and its consequences if treated appropriately at the hospital. These combinations could 
result in a shift in the pattern of severe disease away from a peak at early ages (greater than 70% relative 
reduction in 0-5 year olds in Mwanza) towards a more sustained lower incidence pattern across 0-20 years 
of age similar to that seen in Mbeya and low prevalence settings.  This is not an effect of immunity but of 
health systems interventions potentially preventing the development of severe disease in those that are at 
risk.   
If effective treatment in a hospital could be provided, then these cases would be averted. In the model, if 
these cases are not successfully treated they enter the HSev compartment where they are still infectious (in 
the model, the state HSev is as infectious as Sev). Hence, in these two scenarios there is no change in 
population prevalence seen in these age groups, as the probability of being treated remains unchanged.   
Impact on malaria mortality follows a similar pattern but significant reduction requires improvement in 
hospital-based treatment; here related to the stock levels of artesunate. This is especially the case in Mtwara 
where no hospital reported artesunate stocks. Under conditions of 100% referral of potential severe cases 
from the community, 100% access or probability of seeking care at a hospital and 100% treatment at 
hospital, the model predicted over 96% reduction in malaria mortality even in high prevalence settings.  
100% referral and 100% hospital treatment halved mortality in Mtwara and Mwanza in the under-five age 
group. The potential reduction in U5 mortality with this strategy was greater than the potential reduction 
achieved by improving the treatment of potentially severe cases in clinic with rectal/IM artesunate (9.5% 
relative reduction in Mtwara; 32% in Mwanza). This is because of higher levels of private sector preference 
in these regions, but also because developing hospital capacity also allows treatment of those patients who 
develop severe disease as a result of delayed or ineffective treatment of uncomplicated malaria (which is not 
affected by community severe disease treatment in this model). Thus placing specific interventions to target 
malaria mortality may be more effective in some contexts through a hospital-based strategy rather than a 
community-based strategy, provided high levels of referral and hospital access can be achieved. 
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Figure 54: The impact of single and packages of interventions in preventing severe disease incidence and reducing malaria-related mortality on age-incidence curves for each 
region.   
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5.5.8 Hierarchy of packages and addressing local priorities 
The results presented so far have highlighted the need to consider the barriers posed by local health system 
structures and prevailing population preferences as well as malaria epidemiology to the implementation of 
ACT treatment programmes. In addition regional control priorities, for example reducing parasite prevalence 
versus preventing severe disease, should determine interventions to bolster the ability of the programme to 
meet its objectives.  
Clinical interventions based on treatment of infected cases are dependent on many health systems variables, 
as demonstrated above, but also on the probability of an individual becoming symptomatic.  In high 
transmission settings, this is most likely in children under the age of 5, as depicted in Figure 50, but this is 
not the age group in whom slide prevalence is greatest.  Few of the interventions considered in this analysis 
exert a greater relative effect on the parasite prevalence in this older age group compared with the under-
fives.  This occurred in the Mtwara region, a high transmission setting where levels of treatment seeking in 
the over 5 age group are higher than that in other regions as shown in Table 32.  
In Table 32 I rank for each region, as well as for all regions of Tanzania, the 5 interventions that produce the 
largest relative reduction in the three outcomes listed, namely parasite prevalence in the 0-5 years and 2-10 
years age groups and mortality in the under 5s. In addition, I include an estimate of the probability of NMFI 
receiving an ACT in that scenario (low, baseline or high) to indicate whether this strategy might also result in 
inappropriate treatment with anti-malarials.   
The hierarchy for reduction of parasite prevalence in each region was the same for both age groups, and all 
the interventions were community-based. The most effective intervention in all settings for affecting 
transmission and parasite prevalence was overhauling the provision of care through the private sector by 
achieving 100% diagnostic availability, use and compliance alongside ACT stock. This is due to a combination 
of individuals preferring to access antimalarials through the private sector and low baseline levels of quality 
at drugs shops and pharmacies. In Mtwara, where the population prefer seeking treatment at the private 
sector but which at the time of the survey experienced complete ACT stockouts in drug shops, prevalence is 
predicted to be reduced by greater than 70% relative to baseline. In Mwanza where drug shops had ACT in 
stock, this improvement from baseline is predicted to be greater than 80% due to a very strong private 
sector preference. 
In Mwanza the top 3 intervention packages were all in the private sector.  Presumptive treatment at drug 
shops for all ages ranked second, lower than the package of 100% diagnostic availability, use and compliance 
alongside ACT stock, for the reduction of parasite prevalence indicating that ACT stocks did act as a small 
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constraint here.  However the third most effective package to impact on prevalence levels was 100% 
diagnostic availability, use & compliance. This suggests that improved identification of malaria cases, when 
stock levels are only a minor constraint, can prove a successful means of achieving ACT effectiveness.  The 
fourth and fifth most useful packages in the Mwanza region, as regards addressing parasite prevalence, are 
much less effective than the top 3 (less than 25% relative reduction compared with 65-85% reductions 
described earlier).   
In Mtwara, the success of packages to reduce parasite prevalence levels is influenced by the lack of ACTs in 
drug shops in the endline survey. Hence whilst the most effective package is in the private sector though 
100% availability, use and compliance with diagnostics as well as 100% ACT stock, the second most effective 
intervention would be to eliminate any care at the private sector and ensure only public sector treatment, 
thereby halving the parasite prevalence in U5s. In Mtwara, the success of the third most effective 
intervention package drops to 28%, suggesting that barriers in terms of access and sector preference as well 
as quality need to be addressed in this region. 
Considering the “all-Tanzania” scenario, the second to fourth most effective packages for the reduction of 
malaria prevalence were all health facility based, which can be explained by the assumed preference for 
public sector care overall. 100% diagnostic availability, use and compliance alongside 100% ACT stock in a 
facility gave similar reductions as the same intervention in the private sector. Each of the top five 
intervention packages in the “all-Tanzania” setting were predicted to lead to a greater than 60% relative 
reduction in parasite prevalence. 
This is likely to have been skewed by the results obtained for the Mbeya setting where all of the top 5 
interventions modelled led to 100% reduction in parasite prevalence levels.  Mbeya is a low transmission 
setting, so although the actual predicted reductions may have been small, they may be sufficient to 
eliminate the malaria parasite. These results suggest that in low prevalence areas, the health systems 
barriers to achieving the full effectiveness of ACTs in reducing transmission may be achievable through 
health systems improvements, such as ensuring all febrile patients attend a source of treatment even if the 
quality of treatment provided is not actually improved. 
 
  
226 
 
Table 32: Hierarchy of interventions for each region with respect to relative reduction in parasite prevalence (in under-fives and 2-10 years) and mortality (under-fives) 
  % reduction in parasite prevalence  from baseline  % reduction in mortality from baseline 
 
Source Intervention 
f_NMFI @ 
source 
0-5 
years 
2-10 
years 
Source Intervention 
f_NMFI @ 
source 
0-5 years 
All Tz Private 
100% diagnostic availability, 
use & compliance & ACT stock 
Low 63.8 60.6 Hospital 100% referral, access & treatment  N/A 95.4 
 
Clinic 
100% diagnostic availability, 
use & compliance & ACT stock 
Low 63.4 60.2 Hospital 100% referral & treatment N/A 67.9 
 
Clinic Presumptive treatment High 61.8 58.3 Private 
100% diagnostic availability, use & 
compliance & ACT stock 
Low 47.6 
 
Clinic 100% ACT High 57.3 53.8 Clinic Presumptive treatment High 47.5 
 
Private Presumptive treatment High 52.6 49.1 Clinic 
100% diagnostic availability, use & 
compliance & ACT stock 
Low 47.3 
Mbeya Private 
100% diagnostic availability, 
use & compliance & ACT stock 
Low 100.0 100.0 Private 
100% diagnostic availability, use & 
compliance & ACT stock 
Low 100 
 Private Presumptive treatment High 100.0 100.0 Private Presumptive treatment High 100 
 Clinic 
100% diagnostic availability, 
use & compliance 
Low 100.0 100.0 Clinic 
100% diagnostic availability, use & 
compliance 
Low 100 
 Clinic Access to clinic only  Baseline 100.0 100.0 Clinic Access to clinic only Baseline 100 
 Clinic Presumptive treatment High 99.9 99.9 Clinic Presumptive treatment High 100 
Mtwara Private 
100% diagnostic availability, 
use & compliance & ACT stock 
Low 69.8 73.9 Hospital 100% referral, access & treatment  N/A 95.1 
 Clinic Access to clinic only High 46.4 51.1 Hospital 100% referral & treatment N/A 58.9 
 Private 
100% diagnostic availability & 
ACT stock 
High 28.0 31.8 Private 
100% diagnostic availability, use & 
compliance & ACT stock 
Low 40.9 
 Private 100% ACT High 27.8 31.6 Hospital 100% Hospital Treatment N/A 36.3 
 Clinic 
100% diagnostic availability, 
use & compliance & ACT stock 
Low 12.4 14.6 Clinic Access to clinic only Baseline 25.6 
Mwanza Private 
Private: 100% diagnostic 
availability, use & compliance 
& ACT stock 
Low 85.9 83.6 Private 
100% diagnostic availability, use & 
compliance & ACT stock 
Low 66.3 
227 
 
 Private Presumptive treatment High 74.1 70.3 Private Presumptive treatment High 53.8 
 Private 
100% diagnostic availability, 
use & compliance 
Low 61.0 -56.8 Private 
100% diagnostic availability, use & 
compliance 
Low 41.7 
 Clinic 
100% diagnostic availability, 
use & compliance & ACT stock 
Low 21.9 19.2 Private 100% diagnostic stock & use Low 14.6 
 Private 100% diagnostic stock and use Low 21.6 19.0 Clinic 
100% diagnostic availability, use & 
compliance & ACT stock 
Low 9.5 
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Table 32 also lists the five packages of interventions predicted to most successfully reduce malaria mortality 
in the U5s.  Across Tanzania, improving hospital referral, access and treatment reduces mortality in this age 
group by 95%, which exceeds the targets set by Roll Back Malaria to be achieved by 2015 (WHO, 2013).  
Community level interventions such as the top three packages to impact on prevalence are predicted to 
halve mortality rates. 
Hospital-based interventions are also the most effective packages in Mtwara to reduce U5 mortality from 
malaria. In this setting where there is a low probability of receiving an ACT in the community due to private 
sector stockouts, mortality may be prevented through improvements at hospital level. Whilst ensuring 100% 
hospital referral, access and treatment is predicted to reduce mortality by 96%, the top intervention to 
reduce parasite prevalence (namely 100% diagnostic availability, use and compliance alongside 100% ACT 
stock in the private sector) can only decrease U5 mortality by 41% relative to baseline. In contrast, instituting 
100% treatment of all severe cases in hospital with artesunate and ACTs alone can decrease mortality in U5s 
by a third. Eliminating all private sector treatment, i.e. ensuring all treatment seekers are diverted to the 
health facility, may reduce mortality by 25% compared to baseline. 
In contrast to these two settings, in Mwanza, a medium-high transmission setting, the most effective 
packages are all at community level, particularly in the private sector. This is because the baseline high 
probability of hospital treatment at the Mwanza hospital is higher than other settings, thus the relative 
impact of interventions is less, in combination with poor probabilities of receiving an ACT in either sector at 
baseline due to stockouts. Therefore the interventions that relatively affect childhood mortality levels are 
those that address the greatest barriers, namely community level treatment. In Mwanza the most successful 
packages to tackle U5 malaria mortality are also those that are most effective in relatively reducing parasite 
levels, and these private sector packages also have a greater relative impact in Mwanza than they do in 
other regions. Thus driving control efforts through drug shops and pharmacies in Mwanza is predicted to 
decrease malaria mortality by 40-60% whilst reducing malaria prevalence in the U5s by up to 80%. The 
relative reductions are less profound than those predicted with hospital-based interventions in other 
settings as expected as these intervention packages do not directly impact on the management severe 
disease but instead on preventing progression to morbidity and mortality.   
In Mbeya, as community level interventions are predicted to eliminate parasite prevalence, they similarly 
reduce mortality to zero. 
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5.6 DISCUSSION 
Using IMPACT 2 study data in a decision-tree and then in a malaria transmission model extended to 
incorporate access and quality of healthcare, I have demonstrated that health systems pose barriers to 
realising the potential effectiveness of ACTs in both treating clinical disease and reducing transmission.  
These constraints are often region-specific and need to be considered in conjunction with local epidemiology 
in order to maximise the impact of using ACTs as both treatment and prevention. 
In the examples used here, the hierarchy of intervention packages at an “all-Tanzania” level are different to 
those for the low transmission setting of Mbeya and the medium-high settings of Mwanza and Mtwara when 
addressing malaria parasite prevalence or mortality in children under 5.  Stockouts and the local population’s 
preference for buying anti-malarials at drug shops when febrile, as well as differences in provider behaviour 
with respect to the use of diagnostics, lead to varying predicted outcomes for the Mwanza and Mtwara 
settings despite similar parasite prevalence levels. 
In low prevalence scenarios, such as Mbeya, some single interventions such as ensuring all health facilities 
have stocks of ACTs or that all cases of fever seek care at any source, if implemented ideally are modelled to 
eliminate malaria in the region and thus also any ensuing mortality. However a policy of presumptive 
treatment for U5s alone, in either sector, does not reduce malaria mortality due to the epidemiology of 
clinical malaria in low transmission: most symptomatic disease occurs above the age of five years. 
Intervention packages in higher prevalence scenarios are more complicated, and need to be formulated with 
careful consideration to local priorities as well as health systems. For example, improving access through 
promotion of treatment seeking or a programme of community healthcare workers is not effective if drug 
shops or facilities have stock outs of ACTs.  In addition, aiming to increase the proportion who seek care 
within 24 hours can reduce malaria mortality in U5s but has little impact on parasite prevalence or 
transmission. 
Improvements in the quality of care received, by addressing barriers such as ACT stockouts or the use of 
diagnostics, need to be broad ranging and in the sector preferred by the local population in order to have 
significant effect. This means in Mwanza and Mtwara that innovative ways may need to be found of 
including the private sector in malaria control efforts. The ADDO programme had been rolled out in Mtwara 
before the time of the IMPACT 2 baseline survey.  However only small sample of outlets were surveyed here 
and at endline reported no ACT stock, which would have prevented the effects of this being seen in this 
analysis. The ADDO programme was implemented in the Mwanza region after the IMPACT 2 study data 
collection, but the modelling of packages shows that if this private sector improvement had been rolled out 
here earlier there might have been important clinical gains. The AMFm initiative in private outlets did lead to 
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significant improvements in stock levels in Mwanza and Mbeya as well as overall across Tanzania.  In these 
areas decreases in slide prevalence were observed in study data and predicted by the model (Figure 35). 
However changes over this time period were also being made in the public sector health facilities, including 
the roll out of RDTs and increase in availability of other malaria interventions, and so the reductions in 
prevalence cannot entirely be attributed to private sector drug subsidies. 
I also examined the competing policies of improving ACT stocks and improving diagnostic availability and 
use.  RDT use has been advocated in the T3 strategy (WHO, 2012b) to reduce overtreatment of non-malarial 
febrile illness, and the IMPACT 2 study data suggests that there is improved compliance to test results, when 
RDTs are used. The model predicts that a holistic testing strategy, in the absence of better ACT stocks, would 
have limited effect on transmission (especially if RDT quality was poor and did not identify asymptomatic 
infections) but could reduce mortality levels, through improved identification of malaria cases.  IMPACT 2 
study data highlights that malaria undertreatment, i.e. cases not receiving ACTs, does occur even when ACTs 
were present, and so further underlines the value of including testing in treatment guidelines. 
As explained previously, the model is structured so that severe disease occurs through the lack of effective 
or delayed treatment of uncomplicated malaria, or may follow an acute course with severe disease on 
presentation.  Severe disease may therefore be averted by improved timely community treatment (private 
or public sector). It may also be averted by administration of artesunate and ACTs in the community or by 
referral to hospital. The model therefore counts cases referred as not having disease, if they are not 
appropriately treated at hospital then they enter a separate hospitalised severe state alongside established 
severe disease that is not treated with a higher risk of mortality (HSev). The results from the model 
demonstrate that the potential to avert severe disease (provided hospital treatment can be administered) is 
greater with improved access to hospitals, i.e. increased probability of attending a hospital and increased 
rates of referral of acute severe cases than relying on community management.  Hospital-based strategies in 
the all-Tanzania and Mtwara settings were also the most effective means of reducing malaria mortality.  In 
Mwanza, the quality of hospital treatment was better than in other regions, and in this setting the model 
predicted that addressing mortality through community health systems interventions would be more 
effective.   
However community based interventions have the advantage of also impacting transmission, because it is in 
the community that clinical cases as well as sub-patent and asymptomatic reservoirs of infection (Manjurano 
et al., 2011, Okell et al., 2009a) may be treated.  Okell et al suggested that presumptive treatment may allow 
the prophylactic effect to extend to individuals without malaria and therefore reduce transmission (Okell et 
al., 2008a), and this is also shown here when modelling the impact of a policy of presumptive treatment in 
either sector with high rates of NMFI treatment with ACTs. However, in all the settings, instituting 
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diagnostic-led treatment with good stocks of ACTs in the sector that the local population preferred was 
more or equally effective as a policy of presumptive treatment in that sector. Thus improved targeting of 
malaria clinical cases and asymptomatic NMFI cases treated opportunistically (but not sub-patent infections) 
may allow similar levels of transmission reduction as administration of ACTs to all with a fever.  This is based 
on the assumption that RDT specificity and sensitivity did not vary across the settings, which may cause this 
strategy to be less effective in cases of poor quality diagnostic procedure. 
The model is limited by its dependence on data collected through 3 different surveys. In particular the 
household and outlet surveys were based on recall data that is subject to recall bias, and has been shown to 
be unreliable (Eisele et al., 2013). Small sample numbers in some regions, for example just 3 outlets in the 
Mtwara outlet survey at endline, none of whom stocked ACTs, can skew the inputs and hence the model 
outcome, and reduce the applicability of the regional results.  In addition, the surveys did not control for the 
“Hawthorne effect” (McCambridge et al., 2014), and so the presence of a survey team may alter the 
behaviour of staff or outlet owners as well as attracting the interest of individuals who may have otherwise 
not attended.  This could alter estimates for the probability of testing and adherence to guidelines as well as 
potentially overestimating the numbers of NMFI attending. A lack of control areas in the surveys and timing 
proximity to multiple interventions, e.g. AMFm and facility-based RDT rollout, mean that it is difficult to 
attribute the impacts seen to any particular health systems intervention. 
In addition, the decision-tree analysis was only able to capture dependencies between variables for some 
parameters in the public sector, for example the probability of receiving an ACT for a positive test if ACT was 
in stock. This was not possible in the private sector analysis due to using an amalgamation of outlet and 
household surveys. In addition I did not include the possibility of individuals attending multiple sources of 
treatment in case of stockouts at the initial point of care. Other potential dependencies, for example the 
probability of testing provided ACTs were in stock or the impact of recent stockouts on current prescribing 
were not accounted for, and may be important as seen where ACTs were not prescribed for a positive test 
despite stock in place. 
Tanzania has made great progress over the past decades in addressing malaria control through a variety of 
innovative local (e.g. ADDO programmes) and global (e.g. AMFm) initiatives. This research has attempted to 
bring together both quality of care, community coverage and access interventions at primary and tertiary 
levels to model and quantify their predicted combined impact.  It highlights that key policy considerations 
should include local patterns of health system utilisation as well as epidemiology, in order to develop 
targeted and nuanced malaria control plans for each region to maximise the potential of ACTs as treatment 
and to reduce transmission.  
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6 DISCUSSION 
This thesis has described the development of a mathematical malaria transmission model to explore the 
impact of health systems barriers on the effectiveness of an ACT (Artemisinin Combination Therapy) 
treatment programme on clinical outcomes such as malaria related morbidity and mortality as well as 
transmission outcomes such as parasite prevalence.  It considers public and private sector sources of care, as 
well as tertiary care for severe illness.  A decision-tree model was developed to estimate the probability of 
malaria and NMFI case management with ACTs. In addition, it examines the potential gains to be made 
through alleviating these health systems barriers, and considers optimal packages of interventions for 
different transmission settings.  Discussion of the detailed findings is included in the relevant Chapters.  This 
Chapter provides an overall summary of the key findings, describes some of the main limitations of the 
thesis, considers the implications of the findings within the wider context of malaria control and makes some 
suggestions regarding work which would further this stream of research. 
 
6.1 SUMMARY OF FINDINGS 
 
In Chapter 1, I outlined the epidemiology and clinical features of malaria infection, and the role of ACTs as 
first-line treatment.  I summarised the evidence for the use of ACTs in malaria control through successful 
treatment programmes (symptomatic case management) in South Africa, Ethiopia  and Zanzibar , and also 
more recent attempts using ACTs to reduce transmission through mass drug administration (MDA) and mass 
screening and treatment (MSAT). Although mathematical modelling of such strategies has shown promise 
(Okell et al., 2011), field trials have proved less successful in delivering sustainable change.  A potential cause 
for such policies not proving as effective as predicted through modelling, is achieving the necessary coverage 
in a sustained fashion. Although as described in Chapter 1, health systems in many malaria endemic 
countries are recognised as impoverished and weak, there has been little modelling of the role of health 
systems factors in reducing transmission. Tediosi et al. used a decision-tree modelling approach to predict 
incidence and mortality, and integrated this into a malaria transmission model to predict the cost-
effectiveness of treatment in different prevalence and coverage scenarios (Tediosi et al., 2006). Cost-
effectiveness analysis has been used to evaluate the use of RDTs to reduce childhood mortality in different 
transmission settings (Rafael et al., 2006). However previous studies modelling health systems effects on 
malaria transmission were not identified. 
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The literature review in Chapter 2, used the “systems effectiveness” framework to identify potential systems 
constraints to the effectiveness of ACT treatment programmes, summarized in two main categories:  
a) ensuring timely access to healthcare, i.e. distance to sources of care, the costs of travel, delays and 
the probability of seeking treatment 
b) the quality of care received at a source of treatment, dependent on several components including 
shortage of trained staff, drug stockouts, and the overtreatment of non-malarial febrile illness 
(NMFI) with ACTs due to presumptive treatment of fevers which occurred especially in the private 
sector. 
The same approach was used to review the evidence for interventions to address these barriers to successful 
implementation of ACT case management.  The studies reviewed suggested that some strategies that have 
traditionally formed a part of health systems strengthening such as training may have less impact than 
intended.  However novel use of mobile phones to enable improved stock-management and task shifting to 
community health care workers to reduce delays and promote treatment seeking whilst still providing 
quality care were reported to show promising results.  Few of these interventions had been implemented at 
scale. However AMFm (Affordable Medicines Facility-malaria) a multi-national scheme to harness the private 
sector, i.e. drug shops and pharmacies, as well as the public sector into national control efforts through the 
provision of subsidised and quality assured ACTS (QAACTs), has proved successful.  When evaluated in the 
initial malaria endemic countries to implement the scheme, drug subsidy to the end user was found to have 
been passed on and stocks of QAACTs in formerly poorly regulated outlets had improved.   
In Chapter 3, a deterministic compartmental model of malaria transmission previously developed (Griffin et 
al., 2010, Griffin et al., 2014) was extended in stages to incorporate dimensions of access to primary level or 
community sources of ACTs i.e. public sector health facilities and private retail outlets, and the quality of 
care received at each source.  Quality of care was assumed to be the probability of receiving an ACT, and this 
was iteratively expanded to address the issue of NMFI treatment, including for the opportunistic treatment 
of asymptomatic malaria infections. From a public health perspective, the effectiveness of a treatment 
programme must also be considered with respect to averting morbidity and mortality and not only impact 
on transmission. Therefore different pathways by which the development of severe malaria could be 
avoided or treated in the community or at tertiary levels facilities were also integrated. At this stage 
parameters were sought from the literature. Model outputs identified that systems interventions have a 
proportionately greater clinical impact than epidemiological impact in all settings, and that both have a 
larger relative impact at low transmission levels.  Although the prophylactic effects of treatment potentially 
may have an impact on transmission, modelling a reduction in NMFI overtreatment did not lead to 
unwanted rises in infection, at assumed baseline levels of malaria care.  Whilst at low transmission settings, 
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improved provision of community level care was modelled to reduce the incidence of severe disease and 
mortality, in higher transmission scenarios developing tertiary care, both in terms of access and quality, is 
required to decrease malaria-related mortality. 
Chapter 4 sought to develop an approach to estimate the key quality of care parameters, i.e. the probability 
of a malaria case receiving an ACT and the probability of an NMFI receiving an ACT when attending a health 
facility or buying drugs from a private pharmacies and retail outlets. A decision-tree framework, 
incorporating the chief steps of case management, was used to account for the multiple pathways by which 
a febrile case attending a source of care may receive an ACT, whether they are tested or untested.  At this 
stage, the decision tree was parameterised using values sourced from the literature.  In the public sector, the 
most critical step to improving malaria cases receiving treatment was the presence of ACT stocks (29% 
increase; 95% UI: 20.5-36.1%).  Interventions targeting diagnostic use reduced NMFI mismanagement, but 
had less effect on malaria treatment. In the private sector, the probability of malaria cases receiving QAACTs 
was very low, and required a large spectrum of interventions to improve case management.   
Using Tanzania as a case study, the probability of receiving an ACT was compared before and soon after the 
rollout of the T3 guidelines promoting diagnostic led management of fever at all ages.  The model predicted 
that overall the proportion of malaria cases receiving an ACT would have reduced by 19.5% (95%UI: 11-27%), 
despite a doubling in cases tested and treated appropriately.  However this was outweighed by a fourfold 
reduction in malaria cases receiving ACTs through other pathways, e.g. if untested.  Tanzania was also used 
as a case study to assess the AMFm initiative.  The model predicted that the proportion of malaria cases 
treated with QAACTs would increase from 0.07% to 13.6% (95% UI: 10.8-16.6%), but that NMFI 
overtreatment would also similarly increase, as testing and prescribing practices were not concurrently 
reported to improve.   
The decision-tree approach was used to consider how case management interventions could reduce the 
treatment gap whilst decreasing treatment excess, e.g. at baseline in the Tanzania public sector case study 
only half the patients that need ACTs were predicted to actually receive them, whilst only 20% of those who 
were treated with ACTs needed this treatment.  The results from modelling interventions to improve this 
balance suggest a tension between addressing issues of stock or provision or ACTs and the use of diagnostic 
tools, depending on local priorities. 
Chapter 5 integrated the model developed in Chapter 3 and the decision-tree approach from Chapter 4 to 
predict the impact of changes in health systems factors and case management on clinical outcomes and 
malaria prevalence. The model used data collected by the IMPACT 2 study in baseline (mid-late 2010) and 
endline (late 2011-mid 2012) household, health facility and outlet surveys in three regions of Tanzania with 
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differing transmission settings (Mbeya, Mtwara and Mwanza). The IMPACT 2 study aimed to evaluate the 
operational success of the rollout of RDTs in government health facilities and AMFm in private outlets.  The 
model outcomes demonstrate that the optimal packages of interventions at a national level are not always 
the ideal interventions at a regional level, but that success depends on local epidemiology, prevailing health 
systems and population preference for either government-funded primary care or private drug shops and 
pharmacies. 
In low prevalence scenarios (e.g. Mbeya) modelling some single interventions, such as increased ACTs stocks 
or improved access to any source of anti-malarials, if implemented at high levels of coverage may reduce 
prevalence of malaria sufficiently to eliminate transmission and clinical complications. A policy of 
presumptive treatment of U5s, as per international guidance prior to 2010, was not predicted to be as 
effective in this setting, presumably because symptomatic disease occurs in older children and adults.  
Modelling interventions in medium-high transmission settings (e.g. Mwanza and Mtwara) required 
combinations of health systems strengthening to impact clinical and transmission outcomes, depending on 
the baseline state of healthcare provision and the local community’s preference for private or public care. 
For example, improving access to health facilities, e.g. through increased health posts or community health 
workers, is limited in its effect if ACT stocks are the constraint to treatment. The rollout of the T3 guidance 
promoting diagnostic-led treatment in the public sector was predicted to have had a limited effect on 
parasite prevalence, but could reduce mortality levels through identification of malaria cases (and reducing 
under-treatment) assuming high quality tests. 
In medium-high prevalence scenarios (with a private sector preference in both) improving diagnostic use and 
compliance in the private sector was insufficient to impact severe disease incidence noticeably.  Similarly 
improving ACT stock in drug shops (as per AMFm) without improving diagnostic use or compliance (given 
that these are not dependent on stock), overcame the constraints imposed by stock levels hence reducing 
the proportion of uncomplicated disease that if untreated can progress to severe disease but did not avert 
the risk of progression those with early severe disease, which was assumed to require artesunate.  Improving 
access to tertiary care is modelled to be more effective in averting severe disease, if treatment with 
artesunate and ACTs can be administered at hospital, than management of those at risk of early severe 
disease at a primary care level (i.e. with rectal or intramuscular artesunate), although in reality both 
strategies may be needed.   
Combinations of interventions such as 100% referral to hospital from both primary care sources, or 100% 
referral with 100% probability of attending a hospital, was modelled to result in a shift in the pattern of 
severe disease away from a peak at early ages (greater than 70% relative reduction in 0-5 year olds in 
Mwanza) towards a more sustained lower incidence pattern across 0-20 years of age similar to that seen in 
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Mbeya and low prevalence settings.  This was not an effect of immunity but demonstrates the impact of 
health systems interventions potentially preventing the development of severe disease in those that are at 
risk. Hospital-based strategies were also the most effective means of reducing mortality, through the 
treatment of severe hospitalized disease in these settings.   
However primary care based interventions were more effective as regards impact on transmission.  
Diagnostic-led therapy in association with adequate stocks of ACTs were as effective in all settings as a policy 
of presumptive treatment of all fevers as malaria, reducing parasite prevalence in U5 in Mwanza by 86% 
when implemented in the private sector compared with 74% reduction with a policy of presumptive 
treatment in the private sector. This suggests that potential opportunistic benefits of NMFI treatment of 
asymptomatic cases and the prophylactic effect associated with ACTs may be matched by a policy of 
targeting and treating symptomatic cases across all settings. 
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6.2 LIMITATIONS OF THE THESIS 
Mathematical modelling is inherently limited by the complexity of vector-borne disease dynamics, reliance 
on input data and uncertainty of underlying assumptions especially regarding the applicability across 
settings.  
6.2.1 Model limitations 
The structure of the transmission model was based on a previously developed model (Griffin et al., 2010, 
Griffin et al., 2014, Griffin et al., 2014 ), which incorporates acquisition and loss of malaria immunity in order 
predict age-related patterns of disease.  The extensions made regarding sources of ACT treatment simplified 
the sectors to only public health facilities and private retail outlets at community level, as well as larger 
health centres or hospitals with inpatient capacity for management of severe disease. In reality the spectrum 
of sources of antimalarials at primary level is wide (Littrell et al., 2011a) and varies between rural and urban 
settings, as well as between countries. This simplification may lead to the model outputs not reflecting some 
of the nuances of health systems particular to these different scenarios, as well as either over or 
underestimating the impact of interventions implemented through a sector e.g. the impact of drug subsidies 
may be greater in urban areas (Cohen et al., 2010) where there is a greater density of accredited pharmacies 
than in rural areas. 
Chapter 2 summarised the potential effect that distance to a treatment source and the ability to access care 
(e.g. costs of travel) may have on the effectiveness of a treatment programme.  These dimensions of access 
were aggregated into a single parameter, namely the probability of seeking treatment which does not 
capture the contributions that each of these dimensions individually but was more readily available in the 
literature and through survey data.  It would be interesting to disaggregate the interaction of distance and 
cost in future work, especially to model the impact of schemes aimed at addressing the barrier of access 
such as Community Health Workers.  In addition the structure of the model did not allow for treatment 
seeking at more than one source of treatment, which could account for the higher levels of ACT treatment 
estimated in the IMPACT 2 study than within this analysis and reduce the predicted impact of stockouts. 
A further limitation is the absence of seasonality in the model, not only in the transmission model itself but 
also with respect to seasonal changes in access to care or quality of care.  IMPACT 2 study collected data in 
both the rainy season in Tanzania but also throughout drier seasons. It is unclear whether treatment seeking 
varies with the weather, but also if individuals recognise varying probability that a fever is due to malaria in 
the face of seasonal peaks in malaria transmission. During drier seasons, the rate of clinical episodes is less 
and so the impact of ACT may also be limited. However this model and other studies (Tediosi et al., 2006) 
predict that the impact of improving ACT delivery is proportionately greater in low transmission settings 
since infections are more likely to develop symptoms. A greater understanding of the relationship of 
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seasonality and health seeking behaviour would help guide implementation of interventions at different 
times of the year. 
The model did not include adherence to treatment, instead assuming all patients took the prescribed 
treatment. The INESS study in Ghana found that adherence to treatment was one of the most important 
factors in determining effectiveness (Binka et al., 2012), however a systematic review of how patients take 
antimalarial drugs found that variations in adherence relates not only to patient characteristics, but also the 
nature of their interaction with the source of care, which may in itself be distorted by study procedures 
(Littrell et al., 2011b). Given that it is still unclear what levels or features of adherence are required for ACTs 
to maintain their efficacy, this thesis focused on the upstream features of ACT delivery.  Although the review 
found that most studies reported high levels of adherence, estimates of the percentage of patients adherent 
ranged from 1.5% to 100%, and so considerations of whether patients do take their prescribed drugs will be 
important in realising the full efficacy of ACTs. 
I have assumed a fixed duration of minimum inhibitory ACT concentration (10 days) and reduction in onward 
infectiousness (95%) in this model, based on literature review.  These are based in particular on studies using 
Artmether Lumefantrine (AL), but may vary with other partner-drugs especially in the case of duration of 
prophylaxis. I have not accounted for the impact of immunity on the prophylactic or treatment effects nor 
have I included any consideration of anti-malarial resistance. This may lead to overestimated impact of 
treatment, and the model should be recalibrated as resistance patterns in this region become better 
defined. 
Estimates for the probability a malaria case or NMFI of receiving treatment at any particular outlet through 
the decision-tree approach did not match those from the IMPACT 2 study. The differences for estimates in 
the private sector have been previously discussed in Section 5.5.1, due to combining different survey data 
sets. The health facility estimates however were based on the same input data. Despite accounting for some 
dependencies, for example the probability of prescribing an ACT provided ACTs were in stock, it is clear that 
there may be some interactions not captured; the probability of testing may depend on the presence of ACT 
stock or the probability of prescribing may be related to anxiety regarding stockouts in the future. In 
addition, possible interactions between health-seeking behaviour and quality of care were not explored or 
included. Fears of stockouts may influence where patients choose to attend, and patient preference 
(including cost considerations) may also determine provider behaviour in prescribing ACTs or not.  Further 
work is required to gain an understanding of patient and provider behaviour and the linkages between these 
factors. Any insights however are likely to be context specific and the linear approach adopted in this 
analysis may allow wider application of model results. There was insufficient evidence from literature review 
or the IMPACT 2 study to include staff training in the decision-tree to estimate quality of care. 
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This thesis has explicitly focused on the use of ACTs and has considered all other types of antimalarials as 
equivalent to ineffective treatment including the use of quinine in severe malaria.  I also have not included 
the impact of co-administered antimalarials.  My hypothesis was that poor access and treatment delivery 
reduced the effectiveness of efficacious treatments such as ACTs, and my intention was to predict the 
impact of addressing these barriers to effectiveness.  However, it will be necessary in future work to include 
prescription of other antimalarials in order to more accurately assess impact on transmission and particularly 
on mortality, as well as interventions that may be required to include short course primaquine effectively 
(Littrell et al., 2011b). 
6.2.2 Data limitations 
The fitting of the original malaria transmission model was to data from 23 sites in sub-Saharan Africa. The 
authors admit that key parameters in the model were based on limited data and understanding especially of 
the natural history of malaria infection (and super-infection), and the complex evolution and manifestation 
of immunity (Griffin et al., 2010). 
The model is further limited by its reliance on summary statistics of data collected through three different 
surveys, which were not powered to detect differences between the regions or controlled to reliably 
attribute any impact seen to particular health systems interventions. In particular, estimates of sector 
preference and the probability of being tested and/or receiving ACTs in the private sector were derived 
through patient recall.  Patient recall is recognised to be unreliable (Eisele et al., 2013) and in this case may 
also be discordant with the findings of the outlet survey, e.g. complete stockouts on the day of the survey, 
despite patient reports of being treated with ACTs. The surveys did not control for the Hawthorne effect 
(McCambridge et al., 2014) and so provider behaviour may have been altered by the presence of a survey 
team.  Data regarding hospitals and tertiary care was extremely limited. 
Model parameterisation regarding the incidence of NMFI was estimated from an amalgamation of two 
surveys collecting demographic and clinical information during the rainy season in different regions of 
Tanzania to those of the IMPACT 2 study, as well as Tanzanian DHS data.  It is unclear how applicable these 
estimates are to the different regions and across the dry season.   
6.2.3 Interventions 
This thesis has compared actual changes in selected health systems variables through the IMPACT 2 study as 
well as modelling a sequence of idealized scenarios. However, it is assumed that any changes are 
implemented at one time across the region, as though in a trial setting.  In reality measures are taken over a 
period of time, which in itself may be related to the strength of the prevailing health system.  In addition, I 
have assumed that these interventions are sustained successfully over time and long enough for them to 
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have an effect.  Detailed data regarding the speed with which coverage of interventions is scaled up, 
heterogeneity in coverage levels achieved, and the degree of adherence to the interventions over time 
would allow more realistic predictions of the impact of health systems strengthening and the means by 
which it should optimally be achieved. This model has not considered dimensions of health systems 
strengthening related to health leadership and governance, which may be important in how interventions 
are implemented. 
My analysis has not considered host-factors other than malaria infection and age-related immunity. The 
means by which individuals interact with health services and respond to treatment may be affected by other 
health-related factors, for example malnutrition or co-infection with HIV.  The geographic distribution of HIV 
overlaps with malaria.  It has been reported that HIV infection increases malaria susceptibility and reduces 
the efficacy of antimalarial drugs (Flateau et al., 2011, Gonzalez et al., 2012), and the interpretation of these 
interactions may depend on which source of healthcare is accessed.  In addition, the analysis has assumed a 
stable setting, whereas in several malaria-endemic countries such as the Democratic Republic of Congo 
which are affected by ongoing conflict and unrest, alternative treatment delivery solutions may be more 
appropriate.   
Finally I have considered the impact of introducing health systems interventions in isolation for this thesis; 
other concurrent malaria control programmes have not been included.  Potential synergies between control 
measures such as LLINs, MDA or even malaria vaccination should be explored to see whether focusing 
interventions in specific population groups would influence transmission dynamics and treatment impact. 
It would be ideal to validate the health systems model against data from a region that had scaled up health 
systems interventions in a systematic and controlled manner to compare predicted impact.  The scope of 
data required would be immense, but may be possible in limited populations, for example control 
programmes on islands such as Zanzibar, to study which interventions were most critical. 
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6.3 IMPLICATIONS OF FINDINGS IN THE CURRENT MALARIA CONTROL CONTEXT 
 
Roll Back Malaria and the World Health Assembly have set a goal of reducing malaria case incidence rates by 
75% by 2015 and the fourth Millennium Development Goal is to reduce U5 mortality, to which malaria is a 
major contributor, by two thirds by the same year. An updated Global Malaria Action Plan has set an 
objective of reducing malaria deaths to near-zero levels by 2015 (WHO, 2013).  The specified route to 
achieve these goals entails not only malaria prevention strategies but also includes targets of universal 
access to case management in the public and private sectors, and community case management of malaria 
(CCM) through  community health workers. Health systems indicators for these targets relate to levels of 
treatment-seeking, use of testing, diagnostic-led prescription of ACTs and availability of inpatient care. 
 
The model defined in this thesis enables policy-makers to consider which of these indicators should be 
addressed first and in which sector to promote transmission and mortality reductions locally.  For example, 
reduced time to access care is a target in many malaria control plans, but the results presented here suggest 
that this may reduce mortality but have little impact on transmission. Hence the policy may have less 
significance in a low transmission setting in elimination planning but be an important consideration for 
higher transmission contexts.  Similarly, hospital-based interventions are predicted to proportionally reduce 
mortality more than health systems improvements at a primary level in some medium-high prevalence 
contexts, and hence may be preferred if death rates are the main local concern.  The model could also be 
used to evaluate the potential implications of policies in terms of overtreatment of NMFI and 
undertreatment of malaria cases. For example, it could be used to evaluate whether drug wastage was 
important or if allowing a more presumptive treatment approach would be better when prioritising the 
reduction of malaria deaths.  
  
The findings of this theoretical model need to be considered in a practical context.  Interventions to improve 
levels of diagnostic led treatment in the private sector, which were highly effective in the hierarchy of 
packages in Chapter 5, are also included in the Global Malaria Action Plan.  100% coverage of this target may 
not be feasible in a short timeframe and will undoubtedly require large investments (Hansen et al., 2013, 
Tougher et al., 2012).  However the costs of harnessing the private sector in malaria control efforts should be 
evaluated against the costs of malaria disease. For example, the loss of potential future earnings due to 
premature child mortality in those under-12 months is estimated to be US$ 6,900 and US$ 8,100 in those 
under 5 years. The authors of the analysis estimated the annual cost of clinical malaria disease in Tanzania at 
US$131.9 million, including an average treatment cost per case of US$6.79 (Sicuri et al., 2013). It would be 
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important and informative to apply a cost-effectiveness framework to the outputs of this model to guide the 
focus on health systems strengthening measures to achieve the international objectives.  
 
The role of improving ACT treatment programmes in transmission reduction may be compared to the 
predicted impact of the other control interventions in the Global Malaria Action Plan, such as LLINs, ITNs and 
IRS.  A systematic review of 22 randomized control trials of ITNs estimated sustained use could reduce 
malaria incidence by 50% and mortality in children by one-fifth even in moderate transmission settings 
(Lengeler, 2004). More recent modelling suggests that in low prevalence settings, high (>80%) levels of 
coverage of LLINs may reduce parasite prevalence to less than 1% and that combinations of interventions 
may achieve similar reductions in moderate transmission settings (Chitnis et al., 2010, Agusto et al., 2013, 
Gatton and Cheng, 2010, Griffin et al., 2010).   
 
The model outlined in this thesis estimated that at low transmission settings (i.e. Mbeya: approximately 6 
clinical episodes per 1000 all-age persons per year, 3 episodes per 1000 U5s per year), some single health 
systems interventions such as 100% access or 100% ACT stock in public clinics or private outlets had the 
potential to reduce clinical incidence by 100% in all age groups.  In contrast, in the medium-high Mwanza 
scenario (approximately 375 clinical episodes per 1000 all-age persons per year, 400 clinical episodes per 
1000 U5s per year), the most effective package of interventions (namely 100% access to, use of and 
compliance with diagnostics and 100% ACT stock in the private sector) is predicted to reduce clinical 
incidence across all ages by 50% but by approximately 75% in U5s. It is important to also bear in mind that if 
aiming to interrupt transmission, then modest absolute benefits in the levels of severe disease or EIR may be 
sufficient to meet the programme's objective. 
 
It would be important to model the impact of health systems improvements alongside other control 
measures to assess the consequences for local epidemiology, especially to explore targeting interventions to 
the age groups most likely to present with symptoms or with high asymptomatic parasite prevalence.  
Interventions may act synergistically through impact on vectors and human hosts to reduce parasite 
prevalence levels but may also overlap, for example the ACT-related prophylactic effect (whether through 
case management or MSAT) may be redundant in the context of high LLIN use. 
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6.4 FUTURE RESEARCH 
Potential extensions to the structure of the model and the need for further data and understanding of health 
seeking and provider behaviour to improve parameterisation of the model have been described in Section 
1.2.  In particular further modelling work should focus on: 
 Cost effectiveness analysis to estimate how the costs of addressing health systems barriers may be 
offset by morbidity and mortality averted 
 Interactions of improving case management and access to care alongside other malaria control 
measures including potential synergies with malaria vaccine candidates 
 Inclusion of appropriate treatment for NMFI to model a holistic approach to improving fever 
management 
 Modelling interventions to enable case management to become more responsive to systems 
constraints i.e. communicating with communities to direct treatment seeking in case of stockouts  
 Development of a user-friendly interface to aid planning at funding or local operational levels 
 
6.5 CONCLUDING REMARKS 
 
The research presented in this thesis has demonstrated that weak health systems and a poorly controlled 
diversity of antimalarial sources in malaria-endemic countries act as barriers to deploying ACTs effectively as 
both a first line treatment and a control measure.  Addressing these constraints through specific planning 
may improve progress towards the targets set by Roll Back Malaria to decrease clinical disease and 
mortality, and in low transmission settings, to approach elimination. 
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APPENDIX 1: MODEL EQUATIONS 
Model 1: The aim in this first extension of the original transmission model is to incorporate the two main 
community sources of treatment - public sector health facilities and private sector informal outlets. I capture 
how access to healthcare and the quality of care received varies through three parameters:- 
1. Following onset of symptoms, the probability of not seeking treatment (i.e. lack of access), the 
probability of attending a health facility and the probability of accessing a private drug shop (sector 
preference) 
2. time taken to seek treatment at either a private outlet or a public facility, by those who do access 
care (i.e. delays to access) 
3. probability of receiving an ACT for malaria infection in the public and private sectors (i.e. quality of 
care) 
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Key to model states: Model 1 
State Definition Explanation 
S Susceptible Susceptible: not infected 
NT Not Treated Clinically Symptomatic but not treated 
Pr Private Sector outlet Clinically Symptomatic case seeking care at private outlet 
CL Clinic/Health facility Clinically Symptomatic case seeking care at health facility 
PrNT Private Not Treated Clinically Symptomatic case not given ACTs at private outlet 
CLNT Clinic Not Treated Clinically Symptomatic case not given ACTs at health facility 
Tx Treated Clinically Symptomatic case given ACTs  
D Disease Progression to Diseased state: if Untreated/Ineffectively treated  
Sev Severe Disease Progression to Severe Malaria: if Untreated/Ineffectively treated 
A Asymptomatic Asymptomatic (patent) malaria infection 
U Undetectable (Sub patent) Subpatent malaria infection 
P Prophylaxed Successfully treated malaria case in prophylaxed state 
 
Key to model rates and parameters: Model 1 
Parameter Definition 
   Force of infection 
   Probability of developing clinical symptomatic disease 
fNTX Probability of not seeking or accessing early treatment if infected and symptomatic  (1-
fPR– fCL) 
fPR Probability of accessing care at a private trader/ informal outlet for a mild episode 
fCL Probability of accessing care at a primary care clinic/public sector health facility for a 
mild episode 
rPR Average rate of seeking treatment seeking at a private trader 
rCL Average rate of seeking treatment seeking at a health facility 
ftrPR Probability of receiving ACT treatment at private sector outlet for clinical malaria episode 
ftrCL Probability of receiving ACTs at a public sector/government health clinic for clinical 
malaria episode 
rNTX Average rate of developing disease (D) or Severe malaria if untreated 
rNTXPR Average rate of developing disease (D) or Severe malaria if untreated with an ACT at a 
private trader 
rNTXCL Average rate of developing disease (D) or Severe malaria if untreated with an ACT at a 
health facility 
   Proportion of untreated infections that progress to severe disease 
 SEV Proportion of untreated severe infections that progress to death 
rACT Mean rate of reduction in gametocytaemia after treatment with ACT treatment 
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fEFF Probability that ACT treatment is efficacious 
rD Average rate of recovery of an uncomplicated untreated symptomatic episode to 
asymptomatic state 
rA Average rate of recovery  from detectable asymptomatic state to undetectable (sub-
patent) state 
rP Average rate of reduction of prophylactic effect after ACT treatment 
rU Average rate of clearance of sub-patent infection to return to susceptible state 
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Model 2: The aim of the second is capture the potential impact of overtreatment of non-malarial febrile 
illness (NMFI) with ACTs.  I therefore extended Model 1 to investigate the clinical and transmission outcomes 
arising from policies of:- 
1. Presumptive treatment in the private sector 
2. Improved levels of diagnostic-led management (and hence quality of care) in private and public 
sectors. 
I included the probability of febrile individuals (any cause) without malaria receiving ACTs at both private 
outlets and public health facilities.  There are three main groups involved in the overtreatment of NMFI 
cases with ACTs:- 
1. Febrile cases with no malaria infection 
2. Febrile cases with subpatent malaria infection (i.e. undetectable by standard malaria testing) 
3. Febrile cases with asymptomatic malaria infection (i.e. detectable by malaria testing). 
 
Model 2 equations 
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Key to additional model states: Model 2 
State Definition Explanation 
SPr Susceptible NMFI: Private Uninfected case with NMFI seeking care at private outlet 
SCL Susceptible NMFI: Clinic Uninfected case with NMFI seeking care at a clinic 
UPr Sub-Patent NMFI: Private Undetectable infection with NMFI seeking care at private outlet 
UCL Sub-Patent: Clinic Undetectable infection with NMFI seeking care at a clinic 
UTx Sub-Patent: Treated Undetectable infection with NMFI treated with ACTs 
APr Asymptomatic NMFI: 
Private 
Asymptomatic infection with NMFI seeking care at private outlet 
ACL Asymptomatic NMFI: Clinic Asymptomatic infection with NMFI seeking care at a clinic 
ATrx Asymptomatic NMFI: 
Treated 
Asymptomatic infection with NMFI treated with ACTs 
 
Key to additional model rates and parameters: Model 2 
Parameter Definition 
rNMFI Average rate of seeking treatment for a NMFI 
ftrNMFICL Probability of receiving ACT treatment at a clinic for an NMFI episode 
ftrNMFIPR Probability of receiving ACT treatment at a private outlet for an NMFI episode 
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Model 3: The initial two models consider management of uncomplicated malaria only at community level 
and do not include any management of severe malaria; which is modelled to as a result of ineffective, 
delayed or a lack of ACT treatment.  Severe cases are assumed to either progress to death or recover to an 
asymptomatic state.  In Model 3 is expanded to include a second pathway by which severe malaria may 
occur, namely acute severe malaria at presentation due to poor acquired immunity which can rapidly 
progress to severe fulminant state.   
Three routes to potentially avert or treat severe disease are included: 
1. Prevention of progression to fulminant severe disease in those at risk of early acute severe malaria 
by treatment with rectal artesunate and ACTs – which may occur at public facilities or private outlets 
2. Referral of those at risk of early acute severe malaria to hospital/tertiary level facilities – which may 
occur from public facilities or private outlets 
3. Treatment of severe malaria at a hospital/tertiary level facility with artesunate and ACTs – which 
may be early acute severe malaria or those uncomplicated symptomatic malaria cases that may not 
have sought treatment or were unsuccessfully treated either at a public facility or private outlets. 
The aim of the extensions made to Model 3 is to investigate 
1. The impact of health systems on the morbidity and mortality associated with malaria 
2. The role of tertiary level health institutions e.g.  district hospitals in the management of severe 
malaria and its consequences 
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Key to additional model states: Model 3 
State Definition Explanation 
wSev Waiting state: severe 
malaria 
Susceptible: not infected 
CLSev Acute severe malaria: 
Clinic 
Acute severe malaria seeking care at clinic 
PrSev Acute severe malaria: 
Private 
Acute severe malaria not given ACTs and artesunate at private 
outlet 
SevCLNT Untreated Acute severe 
malaria: Clinic 
Acute severe malaria not given ACTs and artesunate at clinic 
SevPrNT Untreated Acute severe 
malaria: Private 
Acute severe malaria seeking care at private outlet 
Href  Acute severe malaria 
referred to tertiary care 
Acute severe malaria referred to tertiary care/hospital 
HTx Treated severe malaria: 
tertiary care 
Severe malaria/Referred malaria given Artesunate and ACTs at 
tertiary care/hospital  
HSev Untreated severe 
malaria/Fulminant disease 
Severe malaria/Referred malaria not or ineffectively treated:   
 
Key to additional model rates and parameters: Model 3 
Parameter Definition 
wSEV Force of infection 
fH Probability of accessing care at a hospital/tertiary facility for a severe episode 
ftrREFCL Probability of being referred to hospital for an acute severe malaria episode from a clinic 
ftrREFPR Probability of being referred to hospital for an acute severe malaria episode from a private 
outlet 
ftrSEVCL Probability of being treated with artesunate and ACTs for an acute severe malaria episode 
at a clinic 
ftrSEVPR Probability of being treated with artesunate and ACTs for an acute severe malaria episode 
at a private outlet 
rH Average rate of accessing care at a hospital/tertiary facility 
ftrH Probability of being treated with artesunate and ACTs for severe malaria at a hospital 
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APPPENDIX 2: PUBLISHED PAPERS FROM THESIS 
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